[
  {
    "id": 1,
    "paragraph": "The EMBO Journal Vol.18 No.13 pp.3564–3574, 1999 The Mll–AF9 gene fusion in mice controls myeloproliferation and speciﬁes acute myeloid leukaemogenesis C.L.Dobson, A.J.Warren, R.Pannell, A.Forster, I.Lavenir, J.Corral1, A.J.H.Smith2 and T.H.Rabbitts3 MRC Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Hills Road, Cambridge, CB2 2QH, UK",
    "jurnal": "003564.pdf"
  },
  {
    "id": 2,
    "paragraph": "1Present address: Centro Regional de Hemodonacion, Servicio de Hematologia, Hospital Clinico Universitario, Ronda de Garay s/n, Murcia 30003, Spain 2Present address: Centre for Genome Research, University of Edinburgh, King’s Buildings, West Mains Road, Edinburgh EH9 3JQ, UK 3Corresponding author The MLL gene from human chromosome 11q23 is",
    "jurnal": "003564.pdf"
  },
  {
    "id": 3,
    "paragraph": "involved in >30 different chromosomal translocations resulting in a plethora of different MLL fusion proteins. Each of these tends to associate with a speciﬁc leuk- aemia type, for example, MLL–AF9 is found mainly in acute myeloid leukaemia. We have studied the role",
    "jurnal": "003564.pdf"
  },
  {
    "id": 4,
    "paragraph": "of the Mll–AF9 gene fusion made in mouse embryonic stem cells by an homologous recombination knock- in. Acute leukaemias developed in heterozygous mice carrying this fusion as well as in chimeric mice. As with human chromosomal translocation t(9;11), the majority of cases were acute myeloid leukaemias",
    "jurnal": "003564.pdf"
  },
  {
    "id": 5,
    "paragraph": "involving immature myeloblasts, but a (AMLs) minority were acute lymphoblastic leukaemia. The AMLs were preceded by effects on haematopoietic differentiation involving a myeloproliferation resulting in accumulation of Mac-1/Gr-1 double-positive mature myeloid cells in bone marrow as early as 6 days after",
    "jurnal": "003564.pdf"
  },
  {
    "id": 6,
    "paragraph": "birth. Therefore, non-malignant expansion of myeloid precursors is the ﬁrst stage of Mll–AF9-mediated leuk- aemia followed by accumulation of malignant cells in bone marrow and other tissues. Thus, the late onset of overt tumours suggests that secondary tumorigenic mutations are necessary for malignancy associated with",
    "jurnal": "003564.pdf"
  },
  {
    "id": 7,
    "paragraph": "MLL–AF9 gene fusion and that myeloproliferation provides the pool of cells in which such events can occur. Keywords: ALL-1/chromosomal translocations/ haematopoiesis/HRX/leukaemia Introduction Chromosomal translocations are present in many tumours and are involved in the development of the tumours which carry them (Rabbitts, 1994; Look, 1997). The cloning of",
    "jurnal": "003564.pdf"
  },
  {
    "id": 8,
    "paragraph": "translocation the genes involved in the chromosomal breakpoints in leukaemias and solid tumours of mesen- chymal origin, have shown that a major molecular con- sequence of these aberrant chromosomes is creation of fusion genes, and therefore of fusion proteins, when the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 9,
    "paragraph": "breaks occur between exons of genes on each chromosome. This was ﬁrst recognized for the fusion of BCR and ABL genes resulting from the Philadelphia chromosome (Nowell and Hungerford, 1960; Rowley, 1973; de Klein et al., 1982; Bartram et al., 1983; Groffen et al., 1984).",
    "jurnal": "003564.pdf"
  },
  {
    "id": 10,
    "paragraph": "Molecular studies of these chromosomal breakpoints demonstrated that two forms of the BCR–ABL fusion gene result from distinct chromosomal breakage within the BCR gene, linking it to the same coding part of the ABL gene (Bartram et al., 1983; de Klein et al., 1986). More recently,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 11,
    "paragraph": "complex situations have been described in subsets of leukaemias with breaks in chromosome 11, band q23 within the MLL/HRX/ALL-1 gene (Ziemin-van der Poel et al., 1991; Djabali et al., 1992; Gu et al., 1992; McCabe et al., 1992; Tkachuk et al., 1992; Domer et al., 1993)",
    "jurnal": "003564.pdf"
  },
  {
    "id": 12,
    "paragraph": "and in sarcomas such as those with breaks within the EWS and FUS/TLS genes (Delattre et al., 1992; Crozat et al., 1993; Rabbitts et al., 1993; Aman et al., 1996; Panagopoulos et al., 1996). Under these circumstances, the respective genes become involved with a multitude of",
    "jurnal": "003564.pdf"
  },
  {
    "id": 13,
    "paragraph": "different chromosomal translocations which are predomin- antly associated with a particular sub-type of leukaemia or sarcoma. Furthermore, the FUS gene has a role in translocations in both sarcomas and in acute myeloid leukaemia (Ichikawa et al., 1994; Panagopoulos et al., 1994) depending on the cell type or on the fusion partner.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 14,
    "paragraph": "These observations raise issues about possible roles of the fusion genes in tumour type, particularly the role the fusion partner might play in the speciﬁcity of the tumour phenotype. The chromosome 11 region q23 is involved in ~10% of acute myeloid leukaemias (AMLs) and acute lympho-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 15,
    "paragraph": "blastic leukaemias (ALLs), as well as in mixed lineage leukaemias and in some lymphomas. In addition, balanced chromosome 11q23 translocations are also observed in therapy-related leukaemias, especially in patients pre- viously treated with inhibitors of topoisomerase II (Ratain et al., 1987; Pui et al., 1989; Cimino et al., 1997; Nasr",
    "jurnal": "003564.pdf"
  },
  {
    "id": 16,
    "paragraph": "et al., 1997; Rowley et al., 1997; Sobulo et al., 1997; Atlas et al., 1998; Felix, 1998). The cloning of the chromosome 11q23 breakpoint region (Ziemin-van der Poel et al., 1991) revealed the MLL/HRX/ALL-1 gene (Djabali et al., 1992; Gu et al., 1992; McCabe et al.,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 17,
    "paragraph": "1992; Tkachuk et al., 1992; Domer et al., 1993) (herein designated the MLL gene), which encodes a 432 kDa protein with several regions of structural homology to other proteins, for instance to Drosophila trithorax (Mazo et al., 1990; Djabali et al., 1992; Gu et al., 1992; Tkachuk",
    "jurnal": "003564.pdf"
  },
  {
    "id": 18,
    "paragraph": "et al., 1992). More than 30 different chromosomal bands translocations with have been found in chromosomal chromosome 11q23, and molecular showed rearrangements with the MLL gene in all cases (reviewed in Rowley, 1993; Thirman et al., 1993; Bernard and Berger, 1995; Rubnitz et al., 1996b; Gilliland, 1998).",
    "jurnal": "003564.pdf"
  },
  {
    "id": 19,
    "paragraph": "Among the most common reciprocal translocations are studies 3564 © European Molecular Biology Organization t(4;11)(q21;q23), t(9;11)(p22;q23) and t(11;19)(p13;q23). These fuse MLL with AF4/FEL, AF9/LTG9 and ENL/ LTG19 genes, respectively (Gu et al., 1992; Tkachuk et al., 1992; Chen et al., 1993; Iida et al., 1993; Morrissey",
    "jurnal": "003564.pdf"
  },
  {
    "id": 20,
    "paragraph": "et al., 1993; Nakamura et al., 1993; Yamamoto et al., 1993). There is a strong correlation between the leukaemia phenotype and each of these speciﬁc MLL translocation fusions (Corral et al., 1993; Thirman et al., 1993). The translocation t(9;11)(p22;q23) is mainly associated with",
    "jurnal": "003564.pdf"
  },
  {
    "id": 21,
    "paragraph": "AMLs (Iida et al., 1993; Nakamura et al., 1993) while the translocation t(4;11)(q21;q23) is found predominantly in ALLs (Gu et al., 1992; Domer et al., 1993; Iida et al., 1993; Morrissey et al., 1993; Nakamura et al., 1993; Downing et al., 1994). The t(11;19)(p13;q23) translocation",
    "jurnal": "003564.pdf"
  },
  {
    "id": 22,
    "paragraph": "on the other hand occurs in both ALL and AML but with higher frequency in ALL (Nakamura et al., 1993; Yamamoto et al., 1993; Rubnitz et al., 1996a). These ﬁndings suggest that the incoming fusion partner of MLL helps to specify the cell type of the tumour. Thus, the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 23,
    "paragraph": "fusion protein itself may inﬂuence tumour type if the chromosomal translocation occurs in a pluripotent pre- cursor cell. It is nonetheless possible that the chromosomal translocation may occur in a committed precursor because the chromosomal region is accessible for the chromosomal",
    "jurnal": "003564.pdf"
  },
  {
    "id": 24,
    "paragraph": "translocation event, in which case the protein fusion would not strictly specify tumour type. Several biological models have been established to gain insights into the role of the MLL fusions in tumorigenesis. The use of retroviruses encoding the MLL/HRX–ENL fusion to infect primitive",
    "jurnal": "003564.pdf"
  },
  {
    "id": 25,
    "paragraph": "cells showed that myeloid cell proliferation could be observed and that tumours of this lineage emerged (Lavau et al., 1997; Slany et al., 1997). These experiments suggest that a gain-of-function mechanism at least partly explains the role of this fusion protein which is made after the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 26,
    "paragraph": "chromosomal translocation t(11;19) in humans. The fusion of the AF9 gene with the Mll gene also resulted in the emergence of AML in mice (Corral et al., 1996). In the present study we show that an Mll–AF9 gene fusion [made in embryonic stem (ES) cells by homologous",
    "jurnal": "003564.pdf"
  },
  {
    "id": 27,
    "paragraph": "recombination] carried in the mouse germline contributes to AML. In both chimeras and heterozygous mice, the majority of mice developed AML and a small percentage developed ALL. The features of this disease reﬂect those of the disease which develops in humans carrying the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 28,
    "paragraph": "MLL–AF9 translocation. Furthermore, a selective prolifer- ation of Gr-1-positive myeloid bone marrow cells was observed in heterozygous animals before the symptoms of leukaemia occurred. The propensity for myeloid tumour formation therefore seems to be a consequence of the advantageous growth of myeloid precursors caused by the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 29,
    "paragraph": "Mll–AF9 fusion, thereby providing a pool of cells in which secondary mutations, necessary for overt tumour development, can occur. Results Mll–AF9 mice develop acute leukaemia An Mll–AF9 fusion gene was created in mouse ES cells, by knock-in homologous recombination (Corral et al.,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 30,
    "paragraph": "1996), in which an AF9 cDNA was fused into exon 8 of one allele of the endogenous Mll gene (a diagram of the targeted allele is shown in Figure 1A). These ES cells were injected into C57Bl/6 blastocysts and chimeric mice",
    "jurnal": "003564.pdf"
  },
  {
    "id": 31,
    "paragraph": "Mll–AF9 fusion causes myeloproliferation Fig. 1. Germ-line transmission of the Mll–AF9 targeted allele in mice. (A) A diagrammatic map of the Mll–AF9 targeted allele is shown (Corral et al., 1996). The human AF9 cDNA sequences were fused at exon 8 of Mll and MC1-neo-poly(A) cassette (Thomas and Capecchi,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 32,
    "paragraph": "1987) was cloned into the targeting vector as a positive selection marker. The restriction fragments corresponding to the wild-type Mll and the targeted Mll–AF9 genes are 10 and 13 kb BglII fragments, respectively. The probe used to detect homologous recombination events [1.5RXT2 (Corral et al., 1996)] is indicated. (B) Filter",
    "jurnal": "003564.pdf"
  },
  {
    "id": 33,
    "paragraph": "hybridization of tail biopsy DNA. Lanes a–j show hybridization of DNA extracted from a litter of Mll–AF9 mice produced by crossing a male chimera with a wild-type mouse. The DNA was digested with BglII and hybridized with the EcoRI–XhoI fragment from clone",
    "jurnal": "003564.pdf"
  },
  {
    "id": 34,
    "paragraph": "p1.5RXT2. Two heterozygous carrier mice were present. 129 DNA corresponds to a 129 mouse liver and B1-89 represents DNA from the original Mll–AF9 targeted ES clone. Germline and targeted alleles are indicated. were produced which developed haematopoietic tumours, mainly AML, after 6 months (Corral et al., 1996). Germ-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 35,
    "paragraph": "line transmission of this Mll–AF9 fusion gene was obtained by crossing chimeras with wild-type females. Hetero- zygotes obtained from these crosses were identiﬁed by ﬁlter hybridization of somatic DNA using an internal probe from the targeting region (1.5RXT2 probe, Figure 1A). The probe detects a 10 kb germ-line Mll band and a",
    "jurnal": "003564.pdf"
  },
  {
    "id": 36,
    "paragraph": "13 kb band corresponding to the homologous recombin- ation fusion gene (Figure 1B shows the hybridization of DNA from one litter, designated a–j, compared with 129 liver DNA and DNA from an initial targeted ES clone B1-89). No homozygous Mll–AF9 mice were found in",
    "jurnal": "003564.pdf"
  },
  {
    "id": 37,
    "paragraph": "any litter from a heterozygous cross (41 pups from four litters were analysed), indicating embryonic lethality of the knock-in gene as reported for the Mll null mutant mice (Yu et al., 1995). Our previous report on the Mll–AF9 fusion gene expressed in chimeric mice showed that most animals",
    "jurnal": "003564.pdf"
  },
  {
    "id": 38,
    "paragraph": "succumbed to acute leukaemia within one year (Corral et al., 1996). Whilst many of these were diagnosed as myeloid, a complete analysis was not performed in all cases. A detailed investigation of the leukaemias in Mll– AF9 heterozygous and chimeric mice has now been",
    "jurnal": "003564.pdf"
  },
  {
    "id": 39,
    "paragraph": "undertaken to deﬁne more precisely the type of malignancy and to address issues relating to the mode of onset of overt malignancy. Cohorts of Mll–AF9 mice were com- pared with mice which had been made with an epitope tag fused (this line of mice has been designated Mll–myc;",
    "jurnal": "003564.pdf"
  },
  {
    "id": 40,
    "paragraph": "Corral et al., 1996) at the same Mll exon 8 position at 3565 C.L.Dobson et al. Fig. 2. Acute leukaemia occurrence in Mll–AF9 mice. The rate of leukaemia occurrence (age in months of detection of disease versus number of mice with disease) in Mll–AF9 chimeric and heterozygous",
    "jurnal": "003564.pdf"
  },
  {
    "id": 41,
    "paragraph": "mice. Diagnosis of leukaemia was obtained by histological analysis of bone marrow, spleen, thymus and liver, and in most cases by FACS analysis of cell surface marker expression. AML developed in 21 out of 28 heterozygous Mll–AF9 mice (circles), in 22 out of 24 Mll–AF9",
    "jurnal": "003564.pdf"
  },
  {
    "id": 42,
    "paragraph": "chimeras (squares) and ALL developed in two out of 24 Mll–AF9 chimeras (diamonds). No Mll–myc heterozygous mice developed a malignancy in the 18 month period of this experiment (four tumours were detected in the cohort of 27 Mll–myc mice but these occurred at",
    "jurnal": "003564.pdf"
  },
  {
    "id": 43,
    "paragraph": "28, 29, 32 and 32 months). which the AF9 sequences were fused. These groups were analysed over a period of 18 months, and during this time both the Mll–AF9 chimeras and heterozygotes began to show signs of distress. No disease was observed in Mll–",
    "jurnal": "003564.pdf"
  },
  {
    "id": 44,
    "paragraph": "myc mice within the 18 month experimental period (there were 27 Mll–myc mice in the control group; four developed AML tumours but these occurred after two years sug- gesting that they were of sporadic origin rather than due to the manipulation of the Mll gene).",
    "jurnal": "003564.pdf"
  },
  {
    "id": 45,
    "paragraph": "Post-mortem examination of Mll–AF9 mice showed consistent evidence of haematological disease. Signs included pale femurs, splenomegaly, heptomegaly and pale kidneys. All the mice analysed were diagnosed as having acute leukaemias and no tumours of other tissues were observed, despite widespread activity of the Mll",
    "jurnal": "003564.pdf"
  },
  {
    "id": 46,
    "paragraph": "promoter (Yu et al., 1995; Corral et al., 1996). The development of these acute leukaemias is shown in Figure 2. The disease was classiﬁed as predominantly AML with rare examples of ALL, mirroring the spectrum and ratio of acute leukaemias found in humans with the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 47,
    "paragraph": "chromosomal translocation t(9;11). The rate of develop- ment of AML was overall slightly faster in heterozygous animals compared with the chimeras (Figure 2), the point at which 50% of each cohort had succumbed to AML being 5 and 7 months for heterozygotes and chimeras,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 48,
    "paragraph": "respectively. Twenty-two of the 24 chimeras and 21 of the 28 heterozygous Mll–AF9 mice developed AML in the 18 month period. Two Mll–AF9 chimeras developed ALL rather than AML. Acute myeloid and lymphoblastic leukaemia in Mll–AF9 mice Almost all Mll–AF9 heterozygous and chimeric mice",
    "jurnal": "003564.pdf"
  },
  {
    "id": 49,
    "paragraph": "developed malignancy within one and a half years. 3566 Detailed tissue histology was carried out on mice as pathological signs of disease developed, to classify the types of leukaemia present and to establish a diagnosis of disease. This analysis conﬁrmed the presence of acute",
    "jurnal": "003564.pdf"
  },
  {
    "id": 50,
    "paragraph": "leukaemias in all the mice with symptoms and showed the occurrence of either myeloid or lymphoid malignancies. Marked inﬁltration of leukaemic cells was seen in the bone marrow, peripheral blood and liver of Mll–AF9 mice. Figure 3 shows a comparison of the histology of tissues",
    "jurnal": "003564.pdf"
  },
  {
    "id": 51,
    "paragraph": "from an Mll–myc mouse (Figure 3A) with those from Mll–AF9 mice. The AML was observed in two different forms, overt myeloid leukaemia and extramedullary leuk- aemia. Mice exhibiting overt myeloid leukaemia were distinguished by (cid:249)30% of nucleated cells in the bone",
    "jurnal": "003564.pdf"
  },
  {
    "id": 52,
    "paragraph": "marrow being blasts. Heavy inﬁltration of the peripheral blood with myeloblasts was observed in these mice (either chimeras or heterozygotes). The myeloblasts were charac- terized by their large, granular appearance and were frequently observed in the liver (Figure 3B shows histology",
    "jurnal": "003564.pdf"
  },
  {
    "id": 53,
    "paragraph": "from a heterozygous mouse and Figure 3C shows histology from a chimeric mouse, both with AML). Other tissues were also involved at this stage, for instance kidney. The alternative form of myeloid disease was extramedullary leukaemia (Figure 3D), in which extensive extramedullary",
    "jurnal": "003564.pdf"
  },
  {
    "id": 54,
    "paragraph": "inﬁltration of myeloblasts was found in the liver, with peri-vascular deposits of malignant cells. In the example shown (histology from a chimeric mouse), the bone marrow shows signiﬁcantly (cid:44)30% inﬁltration with myelo- blasts. Similarly, few abnormal cells were observed in the peripheral blood in the extramedullary stage of the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 55,
    "paragraph": "malignancy. Detailed analysis of tissue histology in the Mll–AF9 mice (one example is shown in Figure 3E) indicated that two ALLs arose. In these mice the bone marrow samples were hypercellular, with normal haematopoiesis sup- pressed, and (cid:46)90% of the mononuclear cells were lympho-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 56,
    "paragraph": "blasts with many active mitoses seen. An enlarged thymus was evident in these mice in addition to a pale femur, enlarged, pale spleen and pale kidneys. Extra-medullary haematopoiesis was evident in the liver which showed the characteristic peri-vascular accumulation of leukaemic",
    "jurnal": "003564.pdf"
  },
  {
    "id": 57,
    "paragraph": "cells. The circulating blood of the mouse shown is packed with lymphoblasts. In addition, the peripheral blood ﬁlm indicates that this mouse was also suffering from anaemia. Immunoglobulin gene rearrangement analysis showed that both of the ALLs were of B cell origin. Filter",
    "jurnal": "003564.pdf"
  },
  {
    "id": 58,
    "paragraph": "hybridization was carried out with an immunoglobulin heavy chain probe and spleen cell DNA of the two ALL- bearing mice compared with a myeloma cell line (J558) and a T cell line (BW) and kidney DNA from C57Bl/6 and 129 mice (Figure 4A). The probe detects a 6.5 kb",
    "jurnal": "003564.pdf"
  },
  {
    "id": 59,
    "paragraph": "EcoRI germ-line band in the kidney DNA samples and the BW (T cell) DNA, but detects two rearranged bands in the myeloma (B cell) DNA representing heavy-chain gene rearrangements. DNA from both of the Mll–AF9 tumours similarly had two distinct rearranged bands",
    "jurnal": "003564.pdf"
  },
  {
    "id": 60,
    "paragraph": "together with faint germ-line bands, indicative of clonal B cell tumours in these mice. Rearrangement of T cell receptor b -chain genes was also investigated with Jb 2 and Cb 1 probes, but no rearrangements were found in the tumour DNA from either ALL mouse (data not shown).",
    "jurnal": "003564.pdf"
  },
  {
    "id": 61,
    "paragraph": "FACS analysis of bone marrow cells from mouse 1 Mll–AF9 fusion causes myeloproliferation Fig. 3. Histology of leukaemias arising in Mll–AF9 mice. Histology was carried out on tissues from all mice with symptoms of disease. Tissues were dissected and ﬁxed in 10% formalin. Sections were prepared from wax-embedded specimens and stained with haematoxylin and eosin (H&E).",
    "jurnal": "003564.pdf"
  },
  {
    "id": 62,
    "paragraph": "Blood ﬁlms were stained with May–Gru¨nwald–Giemsa (MGG). Representative examples of histology are shown. (A) Mll–myc mouse 2021 (age 24 months): this mouse had no symptoms of disease and serves as a control. (B) Mll–AF9 heterozygous mouse 4134 (age 6 months) with overt",
    "jurnal": "003564.pdf"
  },
  {
    "id": 63,
    "paragraph": "AML. In this example, the bone marrow is extensively inﬁltrated with myeloblasts and the liver has signiﬁcant deposits. The peripheral blood has many circulating myeloblasts. (C) Mll–AF9 chimera 4039 (age 7 months) with overt AML similar to heterozygous mouse 4134. (D) Mll–AF9",
    "jurnal": "003564.pdf"
  },
  {
    "id": 64,
    "paragraph": "chimera 4019 (age 12 months) showing signs of extramedullary leukaemia with myeloblast deposits in the liver but normal bone marrow pattern. (E) Mll–AF9 chimera 4005 (age 12 months). This mouse has ALL, with lymphoblasts in the bone marrow and peripheral blood. The liver has",
    "jurnal": "003564.pdf"
  },
  {
    "id": 65,
    "paragraph": "signiﬁcant lymphoblast inﬁltration. 3567 C.L.Dobson et al. Fig. 4. Mll–AF9 mice develop ALL at low frequency. Two Mll–AF9 chimeric mice showed acute leukaemia (ages 11 and 12 months) with cells morphologically identiﬁed as lymphoblasts (see Figure 3E); mouse 1: number 4005, mouse 2: 4020. Bone marrow cells were",
    "jurnal": "003564.pdf"
  },
  {
    "id": 66,
    "paragraph": "examined by gene rearrangement using ﬁlter hybridization (A) and lymphoid surface marker expression (B) to specify the lineage. (A) Filter hybridization. DNA was extracted from the spleen of Mll–AF9 mice, of J558 (myeloma) or BW (T) cells and of C57Bl/6 or",
    "jurnal": "003564.pdf"
  },
  {
    "id": 67,
    "paragraph": "129 kidney. DNA was digested with HindIII, separated by gel electrophoresis and transferred to nylon membranes. The membranes were hybridized with a radiolabelled immunoglobulin enhancer probe (Neuberger and Williams, 1986) and the washed ﬁlters autoradio- graphed at –70°C with pre-fogged ﬁlm. (B) FACS analysis of Mll–",
    "jurnal": "003564.pdf"
  },
  {
    "id": 68,
    "paragraph": "AF9 mouse 4005 (mouse 1): bone marrow cells were prepared as single cell suspensions from mouse 4005 or an age-matched wild-type mouse and were stained with ﬂuorescent antibodies recognizing the T cell marker CD4, the B cell marker B220 and the myeloid marker",
    "jurnal": "003564.pdf"
  },
  {
    "id": 69,
    "paragraph": "Gr-1. Graphs represent cell number (y-axis) versus ﬂuorescence intensity (x-axis). Similar data were obtained with Mll–AF9 mouse 4020 (mouse 2). No evidence of mixed lineage phenotype was found for either of the ALL tumour-bearing Mll–AF9 mice. conﬁrmed that the tumour was comprised of predominantly",
    "jurnal": "003564.pdf"
  },
  {
    "id": 70,
    "paragraph": "B220 antigen-expressing B lymphocytes, which are usually found in low numbers in the bone marrow. In contrast, the normal constituents of the bone marrow (Figure 4B) such as Gr-1- or CD4-positive cells are depleted compared with wild-type mouse controls. A similar pattern of surface",
    "jurnal": "003564.pdf"
  },
  {
    "id": 71,
    "paragraph": "marker expression was observed with bone marrow for ALL mouse 2 (data not shown). No evidence of mixed lineage tumours was obtained. Glucose phosphate iso- merase (GPI) analysis (Papaioannou and Johnson, 1993) was performed on spleen samples from the two mice with",
    "jurnal": "003564.pdf"
  },
  {
    "id": 72,
    "paragraph": "ALL to estimate the contribution originating from the 3568 CCB-derived ES cells, injected into the C57Bl/6 blasto- cysts. Both mice had signiﬁcant CCB ES cell contribution in the spleen (data not shown) suggesting that the lympho- blastic tumours are of ES cell origin.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 73,
    "paragraph": "Myeloproliferation is observed in Mll–AF9 mice prior to leukaemia occurrence The normal function of Mll appears to be related to the embryonic developmental plan by affecting Hox gene expression proﬁles (Yu et al., 1995) and it may also have a speciﬁc role in some aspects of haematopoiesis (Fidanza",
    "jurnal": "003564.pdf"
  },
  {
    "id": 74,
    "paragraph": "et al., 1996; Hess et al., 1997). One of several possible roles for the tumour-speciﬁc MLL–AF9 fusion protein is an inﬂuence on the molecular interactions which are important for haematopoietic differentiation, which could thus partly explain the predominant association of the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 75,
    "paragraph": "chromosomal translocation t(9;11) with myeloid malig- nancies. A corollary of this is that the lineage from which the majority of tumours arise (i.e. the myeloid lineage) is selectively increased in the heterozygous Mll–AF9 mice. In order to assess this situation, we ﬁrst examined the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 76,
    "paragraph": "surface antigen phenotype of the myeloid tumours. Anti- bodies binding to surface proteins of myeloid cells (Mac-1 and Gr-1), B-lymphocytes (B220) and T lymphocytes (CD3 and CD4) were used to detect antigen expression on spleen and bone marrow cells. On the whole, tumour",
    "jurnal": "003564.pdf"
  },
  {
    "id": 77,
    "paragraph": "cells were found in bone marrow and in spleen, and in mice with AML malignant cells typically expressed Mac-1 and Gr-1 surface markers. Figure 5 shows FACS analysis of the bone marrow and spleen cells from a typical Mll– AF9 heterozygous mouse (mouse number 4299) with",
    "jurnal": "003564.pdf"
  },
  {
    "id": 78,
    "paragraph": "AML. The inﬁltration of Gr-1-positive tumour cells into the spleen population is very marked with the concomitant loss of B220(cid:49) B cells and CD4(cid:49) T cells, compared with splenocytes from a wild-type mouse. In the bone marrow there was also a striking difference between AML-bearing",
    "jurnal": "003564.pdf"
  },
  {
    "id": 79,
    "paragraph": "mice and wild-type mice. In the latter, there are usually ~50% Gr-1(cid:49) cells exhibiting a narrow ﬂuoresence proﬁle corresponding to mature myeloid cells, the ﬂuorescence proﬁle of the Mll–AF9 mouse had a broad appearance consistent with there being mainly immature myeloid cells",
    "jurnal": "003564.pdf"
  },
  {
    "id": 80,
    "paragraph": "(Figure 5). A small population of B220(cid:49) bone marrow cells found in the wild-type mouse was absent from the Mll–AF9 mouse. The examination of the Gr-1(cid:49)/Mac-1(cid:49) population in young heterozygous Mll–AF9 mice was used as a basis for determining whether a pre-leukaemic effect on myeloid",
    "jurnal": "003564.pdf"
  },
  {
    "id": 81,
    "paragraph": "cell differentiation resulted from the presence of the fusion gene. FACS analysis was carried out on young Mll–AF9 mice using Gr-1 and Mac-1 (myeloid markers), Ter119 (erythrocyte marker), B220 (B cell marker), CD4 (T cell marker), Thy 1.2 (T-lymphocytes, monocytes, B-lymphocytes), Sca-1 (multipotent haematopoietic stem",
    "jurnal": "003564.pdf"
  },
  {
    "id": 82,
    "paragraph": "cells, mature myeloid cells), CD44 (leukocytes, erythro- cytes, epithelia) and c-Kit (haematopoietic progenitor cells and mast cells). Only effects on the myeloid markers were detectable. Bone marrow from Mll–AF9 heterozygous mice of either 6 days or 5 weeks of age were analysed",
    "jurnal": "003564.pdf"
  },
  {
    "id": 83,
    "paragraph": "and compared with either wild-type or Mll–myc mice of similar age (Figure 6). While there was a modest increase in Mac-1/Gr-1 double-positive cells in the Mll–AF9 bone marrow compared with the two controls at 6 days of age Mll–AF9 fusion causes myeloproliferation",
    "jurnal": "003564.pdf"
  },
  {
    "id": 84,
    "paragraph": "Fig. 5. Surface phenotype of AMLs in Mll–AF9 mice. Mll–AF9 mice with signs of disease were sacriﬁced and single cell suspensions were made from the spleen and bone marrow. Cells were stained with ﬂuorescent antibodies recognizing the myeloid marker, Gr-1, the T cell markers, CD3 and",
    "jurnal": "003564.pdf"
  },
  {
    "id": 85,
    "paragraph": "CD4, and the B cell marker, B220. Twelve out of 24 Mll–AF9 chimeras and 15 out of 28 Mll–AF9 heterozygotes were analysed. In the representative example shown, the Mll–AF9 heterozygous mouse 4299 developed AML (age 4 months) and FACS analysis was performed and",
    "jurnal": "003564.pdf"
  },
  {
    "id": 86,
    "paragraph": "compared with a wild-type mouse of comparable age. Graphs represent cell number (y-axis) versus ﬂuorescence intensity (x-axis). (35% compared with 21 and 15% for wild-type and Mll– myc mice, respectively), a much larger population (~85%) was observed in the Mll–AF9 mice at 5 weeks compared",
    "jurnal": "003564.pdf"
  },
  {
    "id": 87,
    "paragraph": "with either the wild-type (48%) or the Mll–myc (54%) mice. The Gr-1(cid:49) cells in the Mll–AF9 heterozygotes seem to represent a true increase in myeloid lineage cells, rather than overtly leukaemic cells. This is indicated by the narrow ﬂuorescence proﬁle which is similar to those of",
    "jurnal": "003564.pdf"
  },
  {
    "id": 88,
    "paragraph": "the control mice (wild type or Mll–myc; Figure 6), as compared with the broad proﬁle found with AML bone marrow. These data indicate that an early proliferation of cells in the myeloid lineage, driven by the Mll–AF9 fusion protein, occurs prior to the development of malignancy.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 89,
    "paragraph": "The increase in proportion of Mac-1/Gr-1 double-positive cells in Mll–AF9 heterozygous mice at 6 days of age compared with wild-type or heterozygous Mll–myc mice was veriﬁed using cells obtained from 6 day pups from litters obtained by mating heterozygous Mll–myc or",
    "jurnal": "003564.pdf"
  },
  {
    "id": 90,
    "paragraph": "heterozygous Mll–AF9 mice. The bone marrow cells were analysed by FACS and the percentage of Mac-1/Gr-1 double-positive cells determined (Figure 7A). In these litters, there were four Mll–AF9 heterozygous mice, three of which had high Mac-1/Gr-1 double-positive cell counts compared with the (cid:49)/– Mll–myc or (cid:49)/(cid:49) litter mates. Thus,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 91,
    "paragraph": "a high Mac-1/Gr-1 double-positive count is predictive of Mll–AF9 heterozygosity soon after birth. As the number of Mac-1/Gr-1 bone marrow cells naturally increases as mice mature, we examined groups of littermates at between 5 and 12 weeks of age in which environmental disturbances",
    "jurnal": "003564.pdf"
  },
  {
    "id": 92,
    "paragraph": "should be less signiﬁcant. In this analysis, we examined bone marrow cells from seven Mll–AF9 (cid:49)/– mice, eight wild-type (cid:49)/(cid:49) mice (Figure 7B) and 14 Mll–myc (cid:49)/– mice (Figure 7C). Of the seven Mll–AF9 heterozygous mice analysed, the proportion of Mac-1/Gr-1 double-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 93,
    "paragraph": "positive cells in the bone marrow ranged from 71–93%, with an average of 82%. These ﬁgures are consistently higher than those we observed for wild-type mice (Figure 7B), in which the average number of Mac-1/Gr-1 double- positive cells is 52%; one mouse had 77% double-positive",
    "jurnal": "003564.pdf"
  },
  {
    "id": 94,
    "paragraph": "bone marrow cells but this was exceptional. Furthermore, the 14 Mll–myc heterozygous mice had an average of 50% Mac-1/Gr-1 bone marrow cells, ranging from 43– 60%. The standard errors from these cohorts of mice were calculated at 3, 4 and 1.2% for Mll–AF9, (cid:49)/(cid:49) wild-type",
    "jurnal": "003564.pdf"
  },
  {
    "id": 95,
    "paragraph": "and Mll–myc mice, respectively, indicating a signiﬁcant proliferative advantage for the myeloid cell compartment in the bone marrow of the Mll–AF9 mice. Only the 3569 C.L.Dobson et al. Fig. 6. Young Mll–AF9 mice exhibit increased myeloproliferation. Mll–AF9 heterozygous mice were analysed at 6 days or 5 weeks of age to",
    "jurnal": "003564.pdf"
  },
  {
    "id": 96,
    "paragraph": "determine the status of haematopoietic differentiation, prior to the development of overt leukaemia. Mice were selected from litters of Mll–AF9, Mll–myc and wild-type mice at 6 days or 5 weeks of age and single cell suspensions were made from the bone marrow. Cells were stained with an",
    "jurnal": "003564.pdf"
  },
  {
    "id": 97,
    "paragraph": "anti-Mac-1 antibody coupled with phycoerythrin (PE) together with an anti-Gr-1 antibody coupled with ﬂuorescein isothiocyanate (FITC) to detect the myeloid population of cells. (A) Populations of bone marrow cells expressing both Mac-1 and Gr-1 markers are depicted. Percentage values are shown for the upper right-hand quadrant of Gr-1/Mac-1 double-positive cells. (B) Fluorescence proﬁles of the same bone marrow cell populations",
    "jurnal": "003564.pdf"
  },
  {
    "id": 98,
    "paragraph": "for anti-Gr-1 antibody binding. The peaks of ﬂuorescence intensity for wild-type and Mll–AF9 mouse bone marrow cells are similar indicating these are not transformed myeloid cells (compared with the AML bone marrow shown in Figure 5) at the stage of analysis, but rather there is an increase",
    "jurnal": "003564.pdf"
  },
  {
    "id": 99,
    "paragraph": "in myeloid cell compartment size. presence of the Mll–AF9 gene fusion was capable of eliciting this change, and not the truncation of the Mll gene by addition of the myc epitope. Thus, one function of the Mll–AF9 fusion gene appears to be to confer a",
    "jurnal": "003564.pdf"
  },
  {
    "id": 100,
    "paragraph": "proliferative advantage for cells of the myeloid lineage, prior to the onset of AML. 3570 Mll–AF9 fusion causes myeloproliferation Discussion In vivo fusion of Mll and AF9 in mice provides a model for human cancer caused by chromosome 11q23 translocations In vivo models of cancer development occurring after",
    "jurnal": "003564.pdf"
  },
  {
    "id": 101,
    "paragraph": "chromosomal translocations are needed for a compre- hensive understanding of the biological consequences of these aberrant chromosomes and as a means to test possible therapies. The propensity of the MLL gene to form fusion genes after chromosomal translocations is important because (cid:46)15% of all acute leukaemias in man have MLL",
    "jurnal": "003564.pdf"
  },
  {
    "id": 102,
    "paragraph": "gene fusions and because there is an association of particular MLL fusions with particular subtypes of acute leukaemia. For instance, MLL–AF4/FEL fusions are typic- ally found in lymphoblastic tumours, whereas MLL–AF9 fusions are typically found in myeloid tumours (Djabali et al., 1992; Gu et al., 1992; Domer et al., 1993; Iida",
    "jurnal": "003564.pdf"
  },
  {
    "id": 103,
    "paragraph": "et al., 1993; Morrissey et al., 1993; Nakamura et al., 1993). This implies a speciﬁc role for the chimeric protein in determination of the type of leukaemia which develops. Nonetheless, an alternative possibility is based purely on mechanism and accessibility of genes in chromosomes.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 104,
    "paragraph": "Thus the ability of MLL and AF9 or MLL and AF4 genomic regions to take part in an inter-chromosomal translocation may be greater in committed myeloid or lymphoid cells, respectively. The alternative models can be assessed using animal models of disease in which gene",
    "jurnal": "003564.pdf"
  },
  {
    "id": 105,
    "paragraph": "fusion is either controlled by speciﬁc interchromosomal events (Smith et al., 1995; van Deursen et al., 1995) or by knock-in of the fusion gene partner (Thomas and Capecchi, 1987; Corral et al., 1996). We have developed and analysed a model for MLL–AF9-induced leukaemia",
    "jurnal": "003564.pdf"
  },
  {
    "id": 106,
    "paragraph": "using homologous recombination to knock-in the AF9 into the endogenous mouse Mll gene (Corral et al., 1996). In this model system, we ﬁnd that the fusion causes tumours in both chimeric mice and mice heterozygous for the Mll– AF9 fusion gene. The majority of tumours observed in",
    "jurnal": "003564.pdf"
  },
  {
    "id": 107,
    "paragraph": "these mice were myeloid as has been reported in humans translocation t(9;11). Two acute with chromosomal lymphoblastic tumours also arise reﬂecting the relative occurrence of AML:ALL in humans. In the knock-in mice, the ALL cases occurred with a longer latency than the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 108,
    "paragraph": "acute myeloid tumours. The pathological features of the haematopoietic malig- nancies in the Mll–AF9 mice were very similar to those of human MLL–AF9 associated tumours, providing a striking counterpart between the pathology of the murine and human leukaemias associated with the t(9;11). In",
    "jurnal": "003564.pdf"
  },
  {
    "id": 109,
    "paragraph": "man, the most common French-American-British (FAB) subtypes found in this context are AML, M5 (monoblastic/ monocytic), M4 (myelomonocytic), and occasionally M1 or M2 (Bain, 1993). Comparable morphologies were evident in the mice used in the investigation. The pattern of organ inﬁltration described in the mice has close",
    "jurnal": "003564.pdf"
  },
  {
    "id": 110,
    "paragraph": "similarities to the clinical ﬁndings in man. Thus, enlarge- ment of the superﬁcial lymph nodes, liver and spleen is common in human AML, with 90% of cases showing inﬁltration of the liver and spleen at autopsy. Extramedul- lary inﬁltration of leukaemic myeloblasts is most common",
    "jurnal": "003564.pdf"
  },
  {
    "id": 111,
    "paragraph": "in monocytic or myelomonocytic leukaemia. Although usually diffuse, disease may occur as tumorous deposits (granulocytic sarcoma). This may be the initial manifesta- 3571 Fig. 7. Mll–AF9 mice exhibit myeloproliferation prior to development of overt leukaemia. The cell populations of bone marrow, from mice",
    "jurnal": "003564.pdf"
  },
  {
    "id": 112,
    "paragraph": "aged 6 days or between 5 and 12 weeks, were analysed by ﬂow cytometry. Single cell suspensions were made from the bone marrow and cells stained with an anti-Mac-1 antibody coupled with PE together with an anti-Gr-1 antibody coupled with FITC. Data are",
    "jurnal": "003564.pdf"
  },
  {
    "id": 113,
    "paragraph": "expressed as the percentage of double staining cells. Genotypes were determined by ﬁlter hybridization of DNA from tail biopsies. (A) Histogram showing the percentage of Gr-1(cid:49)Mac-1(cid:49) cells in the bone marrow of individual 6 day old mice from one litter of a",
    "jurnal": "003564.pdf"
  },
  {
    "id": 114,
    "paragraph": "heterozygous Mll–myc cross (nine pups) and one litter of Mll–AF9 mated with a wild-type mouse (12 pups). (B) Histogram showing the percentage of Gr-1(cid:49)Mac-1(cid:49) cells in the bone marrow of 5- to 12- week-old wild-type (eight mice) or Mll–AF9 mice (seven mice).",
    "jurnal": "003564.pdf"
  },
  {
    "id": 115,
    "paragraph": "(C) Histogram showing the percentage of Gr-1(cid:49)Mac-1(cid:49) cells in the bone marrow of 5- to 12-week-old Mll–myc mice (14 mice). C.L.Dobson et al. tion of AML, with the appearance of the disease in the bone marrow following later if the patient remains",
    "jurnal": "003564.pdf"
  },
  {
    "id": 116,
    "paragraph": "untreated. Hepatic inﬁltration by leukaemic myeloblasts in the absence of heavy marrow disease was a recurrent feature of the t(9;11) leukaemia in our mice. Since the mice in our experimental group develop a malignancy which mimics the disease occurring in humans with the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 117,
    "paragraph": "translocation t(9;11), they could be used to test therapies which might later be applicable to human cancer management. An early effect of Mll–AF9 on myeloproliferation Various fusion partners can be linked to the MLL gene after the formation of the abnormal chromosomes (reviewed in",
    "jurnal": "003564.pdf"
  },
  {
    "id": 118,
    "paragraph": "Rowley, 1993; Bernard and Berger, 1995; Rubnitz et al., 1996b; Gilliland, 1998). However, it is not clear whether the timing of the translocation is important for determining the type of leukaemia which develops or whether the incoming fusion partner has an important role in determin-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 119,
    "paragraph": "ing the nature of the tumour. We have found that myelo- proliferation occurs prior to the acute myeloid disease that arises in most Mll–AF9 mice. These data therefore suggest that the disease in the majority of animals initiates in a proliferating pool of myeloblasts from which leukaemic",
    "jurnal": "003564.pdf"
  },
  {
    "id": 120,
    "paragraph": "precursors arise as a result of secondary mutations. The surviving Mll–AF9 mice without tumours are presumbaly ones in which secondary mutations have not occurred. Thus, our observations with the Mll–AF9 knock-in mice suggest that the role of the MLL–AF9 fusion is to specify",
    "jurnal": "003564.pdf"
  },
  {
    "id": 121,
    "paragraph": "lineage. However, a number of other factors need to be taken into account. No signﬁcant numbers of tumours arose in Mll–myc mice (Corral et al., 1996) and further study showed that four out of 27 mice developed AML after two years. Similarly, no signiﬁcant numbers of mice",
    "jurnal": "003564.pdf"
  },
  {
    "id": 122,
    "paragraph": "developed tumours when the lacZ gene was fused to exon 3 of Mll (Corral et al., 1996). However, we have recently found that fusion of Mll exon 8 with lacZ results in the occurrence of AML (C.L.Dobson, A.J.Warren, A.Forster, R.Pannell and T.H.Rabbitts, unpublished) but",
    "jurnal": "003564.pdf"
  },
  {
    "id": 123,
    "paragraph": "with a much longer latency than seen with Mll–AF9 fusion mice. This implies that formation of a stable MLL fusion protein per se is sufﬁcient for tumorigenesis and that fusion of Mll with AF9 in mice has an accelerating function due to speciﬁcation of the myeloid lineage cell",
    "jurnal": "003564.pdf"
  },
  {
    "id": 124,
    "paragraph": "population. that the chromosomal A further complicating issue is that a small proportion of the Mll–AF9 mice develop lymphoblastic malignancies, as do humans with the t(9;11) translocation. This would translocation does not suggest usually occur in a committed myeloid progenitor cell but",
    "jurnal": "003564.pdf"
  },
  {
    "id": 125,
    "paragraph": "rather in an early progenitor, which retains the ability to differentiate along lymphoid or myeloid lineages and thus form tumours of either type. The latency of the tumours in Mll–AF9 mice suggests that secondary mutations must be occurring prior to overt leukaemia. The corollary is",
    "jurnal": "003564.pdf"
  },
  {
    "id": 126,
    "paragraph": "that different mutations are likely to accompany lymphoid as opposed to myeloid leukaemia. Furthermore, at least one of these must occur early for a lymphoid tumour to arise, as the myeloproliferation conferred by the MLL– AF9 fusion would presumably commit the majority of cells",
    "jurnal": "003564.pdf"
  },
  {
    "id": 127,
    "paragraph": "beyond the boundary for lymphoid tumour development. These arguments suggest that other major recurring MLL fusions, such as with AF4/FEL or ENL/LTG19 also 3572 function to specify the lineage of the tumours, which explains why there is such a strong association between",
    "jurnal": "003564.pdf"
  },
  {
    "id": 128,
    "paragraph": "these fusions and lymphoblastic tumours (Gu et al., 1992; Domer et al., 1993; Morrissey et al., 1993; Nakamura et al., 1993; Yamamoto et al., 1993; Downing et al., 1994; Rubnitz et al., 1996a). In the case of MLL–ENL fusions, retroviral transduction experiments with mouse bone",
    "jurnal": "003564.pdf"
  },
  {
    "id": 129,
    "paragraph": "marrow cells have clearly shown that a gain-of-function mechanism is operational (Lavau et al., 1997; Slany et al., 1997) and that myeloid differentiation and myeloid transformation are paramount. Therefore, the spectrum of mutations in other genes, which must occur in cells with",
    "jurnal": "003564.pdf"
  },
  {
    "id": 130,
    "paragraph": "chromosomal translocations involving the MLL gene, may well differ in the context of tumour types with the different MLL fusions. The nature of these mutations, the pattern of perturbation of gene expression and the biological consequences of AF4 fusion with MLL are now our major",
    "jurnal": "003564.pdf"
  },
  {
    "id": 131,
    "paragraph": "objectives. Materials and methods Construction of the targeting vectors and analysis of targeted ES cells The plasmid constructs for gene targeting have been described (Corral et al., 1996). Mll–AF9 comprises a knock-in of the AF9 short form (Iida et al., 1993; Nakamura et al., 1993) into exon 8 of the mouse Mll gene",
    "jurnal": "003564.pdf"
  },
  {
    "id": 132,
    "paragraph": "whilst Mll–myc comprises a knock-in of a short epitope tag into the same location in exon 8. CCB ES cells were transfected with the Mll– AF9 targeting vector DNA as described previously (Warren et al., 1994). Homologous recombination was assessed by ﬁlter hybridization of BglII",
    "jurnal": "003564.pdf"
  },
  {
    "id": 133,
    "paragraph": "digested DNA using the EcoRI–XhoI fragment from clone p1.5RXT2 as a probe. The presence of a single insertion site was conﬁrmed with a neomycin probe. Targeted ES cell clones were injected into C57Bl/6 blastocysts, which were transferred into recipient females. Chimeric",
    "jurnal": "003564.pdf"
  },
  {
    "id": 134,
    "paragraph": "mice thereby generated were estimated by coat colour. Heterozygous mice were obtained for both Mll–AF9 and Mll–myc fusion genes by crossing chimeric males with wild-type MF1 females. Mouse pathology Leukaemia development in mice was characterized by indolent habit, hunched gait and rufﬂed hair. On developing sickness, mice were culled",
    "jurnal": "003564.pdf"
  },
  {
    "id": 135,
    "paragraph": "and a post-mortem carried out. Tissues were taken for analysis and were ﬁxed in 10% formalin and embedded in parafﬁn wax. Blocks were sectioned and slides were processed and stained with haematoxylin and eosin (H&E) by routine techniques. Blood ﬁlms were stained with May–",
    "jurnal": "003564.pdf"
  },
  {
    "id": 136,
    "paragraph": "Giemsa–Gru¨nwald (MGG) stain. Slides were photographed using Kodak Tungsten 160 ﬁlm. Glucose phosphate isomerase (GPI) isozyme analysis was performed on spleen samples as described previously (Papaioannou and Johnson, 1993). Immunoglobulin gene rearrangement assays DNA was prepared from various tissues using standard procedures. The",
    "jurnal": "003564.pdf"
  },
  {
    "id": 137,
    "paragraph": "DNA was digested with HindIII, and fractionated on 0.8% agarose gels, transferred to nylon membranes (Southern, 1975) and hybridized with randomly labelled probe (Feinberg and Vogelstein, 1983). An immuno- globulin heavy chain enhancer probe originating from the intron between JH and Cm gene segments (Neuberger and Williams, 1986) was used.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 138,
    "paragraph": "For T cell rearrangement, DNA was digested with EcoRI or HindIII and ﬁlter hybridizations carried out with probes for either Jb 2 or Cb 1 (Malissen et al., 1984). Flow-cytometric analysis of cell surface marker expression Single-cell suspensions were prepared from mouse thymus, spleen and",
    "jurnal": "003564.pdf"
  },
  {
    "id": 139,
    "paragraph": "bone marrow. Cells (100 m l; 5(cid:51)107/ml) were incubated at 4°C for 20 min in phosphate-buffered saline (PBS) with 5% fetal calf serum (FCS) with the following antibodies (PharMingen, San Diego, CA): anti-Gr-1 and anti-Mac-1 (granulocytes), anti-B220 (B cells), anti-CD3 and anti-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 140,
    "paragraph": "CD4 (T cells), anti-Ter119 (erythrocytes), anti-c-Kit (haematopoietic progenitor cells), anti-Thy 1.2 (T lymphocytes, monocytes, B lympho- cytes), anti-CD44 (leukocytes, erythrocytes, epithelia) and anti-Sca-1 (multipotent haematopoietic stem cells). Antibodies were conjugated with either ﬂuorescein isothiocyanate (FITC), or phycoerythrin (PE). Isotype-matched ﬂuoresceinated antibodies were used as controls for",
    "jurnal": "003564.pdf"
  },
  {
    "id": 141,
    "paragraph": "non-speciﬁc immunoﬂuorescence. After antibody labelling, cells were washed once with PBS containing 5% FCS and resuspended in 1 ml of PBS/5% FCS. Flow cytometric analysis was performed using a FACSCALIBUR (Becton Dickinson, San Jose, CA). Data analysis was performed with Cell Quest (Becton Dickinson). Each phenotype analysis",
    "jurnal": "003564.pdf"
  },
  {
    "id": 142,
    "paragraph": "was generated by analysis of 10 000 cells. Acknowledgements This work was supported by the MRC and partly by a grant from the Kay Kendall Leukaemia Research Fund. A.J.W. is the recipient of an MRC Clinician Scientist Fellowship held within the University of",
    "jurnal": "003564.pdf"
  },
  {
    "id": 143,
    "paragraph": "Genomics, 37, 1–8. Atlas,M., Head,D., Behm,F., Schmidt,E., Zeleznik-Le,N.J., Roe,B.A., Burian,D. and Domer,P.H. (1998) Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia, 12, 1895–1902. Bain,B.J. (1993). Leukaemia Diagnosis: A Guide To The FAB Classiﬁcation. Wolfe Publishing, London, UK. Bartram,C.R. et al. (1983) Translocation of c-abl oncogene correlates",
    "jurnal": "003564.pdf"
  },
  {
    "id": 144,
    "paragraph": "with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 306, 277–280. Bernard,O. and Berger,R. 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromo. Cancer, 13, 75–85. (1995) Molecular basis of Chen,C.-S., Hilden,J.M., Frestedt,J., Domer,P.H., Moore,R., Korsmeyer, S.J. and Kersey,J.H. (1993) The chromosome 4q21 gene (AF-4/FEL)",
    "jurnal": "003564.pdf"
  },
  {
    "id": 145,
    "paragraph": "is widely expressed in normal tissues and shows breakpoint diversity in t(4;11)(q21;q23) acute leukemia. Blood, 4, 1080–1085. Cimino,C. et al. (1997) Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res., 57, 2879–2883.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 146,
    "paragraph": "Corral,J. et al. (1993) Acute leukaemias of different lineages have similar MLL1 gene fusions encoding related chimeric proteins resulting from chromosomal translocations. Proc. Natl Acad. Sci. USA, 90, 8538–8542. Corral,J. et al. (1996) An Mll-Af9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to",
    "jurnal": "003564.pdf"
  },
  {
    "id": 147,
    "paragraph": "create fusion oncogenes. Cell, 85, 853–861. Crozat,A., Aman,P., Mandahl,N. and Ron,D. (1993) Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature, 363, 640–644. de Klein,A. et al. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 148,
    "paragraph": "300, 765–767. de Klein,A. et al. (1986) bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukaemia. Blood, 68, 1369–1375. Delattre,O. et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 359,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 149,
    "paragraph": "162–165. Djabali,M., Selleri,L., Parry,P., Bower,M., Young,B.D. and Evans,G.A. (1992) A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nature Genet., 2, 113–118. Domer,P.H., Fakharzadeh,S.S., Chen,C.S., Johansen,L., Silverman,G.A., Kersey,J.H. and Korsmeyer,S.J. (1993) Acute mixed- lineage t(4;11)(q21;q23) generates an MLL–AF4 fusion product. Proc.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 150,
    "paragraph": "Natl Acad. Sci. USA, 90, 7884–7888. Jockel,J., Downing,J.R. et al. (1994) The der (11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. Blood, 83, 330–335. Feinberg,A.P. and Vogelstein,B.A. (1983) A technique for radiolabelling DNA restriction endonuclease fragments to high speciﬁc activity.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 151,
    "paragraph": "Anal. Biochem., 132, 6–13. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase- targeted drugs. Biochim. Biophys. Acta, 1400, 233–255. Fidanza,V., Melotti,P., Yano,T., Nakamura,T., Bradley,A., Canaani,E., Mll–AF9 fusion causes myeloproliferation Calabretta,B. and Croce,C.M. (1996) Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro. Cancer Res., 56,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 152,
    "paragraph": "1179–1183. Gilliland,D.G. (1998) Molecular genetics of human leukemia. Leukemia, 12, S7–S12. Groffen,J., Stephenson,J.R., Heisterkamp,N., de Klein,A., Bartram,C.R. and Grosveld,G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromsome 22. Cell, 36, 93–99. Gu,Y., Nakamura,T., Alder,H., Prasad,R., Canaani,O., Cimino,G.,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 153,
    "paragraph": "Croce,C.M. chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell, 71, 701–708. and Canaani,E. (1992) The t(4;11) Hess,J.L., Yu,B.D., Li,B., Hanson,R. and Korsmeyer,S.J. (1997) Defects in yolk sac hematopoiesis in Mll-Null embryos. Blood, 90, 1799–1806.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 154,
    "paragraph": "Ichikawa,H., Shimizu,K., Hayashi,Y. and Ohki,M. (1994) An RNA- binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res., 54, 2865–2868. Iida,S. et al. (1993) MLLT3 gene on 9p22 in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 155,
    "paragraph": "Oncogene, 8, 3085–3092. Lavau,C., Szilvassy,S.J., Slany,R. and Cleary,M.L. (1997) Immortaliz- ation and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J., 16, 4226–4237. Look,A.T. (1997) Oncogenic transcription factors in the human acute leukemias. Science, 278, 1059–1065. Malissen,M. et al. (1984) Mouse T cell antigen receptor: structure and",
    "jurnal": "003564.pdf"
  },
  {
    "id": 156,
    "paragraph": "organization of constant and joining gene segments encoding the b polypeptide. Cell, 37, 1101–1110. Mazo,A.M., Huang,D.-H., Mozer,B.A. and Dawid,I.B. (1990) The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-ﬁnger domains. Proc. Natl Acad. Sci. USA, 87, 2112–2116.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 157,
    "paragraph": "McCabe,N.R. et al. (1992) Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations. Proc. Natl Acad. Sci. USA, 89, 11794–11798. Morrissey,J., Tkachuk,D.C., Milatovitch,A., Francke,U., Link,M. and Cleary,M.L. (1993) A serine/proline-rich protein is fused to HRX in",
    "jurnal": "003564.pdf"
  },
  {
    "id": 158,
    "paragraph": "t(4;11) acute leukemias. Blood, 81, 1124–1131. Nakamura,T. et al. (1993) Genes on chromosome 4, 9 and 19 involved in 11q23 abnormalities in acute leukemia share homology and/or common motifs. Proc. Natl Acad. Sci. USA, 90, 4631–4635. Nasr,F., Macintyre,E., Venuat,A.M., Bayle,C., Carde,P. and Ribrag,V.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 159,
    "paragraph": "(1997) Translocation t(4;11)(q21;q23) and MLL gene rearrangement in acute lymphoblastic leukemia secondary to anti topoisomerase II anticancer agents. Leuk. Lymph., 25, 399–401. Neuberger,M.S. and Williams,G.T. (1986) Construction of novel antibodies by use of DNA transfection: design of plasmid vectors. Phil. Trans. R. Soc. Lond., 317, 425–432.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 160,
    "paragraph": "Nowell,P.C. and Hungerford,D.A. (1960) A minute chromosome in human granulocytic leukemia. Science, 132, 1497–1500. Panagopoulos,I., Aman,P., Fioretos,T., Hoglund,M., Johannson,B., Mandahl,N., Heim,S., Behrendtz,M. and Mitelman,F. (1994) Fusion of the FUS gene in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromo. Cancer, 11, 256–262.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 161,
    "paragraph": "Panagopoulos,I., Hoglund,M., Mertens,F., Mandhal,N., Mitelman,F. and Aman,P. (1996) Fusion of the EWS and CHOP gene in myxoid liposarcoma. Oncogene, 12, 489–494. Papaioannou,V. and Johnson,R. (1993). Production of chimeras and genetically deﬁned offspring from targeted ES cells. In Joyner,A.C. (ed.), Gene Targeting: A Practical Approach. Oxford University Press,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 162,
    "paragraph": "Oxford, UK, pp. 107–146. Pui,C.-H. et al. (1989) Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med., 321, 136–142. translocations in human cancer. Rabbitts,T.H. (1994) Chromosomal Nature, 372, 143–149. Rabbitts,T.H., Forster,A., Larson,R. and Nathan,P. (1993) Fusion of the",
    "jurnal": "003564.pdf"
  },
  {
    "id": 163,
    "paragraph": "dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nature Genet., 4, 175–180. Ratain,M.J. et al. (1987) Acute non-lymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non- small cell carcinoma of the lung. Blood, 70, 1412–1417.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 164,
    "paragraph": "3573 C.L.Dobson et al. Rowley,J.D. (1973) A new consistent chromosomal abnormality in chronic myelogeneous leukemia identiﬁed by quinaurine ﬂuorescence and giemsa staining. Nature, 243, 290–293. Rowley,J.D. (1993) Rearrangements involving chromosome 11Q23 in acute leukaemia. Semin. Cancer Biol., 4, 387–385. Rowley,J.D. et al. (1997) All patients with the t(11;16)(q23;p13.3) that",
    "jurnal": "003564.pdf"
  },
  {
    "id": 165,
    "paragraph": "involves MLL and CBP have treatment-related hematologic disorders. Blood, 90, 535–541. Rubnitz,J.E., Behm,F.G., Curcio-Brint,A.M., Pinheiro,V.R.P., Carroll, (1996a) t(11;19) breakpoints in childhood acute A.J., Raimondi,S.C., Shurtleff,S.A. Molecular analysis of leukemias. Blood, 87, 4804–4808. and Downing,J.R. Rubnitz,J.E., Behm,F.G. and Downing,J.R. (1996b) 11q23 rearrange-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 166,
    "paragraph": "ments in acute leukemia. Leukemia, 10, 74–82. Slany,R.K., Lavau,C. and Cleary,M.L. (1997) The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol. Cell. Biol., 18, 122–129. Smith,A.J.H., De Sousa,M.A., Kwabi-Addo,B., Heppell-Parton,A.,",
    "jurnal": "003564.pdf"
  },
  {
    "id": 167,
    "paragraph": "(1995) A site-directed chromosomal stem cells by Cre-loxP Impey,H. and Rabbitts,P.H. translocation induced in embryonic recombination. Nature Genet., 9, 376–384. Sobulo,O.M. et al. fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl Acad. Sci. USA, 94, 8732–8737.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 168,
    "paragraph": "(1997) MLL is Southern,E.M. (1975) Detection of Speciﬁc Sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol., 98, 503–517. Thirman,M.J. et al. (1993) Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med., 329, 909–914.",
    "jurnal": "003564.pdf"
  },
  {
    "id": 169,
    "paragraph": "Thomas,K.R. and Capecchi,M.R. (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell, 51, 503–512. Tkachuk,D.C., Kohler,S. and Cleary,M.L. (1992) Involvement of a chromosomal homolog 11q23 translocations in acute leukemias. Cell, 71, 691–700. of Drosophila Trithorax by van Deursen,J., Fornerod,M., van Rees,B. and Grosveld,G. (1995) Cre-",
    "jurnal": "003564.pdf"
  },
  {
    "id": 170,
    "paragraph": "mediated site-speciﬁc translocation between nonhomologous mouse chromosomes. Proc. Natl Acad. Sci. USA, 92, 7376–7380. Warren,A.J., Colledge,W.H., Carlton,M.B.L., Evans,M.J., Smith,A.J.H. and Rabbitts,T.H. (1994) The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell, 78, 45–58. Yamamoto,K. et al. (1993) Two distinct portions of LTG19/ENL at",
    "jurnal": "003564.pdf"
  },
  {
    "id": 171,
    "paragraph": "19p13 are involved in t(11;19) leukaemia. Oncogene, 8, 2617–2625. Yu,B.D., Hess,J.L., Horning,S.E., Brown,G.A.J. and Korsmeyer,S.J. (1995) Altered Hox expression and segmental identity in Mll-mutant mice. Nature, 378, 505–508. Ziemin-van der Poel,S. et al. (1991) Identiﬁcation of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human",
    "jurnal": "003564.pdf"
  },
  {
    "id": 172,
    "paragraph": "leukemias. Proc. Natl Acad. Sci. USA, 88, 10735–10739. Received March 24, 1999; revised and accepted April 27, 1999 3574",
    "jurnal": "003564.pdf"
  },
  {
    "id": 173,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 R E S E A R C H A R T I C L E Open Access Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus Veronique Voisin1,2, Philippe Legault1, Diana Paulina Salazar Ospina1, Yaacov Ben-David2, Eric Rassart1*",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 174,
    "paragraph": "Abstract Background: Acute erythro- and megakaryoblastic leukaemias are associated with very poor prognoses and the mechanism of blastic transformation is insufficiently elucidated. The murine Graffi leukaemia retrovirus induces erythro- and megakaryoblastic leukaemias when inoculated into NFS mice and represents a good model to study",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 175,
    "paragraph": "these leukaemias. Methods: To expand our understanding of genes specific to these leukaemias, we compared gene expression profiles, measured by microarray and RT-PCR, of all leukaemia types induced by this virus. Results: The transcriptome level changes, present between the different leukaemias, led to the identification of",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 176,
    "paragraph": "specific cancerous signatures. We reported numerous genes that may be potential oncogenes, may have a function related to erythropoiesis or megakaryopoiesis or have a poorly elucidated physiological role. The expression pattern of these genes has been further tested by RT-PCR in different samples, in a Friend",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 177,
    "paragraph": "erythroleukaemic model and in human leukaemic cell lines. We also screened the megakaryoblastic leukaemias for viral integrations and identified genes targeted by these integrations and potentially implicated in the onset of the disease. Conclusions: Taken as a whole, the data obtained from this global gene profiling experiment have provided a",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 178,
    "paragraph": "detailed characterization of Graffi virus induced erythro- and megakaryoblastic leukaemias with many genes reported specific to the transcriptome of these leukaemias for the first time. Background Human acute megakaryoblastic (FAB-AML7, [1]) and erythroleukaemias (FAB-AML6, [2]) are regarded as relatively rare entities of acute myeloid leukaemia but",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 179,
    "paragraph": "are associated with a very poor prognosis [3-7]. The poor outcome linked to these 2 types of leukaemias stems from a combination of failure to achieve complete remission, a high relapse rate and therapy-related toxi- city, highlighting the need for more powerful therapies.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 180,
    "paragraph": "Furthermore, AML6 or AML7 diagnosis represents a greater challenge than other types of acute myeloid leu- kaemia (AML) and additional markers are needed [8]. Furthermore, the blasts of patients with AML6 and AML7 share common markers [9] indicating that they * Correspondence: rassart.eric@uqam.ca",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 181,
    "paragraph": "1Laboratoire de Biologie Moléculaire, Département des Sciences Biologiques, Centre BioMed, Université du Québec à Montréal, Case Postale 8888 Succursale Centre-ville, Montréal, QC, H3C-3P8, Canada originate from closely related haematopoietic lineages derived from a common bipotent progenitor [10,11]. We have recently shown that the murine retrovirus",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 182,
    "paragraph": "Graffi is able to induce a broad spectrum of leukaemias when inoculated into newborn mice. The leukaemias developed by these mice are of lymphoid (T-cell and B-cell) and non lymphoid (myeloid, erythroid and mega- karyoblastic) origins. The incidence of erythro- and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 183,
    "paragraph": "megakaryoblastic leukaemias is particularly high in NFS or FVB/n mice inoculated with the GV-1.4 variant of the Graffi virus [12]. The activation of the targeted proto-oncogene or the repression of tumor suppressor genes represents early events in the development of the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 184,
    "paragraph": "murine leukaemia retrovirus (MuLV) induced leukae- mia. It is then followed by a deregulation of numerous additional genes resulting in a cell, blocked at a very immature stage, which aggressively divides and escapes apoptosis. To analyze these cancerous signatures, we © 2010 Voisin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 185,
    "paragraph": "Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 2 of 17 compared the gene profiles of each type of leukaemia",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 186,
    "paragraph": "(T-cell, B-cell, myeloid, erythroid, megakaryoblastic) induced by the Graffi virus. These analyses highlight many genes that may be potential oncogenes and may have a function related to erythropoiesis or megakaryo- poiesis. The results support the importance of the known transcription factors Gata1, Fog1, Fli1, Scl and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 187,
    "paragraph": "Lmo2 in both erythro- and megakaryoblastic leukaemias and the role of Runx1, Pbx1, Meis, Evi1 and Evi3 in the megakaryoblastic leukaemias. Moreover, numerous genes are being reported for the first time and some of these genes are candidate oncogenes: Fgf3, Nmyc, Fap,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 188,
    "paragraph": "Myct1, Gucy1a3, Gulp1 and Fkbp9 specific to megakar- yoblastic leukaemias and Ssx2ip, Rab11a, Ncoa3, Snca, Ltbp2, Rabgef1 and Btbd14a specific to erythroleukae- mias. A screening for viral integrations was performed in mouse tumors. Several genes, amongst which Kit, Gata2, Irf8 and Itga1, were identified as potentially",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 189,
    "paragraph": "implicated in the onset development of the megakaryo- blastic leukaemias. Methods Virus production and mice GV-1.4 viral stock was made as previously described [12]. GV-1.4 viral particles (0.1 ml at a titer of 1.106 PFU/ml) were injected into 1 day newborn NFS mice. The mice",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 190,
    "paragraph": "were checked routinely for clinical signs of disease and moribund mice were sacrificed. Twenty-four diseased mice and 36 control mice were used for the microarray and RT-PCR experiments. Bone marrow cell suspension was prepared by flushing the femurs with IMDM 2% foe-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 191,
    "paragraph": "tal bovine serum (FBS) and spleen cell suspension was prepared by mincing the spleen with scissors and aspirat- ing the pieces up and down through a 1cc syringe in IMDM 2% FBS. The spleen and bone marrow cell sus- pensions were filtered through 70 μm cell strainers (Bec-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 192,
    "paragraph": "ton Dickson, Mississauga, Canada). All the experimental procedures are conformed to the Helsinki Declaration and were approved by the Animal Care and Use Com- mittees of Université du Québec à Montréal. Flow cytometry analyses and cell sorting The flow cytometry staining procedure was performed as",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 193,
    "paragraph": "previously described [12]. The antibodies used were as follows: CD4, CD8a, CD3, CD90, CD19, B220, CD11b, Gr1, CD71, Ter119, CD41, Kit and Sca1 (BD Pharmin- gen, Mississauga, Canada). The leukaemic populations were isolated from the haematopoietic organs by positive selection using magnetic beads with the EasySep Kit",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 194,
    "paragraph": "(StemCell Technologies, Vancouver, Canada) according to the manufacturer’s protocol. The rates of purity and viability of the sorted cells were fixed to be equal to or greater than 95%. Leukaemic T-cells were sorted from the thymus of leukaemic NFS mice, B-cell from the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 195,
    "paragraph": "enlarged lymph nodes and erythro- and megakaryoblastic leukaemic cells were sorted from the infiltrated spleen. Control cells were sorted from the haematopoietic organs of 12 pooled non-infected NFS mice: T-cells were obtained from the thymus, B-cells from the spleen, and erythroblasts from the bone marrow.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 196,
    "paragraph": "RNA extraction and microarray processing Total RNA was extracted from the sorted cell popula- tions with Trizol reagent (Invitrogen, Burlington, Canada) followed by column purification using the Qia- gen RNeasy Kit (QIAGEN, Mississauga, Canada) and processed for hybridization to Affymetrix GeneChip®",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 197,
    "paragraph": "Mouse Genome 430 2.0 arrays (Genome Quebec Inno- vation Centre, Montreal, Canada). Data analysis Data Set Normalization: Affymetrix MicroArray Suite version 5.0 was used to scan and quantify the arrays. Normalization of gene expression data were performed using the Bioconductor implementation of RMA",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 198,
    "paragraph": "(Robust Multi Array, B. Bolstad, University of California, Berkeley) available from the Flexarray software (1.2, R 2.7.2, [13]). Unsupervised learning: Hierarchical clustering (com- plete linkage clustering, correlation uncentered, [14]) and Self-Organization Maps (SOM, parameters G 1-5, A 1-10, [15]) were constructed using GeneCluster software",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 199,
    "paragraph": "(M. Eisen). 3,000 transcripts were selected to be included in the analyses based on the differential expres- sion from the mean. The deviation from the mean was calculated from the RMA values of the 45,000 probesets and the data were ranked in decreasing order to extract",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 200,
    "paragraph": "the first 3,000 genes. Only deviations equal or above 0.585 (1.5 fold change) and equal or below -0.585 (-1.5 fold change) were considered as significant. Supervised learning: Significance Analysis of microar- rays (SAM, [16]). SAM analyses were performed using Flexarray software using the normalized data of the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 201,
    "paragraph": "45,000 probesets. Data with p-values equal or below 0.01 and False Discover Rates (Benjamini Hochberg) equal or below 0.20 were included in further analyses. The data were ranked in decreasing order of the SAM d-score to obtain the list of the differentially expressed genes.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 202,
    "paragraph": "The NetAffx website (Affymetrix, Santa Clara, CA, USA) was used to retrieve gene ontology (GO) annota- tions, probe sequences, and was utilized as a link to Unigene (NCBI) for further functional studies. The microarray dataset was deposited at Gene Expres- sion Omnibus under accession number [GSE12581].",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 203,
    "paragraph": "Cell line and differentiation assay The murine erythroleukaemic cell line HB22.2 was obtained from murine erythroblasts infected with Friend Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 3 of 17 Murine Leukaemia Virus (F-MuLV) [17]. This cell line was maintained in alpha minimum essential medium",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 204,
    "paragraph": "(a-MEM) supplemented with 10% (FBS) (Invitrogen, Frederick, MD) plus a penicillin/streptomycin cocktail. To induce differentiation, HB22.2 cells were incubated in the presence of hemin (Sigma-aldrich H5533) at a concentration of 100 μM. The cells were harvested 24 hours and 72 hours after addition of hemin. K562",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 205,
    "paragraph": "(ATCC, USA), HEL (ATCC, USA), Jurkat (ATCC, USA) and Tk6 (ATCC, USA) cells were grown in RMPI sup- plemented with 10% FBS plus a penicillin/streptomycin cocktail. MEG-01 (ATCC, USA), CMK (DSMZ, Ger- many) and LAMA84 (DSMZ, Germany) cells were grown in RPMI supplemented with 20% FBS plus a",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 206,
    "paragraph": "penicillin/streptomycin cocktail with a concentration of 105 cells/ml. England Biolabs, Pickering, Canada). The ligated product was then digested with ClaI (New England Biolabs, Picker- ing, Canada). A PCR followed by a nested PCR (150 ng of the ligated product) were performed using a primer",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 207,
    "paragraph": "located in the Graffi virus U3 sequence (5’GGTCTC- TTGAAA-CTGCTGAGGG 3’ and 5’GACCTTGATCT- GAACTT-CCCTATTC3’) and one corresponding to the splinkerette oligonucleotide. The PCR program was the following: 94°C for 1 min, 68°C for 30 s (2 cycles), 94°C for 15 s, 58°C for 30 s, 72°C 3 min (27 cycles), 72°C 10 min.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 208,
    "paragraph": "The PCR products were cloned (PCR Cloning Kit, Qiagen, Mississauga, Canada,) and sent for sequencing (Genome Quebec Innovation Centre, Montreal, Canada). The sequences were subjected to BLAST analysis against the annotated mouse genome database using Ensembl Gen- ome Browser (release 45).",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 209,
    "paragraph": "RT-PCR Oligo d(T) primed reverse transcription was performed using Omniscript Reverse Transcriptase (QIAGEN, Mis- sissauga, Canada) in a 20 μl reaction volume (42°C, 1 h) by taking equal amounts of RNA (100 ng) from the Graffi-leukaemic cells and the murine HB22.2 cell line.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 210,
    "paragraph": "cDNA (4 μl) was amplified using Taq polymerase (QIA- GEN, Mississauga, Canada) at 94°C for 5 min, 72°C for 45 s, 57°C for 45 s, 72°C for 45 s, 72°C for 10 min. 25 and 28 cycles were used for the Graffi-leukaemic cells",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 211,
    "paragraph": "and 27 cycles were used for the HB22.2 cell line. 0.01 μl of cDNA and 25 cycles were used to amplify ubiqui- tously expressed b-actin and Gapdh genes. cDNA from the human haematopoietic cell lines was amplified using 500 ng of total RNA and the PCR reactions were per-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 212,
    "paragraph": "formed using 4 μl of cDNA and 30 PCR cycles. Ubiqui- tously expressed human GAPDH gene was amplified using 0.01 μl of cDNA and 25 cycles. The primer sets are listed in supplementary data (Additional file 1). PCR products were analyzed on 2% agarose gels containing",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 213,
    "paragraph": "0.5 μg/ml ethidium bromide. The gels were scanned (Molecular Dynamics Phosphorimager) and the density of the RT-PCR bands were assessed using the Quantity One software. Amplification of retroviral integration sites This protocol was adapted from A. Berns and colleagues [18]. Tumor DNA from the spleen (10 μg) was digested",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 214,
    "paragraph": "with BamHI (New England Biolabs, Pickering, Canada). A splinkerette adaptor was generated by annealing 2 oligo- nucleotides (5’CATGGGCTAAAGAGGACTAATAA- CAAGCGTGGCTGAATGAGACTGGTGTCGA CAC- TAGTGG3’, 5’GATCCCACTAGTGTCGACACCAGT- CTCTAATTTTTTTTTTC AAAAAAA3’, 95°C 5 min, cool-down to room temperature). 1 μg of digested DNA was ligated to the splinkerette oligonucleotide (molar ratio",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 215,
    "paragraph": "DNA/splinkerette 1:10) using a T4 DNA ligase (New Results Erythro- and megakaryoblastic leukaemias induced by the murine Graffi retrovirus and hybridization on microarrays NFS newborn mice inoculated with the Graffi murine retrovirus develop an average of 20% of erythroleukemia and 20% of megakaryoblastic leukemias with a latency",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 216,
    "paragraph": "of about 148 days [12]. These mice suffer from severe anaemia and hepatosplenomegaly. The erythroleukaemic cells, Ter119+CD71+, and the megakaryoblastic leukae- mic cells, CD41+Kit+ or CD41-Kit+, are mainly found in the bone marrow and spleen of the diseased mice [12]. As opposed to Graffi-lymphoid leukaemias, the presence",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 217,
    "paragraph": "of blast cells is rare in blood smears of both erythro- and megakaryoblastic leukaemias, consistent with clini- cal data on human acute erythroleukaemia [8]. To gain insight into the cancerous signatures of the different leukaemias induced by Graffi MuLV, microar- ray experiments were designed to compare the expres-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 218,
    "paragraph": "sion signature of genes from each type of leukaemia. Cells from the infiltrated haematopoietic organs of the leukaemic mice were isolated (Additional file 2) and subjected to microarray analysis. Unsupervised learning methods, hierarchical clustering, and SOM analyses were used to uncover the primary pattern in the data",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 219,
    "paragraph": "(Figure 1). Altogether, four distinct gene clusters repre- senting T-cells (T), B-cells (B), megakaryoblastic/mye- loid cells (Mk/M) and erythroid cells (E) emerged from the clustering (Figure 1A). A more detailed SOM analysis performed on the ery- throid and megakaryoblastic genes further classified",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 220,
    "paragraph": "them into 3 major signatures: erythroid-megakaryoblas- tic EMk (19%), erythroid E (42%) and megakaryoblastic Mk (39%) (Figure 1B). E and Mk represent the genes over-expressed in the erythro- and megakaryoblastic leukaemias, respectively, and EMk represents the genes specifically over-expressed in both types. MkE1 indicates",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 221,
    "paragraph": "genes over-expressed in the 3 megakaryoblastic Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 4 of 17 A B 1 1 T T 2 2 T T 3 3 T T 2 2 B B 1 1 B B",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 222,
    "paragraph": "3 3 B B 1 1 k k M M 3 3 k k M M 1 1 2ME 2ME k k M M 2 2 E E 3 3 E E 3 T 2 2 T T 1 1 T",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 223,
    "paragraph": "T 3 3 B B 2 2 B B 1 M 1 M B B 2 2 k k M M 1 1 k k M M 3 3 k k M M 1 1 E E 2 2 E E",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 224,
    "paragraph": "3 3 E E Mk only MkE1 MkM MkMB Mk 39% E only EMk3 E 42% EMk 19% T B M k M E Figure 1 Hierarchical clustering and data scatter. (A) Heat map of the hierarchical clustering and SOM analyses of all data. (B) Heat",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 225,
    "paragraph": "map of the clustering and SOM analyses of the erythroid and megakaryoblastic over-expressed genes. Each column represents a leukaemia (T-cell: T1, T2, T3; B-cell: B1, B2, B3; Myeloid: M; Erythroid: E1, E2, E3; Megakaryoblastic: Mk1, Mk2, Mk3) and each row is",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 226,
    "paragraph": "assigned to a transcript. A red colour means a positive deviation of 0.595 and above from the mean (over-expression) and a green colour means a negative deviation of -0.595 and below from the mean (under-expression). The black colour corresponds to values",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 227,
    "paragraph": "comprised between 0.595 and -0.595. The result of the clustering on the arrays is shown as a dendrogram on the top of the figure. The nodes of the tree indicate the degrees of similarity between the leukaemias. leukaemias (Mk1-Mk3) and the erythroleukaemia E1.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 228,
    "paragraph": "Similarly, EMk3 corresponds to genes over-expressed in 3 erythroleukaemias (E1-E3) and the megakaryoblastic leukaemia Mk3. These results indicate that the leukae- mias E1 and Mk3 are biphenotypic and express both erythroid and megakaryoblastic markers, which was pre- viously observed in some Graffi-induced erythro- and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 229,
    "paragraph": "megakaryoblastic leukaemias [12]. The MkMB signature includes genes over-expressed in megakaryoblastic leu- kaemias (Mk1-Mk3), myeloid leukaemia (M) and B-cell leukaemias (B1-B3). A detailed analysis of Mk, E and EMk signatures has revealed that many of the genes have not yet been reported in relation to the erythroid",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 230,
    "paragraph": "or the megakaryocytic lineages or to the corresponding leukaemias. The complete lists of genes detailing these non-lymphoid signatures are publicly available at http:// www.biomed.uqam.ca/rassart/microarray.html[19]. The lineage specific expression of genes involved in heme biosynthesis, the megakaryocytic fibrinogen recep- tors and the expression of well known transcription fac-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 231,
    "paragraph": "tors validate the true lineage of these erythro- and megakaryoblastic leukaemias (Table 1). The megakaryoblastic signature The megakaryoblastic specific genes assigned with a functional annotation (GO terms) were divided into dif- ferent functional classes. Table 2 lists some genes poten- tially implicated in the disease but the complete data are",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 232,
    "paragraph": "readily available [19]. Within this list of genes, the onco- genes Meis1 (Myeloid ecotropic viral integration site 1), Pbx1 (Pre B-cell leukaemia transcription factor 1), Evi1 (ecotropic viral integration site 1), Evi3 (Zfp521, zinc fin- ger protein 521) and the co-repressor Cbfa2t3h (Core-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 233,
    "paragraph": "binding factor, runt domain, alpha subunit 2, translo- cated to, 3 (human), Eto2) have already been related to megakaryoblastic leukaemias or megakaryocytic lineage [20-25]. However, several other genes, for example Nmyc (Neuroblastoma myc-related oncogene 1), Fgf3 (Fibro- blast growth factor 3) and Fap (Fibroblast activation",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 234,
    "paragraph": "protein), that are also known oncogenes [26-29], have never been reported with megakaryoblastic leukaemias. Myct1 (Myc target 1) is also potentially implicated in the disease as it is positively regulated by Myc and con- tains tumorigenic properties by itself [30]. Among the list of genes identified as the MkMB sig-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 235,
    "paragraph": "nature, we found Jun (Jun oncogene), Fosl2 (Fos-like antigen 2) and Fes (Feline sarcoma oncogene) (Table 2, [31,32]). The co-repressor Ctbp2 (C-terminal binding protein 2), Sfpi1 (SFFV proviral integration 1, PU.1) and Kit (Kit oncogene) are also MkMB signature elements. Ctbp2 is known to interact with Evi1 and Fog [33]. Sfpi1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 236,
    "paragraph": "was shown to regulate the expression of the integrin aIIb (Itga2B, CD41) in a TPO-induced Mpl-UT7 model [34,35] and it was reported as an insertional target of the Graffi MuLV [36]. Due to technical limitations, no megakaryoblastic con- trol was present in our study. Normal megakaryocytes and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 237,
    "paragraph": "therefore megakaryoblasts represent a minor population in normal mice and it was not possible to obtain enough pur- ified cells with the technique utilized for other samples. We therefore compared our dataset to a study of murine megakaryocytic maturation indicating up- or down-regula-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 238,
    "paragraph": "tion during differentiation (dataset GSE6593, [37]). Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 5 of 17 Table 1 Genes specific to the erythroid and megakaryoblastic leukaemias probeset gene SAM results * FDR d-score Fibrinogen receptor and related genes",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 239,
    "paragraph": "T1 T2 T3 B1 B2 B3 M E1 E2 E3 Mk1 MK2 Mk3 Leukaemic samples** 1417758_at 1421511_at 1416066_at 1456085_x_at 1420558_at 1457782_at 1424595_at 1451097_at 1418261_at 1455349_at Heme biosynthesis 1451675_a_at 1424877_a_at 1426475_at 1423482_at 1417206_at 1422493_at 1416618_at 1418699_s_at Itga2b Itgb3 Cd9 Cd151 Selp Tln1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 240,
    "paragraph": "F11r Vasp Syk Rap1b Alas2 Alad Hmbs Uros Urod Cpox Ppox Fech 10.58 <0.001 - 5.5 7.56 12.03 7.19 5.58 5.24 16.04 4.63 8.85 8.91 13.44 - 10.87 22.18 4.58 8.61 >0.01 0.002 <0.001 <0.001 <0.001 0.002 <0.001 <0.001 <0.001 <0.001",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 241,
    "paragraph": "<0.001 <0.001 - <0.001 <0.001 0.004 <0.001 Erythroid and megakaryoblastic transcription factors 0.01 0.02 <0.01 0.03 0.01 EMk 1450333_a_at Gata2 1423603_at 1449389_at 1454086_a_at 1452001_at EMk3 1449232_at MkE1 Zfpm1(Fog1) Scl/Tal1 Lmo2 Nfe2 Gata1 1441584_at Fli1 Erythroid transcription factors EMk3 1418600_at Klf1 7.4",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 242,
    "paragraph": "5.4 20.8 4.5 8.3 4.6 5.3 6.8 1419311_at Megakaryoblastic transcription factors Trim10 8.9 -2.7 -1.0 1.1 -1.2 -1.0 -0.7 -0.9 -0.8 -2.4 -0.7 -3.4 -1.2 -1.2 -0.6 0.0 -1.6 -0.5 -0.7 -1.9 -1.2 -3.3 -5.1 -4.2 -1.6 -0.7 -2.5 -1.1 -1.2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 243,
    "paragraph": "-0.4 -0.8 -1.3 -2.8 -0.8 0.3 -0.4 -1.0 -0.3 -0.4 -1.2 -0.1 -1.0 -1.6 -1.7 -2.5 -3.8 -3.0 -2.6 -0.7 2.5 -0.7 -1.9 -1.4 -0.9 0.1 -2.8 -1.1 -0.9 0.0 -0.4 -0.2 -0.3 -0.2 -0.3 -0.3 -1.9 -1.4 -3.1 -4.6 -3.4",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 244,
    "paragraph": "-2.9 -0.8 -3.5 -0.7 -1.6 -0.3 -0.8 0.3 2.9 -0.6 -2.5 -1.3 -1.5 -0.3 -1.2 -0.5 0.1 -1.9 -1.7 0.1 -3.2 0.7 -3.8 -2.6 -0.7 -3.6 -0.9 -1.5 -0.8 -0.6 -0.3 2.5 -1.2 -3.8 -1.6 -1.1 0.1 -0.9 -0.8 -0.2 -1.9",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 245,
    "paragraph": "-1.8 -0.6 -2.5 -1.3 -3.0 -2.7 -0.9 -3.6 -0.6 -1.7 -1.0 -1.0 0.3 2.8 -1.0 -3.2 -0.7 -1.1 0.2 -1.0 -1.0 -0.4 -2.0 -1.9 -0.2 -2.5 -0.9 -3.2 -1.6 -0.6 0.6 -0.3 -1.1 0.9 -0.6 0.7 1.4 -0.2 -1.3 -1.6 -1.1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 246,
    "paragraph": "-0.9 -0.3 -1.5 0.0 -0.4 -1.1 -3.9 -2.5 0.7 1.3 3.8 1.6 1.9 1.4 -0.9 2.3 0.2 0.0 -1.5 2.1 4.9 2.2 2.6 0.7 1.8 2.7 0.7 2.5 -0.6 2.0 4.1 2.8 3.7 0.8 -0.7 -1.8 -0.2 -1.7 -1.5 -0.6 -0.6",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 247,
    "paragraph": "-2.0 -0.3 4.9 2.2 3.4 1.5 1.6 3.1 1.4 3.1 2.2 2.0 3.8 3.0 3.5 1.1 -0.7 -2.1 -0.3 -1.6 -0.5 -0.6 -1.0 -3.1 0.9 4.8 2.0 2.7 0.2 1.4 3.2 0.6 2.2 0.6 2.0 3.5 2.9 3.3 3.6 -0.6 3.0",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 248,
    "paragraph": "1.8 4.3 0.8 2.0 0.8 1.5 0.7 -2.8 0.4 -0.8 0.0 -0.6 -1.0 -0.6 -0.7 3.4 1.3 2.6 1.3 2.5 3.6 2.9 4.4 0.8 5.7 1.4 3.1 1.2 1.6 0.9 -0.5 -0.9 -0.9 -0.5 -0.5 -0.7 -0.4 0.0 3.4 0.8 2.9",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 249,
    "paragraph": "2.5 3.7 3.8 3.1 3.5 2.1 4.1 1.3 1.5 0.7 1.8 1.4 3.5 1.2 0.5 0.0 0.3 -0.4 -0.4 1.1 2.8 0.9 2.9 1.8 2.8 0.03 -1.9 -1.9 -2.1 -2.1 -2.3 -2.7 -1.9 4.5 4.1 4.5 0.6 -1.4 2.5 0.1 -0.2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 250,
    "paragraph": "-0.4 -0.5 0.7 0.6 0.5 0.7 2.6 -4.8 -4.9 1.8 2.4 1.6 0.04 0.02 -2.9 -2.0 -2.3 -1.4 -2.4 -2.1 -2.7 -2.1 -2.7 -2.1 -2.8 -2.0 -1.8 -1.5 4.8 5.0 5.4 4.1 5.3 3.8 1.7 -1.0 -1.7 -0.8 2.1 2.1 MkE1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 251,
    "paragraph": "1421461_at Mpl 16.1 <0.001 0.07 -1.9 -1.6 -2.1 -2.0 -2.1 -2.0 -1.3 1.3 -1.0 -1.7 4.9 4.4 MkE1 1440878_at Runx1 4.5 0.11 0.6 -1.8 -1.0 0.2 0.2 0.5 -0.5 0.9 -0.8 -0.1 0.7 0.8 0.3 * SAM p-value less than 0,001 for every sample",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 252,
    "paragraph": "** amplitude of deviation from the mean calculated from the RMA values According to the megakaryocytic GSE6593 dataset, Fgf3 Jun, Kit, Sfpi, Fes and Bmyc are down-regulated upon megakaryocytic differentiation (Table 2). When genes within the MkMB signature were com- pared to GO annotations, one gene class was over-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 253,
    "paragraph": "represented. Many of these genes were membrane receptors and extra-cellular factors known to be expressed by antigen presenting cells (APC) as well as implicated in inflammatory response [19]. For example, Tlr2 (Toll-like receptor 2), Tlr4 (toll-like receptor 4), Syk (Spleen tyrosine kinase) and Ebi3 (Epstein-Barr virus",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 254,
    "paragraph": "induced gene 3) are part of the Toll-like receptor signal- ing pathway to respond to microbial stimuli (LPS) and induce inflammation (Table 2). Confirming our data, Tlr2, Tlr4 and Syk are already known to be expressed by the megakaryocytic lineage [38,39].",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 255,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 6 of 17 Table 2 Genes over-expressed in the megakaryoblastic leukaemias Probeset Gene SAM results d-score p-value FDR T1 T2 T3 B1 B2 Leukaemic samples * E2 B3 M E1 E3 Mk1 Mk2 Mk3",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 256,
    "paragraph": "GSE 6593 Genes potentially implicated in the disease ** Mk 1443260_at 1428647_at 1417155_at 1451332_at 1441350_at 1417552_at 1438325_at Meis1 Pbx1 Nmyc Evi3 Fgf3 Fap Evi1 12.0 10.2 16.0 13.0 5.4 7.2 4.5 <0.001 <0.001 <0.001 <0.001 0.002 <0.001 0.005 1440964_s_at Cbfa2t3h 11.0",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 257,
    "paragraph": "<0.001 0.1 0.07 0.08 0.08 0.12 0.09 0.16 0.08 -1.5 -1.6 -2.0 -1.1 -0.7 -1.7 -1.8 -0.4 -1.3 -1.1 -1.6 -1.3 -0.7 -1.6 -0.9 -0.7 -1.7 -1.1 -1.9 -1.1 -0.6 -1.7 -1.4 -1.1 -1.5 -1.3 -0.7 -1.1 -0.6 -1.8 -1.7 -0.3",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 258,
    "paragraph": "-1.3 -1.3 -0.6 -1.0 -0.7 -1.7 -1.7 -0.6 -1.7 -1.6 -1.2 -0.9 -0.8 -1.7 -1.4 -0.3 -1.4 -1.2 -1.6 -0.7 -0.6 -1.7 -1.8 -0.1 -1.4 -1.2 -1.8 -0.7 -0.4 -1.5 -1.1 0.2 -1.3 -1.1 -1.5 -0.6 -0.6 -1.6 -1.4 -0.6 -1.3",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 259,
    "paragraph": "-1.4 -1.9 -0.9 -0.5 -1.4 -1.5 -0.2 4.5 4.3 4.8 3.5 1.3 5.9 7.3 1.4 5.9 5.3 5.6 3.3 2.9 7.0 2.4 1.4 4.0 3.3 4.4 2.6 1.9 3.6 4.8 1.2 Myct1 7.2 <0.001 0.07 -2.0 -1.7 -1.7 -1.6 -1.5 -1.6",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 260,
    "paragraph": "-1.4 2.0 -1.1 0.6 3.0 4.5 2.5 MkE1 1452072_at MkMB 1437247_at 1417409_at 1434705_at 1452514_a_at 1418747_at 1452410_a_at 1428669_at 1420710_at FosL2 Jun Ctbp2 Kit Sfpi1 Fes Bmyc Rel 10.3 5.1 15.3 10.5 9.9 10.2 5.8 5.8 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 261,
    "paragraph": "<0.001 0.01 0.03 0.01 0.01 <0.01 <0.01 0.04 0.02 Genes potentially implicated in inflammation response MkMB 1449222_at 1418262_at 1419132_at 1418163_at 1456046_at Ebi3 Syk Tlr2 Tlr4 C1qr1 11.2 <0.001 0.01 1.6 6.7 6.3 8.1 <0.001 <0.01 <0.001 <0.001 <0.001 0.01 0.01 <0.01",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 262,
    "paragraph": "Genes selected for RT-PCR validation 1434141_at Gucy1a3 1437687_x_at 1453771_at 1448561_at Fkbp9 Gulp1 Ncf2 1450333_a_at Gata2 18.2 23.7 14.2 18.5 7.4 <0.001 <0.001 <0.001 0.07 0.07 0.07 <0.001 <0.01 <0.001 0.01 -0.8 -0.3 -1.1 -2.2 -2.6 -2.3 0.8 -0.4 -1.4 -2.4 -0.8",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 263,
    "paragraph": "-1.8 -2.2 -1.2 -1.4 -0.7 -2.6 -2.3 -0.5 -1.4 -1.0 -2.1 -1.7 -1.7 -0.9 0.0 -1.3 -2.5 -1.4 -1.6 -3.7 -0.6 -1.3 -0.7 -2.4 -2.0 -0.8 -3.3 -1.6 -2.2 -1.7 -1.7 0.9 -0.8 -1.2 -2.8 -1.6 -1.4 -4.2 -1.0 -1.6 -0.5",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 264,
    "paragraph": "-2.1 -2.3 -0.7 1 -0.9 -2.2 1.4 1.8 -1.5 0.4 -0.7 1.1 -1.1 -2.3 0.9 0.5 -1.2 1.0 -0.8 1.4 -1.3 1.2 1.1 1.0 -0.5 0.9 -1.4 -1.2 -1.3 2.8 0.6 0.5 4.1 -1.0 -1.3 -0.6 2.0 -2.1 2.4 0.1 1.8",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 265,
    "paragraph": "3.9 -1.1 -1.3 -0.9 1.6 -2.4 2.6 0.6 2.2 4.1 -1.2 -1.3 -0.9 1.6 -1.9 1.8 4.1 3.2 2.8 3.0 3.0 1.3 1.0 3.6 1.5 2.4 2.5 3.7 -1.0 -1.1 -0.9 3.0 -1.6 -0.5 -1.3 -1.2 -1.7 -1.7 -1.4 -1.6 -0.9",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 266,
    "paragraph": "-0.7 -1.6 -0.9 -1.2 -2.3 0.2 -1.0 -1.0 -2.1 0.2 -0.5 -1.5 -1.4 -1.6 -1.4 -2.0 -1.2 -1.3 -1.1 -2.2 -1.4 -0.8 -2.2 -1.1 -1.0 -0.9 -2.2 2.4 -0.6 -2.3 -1.9 -2.2 -1.8 -1.9 -1.4 -1.1 -1.6 -2.8 -1.5 -1.3 -4.1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 267,
    "paragraph": "-1.0 -1.1 -0.9 -2.4 1.1 1.6 0.8 3.3 3.8 1.2 1.4 1.7 0.6 2.2 1.4 1 0.4 0.9 3.0 4.1 3.1 1.6 3.6 1.6 0.8 2.7 4.6 2.1 2.2 2.2 -0.1 3.1 1.6 2 0.7 0.6 3.2 4.6 2.6 2.5 4.0",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 268,
    "paragraph": "0.8 0.91 2.4 4.0 1.1 1.1 1.4 0.6 2.23 1.96 0.9 0.0 1.4 2.7 3.9 2.3 1.6 3.4 ND ND NS NS ↓ ND ND NS NS ND ↓ NS ↓ ↓ ↓ ↓ NS ↓ NS ↓ ND ND -",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 269,
    "paragraph": "NS - NS ↓ * amplitude of deviation from the mean calculated from the RMA values ** cell cycle/cell growth/development/angiogenesis/DNA repair/transcription regulation ND (not determined), NS (not significant) To validate the microarray data, the expression of sev- eral megakaryoblastic specific genes was tested by semi-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 270,
    "paragraph": "quantitative RT-PCR in samples different from those analyzed in the microarray experiments (Table 2 and Fig- ure 2). Within these genes, Kit and Gata2 were tested due to their important roles in haematopoiesis. The other genes were selected for experimentation since they",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 271,
    "paragraph": "had no prior association with megakaryocytic lineages or with the corresponding leukaemia and also since their ‘Genes function remained poorly studied (Table 2, selected for RT-PCR validation’). Within these genes, Gulp1 (Engulfment adaptor PTB domain containing 1) and Gucy1a3 (Guanylate cyclase 1, soluble, alpha 3) gave",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 272,
    "paragraph": "the highest specificity in the RT-PCR experiments with a strong expression in the 3 megakaryoblastic leukaemias (Figure 2). Most of the non-megakaryoblastic leukaemias showed very low or no expression of these genes. Ncf2 (Neutrophil cytosilic factor 2) is highly expressed in the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 273,
    "paragraph": "B-cell and megakaryoblastic leukaemias in accordance with the microarray data (Table 2). Fkbp9 (FK506 binding protein 9) is strongly expressed in the megakaryoblastic leukaemias with a weaker but sustained expression in other types of leukaemias. Gata2 is strongly expressed in the megakaryoblastic leukaemias and to a lower level in",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 274,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 7 of 17 Figure 2 Megakaryoblastic specific genes. Semi-quantitative RT-PCR analysis in 3 T-cell (T, 1-3), 3 B-cell (B, 4-7), 1 myeloid (M, 8), 3 erythroid (E, 8-10) and 3 megakaryoblastic leukaemias (Mk, 11-13). RT-PCRs have been performed in quadruplicate for each sample. Two out of 4 RT-PCR",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 275,
    "paragraph": "runs are shown for the leukaemic samples (lane a: 25 PCR cycles; lane b: 28 PCR cycles) and 1 out of 4 are shown for the b-actin internal control (lane c). The histograms represent the quantification of the density of the bands relative to the b-actin sample including all RT-PCR runs for each",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 276,
    "paragraph": "type of leukaemia (T, B, M, E, Mk). the 3 erythroleukaemias. Finally, Kit was amplified in all leukaemias but with the strongest expression in the megakaryoblastic ones (Figure 2). The erythroid signature The results of the erythroid signature were compared to",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 277,
    "paragraph": "the transcriptome analysis of G1E cells during GATA1 induced differentiation (dataset GSE628, [40]). Our results correlate neatly with this dataset although the Affymetrix Genechip MG-U74A used by Welch and col- leagues contains only one third the probes of the MOE 430.2 used in our study. In the Welch et al study, the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 278,
    "paragraph": "genes that displayed increased expression during differ- entiation tended to be under-expressed in the Graffi- induced erythroleukaemias compared to the control sample and vice-versa. This suggests that the Graffi- induced erythroleukaemias are blocked in an earlier stage than the control sample taken from a population",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 279,
    "paragraph": "of Ter119+CD71+ erythroblasts in the bone marrow. Table 3 provides examples of this correlation between the two studies. For example, Car1 (Carbonic anhydrase 1) is over-expressed in the leukaemias in comparison to the control (positive value, column ‘E-CE’) and its expression decreases during erythroid differentiation",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 280,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 8 of 17 Table 3 Genes specific to the erythroid leukaemias FDR T1 T2 T3 B1 B2 B3 M E1 E2 E3 Mk1 MK2 Mk3 E-CE G1E Leukaemic samples* Probeset Gene",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 281,
    "paragraph": "SAM results p- value d- score Correlation with the G1E database 1416193_at 1422316_at 1422817_at Car1 Gp1ba Gp5 1424968_at 1425677_a_at 2210023G05Rik Ank1 1416464_at 1451675_a_at 1418699_s_at Slc4a1 Alas2 Fech 8.2 12.7 7.5 12.3 18.2 11.6 11.0 8.9 <0.001 <0.001 <0.001 <0.001 0.001 <0.001",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 282,
    "paragraph": "<0.001 <0.001 Genes potentially implicated in the disease *** E 1417514_at 1460057_at 1419665_a_at 1443969_at 1417165_at 1449256_a_at 1417396_at EMk3 1422737_at 1435458_at Ssx2ip Gdf3 Nupr1 Irs2 Mbd2 Rab11a Podxl Ncoa3 Pim1 13.97 <0.001 9.4 8.7 6.5 <0.001 <0.001 <0.001 17.38 <0.001 10.59 <0.001",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 283,
    "paragraph": "6.5 <0.001 0.02 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.02 -3.4 -2.5 -3.6 -2.4 -1.5 -2.3 -3.4 -0.8 -1.1 -1.3 -1.5 0.1 -0.7 -1.0 -0.8 -2.1 -2.1 -2.3 -2.3 -1.3 -1.4 0.3 -1.0 -0.8",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 284,
    "paragraph": "-1.2 -1.5 -0.1 -0.1 -0.3 -0.9 -3.2 -1.9 -3.0 -2.1 -1.3 -2.0 -0.9 -0.7 -1.4 -1.0 -1.3 -1.5 -0.4 -1.2 -1.0 -3.0 -1.9 -3.0 -2.2 -1.5 -2.4 -2.5 -1.4 -0.3 -1.3 -1.3 -0.2 0.0 -0.6 -1.0 -3.0 -2.0 -2.9 -2.2 -1.1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 285,
    "paragraph": "-2.7 -3.8 -1.7 -0.3 -0.9 -1.3 -0.4 -0.1 -0.6 -0.9 -3.2 -2.4 -2.8 -1.9 -0.9 -2.0 -3.2 -1.5 -0.5 -1.0 -1.7 0.4 -0.3 -0.3 -0.7 -2.4 -1.9 -1.9 -1.9 -1.0 -1.2 -1.3 -0.5 -0.5 2.0 0.3 -1.0 -0.6 -0.4 -1.0 4.1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 286,
    "paragraph": "5.4 0.003 <0.001 0.10 0.06 -0.3 -1.0 -1.2 -1.3 -0.1 -2.0 -0.5 -0.6 -0.4 -0.4 0.3 -0.4 -0.3 -0.2 Genes selected for RT-PCR validation 1449232_at 1425571_at 1418493_a_at 1418061_at 1419069_at 1427357_at 1417152_at Gata1 Slamf1 Snca Ltbp2 Rabgef1 Cda Btbd14a 4.58 9.9 10.2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 287,
    "paragraph": "15 25.0 25.0 9.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.03 0.02 0.02 0.01 0.01 0.01 0.02 -1.9 -1.3 -3.3 -0.7 -0.5 -1.5 -0.6 -1.9 -1.6 -0.2 -0.7 -0.8 -1.6 -0.9 -2.1 -1.7 -1.0 -0.7 -0.4 -1.6 -0.9 -2.1 -1.2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 288,
    "paragraph": "-2.5 -0.7 -0.9 -1.7 -0.9 -2.3 -1.6 -3.2 -0.8 -1.3 -1.8 -0.8 -2.7 -1.5 -1.8 -0.7 -1.2 -0.6 -0.9 -1.9 -2.0 -1.5 -0.9 -0.8 -1.3 -0.5 * amplitude of deviation from the mean calculated from the RMA values ** ratio E-CE: mean of the deviation of E1, E2 and E3/erythroid control value",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 289,
    "paragraph": "*** cell cycle/cell growth/development/angiogenesis/DNA repair/transcriptionregulation 6.0 4.3 4.5 4.4 3.1 4.7 4.9 2.2 2.8 2.2 3.9 1.1 1.3 1.7 1.3 1.5 1.5 4.5 4.1 4.6 2.2 2.2 4.3 2.3 5.9 3.3 3.6 5.5 3.6 4.6 4.9 2.5 2.7 2.4 2.5 2.1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 290,
    "paragraph": "1.3 1.7 1.6 0.4 1.5 4.1 3.0 4.2 1.5 2.3 4.8 1.5 1.7 1.7 1.7 5.1 3.3 1.7 1.7 1.7 3.0 2.8 3.3 1.4 1.3 1.3 1.7 0.8 1.0 4.5 1.7 1.7 1.7 2.3 4.9 1.7 1.4 0.1 2.4 -0.2 -0.5",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 291,
    "paragraph": "-1.8 -2.8 -0.2 -2.4 -1.3 -0.9 -1.2 -0.6 -0.3 1.6 0.0 0.1 0.6 -0.3 -1.0 -0.5 -0.4 -1.6 -0.4 -2.1 -0.1 1.6 -1.1 -1.1 0.2 -0.5 0.0 -1.4 -1.3 -0.6 -0.5 -0.7 -0.1 0.2 -0.7 0.9 -1.4 -1.2 -0.7 -0.8 -0.4",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 292,
    "paragraph": "-1.7 -0.4 3.0 3.7 3.4 1.4 0.1 3.2 3.5 1.3 0.3 -0.1 0.2 -0.2 -0.2 0.2 -0.1 0.6 0.9 2.5 1.9 2.7 1.4 -0.1 -0.7 1.0 1.2 2.9 3.8 1.3 -0.8 -2.4 -1.1 -2.4 1.1 2.9 4.0 1.2 0.9 1.7 2.4",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 293,
    "paragraph": "2.2 0.6 0.4 4.8 -2.6 2.0 4.8 6.0 2.3 ↓ ↓ ↓ ↓ ↑ ↑ ↑ ↑ ↓ NS - ↑ - - NS NS ↑ ↑ - ↑ NS - - NS (descending arrow, column ‘G1E’). Alas2 (Aminolevuli- nic acid synthase 1), involved in the heme biosynthesis,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 294,
    "paragraph": "is under-expressed in the leukaemias in comparison to the control and its expression increases during erythroid differentiation. Table 3 presents a summary of the erythroid specific genes over-expressed in comparison to the control sample and potentially implicated in the disease but the complete",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 295,
    "paragraph": "data are readily available [19]. Within these genes, Gdf3 (Growth differentiation factor 3), Podxl (Podocalyxin-like), Nupr1 (Nuclear protein 1), Pim1 (Proviral integration site 1) and Isr2 (Insulin receptor substrate 2) are known to be regulated by erythropoietin [41-43]. The oncogene Pim1",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 296,
    "paragraph": "was found rearranged in Friend helper MuLV-induced erythroleukaemias and Graffi-induced leukaemias [36,44]. Ssx2ip (Synovial sarcoma, X breakpoint 2 interacting pro- tein) was found over-expressed in some AML patients and is expressed by K562 erythroid cells [45]. Rab11a (RAB11a, member RAS oncogene family) was reported to",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 297,
    "paragraph": "regulate the recycling of the transferrin receptor [46]. This protein interacts with Evi5 [47] and has a potential role in cancer [48]. The oncogene Ncoa3 (Nuclear receptor coacti- vator 3) is over-expressed in numerous cancer types such as breast, prostate, ovarian, gastric, pancreatic and colorec-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 298,
    "paragraph": "tal cancers [49]. Many genes have not yet been reported in relation to erythroid leukaemias and several others have a still unknown function and some of them have been selected for RT-PCR validation (Table 3 and Figure 3). Gata1 was tested due to its important role in haematopoiesis",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 299,
    "paragraph": "(Figure 3). Among the 7 tested erythroid genes (Table 3, ‘Genes selected for RT-PCR validation’), both Cda (Cyti- dine deaminase) and Ltbp2 (Latent transforming growth factor beta binding protein 2) showed a very high and Voisin et al. BMC Medical Genomics 2010, 3:2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 300,
    "paragraph": "http://www.biomedcentral.com/1755-8794/3/2 Page 9 of 17 Figure 3 Erythroid specific genes. Semi-quantitative RT-PCR analysis in 3 T-cell (T, 1-3), 3 B-cell (B, 4-7), 1 myeloid (M, 8), 3 erythroid (E, 8-10) and 3 megakaryoblastic leukaemias (Mk, 11-13) was utilized for each of the 6 tested genes. RT-PCRs have been performed in quadruplicate for",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 301,
    "paragraph": "each sample. Two out of 4 RT-PCR runs are shown for the leukaemic samples (lane a: 25 PCR cycles; lane b: 28 PCR cycles) and 1 out of 4 are shown for the b-actin control sample (lane c). The histograms represent the quantification of the density of the bands relative to the b-actin",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 302,
    "paragraph": "sample including all RT-PCR runs for each type of leukaemia (T, B, M, E, Mk). Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 10 of 17 specific expression in the 3 erythroleukaemias (Figure 3). Slamf1 (Signaling lymphocytic activation molecule family",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 303,
    "paragraph": "member 1), Snca (Synuclein alpha) and Btbd14a (BTB/ POZ domain containing 14A) are higher expressed in the erythroleukaemias and lower in the megakaryoblas- tic leukaemias but were also amplified in other types of leukaemias. Rabgef1 is specifically expressed in the ery-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 304,
    "paragraph": "throleukaemias at 25 PCR cycles (lane a) but was ampli- fied in all samples at 28 PCR cycles (lane b). Gata1 is equally highly expressed in the erythroid and in the megakaryoblastic leukaemias (Figure 3). RT-PCR validation in a Friend virus murine",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 305,
    "paragraph": "erythroleukaemia cell line The expression of the erythroid and megakaryoblastic specific transcripts validated by RT-PCR (Figures 2 and 3) was further assessed on a different erythroid model (Figure 4). The erythroleukaemia cell line HB22.2 has been derived from a leukaemia induced by the Friend",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 306,
    "paragraph": "Murine Leukaemia virus (F-MuLV) and it presents a very immature erythroid phenotype (Kit+CD71+Ter119- CD41-) ([17]). The 6 erythroid genes (Slamf1, Snca, Ltbp2, Rabgef1, Cda and Btbd14a) are expressed in HB22.2 but the intensity of the Ltbp2 and Btdb14a bands were weaker (Figure 4A). In accordance with our",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 307,
    "paragraph": "expectations, the megakaryoblastic genes, Ncf2, Gucy1a3 and Gulp1, could not be amplified. Fkbp9 is the only megakaryoblastic gene that gave a weak signal in this erythroid cell line. Indeed, Fkbp9 showed the strongest erythroid amplification in the RT-PCR validation experi- ment (Figure 2). Thus, these results show that, despite",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 308,
    "paragraph": "relationship between erythroid and the close Figure 4 Expression of the erythroid and megakaryoblastic specific genes in the murine erythroleukaemia cell line HB22.2 during hemin-induced differentiation. (A) Semi-quantitative RT-PCR analysis of 6 erythroid specific genes (E) and 4 megakaryoblastic specific genes",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 309,
    "paragraph": "(Mk). The first lane (M) indicates the low-range DNA marker. (B) Hemin-induced differentiation assay of HB22.2 cells. Semi-quantitative RT-PCR analysis of Hba as differentiation control, Btbd14a and Ltbp2 was performed in non-induced (NI) and induced (Hemin) cells at day 1 (D1) and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 310,
    "paragraph": "day 3 (D3) following hemin addition. GAPDH expression was used as internal control. Three independent RT-PCR reactions were performed on each sample using increasing amount of the RT reaction (0.75 volume, 1 volume, 1.25 volume). The band intensity was measured and indicated",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 311,
    "paragraph": "below each band. On the right half of the figure, the histograms show the average results of the band intensities relative to the Gapdh control sample. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 11 of 17 megakaryoblastic leukaemias, this experiment’s design",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 312,
    "paragraph": "enabled us to find genes that can distinguish these 2 types of murine leukaemias from each other. We then induced HB22.2 differentiation with hemin and tested the expression of the erythroid specific genes at different time-points (Figure 4). Integration of F-MuLV upstream of Fli-1 is shown to block differen-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 313,
    "paragraph": "tiation of this cell line [17]. However, these cells are able to undergo differentiation with hemin associated induction of alpha globin (Figure 4B). Among the 6 ery- throid genes tested, both Btbd14a and Ltbp2 showed reproducible changes with a decrease and an increase",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 314,
    "paragraph": "with differentiation, respectively (Figure 4B). The increased expression of Ltbp2 indicates that it likely plays a role in mature erythroid cells whereas Btbd14a is likely to play a role in immature erythroid cells and this correlates well with a putative oncogenic role for",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 315,
    "paragraph": "this gene. Validation in human leukaemic cell lines The proteins encoded by these erythroid and megakaryo- blastic specific genes have high homologies with their human counterparts. This makes it likely that these human and murine proteins have the same functional role. Gene expression was first tested in 2 human ery-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 316,
    "paragraph": "throid-like cell lines, HEL and K562, a human B-cell leu- kaemia cell line, TK6, and a human T-cell leukaemia cell line, Jurkat (Figure 5A). Because HEL and K562 are known to harbour mixed myeloid lineage phenotype, the genes were further tested in 2 human megakaryoblastic",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 317,
    "paragraph": "cell lines, MEG-01 and CMK, and 1 erythroid cell line LAMA-84 (Figure 5B). The results show that all tested erythroid and mega- karyoblastic specific genes were amplified in some or all of the cell lines confirming their expression in human erythroid or megakaryoblastic cell lines. Moreover, sev-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 318,
    "paragraph": "eral were also amplified in the lymphoid lines TK6 and/ or in Jurkat. RABGEF1 and BTBD14A were the most ubiquitous genes with a strong amplification in lym- phoid and non-lymphoid cell lines. GULP1 and SNCA were the most specific to the non-lymphoid lineage with",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 319,
    "paragraph": "no expression in TK6 or Jurkat cell lines. Viral integrations in the megakaryoblastic leukaemias We also identified retroviral integration sites (RIS) in the 3 megakaryoblastic leukaemias (Mk1-3) in order to search for genes that may have contributed to the oncogenic transformation. Several RIS were amplified,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 320,
    "paragraph": "cloned and sequenced in these 3 tumors (11 in Mk1, 5 in Mk2 and 10 in Mk3) (Table 4). No common inte- gration sites (CIS) that could clearly indicate the con- tribution to the oncogenic events were found. Therefore, the results were compared to the retroviral",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 321,
    "paragraph": "tagged cancer gene database (RTCGD, [50]) that compiles the RIS identified in different murine cancer models (underlined in Table 4). Genes identified in multiple screens have a high probability of involvement in oncogenic transformation. Eleven genes near the RIS were found in the RTCGD (underlined in Table 4).",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 322,
    "paragraph": "Some of these genes, such as Ccnd1 and Myc, are lar- gely known to be involved in leukaemia. Foxf1 is a transcription factor known to regulate the megakaryo- cytic integrin b3 (CD61) [51]. Interestingly, Kit and Gata2 are also part of RIS. The presence of the RIS",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 323,
    "paragraph": "near Kit in Mk1 and near Gata2 in Mk3 has been vali- dated by PCR in the sorted leukaemic megakaryoblas- tic population (not shown). Two other genes, Irf8 and Itga1 targeted by a RIS (Table 4) are also of interest: Irf8 is not included in the RTCGD database but is a",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 324,
    "paragraph": "known CIS [52] and the ITGA1 locus is repressed by methylation during megakaryopoiesis in humans [53]. Discussion Characterization of genes specific to erythro- and megakaryoblastic leukaemias Patient survey studies revealed that erythroleukaemias represent an average of 5% of all cases of acute myeloid",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 325,
    "paragraph": "leukaemias [3-5] and megakaryoblastic leukaemias have an incidence of approximately 1% in adults and 5-10% in children [6,7]. However, the overall survival rate is extremely poor and ranges from 6% to 17% [3,7]. Chil- dren suffering from Down Syndrome are an exception",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 326,
    "paragraph": "as they have a higher risk of developing megakaryoblas- tic leukaemias but respond better to therapy [54]. Acute erythro- and megakaryoblastic leukaemias are less stu- died than the more frequent types of leukaemias. Thus, genes involved in the development of these leukaemias",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 327,
    "paragraph": "remain insufficiently elucidated. Our experimental design is based on the comparison of non-lymphoid versus lymphoid murine leukaemias and provides the whole picture of genes specific to these 2 groups and subgroups. The sole comparison of the non-lymphoid leukaemias and their respective con-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 328,
    "paragraph": "trols without including the lymphoid group would not have provided such a dataset. Therefore, numerous genes not described previously or uncharacterized emerged from this study. We estimated that, within the identified gene signatures, there are oncogenes directly implicated in the disease and also genes",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 329,
    "paragraph": "related to the normal commitment of the cells toward the erythro- or megakaryoblastic lineages. To deter- mine which genes are potential oncogenes, we first compared the erythroleukaemias to the erythroid con- trol samples and to the study of Welch and colleagues",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 330,
    "paragraph": "[40]. The comparison with the Welch’s study enabled to assess the differentiation state of the leukaemias and the control. Consequently, we could assume that the genes under-expressed in comparison to the control Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 331,
    "paragraph": "Page 12 of 17 Figure 5 Validation in human cell lines. (A) RT-PCR analysis in the erythroid-like human cell lines K562 and HEL, the B- cell lymphoblastic cell line TK6 and the T-cell leukaemia cell line Jurkat. (B) RT-PCR analysis in the human megakaryoblastic cell lines MEG-01 and CMK and the human",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 332,
    "paragraph": "erythroid cell line LAMA-84. The left and right parts of each panel correspond to genes identified in the erythro- and megakaryoblastic leukaemias, respectively. GAPDH was used as internal control. are late stage genes and that oncogenes are more likely to be within the over-expressed genes. We validated",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 333,
    "paragraph": "this hypothesis with Ltbp2 and Btbd14a in a differen- tiation assay in the HB22.2 erythroid cell line. Second, to gain more insights into the function of the megakar- yoblastic genes and in the absence of a control sample, we compared our list of genes to the study of Shivda-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 334,
    "paragraph": "sani and colleagues [37]. The comparison with the stu- dies of Welch for the erythroid leukaemias [40] and of Shivadasani [37] for the megakaryoblastic leukaemias provides valuable information about the behaviour of the genes during normal differentiation. However, their respective microarray chips contained less probesets",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 335,
    "paragraph": "than ours and we could not perform the comparison on the whole dataset. Therefore, further experiments are required to identify the unknown role played by these genes and megakaryoblastic leukaemias. in erythro- Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 336,
    "paragraph": "Page 13 of 17 Table 4 Graffi-virus integration sites in the megakaryoblastic leukaemias Sample Chromosome Genome Upstream genes* Integra-tion within a gene Downstream genes* Mk1 Mk2 Mk3 1D 1G2 4B1 5E 1 6F3 6G1 11B4 11B5 15D3 15F2 16B3 1 E4",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 337,
    "paragraph": "6A3 8 E1 12C1 93018002 153451217 gene 1 Gm817 Rnf2 41816941 2310028H24Rik 75741720 128801887 135264443 70471623 80139013 62283939 95582212 33700976 132543823 25759728 123703449 52786246 Pdgfra Klrb1b Gsg1 Pfn1** Rhot1 Pvt1 Dbx2 Heg1 Pfkb2 Pot 1a Irf8 Hectd1 Pelo kb 17 188",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 338,
    "paragraph": "133 216 10 61 0.8 55 211 100 13 0.4 14 81 120 46 gene 2 Lrrfip1 1190005F20Rik 1700066J25Rik Gsh2 Clec2h Hebp1) Rnf167 Rnf135 Myc** Nell2 Slc12a8 C4bp Grp37 Cox4i1 EG544864 Itga1 13D2.3 116255725 1C5 1F 2H3 5B1 6D2 7B4 7F5",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 339,
    "paragraph": "13A1 14C3 19A Glrp1 146 Spp2 139621937 165618991 43941 88086902 45356428 144856850 3830652 53491694 4301566 - Prkcbp1** Rheb Rpn1 Bax Ccnd1** Calm13 Prmt5 Ankrd13d 43 23 16 21 Eya2 Cryng EG434064 Flt1 107 Oraov1 27 20 18 Rem2 Ssh3 kb 60",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 340,
    "paragraph": "230 138 382 159 130 4 123 463 225 118 54 120 149 35 33 230 156 83 115 28 167 57 32 Ramp1** Niban Dnaic1 - - - - Rhbd13 - - - - - - - - - -",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 341,
    "paragraph": "- - Dhdh - - - kb 95 92 29 114 50 10 1.7 60 gene 1 Ube2f Edem3 Cntfr Kit** Clec21 Pbp2 Eno3 Zfp207 - - Muc13 12 gene 2 Scly Q8K3Do Dcnt3 Kdr Klrb1f Dynlt1 Spag7 Psmd11 - Tmem16f",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 342,
    "paragraph": "Itgb5 ** Yod1 - Foxf1a** Heatr5a - Arl14c Ptprc Ncoa3 Prkag2** Gata2** Nucb1 Tpcn2) Calm4 D14Ertd500e 0.8 AA986890 - Mthfsd 6530401NO4Rik - Sh3bp4 Atp6v1g3 Sulf2 1500035N22Rik Dnajb8 Tulp2 Mrgprf Calm5 Jub FBXL13 269 11 161 257 65 20 72 4 167",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 343,
    "paragraph": "6 4 15 kb 130 199 86 472 208 50 8.2 105 36 48 1 280 124 413 466 146 144 100 25 253 22 31 15 Adrbk1** Fbxl13 * the 2 most proximal genes located at a maximum distance of 500kb upstream (5’) or downstream (3’) of the integration site",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 344,
    "paragraph": "** genes present in the RTCGD database Erythroid and megakaryoblastic genes Erythroid and megakaryoblastic lineages, emerging from the same bipotent progenitor, are very closely related [11] and, as confirmed by our study, several transcrip- tion factors are commonly expressed. This strengthens",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 345,
    "paragraph": "the hypothesis that a very fine tuning of these factors influences the commitment toward the erythroid or megakaryocytic lineages. Our microarray data indicate that Gata1, Gata2, Fog1, Scl and Lmo2 are expressed both in the Graffi-induced erythro- and megakaryoblastic leukaemias (Table 1).",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 346,
    "paragraph": "They are known to act on the promoter of their target as multimeric complexes. Our study highlights that PU.1 (Sfpi1), Ctbp2, Cbfa2t3h (Eto2), Evi1 and Runx1 have a strong megakaryoblastic pattern. PU.1 is a known determinant of erythroid versus megakaryoblastic differ-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 347,
    "paragraph": "entiation and the Gata2 protein acts on PU.1 [55]. The Cbfa2t3h protein binds to the multimeric complex formed by Gata1, Fog1, Scl and Lmo2 and is known to repress the transcription of the target genes. The co- repressor Ctbp2 is known to bind to Evi1 and Fog1 [56].",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 348,
    "paragraph": "Runx1 cooperates with Gata1 during megakaryocytic commitment [22,23] and the Runx1-Evi1 fusion protein leads preferentially to the development of megakaryo- blastic leukaemias in transgenic mice [57]. In a model of in vitro differentiation, Evi1 is strongly induced and sus- tained upon thrombopoietin treatment of CD34+ cells in",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 349,
    "paragraph": "a pattern very similar to Gata2 and PU.1 but only weakly upon erythropoietin treatment [58]. Great evi- dence indicates that Evi1 is a direct activating target of Gata2 [59]. Thus, our study reinforces the importance of these genes in the megakaryoblastic leukaemias.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 350,
    "paragraph": "RT-PCR validated megakaryoblastic genes The specific megakaryoblastic expression of several genes with poorly elucidated physiological roles was validated by Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 14 of 17 RT-PCR. Our study reports for the first time Gucy1a3,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 351,
    "paragraph": "Gulp1 and Fkbp9 as being specific to megakaryoblastic leukaemias. The function of these genes, related to the normal development or transformation of megakaryocytic cells, has yet to be elucidated. Insight into their physiologi- cal roles can be provided by their already known functions",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 352,
    "paragraph": "in other cell types. Gucy1a3 is known to heterodimerize with Gucy1b3, which gene is also specific to the Graffi- induced megakaryoblastic leukaemias. The Gucy1a3/b3 complex produces cGMP after activation by nitric oxide (NO) itself produced by the NADPH oxidase from reactive",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 353,
    "paragraph": "oxygen species. As expected, Ncf2 and other components of the NADPH oxidase (Ncf1, Ncf4, Cybb) are specifically over-expressed in the Graffi-induced megakaryoblastic leukaemias (Figure 2 and not shown). In human cancerous glioma cell lines, it is hypothesized that GUCY1a3/b3 may be responsible for VEGF over-expression resulting in an",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 354,
    "paragraph": "increased amount of NO [60]. NO is also known to play a role in platelet activation [61]. Gulp1 could be involved in the intracellular vesicular trafficking [62] which is of high importance in megakaryocytes for transporting the mole- cules in the storage organelles and during proplatelet for-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 355,
    "paragraph": "mation. Fkbp9 is poorly studied and this present study reports its expression for the first time in cells of haemato- poietic origin. It is strongly expressed in our megakaryo- blastic leukaemias, in human non-lymphoid leukaemias HEL, K562, CMK, Meg-01 and LAMA84, and to a lesser",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 356,
    "paragraph": "extent, in the murine erythroid leukaemias and cell line. RT-PCR validated erythroid genes The selected erythroid genes with poorly elucidated phy- siological roles were Slamf1, Snca, Ltbp2, Rabgef1, Cda and Btbd1a. Slamf1 is known to be expressed by activated lymphocytes but not yet identified in relation to erythroid",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 357,
    "paragraph": "leukaemias. The expression of Slamf1 in Friend virus- induced erythroleukaemic cell line HB22.2 confirms the Graffi model. The gene was recently revealed as a marker of haematopoietic stem cells distinguishing these cells from more differentiated progenitors [63]. Snca has already been reported in erythrocytes [64,65]. Its over-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 358,
    "paragraph": "expression in the control sample and its increased expres- sion during erythroid differentiation (G1E dataset, Table 3) indicate that it may be implicated in normal erythroid cells function. We did not observe a significant increase during HB22.2 induced differentiation. Ltbp2 is strongly",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 359,
    "paragraph": "expressed in our erythroleukaemias and increases signifi- cantly during differentiation. It shows a non-lymphoid expression pattern in the tested human cell lines and is identified in relation to haematopoietic cells for the first time. Some studies suggest a role for Ltbp2 in cell adhe-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 360,
    "paragraph": "sion and in cell migration [66]. Rabgef1 has never been reported in relation to erythroid lineage or leukaemia and the encoded protein is known to interact with Rab5, Rab21 or Rab22 [67]. Rab22a is indeed specifically over-expressed in the 3 tested erythroleukaemias (not",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 361,
    "paragraph": "shown). RAB proteins are implicated in the intra-cellular vesicular traffic regulation and Rabgef1 is expressed in mast cells where it acts on Kit internalization [68]. Even though Rabgef1 expression pattern is more erythroid, it was amplified in all other Graffi-induced leukaemias and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 362,
    "paragraph": "in all the tested human cell lines, indicating its ubiquitous expression in haematopoietic cells. Cda, responsible for resistance to chemotherapy treatment, is highly expressed in our erythroleukaemias, in HB22.2, K562 and HEL. The GEO database shows that CDA is up-regulated during the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 363,
    "paragraph": "differentiation of human CD34+ cells toward the erythroid lineage (NCBI GEO, GSE4655). As of this day, Btbd14a has never been studied. It is highly expressed in the Graffi- induced erythroleukaemias and in HB22.2. Finally, Btbd14a appears ubiquitously expressed in the haemato-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 364,
    "paragraph": "poietic system. The BTB/POZ domain of Btb14a is pre- sent in many oncogenes involved in the development of leukaemia and is often found at the N-terminus of tran- scription factors. Thus, this gene is particularly interesting to further study as it shows a decreased expression during",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 365,
    "paragraph": "HB22.2 induced differentiation and could represent a potential oncogene. The MkMB Signature Numerous genes were commonly over-expressed in the megakaryoblastic, the myeloid leukaemias and/or the B- cell leukaemias. These genes are, in most cases, already known to be expressed by cells implicated in innate",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 366,
    "paragraph": "immunity. Platelets function is too often considered lim- ited to blood coagulation and formation of thrombosis but some studies now emphasize that the platelets’ role is underestimated in innate immunity and inflammation response [39,69-72]. Upon activation, platelets can release microbicidal proteins, interleukins that trigger a",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 367,
    "paragraph": "general inflammation response and chemokines that recruit immune cells such as leukocytes. Pathogens such as bacteria and lentiviruses can be ingested by platelets [73]. The MkMB signature seems to reflect partly the complexity of the platelet function. Only very few exam-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 368,
    "paragraph": "ples are shown in Table 2 but the complete list is avail- able in the supplementary data [19]. The unique design of this gene expression study that compared different types of leukaemias highlights this signature. Retroviral integration and genes potentially implicated in",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 369,
    "paragraph": "the onset of the disease The analysis of retroviral integration enables the identi- fication of genes that may be responsible for malignant transformation. In this study, we screened the 3 mega- karyoblastic leukaemias for viral integration sites as oncogenic transformation events leading to megakaryo-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 370,
    "paragraph": "blastic leukaemias remain unknown. No CIS were iden- tified but some genes in the RTCGD have drawn our Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 15 of 17 attention due to their known functions. Within these genes, Kit and Gata2 are of particular interest as accu-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 371,
    "paragraph": "mulating evidences point at their role in megakaryopoi- esis and megakaryoblastic leukaemias. Gata2 was recently reported for the first time as a com- mon integration site in leukaemias induced by the MOL4070LTR retrovirus in the NHD13 mouse [74]. In vitro studies showed that Gata2 over-expression redirects",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 372,
    "paragraph": "the haematopoietic differentiation from the macrophage lineage toward the erythroid or the megakaryocytic lineages or from the erythroid toward the megakaryocytic lineage [55,75]. The importance of Gata2 on megakaryo- poiesis was also demonstrated in a differentiation study in which this gene is strongly induced and sustained",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 373,
    "paragraph": "upon thrombopoietin treatment of CD34+ cells but only weakly induced upon erythropoietin treatment [58]. The authors made the interesting hypothesis that GATA2 might repress the expression of the erythroid markers in maturing megakaryocytic cells since its activation inhibits erythroid differentiation in some systems.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 374,
    "paragraph": "Kit is involved in many cancers and is regulated by the SCL complex (Gata1/2, SCL, Lmo2) in haematopoietic cells [76]. More evidence begins to emerge for its role in very early stages of megakaryopoiesis [77,78] and in megakaryoblastic leukaemias [79,80]. Bourquin et al.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 375,
    "paragraph": "reported increased levels of KIT, GATA2 and MYC in DS AMKL cells harbouring a GATA1 mutation com- pared to non-DS AMKL cells. They hypothesized that the mutated GATA1 in DS AMKL cells failed to repress the expression of these 3 genes [79].",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 376,
    "paragraph": "The 3 megakaryoblastic leukaemias express very high levels of Kit and Gata2. We hypothesize that the viral inte- grations may block the repression of these genes by con- tinuously activating the transcription or inhibiting the binding of repressor molecules. Kit and Gata2 levels nor-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 377,
    "paragraph": "mally decrease during megakaryocytic differentiation (Table 2 ‘GSE6593’). These 2 genes, affected by the retro- viral integration, would send continuous signals of prolif- eration and survival to the cell. The analysis of a larger sample of Graffi-induced megakaryoblastic leukaemias would be required to prove more efficiently the involve-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 378,
    "paragraph": "ment of Gata2 and Kit in this particular type of leukaemia. Conclusions In this report, we compared the gene profiles of the ery- thro- and megakaryoblastic leukaemias induced by the Graffi virus. Our study identifies genes that are highly expressed in the Graffi-induced erythro- and megakar-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 379,
    "paragraph": "yoblastic leukaemias. The complete dataset of this study is readily available (GSE12581 and [19]). Within the data, numerous genes have not yet been assigned with a known function and some of them could be used as markers for specific types of leukaemias and even the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 380,
    "paragraph": "target of new therapies. We selected and RT-PCR validated genes those functions in normal cells are poorly characterized. For the majority, their expression in these lineages is shown for the first time and further functional characterization will surely complement the knowledge of erythroid and megakaryocytic lineages.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 381,
    "paragraph": "Additional file 1: Oligonucleotides utilized in the RT-PCR experiments. sequences of forward and reverse primers utilized in the RT-PCR experiments Click here for file [ http://www.biomedcentral.com/content/supplementary/1755-8794-3-2- S1.DOC ] Additional file 2: Immunophenotype of the leukaemic samples selected for the microarray experiments. the table lists the leukaemias",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 382,
    "paragraph": "included in the microarray experiments including sample name, leukaemia type, immunophenotype, antibody used for sorting and tumor origins. Click here for file [ http://www.biomedcentral.com/content/supplementary/1755-8794-3-2- S2.DOC ] Acknowledgements We thank André Ponton, Michal Blazejczyk and Mathieu Miron from McGill University and Genome Quebec Innovation Centre (Montreal, Canada) for",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 383,
    "paragraph": "their help with the design and analyses of the microarray experiments. This work was supported by Canadian Institutes of Health Research grants MOP- 37994 (ER) and MOP-84460 (YBD). Author details 1Laboratoire de Biologie Moléculaire, Département des Sciences Biologiques, Centre BioMed, Université du Québec à Montréal, Case Postale 8888",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 384,
    "paragraph": "Succursale Centre-ville, Montréal, QC, H3C-3P8, Canada. 2Sunnybrook Health Sciences Center, 2075 Bayview Ave. S223B, Toronto. ON, M4N 3M5, Canada. Authors’ contributions VV designed and performed the microarray, RT-PCR, differentiation assay and cloning of the viral insertion sites experiments, analyzed and interpreted the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 385,
    "paragraph": "data, and wrote the manuscript. PL performed the RT-PCR experiments on the human haematopoietic cell lines. DPSO optimized the protocol for the cloning of viral integration sites. YBD provided the HB22.2, K562 and HEL cell lines and critically revised the manuscript. ER guided the project and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 386,
    "paragraph": "Sultan C: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103(3):460-462. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 387,
    "paragraph": "American-British (FAB) co-operative group. British journal of haematology 1976, 33(4):451-458. Colita A, Belhabri A, Chelghoum Y, Charrin C, Fiere D, Thomas X: Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: A retrospective study of 54 cases. Annals of Oncology 2001,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 388,
    "paragraph": "12:451-455. 2. 3. 4. Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR: Erythroleukaemia in the north of England: a population based study. Journal of Clinical Pathology 2001, 54:608-612. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 389,
    "paragraph": "Page 16 of 17 5. 6. 7. 8. 9. Domingo-Claros A, Larriba I, Rozman M, Irriguible D, Vallespi T, Aventin A, Ayats R, Milla F, Sole F, Florensa L, et al: Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 390,
    "paragraph": "2002, 87(2):148-153. Rogelio Paredes-Aguilera LR-GNL-SRAT: Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children. American Journal of Hematology 2003, 73:71-80. Garderet L, Labopin M, Gorin NC, Polge E, Baruchel A, Meloni G, Ortega J, Vossen J, Bunjes D, Leverger G, et al: Hematopoietic stem cell",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 391,
    "paragraph": "transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2005, 105(1):405-409. Park S, Picard F, Dreyfus F: Erythroleukemia: a need for a new definition. Leukemia 2002, 16(8):1399-1401.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 392,
    "paragraph": "Linari S, Vannucchi AM, Ciolli S, Leoni F, Caporale R, Grossi A, Pagliai G, Santini V, Paoletti F, Ferrini PR: Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. British journal of haematology 1998, 102(5):1335-1337.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 393,
    "paragraph": "10. Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, Vainchenker W: Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood 1996, 88(4):1284-1296. 11. Nakorn TN, Miyamoto T, Weissman IL: Characterization of mouse clonogenic megakaryocyte progenitors. Proceedings of the National",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 394,
    "paragraph": "Academy of Sciences of the United States of America 2003, 100(1):205-210. 12. Voisin V, Barat C, Hoang T, Rassart E: Novel insights into the pathogenesis of the Graffi murine leukemia retrovirus. J Virol 2006, 80(8):4026-4037. 13. Blazejczyk M, Miron M, Nadon R: FlexArray: A statistical data analysis",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 395,
    "paragraph": "15. 14. software for gene expression microarrays. Genome Quebec, Montreal, Canada, URL http://genomequebec.mcgill.ca/FlexArray. 2007. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(25):14863-14868.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 396,
    "paragraph": "Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR: Interpreting patterns of gene expression with self- organizing maps: methods and application to hematopoietic differentiation. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(6):2907-2912.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 397,
    "paragraph": "Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(9):5116-5121. 17. Wong KS, Li YJ, Howard J, Ben-David Y: Loss of p53 in F-MuLV induced-",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 398,
    "paragraph": "erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence. Oncogene 1999, 18(40):5525-5534. 16. 18. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A: High- throughput retroviral tagging to identify components of specific",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 399,
    "paragraph": "signaling pathways in cancer. Nature genetics 2002, 32(1):153-159. 19. Voisin V, Rassart E: Erythroid and megakaryoblastic leukemias induced by the murine retrovirus Graffi Gene expression profiling MOE 430.2 GEO: GSE12581 Additional analyses and Downloadable excel filesURL: http:// www.biomed.uqam.ca/rassart/microarray.html. 2009. 20. Hao X, Shin MS, Zhou JX, Lee CH, Qi CF, Naghashfar Z, Hartley JW,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 400,
    "paragraph": "Fredrickson TN, Ward JM, Morse HC: Histologic and molecular characterizations of megakaryocytic leukemia in mice. Leuk Res 2006, 30(4):397-406, Epub 2005 Oct 2010.. 21. Hamlett I, Draper J, Strouboulis J, Iborra F, Porcher C, Vyas P: Characterization of megakaryocyte GATA1-interacting proteins: the",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 401,
    "paragraph": "corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation. Blood 2008, 112(7):2738-2749. 22. Nucifora G, Laricchia-Robbio L, Senyuk V: EVI1 and hematopoietic 23. disorders: history and perspectives. Gene 2006, 368:1-11. Kilbey A, Alzuherri H, McColl J, Cales C, Frampton J, Bartholomew C: The",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 402,
    "paragraph": "Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity. British journal of haematology 2005, 130(6):902-911. 24. Bond HM, Mesuraca M, Carbone E, Bonelli P, Agosti V, Amodio N, De 25. Hentges KE, Weiser KC, Schountz T, Woodward LS, Morse HC, Justice MJ:",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 403,
    "paragraph": "Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B- cell leukemia. Oncogene 2005, 24(7):1220-1230. 26. Hu L, Sham JS, Xie D, Wen JM, Wang WS, Wang Y, Guan XY: Up-regulation of fibroblast growth factor 3 is associated with tumor metastasis and",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 404,
    "paragraph": "recurrence in human hepatocellular carcinoma. Cancer Lett 2007, 252(1):36-42. van Lohuizen M, Breuer M, Berns A: N-myc is frequently activated by proviral insertion in MuLV-induced T cell lymphomas. Embo J 1989, 8(1):133-136. 27. 28. Yancopoulos GD, Nisen PD, Tesfaye A, Kohl NE, Goldfarb MP, Alt FW: N-myc",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 405,
    "paragraph": "can cooperate with ras to transform normal cells in culture. Proc Natl Acad Sci USA 1985, 82(16):5455-5459. 29. Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM: Abrogation of fibroblast activation protein",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 406,
    "paragraph": "enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005, 4(3):351-360. 30. Rogulski KR, Cohen DE, Corcoran DL, Benos PV, Prochownik EV: Deregulation of common genes by c-Myc and its direct target, MT-MC1. Proceedings of the National Academy of Sciences of the United States of",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 407,
    "paragraph": "America 2005, 102(52):18968-18973. 32. 31. Yates KE, Gasson JC: Role of c-Fes in normal and neoplastic hematopoiesis. Stem cells (Dayton, Ohio) 1996, 14(1):117-123. Emilia G, Donelli A, Ferrari S, Torelli U, Selleri L, Zucchini P, Moretti L, Venturelli D, Ceccherelli G, Torelli G: Cellular levels of mRNA from c-myc,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 408,
    "paragraph": "c-myb and c-fes onc-genes in normal myeloid and erythroid precursors of human bone marrow: an in situ hybridization study. British journal of haematology 1986, 62(2):287-292. Fox AH, Liew C, Holmes M, Kowalski K, Mackay J, Crossley M: Transcriptional cofactors of the FOG family interact with GATA proteins",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 409,
    "paragraph": "by means of multiple zinc fingers. The EMBO journal 1999, 18(10):2812-2822. 33. 34. Hromas R, Orazi A, Neiman RS, Maki R, Van Beveran C, Moore J, Klemsz M: Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. Blood 1993, 82(10):2998-3004.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 410,
    "paragraph": "35. Doubeikovski A, Uzan G, Doubeikovski Z, Prandini MH, Porteu F, Gisselbrecht S, Dusanter-Fourt I: Thrombopoietin-induced expression of the glycoprotein IIb gene involves the transcription factor PU.1/Spi-1 in UT7-Mpl cells. The Journal of biological chemistry 1997, 272(39):24300-24307. 36. Denicourt C, Edouard E, Rassart E: Oncogene activation in myeloid",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 411,
    "paragraph": "leukemias by Graffi murine leukemia virus proviral integration. J Virol 1999, 73(5):4439-4442. 37. Chen Z, Hu M, Shivdasani RA: Expression analysis of primary mouse megakaryocyte differentiation and its application in identifying stage- specific molecular markers and a novel transcriptional target of NF-E2.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 412,
    "paragraph": "Blood 2007, 109(4):1451-1459. 38. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P: Platelets express functional Toll-like receptor-4. Blood 2005, 106(7):2417-2423. 39. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O: Evidence of Toll-like receptor molecules on human platelets. Immunology",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 413,
    "paragraph": "and cell biology 2005, 83(2):196-198. 40. Welch JJ, Watts JA, Vakoc CR, Yao Y, Wang H, Hardison RC, Blobel GA, 41. 42. 43. Chodosh LA, Weiss MJ: Global regulation of erythroid gene expression by transcription factor GATA-1. Blood 2004, 104(10):3136-3147. Fang J, Menon M, Kapelle W, Bogacheva O, Bogachev O, Houde E,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 414,
    "paragraph": "Browne S, Sathyanarayana P, Wojchowski DM: EPO modulation of cell- cycle regulatory genes, and cell division, in primary bone marrow erythroblasts. Blood 2007, 110(7):2361-2370. Sathyanarayana P, Menon MP, Bogacheva O, Bogachev O, Niss K, Kapelle WS, Houde E, Fang J, Wojchowski DM: Erythropoietin modulation",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 415,
    "paragraph": "of podocalyxin and a proposed erythroblast niche. Blood 2007, 110(2):509-518. Sathyanarayana P, Dev A, Fang J, Houde E, Bogacheva O, Bogachev O, Menon M, Browne S, Pradeep A, Emerson C, et al: EPO receptor circuits for primary erythroblast survival. Blood 2008, 111(11):5390-5399.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 416,
    "paragraph": "Rosa G, Di Nicola M, Gianni AM, Moore MA, et al: Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells. Blood 2004, 103(6):2062-2070. 44. Dreyfus F, Sola B, Fichelson S, Varlet P, Charon M, Tambourin P, Wendling F,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 417,
    "paragraph": "Gisselbrecht S: Rearrangements of the Pim-1, c-myc, and p53 genes in Friend helper virus-induced mouse erythroleukemias. Leukemia 1990, 4(8):590-594. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 17 of 17 45. Breslin A, Denniss FA, Guinn BA: SSX2IP: an emerging role in cancer.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 418,
    "paragraph": "Biochemical and biophysical research communications 2007, 363(3):462-465. 46. Ren M, Xu G, Zeng J, De Lemos-Chiarandini C, Adesnik M, Sabatini DD: Hydrolysis of GTP on rab11 is required for the direct delivery of transferrin from the pericentriolar recycling compartment to the cell",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 419,
    "paragraph": "surface but not from sorting endosomes. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(11):6187-6192. 47. Westlake CJ, Junutula JR, Simon GC, Pilli M, Prekeris R, Scheller RH, 65. presynaptic protein implicated in Parkinson’s disease, in erythropoietic",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 420,
    "paragraph": "lineage. Biochemical and biophysical research communications 2007, 358(1):104-110. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, et al: GATA transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein. Proceedings",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 421,
    "paragraph": "of the National Academy of Sciences of the United States of America 2008, 105(31):10907-10912. Jackson PK, Eldridge AG: Identification of Rab11 as a small GTPase binding protein for the Evi5 oncogene. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(4):1236-1241.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 422,
    "paragraph": "66. Vehvilainen P, Hyytiainen M, Keski-Oja J: Latent Transforming Growth Factor-b-binding Protein 2 Is an Adhesion Protein for Melanoma Cells. The Journal of Biochemical Chemistry 2003, 278:24705-24713. 48. Palmieri D, Bouadis A, Ronchetti R, Merino MJ, Steeg PS: Rab11a 67. Mattera R, Tsai YC, Weissman AM, Bonifacino JS: The Rab5 guanine",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 423,
    "paragraph": "differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast cancer research and treatment 2006, 100(2):127-137. 49. Yan J, Tsai SY, Tsai MJ: SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta pharmacologica Sinica 2006, 27(4):387-394. 50. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG: RTCGD:",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 424,
    "paragraph": "retroviral tagged cancer gene database. Nucleic acids research 2004, , 32 Database: D523-527. 51. Malin D, Kim IM, Boetticher E, Kalin TV, Ramakrishna S, Meliton L, Ustiyan V, Zhu X, Kalinichenko VV: Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-beta3 expression.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 425,
    "paragraph": "Molecular and cellular biology 2007, 27(7):2486-2498. 52. Ma SL, Sorensen AB, Kunder S, Sorensen KD, Quintanilla-Martinez L, Morris DW, Schmidt J, Pedersen FS: The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus. Virology 2006, 352(2):306-318.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 426,
    "paragraph": "53. Cheli Y, Kanaji S, Jacquelin B, Chang M, Nugent DJ, Kunicki TJ: Transcriptional and epigenetic regulation of the integrin collagen receptor locus ITGA1-PELO-ITGA2. Biochimica et biophysica acta 2007, 1769(9-10):546-558. 54. Hitzler JK, Zipursky A: Origins of leukaemia in children with Down",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 427,
    "paragraph": "55. syndrome. Nat Rev Cancer 2005, 5(1):11-20. Kitajima K, Tanaka M, Zheng J, Yen H, Sato A, Sugiyama D, Umehara H, Sakai E, Nakano T: Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2. Blood 2006, 107(5):1857-1863. 56. Chinnadurai G: CtBP, an unconventional transcriptional corepressor in",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 428,
    "paragraph": "development and oncogenesis. Molecular cell 2002, 9(2):213-224. 57. Maki K, Yamagata T, Asai T, Yamazaki I, Oda H, Hirai H, Mitani K: Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos. Blood 2005, 106(6):2147-2155. Terui K, Takahashi Y, Kitazawa J, Toki T, Yokoyama M, Ito E: Expression of",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 429,
    "paragraph": "transcription factors during megakaryocytic differentiation of CD34+ cells from human cord blood induced by thrombopoietin. The Tohoku journal of experimental medicine 2000, 192(4):259-273. 58. 68. nucleotide exchange factor Rabex-5 binds ubiquitin (Ub) and functions as a Ub ligase through an atypical Ub-interacting motif and a zinc",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 430,
    "paragraph": "finger domain. The Journal of biological chemistry 2006, 281(10):6874-6883. Kalesnikoff J, Rios EJ, Chen C-C, Nakae S, Zabel BA, Butcher EC, Tsai M, Tam S-Y, Galli SJ: RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proceedings of",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 431,
    "paragraph": "the National Academy of Sciences of the United States of America 2006, 103:2659-2664. 69. Weyrich AS, Zimmerman GA: Platelets: signaling cells in the immune 70. 71. 72. 73. 74. 75. 76. continuum. Trends in immunology 2004, 25(9):489-495. Elzey BD, Sprague DL, Ratliff TL: The emerging role of platelets in",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 432,
    "paragraph": "adaptive immunity. Cellular immunology 2005, 238(1):1-9. Sprague DL, Sowa JM, Elzey BD, Ratliff TL: The role of platelet CD154 in the modulation in adaptive immunity. Immunologic research 2007, 39(1- 3):185-193. von Hundelshausen P, Weber C: Platelets as immune cells: bridging inflammation and cardiovascular disease. Circulation research 2007,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 433,
    "paragraph": "100(1):27-40. Tanaka M, Aze Y, Fujita T: Adhesion molecule LFA-1/ICAM-1 influences on LPS-induced megakaryocytic emperipolesis in the rat bone marrow. Veterinary pathology 1997, 34(5):463-466. Slape C, Hartung H, Lin YW, Bies J, Wolff L, Aplan PD: Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 434,
    "paragraph": "during leukemic transformation. Cancer research 2007, 67(11):5148-5155. Ikonomi P, Rivera CE, Riordan M, Washington G, Schechter AN, Noguchi CT: Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation. Experimental hematology 2000, 28(12):1423-1431. Lecuyer E, Hoang T: SCL: from the origin of hematopoiesis to stem cells",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 435,
    "paragraph": "and leukemia. Experimental hematology 2004, 32(1):11-24. 77. Antonchuk J, Hyland CD, Hilton DJ, Alexander WS: Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors. Blood 2004, 104(5):1306-1313. 59. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 436,
    "paragraph": "78. Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R: 60. Suda T, Morishita K: Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. The EMBO journal 2005, 24(11):1976-1987. Saino M, Maruyama T, Sekiya T, Kayama T, Murakami Y: Inhibition of",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 437,
    "paragraph": "angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3. Oncology reports 2004, 12(1):47-52. 62. 61. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J: Induction of platelet formation from megakaryocytoid cells by nitric oxide.",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 438,
    "paragraph": "Proceedings of the National Academy of Sciences of the United States of America 2001, 98(25):14458-14463. Kiss RS, Ma Z, Nakada-Tsukui K, Brugnera E, Vassiliou G, McBride HM, Ravichandran KS, Marcel YL: The lipoprotein receptor-related protein-1 (LRP) adapter protein GULP mediates trafficking of the LRP ligand",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 439,
    "paragraph": "prosaposin, leading to sphingolipid and free cholesterol accumulation in late endosomes and impaired efflux. The Journal of biological chemistry 2006, 281(17):12081-12092. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ: SLAM family receptors distinguish hematopoietic stem and progenitor cells",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 440,
    "paragraph": "and reveal endothelial niches for stem cells. Cell 2005, 121(7):1109-1121. 63. 64. Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, Ohtaka- Maruyama C, Okado H, Hashimoto M: Expression of alpha-synuclein, a Chemotherapy-induced thrombocytopenia derives from the selective",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 441,
    "paragraph": "death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer research 2007, 67(10):4767-4773. 79. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, et al: Identification of",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 442,
    "paragraph": "distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(9):3339-3344. Toki T, Kanezaki R, Adachi S, Fujino H, Xu G, Sato T, Suzuki K, Tauchi H,",
    "jurnal": "1755-8794-3-2.pdf"
  },
  {
    "id": 443,
    "paragraph": "British Journal of Cancer (2004) 90, 756 – 760 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Minireview ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia (cid:1)(cid:1) (cid:1)",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 444,
    "paragraph": "(cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) E Canaani*,1, T Nakamura2, T Rozovskaia1, ST Smith2, T Mori2, CM Croce2 and A Mazo*,2",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 445,
    "paragraph": "1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel 76100; 2Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA Rearrangements of the ALL-1/MLL1 gene underlie the majority of infant acute leukaemias, as well as of therapy-related leukaemias developing in cancer patients treated with inhibitors of topoisomerase II, such as VP16 and doxorubicin. The rearrangements fuse",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 446,
    "paragraph": "& 2004 Cancer Research UK Keywords: acute lymphoblastic and myelogeneous leukaemia; mouse models; chromatin; epigenetic marking ACUTE LEUKAEMIAS ASSOCIATED WITH ALL-1 REARRANGEMENTS Chromosome band 11q23 is involved in reciprocal chromosome translocations in 5 – 10% of children and adults with acute",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 447,
    "paragraph": "lymphoblastic leukaemia (ALL) or acute myelogeneous leukaemia (AML). Nearly all these rearrangements affect the ALL-1 gene, also termed MLL1, HRX and HTRX, located at 11q23. The transloca- tions occur within an 8.3 kb breakpoint cluster region of the gene and result in the replacement of ALL-1-coding sequence 3’ to the",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 448,
    "paragraph": "breakpoint by the coding sequence of the translocation partner (Gu et al, 1992; Tkachuk et al, 1992). In a second and less frequent type of rearrangement, ALL-1 undergoes partial tandem duplica- tion (self-fusion), resulting in the production of a larger protein",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 449,
    "paragraph": "(Schichman et al, 1995). The most common ALL-1 translocations are t(4; 11), t(9; 11), t(11; 19), t(6; 11) and t(10; 11), accounting for 40, 27, 12, 5 and 5% of cases, respectively. However, the total number of different loci participating in ALL-1 translocations is",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 450,
    "paragraph": "amazingly high and has already exceeded 50 (Huret et al, 2001). There is an association between particular chromosomal translocations involving ALL-1 and subtypes of leukaemias. Thus, t(4; 11) nearly always occurs in ALL, t(9; 11) is mostly associated with AML, as are t(11; 19)(q23;p13.1), t(6;11), t(10;11) and the",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 451,
    "paragraph": "partial duplications. t(11; 19)(q23;p13.3) occurs in both AML and ALL. ALL1-associated ALLs are characterised as CD10(cid:1), CD19 þ and by B-cell precursor phenotype (pro B), with a high frequency of myeloid-associated (CD15 and/or CD65) antigen expression. Hence, they are also designated biphenotypic or mixed-lineage",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 452,
    "paragraph": "leukaemia. The AMLs are usually of the myelomonocytic (FAB- M4) or monoblastic (FAB-M5) morphological subtypes and sometimes express cell-surface lymphoid markers. The prognosis *Correspondence: E Canaani; E-mail: eli_canaani@weizmann.ac.il or A Mazo; E-mail: A_Mazo@lac.jci.tju.edu Received 12 August 2003; revised 14 December 2003; accepted 15",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 453,
    "paragraph": "December 2003 of patients with 11q23 abnormalities is dismal. Age is an important prognostic factor. Thus, less than 25% of infants (o1 year) and adults older than 40 or 50 years, with t(4; 11) or t(9; 11), are cured. Patients of intermediate age, in particular 2 – 9 or 1 – 14 years old,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 454,
    "paragraph": "have significantly better prognosis (Johansson et al, 1998; Swans- bury et al, 1998; Pui et al, 2002). The hallmark of ALL1-associated leukaemias is their epidemiol- ogy (reviewed in Greaves, 1999; Biondi et al, 2000). They predominate infant acute leukaemia (80% of ALL and 65% of",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 455,
    "paragraph": "AML), and account for the majority of therapy-related (secondary) leukaemias developing in 5 – 15% of primary cancer patients who had received intensive chemotherapy, including epipodophyllo- toxins (VP16) and anthracyclines (doxorubicin) (Pui and Relling, 2000). These drugs are inhibitors of topoisomerase II, and act by",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 456,
    "paragraph": "stabilising double-strand DNA breaks generated by this enzyme. In the latency period is both infant and secondary leukaemias, remarkably brief. In infants, ALL-1 rearrangements can be already detected in utero and the average age at diagnosis is 6 months, and in secondary leukaemias, latency averages around 18 – 30 months",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 457,
    "paragraph": "(reviewed in Greaves, 1999; Pui and Relling, 2000). The very brief in time between the initiating event and clinical disease, conjunction with the high rate of concordance in identical twins with infant leukaemia, points to the effectiveness of ALL-1 fusion proteins in driving the initial clone into frank leukaemia. Based on",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 458,
    "paragraph": "the findings from therapy-related leukaemia, it was hypothesised (Ross et al, 1994) that transplacental exposure of the foetus to natural (such as flavonoids in foods and drinks) might play a role in infant leukaemia. Such exposure will induce accumulation of DNA’s",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 459,
    "paragraph": "free ends from within the breakpoint cluster region of ALL-1, and this would eventually result in 11q23 translocations. The results of recent biochemical experiments (Strick et al, 2000) are consistent with this hypothesis. A structural feature shared by many topoisomerase II inhibitors, including anticancer drugs,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 460,
    "paragraph": "is the quinone moiety. The metabolism of quinones is controlled by the enzyme NQO1 that converts toxic benzoquinones to topoisomerase II substances inhibit that hydroxyquinones. A polymorphism in nucleotide 609 of the enzyme substitutes a proline into serine and consequently inactivates the enzyme. Comparison of paediatric leukaemias with",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 461,
    "paragraph": "and without ALL-1 rearrangement indicated significant bias in the former for NQO1 genotypes conferring low or no enzymatic activity (Wiemels et al, 1999; Smith et al, 2002), suggesting that inactivating NQO1 polymorphism increases the risk for ALL-1- associated leukaemias. MOUSE MODELS OF ALL-1 LEUKAEMOGENESIS",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 462,
    "paragraph": "Two methodologies have been used to generate mouse models of ALL-1 leukaemogenesis. Knockin of the partner gene AF9 into the ALL-1 locus by homologous recombination resulted in animals that developed AML at approximately 6 months (Dobson et al, 1999). Transmission of the transgene in the germ line and its",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 463,
    "paragraph": "expression during embryogenesis resulted in viable progeny. This, together with the observation that mice carrying a single null allele of ALL-1 were not predisposed to AML (Corral et al, 1996), rules out a model of leukaemogenesis due to haploinsufficiency (passive loss of function). Rather, an extensive series of investigations",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 464,
    "paragraph": "applying retro viral transduction into cultured haematopoietic followed by transplantation into mice, have progenitor cells, established that ALL-1 fusion genes act as dominant alleles and the disease is due to ALL-1 gain of function. Structure – function analysis of several ALL-1 fusion proteins showed that particular",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 465,
    "paragraph": "elements within the partner proteins, such as transcription effector domains and protein – protein interaction motifs, are critical for the leukaemogenic activity (reviewed in Ayton and Cleary, 2001). The presence of dimerisation domains in some of the partner proteins, such as AF6, AF10, AF17, AF1p, GAS7 and AF3p21",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 466,
    "paragraph": "suggested that self-association might underlie the role of the partner proteins with such motifs in the leukaemogenicity of ALL- 1 fusion proteins. The most compelling experimental evidence for this is that homodimerisation of ALL-1 by synthetic dimerisation modules mimics many of the features of ALL-1 fusion proteins",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 467,
    "paragraph": "(Dobson et al, 2000; So et al, 2003b, Martin et al, 2003). Also, disruption of the dimerisation motifs in some partner proteins eliminated pathogenicity. Although self-dimerisation appears to play a key role in leukaemogenesis associated with partner proteins containing a dimerisation motif,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 468,
    "paragraph": "the most common fusions – ALL-1/AF4, ALL-1/AF9 and ALL-1/ENL – do not dimerise. Both the knockin and retroviral transduction approaches turned out to be biased towards myeloid leukaemia. However, very recent studies with virally transduced ALL1-ENL (Zeisig et al, 2003) and",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 469,
    "paragraph": "ALL1-GAS7 (So et al, 2003a) showed transformation of bipheno- typic lymphoid/myeloid cells and induction of biphenotypic leukaemia. So et al serially plated the transduced bone marrows in methylcellulose and found that the fusion protein conferred long-term growth capacity to multipotential progenitors. The",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 470,
    "paragraph": "progenitors spontaneously differentiated into biphenotypic and myeloid progenitors during culturing in vitro. Moreover, mice injected with the transduced serially-plated progenitors developed either biphenotypic leukaemia, or AML or ALL. On the basis of these experiments, it was proposed that ALL-1 fusion proteins",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 471,
    "paragraph": "enhance the self-renewal potential of multipotent progenitors that retain an ability to differentiate into downstream progeny. The latter are more susceptible to differentiation blocking by ALL-1 fusion proteins, or are prone to secondary mutations required for full malignant transformation. GENE EXPRESSION PROFILES OF ALL-1 LEUKAEMIAS",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 472,
    "paragraph": "DNA microarrays technology has been recently applied to construct expression profiles of ALLs and/or AMLs with ALL-1 rearrangements (Rozovskaia et al, 2001, 2003; Armstrong et al, 2002; Yeoh et al, 2002). Both ALL-1-associated ALLs and AMLs 757 ALL-1/MLL1 and acute leukaemia",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 473,
    "paragraph": "E Canaani et al have distinct expression patterns that distinguish them from other types of ALL and AML, respectively. The distinction is more robust for ALL, probably reflecting the unusual clinical and biological features and the biphenotypic trait of the disease, not shared",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 474,
    "paragraph": "by other classes of ALL. In one study (Rozovskaia et al, 2003), genes whose expression pattern separated ALLs with t(4;11) from other ALLs were further subdivided, enabling the identification of two subfamilies of t(4;11) tumours. In that study, a substantial number of the genes, which were found to correlate in their",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 475,
    "paragraph": "expression with the t(4;11) genotype, had been previously associated with cancer, apoptosis or growth control. These included overexpressed oncogenes (such as HOX A9, HOX A10, MEIS1, LMO2 and MYC), overexpressed genes involved in protection from apoptosis and in survival, underexpressed proapoptotic genes, overexpressed genes",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 476,
    "paragraph": "involved in drug resistance and underexpressed tumour suppressors and growth inhibitors such as FHIT and DAPK1. Determination of which of the genes pointed out in the DNA microarrays analyses plays a direct role in pathogenesis might come from experiments with mice. One approach will be to alter",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 477,
    "paragraph": "the expression (e.g. by interference RNA) of a suspected gene in cell lines with 11q23 translocations, and examine whether the capacity of the cell lines to induce leukaemia in mice is lost. The second approach will be to transduce the fusion genes into mice",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 478,
    "paragraph": "null for genes suspected of playing an essential role in ALL-1 pathogenesis, and examine the effect on leukaemia development. Such an experiment has been recently reported for HOX A9 and HOX A7 (Ayton and Cleary, 2003). These two genes were found",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 479,
    "paragraph": "required for in vitro myeloid immortalisation by the MLL/ENL fusion protein transduced by a retroviral vector into bone marrow cells. Further, HOX A9 was found to be indispensable for ALL-1- dependent leukaemogenesis in vivo. Applying a complementary approach, Kumar et al (2004) bred mice to obtain animals",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 480,
    "paragraph": "transgenic for MLL-AF9 and null for HOX A9 and examined leukaemia development. Surprisingly, the absence of HOX A9 did not affect the incidence and latency of leukaemia, although the malignant cells displayed a more immature myeloid phenotype. The authors suggest that several HOX genes might have to be",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 481,
    "paragraph": "inactivated to impair leukaemogenicity. The reasons for the contrasting conclusion obtained by the two approaches are currently not known. BIOLOGICAL AND BIOCHEMICAL ACTIVITY OF ALL-1 AND ITS DROSOPHILA HOMOLOGUE TRITHORAX (TRX) ALL-1 and TRX are members of the evolutionary conserved gene",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 482,
    "paragraph": "family termed as the Trx group (TrxG) that are positive regulators of the homeotic gene complex (HOX) during development, and whose activity is opposed by the repressive activity of the Polycomb group (PcG). The TrxG and PcG proteins are not required for initiation of HOX genes activity, but act to maintain",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 483,
    "paragraph": "transcriptional states through later stages of development (re- viewed in Brock and van Lohuizen, 2001; Simon and Tamkun, 2002). ALL-1 also acts at the stage of maintenance (Yu et al, 1998). Since considerably more genetic and biological information is in comparison to ALL-1, here we will",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 484,
    "paragraph": "available about TRX, emphasise studies of the former. Approximately 20 genes have been characterised as members of the fly TrxG; however, this number is rapidly growing based on genetic and molecular criteria (Gildea et al, 2000; Faucheux et al, 2003). Further, it has became",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 485,
    "paragraph": "apparent that the target genes of the TrxG are not limited to HOX genes (Kuzin et al, 1994; Maurange and Paro, 2002; Beltran et al, 2003). In this context, we have recently demonstrated (Smith et al, 2004) that following heat induction, the TRX complex is quickly",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 486,
    "paragraph": "recruited to several heat-shock genes on salivary polytene chromosomes, where it is required to maintain a high level of & 2004 Cancer Research UK British Journal of Cancer (2004) 90(4), 756 – 760 758 ALL-1/MLL1 and acute leukaemia E Canaani et al",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 487,
    "paragraph": "already initiated transcription. Such a role is similar to the role of TRX in HOX gene expression. Much effort was devoted to in vivo analysis of the properties of TrxG and PcG response elements (TRE and PRE, respectively) at target loci in Drosophila. The emerging picture of the best studied",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 488,
    "paragraph": "target, the regulatory region of the Drosophila Bithorax complex BX-C gene Ubx, suggests that although TREs and PREs are intermingled within a 1.5 kb region bxd, they may represent separable regulatory elements (Tillib et al, 1999). It is still not clear",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 489,
    "paragraph": "whether the TrxG and PcG proteins occupy their respective responsive elements at all time, or only when the target gene is active or repressed, respectively. Evidence that these proteins may occupy their binding sites depending on the status of gene expression came recently from analysis of Drosophila larval fat",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 490,
    "paragraph": "body (Marchetti et al, 2003). BX-C genes are repressed in the anterior region of the fat body, but are active in the mid-posterior part. In parallel, the PC protein (but not TRX) was detected at the cytological site of bithorax on polytene chromosomes from",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 491,
    "paragraph": "the anterior part of the fat body, while a strong signal of TRX (but not of PC) was detected on chromosomes from the mid-posterior fat body. The mechanism by which TRX and ALL-1 reach their target loci is not known. The absence of sequence-specific DNA-binding",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 492,
    "paragraph": "protein among components of the TRX and ALL-1 complexes (see later) emphasises this quandary. Several recent studies (Bender and Fitzgerald, 2002; Hogga and Karch, 2002; Rank et al, 2002) showed that ectopic or induced transcription through regulatory elements of the Bithorax complex switches the elements from",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 493,
    "paragraph": "silenced to activated states. On the basis of this, it was proposed that passage of the RNA polymerase II complex through a regulatory element displaces the repressive PcG complex, set there by default, and enables recruitment of the TRX complex that",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 494,
    "paragraph": "imprints epigenetic marks instructing transcription of the adjacent HOX gene. Chromatin immunoprecipitation (ChIP) experiments previously identified TRX both on TREs and on promoters within the Bithorax gene complex (Orlando et al, 1998). The ChIP methodology was recently applied to ALL-1 (Nakamura et al,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 495,
    "paragraph": "2002; Milne et al, 2002) and the protein was found bound at the promoters of HOX A9 and HOX C8 in cultured cells expressing these genes (homologues of Drosophila TREs and PREs have not been identified yet in mammals). Elimination of ALL-1, by",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 496,
    "paragraph": "applying interference RNA methodology, blocked transcription of HOX A9. Both studies showed that ALL-1 is a histone methyltransferase that methylates lysine 4 of histone H3. The enzymatic activity is conferred by the C-terminal SET domain. The presence of ALL-1 on the promoters of the two HOX genes is",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 497,
    "paragraph": "linked to H3-Lys4 methylation as well as to acetylation of histones H3 and H4 at the promoter. Several other TrxG, PcG, and other chromatin – associated proteins containing SET domains – were recently shown to methylate histones at specific residues (reviewed",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 498,
    "paragraph": "in Orlando, 2003). Such marking of histones (as are acetylation, phosphorylation and ubiquitination of specific histone residues) conveys heritable transcription patterns (expression or silencing) in an epigenetic manner. the TAC1 complex that The molecular mechanisms by which TRX and ALL-1 act was",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 499,
    "paragraph": "further elucidated by the identification and characterisation of stable protein complexes associated with the two proteins. TRX is a component of includes the histone acetyltransferase (HAT) dCBP, and a SET - binding factor, SBF1 (Petruk et al, 2001). The recruitment of TAC1 components to the",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 500,
    "paragraph": "following heat HSP70 locus in enhanced induction results the gene and correlates with acetylation and expression of methylation of histones (Smith et al, 2004). The ALL-1 complex (Nakamura et al, 2002) completely varies from that of TRX. It contains at least 29 proteins. The majority of",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 501,
    "paragraph": "the latter are components of seven subcomplexes involved in transcription preinitiation, nucleosome remodelling, histone deacetylation, histone methylation or RNA processing. The purified ALL-1 complex methylates, acetylates, deacetylates and remodels nucleo- somes and is bound at the promoter of the target gene HOX A9. It",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 502,
    "paragraph": "appears that a major role of ALL-1 is to assemble this large supercomplex of enzymatic activities. In summary, the recent biochemical experiments indicate that TRX and ALL-1 recruit to target genes a host of enzymatic activities, mostly involved in epigenetic marking. The way in which these marks are inherited to",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 503,
    "paragraph": "progeny cells (memorized) is not known (they have to survive DNA replication, during which the histones are thought to be stripped off the DNA), but it has been speculated (Turner, 2000; Richards and Elgin, 2002) that the modified histones stay at or",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 504,
    "paragraph": "near the replication fork and are incorporated into the daughter DNA strands. UNRESOLVED ISSUES AND FUTURE DIRECTIONS raises the Drosophila BX-C genes While considerable progress was made in identification of the biochemical activities of the ALL-1 and TRX protein complexes, the mechanism by which these complexes are recruited to specific",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 505,
    "paragraph": "sequences (genes) is completely unknown. The recent reports that transcription of regulatory regions induces heritable transcrip- tional activation of the possibility that such a mechanism is involved in the recruitment of TRX and ALL-1 complexes. Another outstanding issue is the identification of genes, other than HOX, that are regulated by ALL-",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 506,
    "paragraph": "1 and TRX. The demonstration that the mammalian PcG protein BMI-1 regulates the important cell cycle locus INK4a/ARF (Jacobs et al, 1999) suggests that looking for additional ALL-1/TRX targets (e.g. by conditional elimination or activation of the two proteins, followed by DNA microarray analysis) might be rewarding.",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 507,
    "paragraph": "Further, the process by which the ALL-1-mediated histone H3- Lys4 methylation induces chromatin alteration (presumably decondensation) and gene expression, and the precise roles of the transcriptional subcomplexes within ALL-1 supercomplex, have yet to be determined. A new line of investigation is likely to",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 508,
    "paragraph": "originate from the recent remarkable finding that the PHD finger motif of the ING2 protein binds phosphoinositides, and that this interaction regulates the biological activity of the latter (Gozani et al, 2003). The presence of four PHD finger motifs in both ALL-1",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 509,
    "paragraph": "and TRX points to a potential central mechanism by which these the reason why ALL-1 (and proteins are regulated. Finally, presumably TRX) is proteolytically cleaved by an evolutionary conserved enzyme into two polypeptides, which are held together, is not known (Nakamura et al, 2002; Yokoyama et al, 2002; Hsieh",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 510,
    "paragraph": "et al, 2003). Mouse models have recently identified the type of precursor cell transformed by ALL-1 fusion proteins, and DNA microarrays analyses focused attention on genes that might play a direct role in leukaemogenesis. Identification of such genes is clearly a focal",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 511,
    "paragraph": "point for understanding the disease in molecular terms and for future therapeutic intervention. However, other central questions remain. First, do all ALL-1 fusions, including self-fusions, trigger a single pathway leading to disease? Why are most fusions associated with specific leukaemia subtype (e.g. ALL1-AF4 with ALL, ALL1-",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 512,
    "paragraph": "AF6 with AML)? Second, since the fusion proteins lack the SET domain with its histone H3-Lys4 methylation activity, how do they retain transcriptional activation capacity? Do they target all genes regulated by normal ALL-1? Do they compete with normal ALL-1 on the same targets? Do they block transcription of some loci?",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 513,
    "paragraph": "Also, the absence of the PHD fingers in ALL-1 fusion proteins should relieve them from potential regulation by phosphoinosi- tides; whether this is an important aspect of the leukaemogenic activity of these proteins has yet to be determined. A third issue is",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 514,
    "paragraph": "whether ALL-1 fusions confer resistance to apoptosis. ALL-1- associated leukaemias are notorious for their poor prognosis with chemotherapy, and exhibit drug resistance. Since it is now believed British Journal of Cancer (2004) 90(4), 756 – 760 & 2004 Cancer Research UK",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 515,
    "paragraph": "ALL-1/MLL1 and acute leukaemia E Canaani et al 759 that the cytotoxic action of most chemotherapeutic drugs is through activation of apoptotic pathways, drug resistance of ALL-1 leukaemias might be due to disruption of apoptotic processes. Such disruptions appear to be crucial for the development of many tumours (reviewed",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 516,
    "paragraph": "in Johnstone et al, 2002). Still, very little has been reported about this issue with regard to ALL-1 leukaemias. In one study (Kersey et al, 1998), ALLs with t(4; 11) were compared to similar tumours without t(4; 11) and found to be dramatically more resistant to serum",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 517,
    "paragraph": "deprivation stress. A recent investigation (Wiederschain et al, 2003) showed nuclear colocalisation of the fusion protein ALL1-ELL with p53, and loss of p53-mediated apoptosis. Whether this phenomenon is unique to that particular fusion protein or is it of a more general",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 518,
    "paragraph": "nature is presently not known. ACKNOWLEDGEMENTS We apologise to our colleagues whose work was not cited, due to space limitations. Work in the authors’ laboratories was supported by NCI Grant CA50507 and by grants from the Israeli Academy of Science, the Israeli Cancer Research Fund and US – Israel BSF.",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 519,
    "paragraph": "Ayton PM, Cleary ML (2001) Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20: 5695 – 5707 Ayton PM, Cleary ML (2003) Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17: 2298 – 2307",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 520,
    "paragraph": "Beltran S, Blanco E, Serras F, Perez-Villamil B, Guigo R, Artavanis- Tsakonas S, Corominas M (2003) Transcriptional network controlled by the trithorax-group gene ash2 in Drosophila melanogaster. Proc Natl Acad Sci USA 100: 3293 – 3298 Bender W, Fitzgerald DP (2002) Transcription activates repressed domains",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 521,
    "paragraph": "in the Drosophila bithorax complex. Development 129: 4923 – 4930 Biondi A, Cimino G, Pieters R, Pui C-H (2000) Biological and therapeutic aspects of infant leukemia. Blood 96: 24 – 33 Brock HW, van Lohuizen M (2001) The polycomb group – no longer an",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 522,
    "paragraph": "exclusive club? Curr Opin Genet Dev 11: 175 – 181 Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie AN, King G, Rabbitts TH (1996) An MLL-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 523,
    "paragraph": "mice: a method to create fusion oncogenes. Cell 85: 853 – 861 Dobson CL, Warren AJ, Pannel R, Forster A, Lavenir I, Corral J, Smith AJ, Rabbitts TH (1999) The MLL – AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukemogenesis. EMBO",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 524,
    "paragraph": "J 18: 3564 – 3574 Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH (2000) Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J 19: 843 – 851 Faucheux M, Roignant JY, Netter S, Charollais J, Antoniewski C, Theodore",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 525,
    "paragraph": "L (2003) Batman interacts with polycomb and trithorax group genes and encodes a BTB/POZ protein that is included in a complex containing GAGA factor. Mol Cell Biol 23: 1181 – 1195 Gildea JJ, Lopez R, Shearn A (2000) A screen for new trithorax group genes",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 526,
    "paragraph": "identified little imaginal discs, the Drosophila melanogaster homologue of human retinoblastoma binding protein 2. Genetics 156: 645 – 663 Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, Villasenor J, Mehrotra B, Chen J, Rao VR,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 527,
    "paragraph": "Brugge JS, Ferguson CG, Payrastre B, Myszka DG, Cantley LC, Wagner G, Divecha N, Prestwich GD, Yuan J (2003) The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinosi- tide receptor. Cell 114: 99 – 111 Greaves M (1999) Molecular genetics, natural history and the demise of",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 528,
    "paragraph": "childhood leukaemia. Eur J Cancer 35: 1941 – 1953 Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E (1992) The t(4;11) chromosome translocation of human acute leukemia fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 529,
    "paragraph": "4 gene. Cell 71: 701 – 708 Hogga I, Karch F (2002) Transcription through the iab-7 cis-regulatory domain of the bithorax complex interferes with Polycomb mediated silencing. Development 129: 4915 – 4922 Hsieh JJ, Cheng EH, Korsmeyer SJ (2003) Taspasel: a threonine aspartase",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 530,
    "paragraph": "required for cleavage of MLL and proper HOX gene expression. Cell 115: 293 – 303 Huret JL, Dessen P, Bernheim A (2001) An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 15: 987 – 989 Jacobs JJL, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999) The",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 531,
    "paragraph": "oncogene and Polycomb group gene bmi-1 regulates cell proliferation and senescence through the INK4a locus. Nature 397: 164 – 168 Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S, Secker-Walker LM (1998) Hemotologic malignancies with t(4;11) (q21;q23): a cytogenetic, morphologic, immunophenotypic and clinical",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 532,
    "paragraph": "study of 183 cases. Leukemia 12: 779 – 787 Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153 – 164 Kersey JH, Wang D, Oberto M (1998) Resistance of t(4;11)(MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 533,
    "paragraph": "extensive extramedullary accumulation of cells and poor prognosis. Leukemia 12: 1561 – 1564 Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, Kersey JH (2004) Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood, inpress, Epub 2003, Nov 13",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 534,
    "paragraph": "Kuzin B, Tillib S, Sedkov Y, Mizrokhi L, Mazo A (1994) The Drosophila trithorax gene encodes a chromosomal protein and directly regulates the region-specific homeotic gene forkhead. Genes Dev 8: 2478 – 2490 Marchetti M, Fanti L, Berloco M, Pimpinelli S (2003) Differential expression",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 535,
    "paragraph": "of the Drosophila BX-C in polytene chromosomes in cells of larval fat bodies: a cytological approach to identifying in vivo targets of the homeotic Ubx, Abd-A and Abd-B proteins. Development 130: 3683 – 3689 Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D, Brock HW,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 536,
    "paragraph": "JL (2003) Dimerization of MLL fusion proteins Slany R, Hess immortalizes hematopoietic cells. Cancer Cell 4: 197 – 207 Maurange C, Paro R (2002) A cellular memory module conveys epigenetic inheritance of hedgehog expression during Drosophila wing imaginal disc development. Genes Dev 16: 2672 – 2683",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 537,
    "paragraph": "Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL (2002) MLL targets SET domain methyltransferase activity to HOX gene promoters. Mol Cell 10: 1107 – 1117 Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassel R,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 538,
    "paragraph": "Dubois G, Mazo A, Croce CM, Canaani E (2002) ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10: 1119 – 1128 Orlando V (2003) Polycomb, epigenomes and control of cell identity. Cell",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 539,
    "paragraph": "112: 599 – 606 Orlando V, Jane EP, Chinwalla V, Harte PJ, Paro R (1998) Binding of Trithorax and Polycomb proteins to the bithorax complex: dynamic changes during early Drosophila embryogenesis. EMBO J 17: 5141 – 5150 Petruk S, Sedkov Y, Smith S, Tillib S, Kraevski V, Nakamura T, Canaani E,",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 540,
    "paragraph": "Croce CM, Mazo A (2001) Trithorax and dCBP acting in a complex to maintain expression of homeotic gene. Science 294: 1331 – 1334 Pui C-H, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DD, Vilmer E, Schrappe M, Camitta B",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 541,
    "paragraph": "(2002) Outcome of treatment in childhood acute lymphoblastic leukemia with rearrangements of the 11q23 chromosomal region. Lancet 359: 1909 – 1915 Pui C-H, Relling MV (2000) Topoisomerase II inhibitor-related acute myeloid leukemia. Br J Haematol 109: 13 – 23 Rank G, Prestel M, Paro R (2002) Transcription through intergenic",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 542,
    "paragraph": "chromosomal memory elements of the Drosophila bithorax complex correlates with an epigenetic switch. Mol Cell Biol 22: 8026 – 8034 Richards EJ, Elgin SCR (2002) Epigenetic codes for heterochromatin formation and silencing. Rounding up the usual suspects. Cell 108: 489 – 500",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 543,
    "paragraph": "Ross JA, Potter JD, Robison LL (1994) Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst 86: 1678 – 1680 & 2004 Cancer Research UK British Journal of Cancer (2004) 90(4), 756 – 760 760 ALL-1/MLL1 and acute leukaemia",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 544,
    "paragraph": "E Canaani et al Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E (2001) Upregulation of Meis1 and HOXA9 in acute lymphocytic leukemias with the (4;11) abnormality. Oncogene 20: 874 – 878",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 545,
    "paragraph": "Rozovskaia T, Ravid-Amir O, Tillib S, Getz G, Feinstein E, Agrawal H, Nagler A, Rappaport EF, Issaeva I, Matsuo Y, Kees UR, Lapidot T, Lo Coco F, Foa R, Mazo A, Nakamura T, Croce CM, Cimino G, Domany E, Canaani E (2003) Expression profiles of acute lymphoblastic and",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 546,
    "paragraph": "myeloblastic leukemias with ALL-1 rearrangements. Proc Natl Acad Sci USA 100: 7853 – 7858 Schichman SA, Canaani E, Croce CM (1995) Self fusion of the ALL-1 gene. A new genetic mechanism for acute leukemia. JAMA 273: 571 – 576 Simon JA, Tamkun JW (2002) Programming off and on states in chromatin:",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 547,
    "paragraph": "mechanisms of polycomb and trithorax group complexes. Curr Opin Genet Dev 12: 210 – 218 Smith MT, Wang Y, Skibola CF, Slater DJ, Lo Nigro L, Nowell PC, Lange BJ, Felix CA (2002) Low NAD(P)H : quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 548,
    "paragraph": "infants and children. Blood 100: 4590 – 4593 Smith ST, Petruk S, Sedkov Y, Cho E, Tillib S, Canaani E, Mazo A (2004) Modulation of heat shock gene expression by TAC1 chromatin modifying complex. Nat Cell Biol, in press So CW, Karsunky H, Passegue´ E, Cozzio A, Weissman IL, Cleary ML",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 549,
    "paragraph": "(2003a) MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3: 161 – 171 So CW, Lin M, Ayton PM, Chen EH, Cleary ML (2003b) Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 550,
    "paragraph": "Cancer Cell 4: 99 – 110 Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 97: 4790 – 4795 Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM (1998)",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 551,
    "paragraph": "Hematological malignancies with t(9;11)(p21-22;q23): a laboratory and clinical study of 125 cases. Leukemia 12: 792 – 800 Tillib S, Petruk S, Sedkov Y, Kuzin A, Fujioka M, Goto T, Mazo A (1999) Trithorax- and Polycomb-group response elements within an ultra- bithorax transcription maintenance unit consist of closely situated but",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 552,
    "paragraph": "separable sequences. Mol Cell Biol 19: 5189 – 5202 Tkachuk DC, Kohler S, Cleary ML (1992) Involvement of a homologue of Drosophila trithorax by 11q23 chromosome translocations in acute leukemias. Cell 71: 691 – 700 Turner BM (2000) Histone acetylation and an epigenetic code. BioEssays 22:",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 553,
    "paragraph": "836 – 845 Wiederschain D, Kawai H, Gu J, Shilatifard A, Yuan Z-M (2003) Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Mol Cell Biol 23: 4230 – 4246 Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 554,
    "paragraph": "MF (1999) A lack of a functional NAD(P)H : quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 59: 4095 – 4099 Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 555,
    "paragraph": "FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve C, Wong L, Downing JR (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 556,
    "paragraph": "Cancer Cell 1: 133 – 143 Yokoyama A, Kitabayashi I, Ayton PM, Cleary ML, Ohki M (2002) Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 100: 3710 – 3718 Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ (1998) MLL, a",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 557,
    "paragraph": "mammalian trithorax-group gene, functions as a transcriptional main- tenance factor in morphogenesis. Proc Natl Acad Sci USA 95: 10632 – 10636 Zeisig BB, Garcia-Cuellar MP, Winkler TH, Slany RK (2003) The oncoprotein MLL – ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene 22:",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 558,
    "paragraph": "1629 – 1637 British Journal of Cancer (2004) 90(4), 756 – 760 & 2004 Cancer Research UK",
    "jurnal": "90-6601639a.pdf"
  },
  {
    "id": 559,
    "paragraph": "Jurnal Kesehatan Perintis 9 (2) 2022 : 76-81 Contents list available at JKP website Jurnal Kesehatan Perintis Journal homepage: https://jurnal.upertis.ac.id/index.php/JKP Nilai Leukosit, Eritrosit dan Trombosit pada Penderita Leukemia Limfoblastik Akut Pasien Anak Rifka Rahmat1, Djong Hon Tjong2 , Almurdi Almurdi3, Meri Wulandari4",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 560,
    "paragraph": "1)Program Studi Bioteknologi Pascasarjana Universitas Andalas, Sumatera Barat, Indonesia 2)Jurusan Biologi Fakultas MIPA Universitas Andalas, Sumatera Barat, Indonesia 3)Fakultas Kedokteran Universitas Andalas, Sumatera Barat, Indonesia 4)Fakultas Kesehatan Universitas Perintis Indonesia, Sumatera Barat, Indonesia Article Information : Received;08 Sept 2022; Accepted 26 Dec 2022; Published online 31 Dec 2022",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 561,
    "paragraph": "*Corresponding author : rifkarahmat@gmail.com ABSTRAK Leukemia merupakan suatu penyakit keganasan sel darah yang ditandai proliferasi leukosit secara tidak terkendali dengan manifestasi adanya sel-sel abnormal. Di Sumatera Barat penyakit ini menunjukkan prevalensi leukemia sebesar 2,4%. Penelitian ini bertujuan untuk melihat gambaran nilai Leukosit, Eritrosit dan Trombosit pada Penderita Leukemia",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 562,
    "paragraph": "Limfoblastik Akut (LLA) Pasien Anak di RSUP DR. M. Djamil Padang. Populasi dalam penelitan ini adalah pasien LLA anak yang menjalani kontrol di poliklinik khusus anak dan melakukan pemeriksaan darah di laboratorium sentral RSUP Dr. M Djamil yang terdiri dari 12",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 563,
    "paragraph": "anak laki-laki dan 6 orang anak perempuan. Sampel adalah pasien yang memenuhi kriteria inklusi. Parameter yang diperiksa adalah trombosit. Prinsip pemeriksaan darah adalah flow cytometri dengan teknik impedance. Dari penelitian yang telah dilakukan bahwa hasil darah pasien LLA anak memperlihatkan rerata jumlah leukosit",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 564,
    "paragraph": "72,10±155,91 pada laki-laki dan 4,50±3,01 pada perempuan, jumlah eritrosit 4,19±0,84 pada laki-laki dan 3,66±0,81 pada perempuan. Selanjutnya rerata trombosit 280±138,69 pada laki- laki dan 243±1,58 pada perempuan. Dari hasil tersebut bahwa terjadi peningkatan leukosit pada laki-laki (72,10±155,91) sedangkan pada anak perempuan masih dalam rentang normal",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 565,
    "paragraph": "(4,50±3,01) (standar normal leukosit: 4,5-13,5). leukosit, eritrosit, dan Kata kunci : Leukosit, eritrosit, trombosit, leukemia limfoblastik akut, anak ABSTRACT Leukemia is a malignant disease of blood cells which is characterized by irregular and uncontrolled proliferation of leukocytes with the manifestation of abnormal cells in the",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 566,
    "paragraph": "peripheral blood. In West Sumatra showed the prevalence of leukemia disease was 2.4%, based on medical record data at the DR. M. Djamil showed an increase in cases of acute lymphoblastic leukemia in children every year. This study aims to describe the value of",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 567,
    "paragraph": "leukocytes, erythrocytes and platelets in patients with acute lymphoblastic leukemia in pediatric patients at RSUP DR. M. Djamil Padang. The population in this study were pediatric ALL patients who underwent control at a special pediatric clinic and performed blood tests at",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 568,
    "paragraph": "leukocytes, erythrocytes, and platelets. The principle of blood hematology examination with XN1500i is flow cytometry with impedance technique. From the research that has been done that the blood results of pediatric ALL patients showed an average leukocyte count of 72.10±155.91 in males and 4.50±3.01 in females, the erythrocyte count was 4.19±0.84 in",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 569,
    "paragraph": "males. and 3.66 ± 0.81 in women. Furthermore, the mean of platelets was 280±138.69 in men and 243±1.58 in women. From these results, there was an increase in leukocytes in men (72.10±155.91) while in girls it was still in the normal range (4.50±3.01) (normal standard of",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 570,
    "paragraph": "leukocytes: 4.5-13.5) . Keywords : Leukocytes, erythrocytes, platelets, acute lymphoblastic leukemia, children PENDAHULUAN Leukemia faktor termasuk penyebab merupakan penyakit keganasan sel darah yang ditandai dengan proliferasi leukosit secara tidak teratur dan tidak terkendali dengan manifestasi adanya sel-sel abnormal dalam darah tepi.",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 571,
    "paragraph": "jenis kanker yang Leukemia menyerang banyak usia dan masih merupakan utama kematian diseluruh dunia. Prevalensi leukemia pada tahun 2018 di seluruh negara dijumpai 2,4% kasus baru dan 3,2% kasus kematian. Berdasarkan data American Cancer Society (ACS) menunjukkan peningkatan kasus leukemia pada tahun",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 572,
    "paragraph": "2016 sampai 2017 di Amerika Serikat. Kasus baru sekitar 60.140 kasus, dengan kematian 24.500 kasus pada tahun 2016, dan pada tahun 2018 didapat sekitar 60.300 kasus baru dengan kematian 24.370. Pada tahun 2019 terdapat 61.780 kasus baru dan 22.840 kasus kematian (ACS, 2019).",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 573,
    "paragraph": "Leukemia Limfoblastik Akut (LLA) merupakan keganasan akibat mutasi somatik sel progenitor limfoid pada salah satu dari beberapa tahap perkembangan limfoblast di proliferasi dan akumulasi sumsum tersebut dapat menyebabkan penekanan hematopoesis yang mengakibatkan terjadinya anemia, neutropenia dan trombositopenia. Proliferasi limfoblast dapat terjadi pada beberapa",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 574,
    "paragraph": "jaringan ekstrameduler seperti bold liver, limpa, kelenjar getah bening Gejala klinis LLA diantaranya adalah rasa lelah, kulit terlihat terjadi lebam, demam, mudah pendarahan atau mimisan, pembesaran kelenjar limfa serta nyeri tulang.Leukemia limfoblastik akut (LLA) berkembang dengan cepat dan berakibat fatal dalam beberapa",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 575,
    "paragraph": "tulang. Proses minggu atau bulan jika (Hunger & Mullighan, 2015) tidak diobati. Di Indonesia, menurut WHO pada tahun 2019 menunjukkan angka kejadian leukemia sebanyak 35.870 kasus dalam lima tahun terakhir dengan kematian mencapai 11.314 (WHO, 2019). Sumatera Barat jiwa menunjukkan prevalensi leukemia sebesar",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 576,
    "paragraph": "2,4%, yang merupakan kejadian terbanyak kedua setelah provinsi Yogyakarta 4,9% (Riskesdas, 2018). Berdasarkan data rekam medis di rumah sakit M djamil menunjukkan peningkatan kasus limfoblastik akut pada anak setiap tahunnya. Tahun 2016 terdapat 51 anak yang terkena LLA. Selanjutnya pada tahun 2017 didapatkan 89",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 577,
    "paragraph": "kasus baru dan terjadi peningkatan dengan didapatkan 142 kasus baru. (Rekam Medis RSUP Dr. M. Djamil Padang, 2019). tahun 2018 leukemia Leukemia limfoblastik akut merupakan jenis kanker anak terbanyak dan dapat jenis kelamin dan menyerang berbagai tingkatan usia di dunia. Jenis leukemia",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 578,
    "paragraph": "limfoblastik akut (LLA) ditemukan sekitar 74% pada anak-anak, dimana banyak terjadi di usia 0-14 tahun. Insidensi puncak kedua terjadi pada dewasa tua, diatas usia 40 tahun. Manifestasi klinis LLA pada umumnya adalah demam, pendarahan, tulang dan lesu, nyeri wajah pucat, persendian, pembesaran hati, limpa dan",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 579,
    "paragraph": "77 Jurnal Kesehatan Perintis 9 (2) 2022 : 76-81 paparan lingkungan. Anak dengan cacat genetik (Sindrom Down, Sindrom Bloom, neutropenia kongenital, Anemia Fancoti, anemia Diamond-Blackfan dan Diskeratosis kongenital) mempunyai kemungkinan lebih tinggi untuk menderita leukemia anak (Isnaini dan Tuntun, 2016). tulang. Gejala",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 580,
    "paragraph": "Gejala klinis LLA pada umumnya adalah anemia, trombositopenia dan leukopenia yang merupakan kegagalan dari proses hematopoesis. Namun pada anak-anak, sekitar 40-50% gejala klinis yang muncul adalah nyeri pada tulang sendi atau artalgia yang disebabkan karna terjadinya infiltrasi ke periosteum, tulang sendi dan perluasan",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 581,
    "paragraph": "rongga sumsum lainnya adalah nyeri punggung, hal ini disebabkan karena adanya massa intradural dan mesti diwaspadai kemungkinan patah tulang belakang. Sekitar 16% penderita LLA pada fraktur vertebral saat anak didapatkan diagnosis, 55% nyeri punggung dan 35% keduanya. penderita mengalami Limfadenopati, dan",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 582,
    "paragraph": "splenomegali merupakan manifestasi leukemia ekstrameduler. Hepatosplenomegali muncul pada dua pertiga pasien dan biasanya tidak disadari (asymptomatic). Limfadenopati biasanya tidak terasa sakit namun bisa teraba secara lokal atau general (Boer, and Boer, 2017). hepatomegali pada juga disebabkan oleh Prekursor sel-B Leukemia Limfoblastik",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 583,
    "paragraph": "Akut (BCP-LLA) merupakan keganasan paling umum pada anak yang disebabkan oleh ekspansi progenitor B-limfoid yang tidak terkontrol di sumsum tulang. Penyakit translokasi ini kromosom dan akan terlihat jika progenitor leukemia mengakumulasi sejumlah delesi gen dan mutasi yang akan mendorong perkembangan penyakit. Meskipun protokol",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 584,
    "paragraph": "pengobatan dengan pendekatan survival jangka panjang telah mendekati 90%, namun pasien relaps masih menimbulkan tantangan klinis yang signifikan (Hunger dan Mullighan, 2015). upaya Kejadian LLA pada anak yang terus meningkat memerlukan yang mutakhir untuk menekan penyakit ini. Upaya tersebut sudah banyak dilakukan oleh",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 585,
    "paragraph": "praktisi dan peneliti seperti pendekatan molekuler dengan mencari berbagai gen yang berhubungan dengan penyakit agar terapi dapat dilakukan dengan lebih efektif, supaya angka kesembuhan lebih baik. jumlah trombosit Hasil penelitian Munthe menunjukkan distribusi pasien anak penderita LLA berdasarkan karakteristik jumlah trombosit",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 586,
    "paragraph": "lebih banyak yang mengalami adalah yaitu kelainan trombositopenia sebanyak 36 orang (43,9%) dan trombositosis sebanyak 7 orang (8,5%) yang mana ditemukan sebanyak 15 orang tanda-tanda perdarahan yang terdapat mengalami kelainan jumlah hb, dan leukosit (Munthe and Jeremia, 2021). Sementara penelitian Alfani menunjukkan bahwa kadar",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 587,
    "paragraph": "eritrosit pada terapi yang dilakukan selama enam minggu mengalami hasil yang normal. Tetapi setelah terapi jangka panjang kadar eritrosit mengalami penurunan. Penurunan terapi sehingga tersebut mengakibatkan hematologi. Kadar leukosit setelah terapi mengalami kenaikan sebesar >50.000/µL, karena tubuh pasien sedang melawan infeksi yang terjadi",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 588,
    "paragraph": "baik dari penyakitnya (LLA) ataupun akibat dari terapi.Kadar trombosit setelah terapi mengalami penurunan sebesar <30.000/ mm3 Penurunan terjadi akibat kemoterapi yang sedang dijalani oleh pasien (Alfani, 2021). terjadi akibat gangguan tersebut Penelitian ini bertujuan untuk melihat gambaran nilai Leukosit, Eritrosit dan",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 589,
    "paragraph": "Trombosit Leukemia pada Penderita Limfoblastik Akut (LLA) Pasien Anak di RSUP DR. M. Djamil Padang karena pada pasien anak penderita LLA lebih banyak yang mengalami kelainan jumlah trombosit dan eritrosit, namun tidak lebih banyak (lebih sedikit). METODE PENELITIAN inklusi yaitu dengan",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 590,
    "paragraph": "Populasi dalam penelitan ini adalah pasien LLA anak yang menjalani kontrol di poliklinik khusus anak dan melakukan pemeriksaan darah di laboratorium sentral RSUP Dr. M Djamil sebanyak 50 orang Sampel adalah pasien yang memenuhi identifikasi kriteria mengenai identitas dan riwayat LLA pasien,",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 591,
    "paragraph": "78 Jurnal Kesehatan Perintis 9 (2) 2022 : 76-81 berdasarkan Sampel yang sudah dikumpulkan diperiksa parameter hematologi dengan menggunakan alat hematology analyzer yaitu, sysmex XN1500i di laboratorium Sentral RSUP Dr. Mdjamil. Prosedur Standard pemeriksaan Operasional Procedur yang dijalankan oleh tersebut. Parameter yang",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 592,
    "paragraph": "laboratorium leukosit, eritrosit, dan diperiksa adalah trombosit. Prinsip pemeriksaan darah hematologi dengan alat XN1500i adalah flow cytometri dengan teknik impedance, dimana cairan darah yang masuk dalam saluran pengukuran diukur berdasarkan kapasitas energi listrik yang dihasilkan dari setiap sel yang masuk.Pemeriksaan hematologi",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 593,
    "paragraph": "dilakukan dengan beberapa tahapan diantaranya: pertama seluruh sampel yang telah disiapkan diinkubasi ke dalam suhu kamar (25-30oC), kedua adalah dengan melakukan homogenisasi sampel agar kadar EDTA yang tercampur dengan cairan darah dapat merata sehingga tidak terjadi bekuan. Selanjutnya diisi identitas sampel",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 594,
    "paragraph": "berdasarkan data sampel. Lalu dimasukkan ke dalam rak sampel untuk dibaca oleh alat. Terakhir, hasil darah yang telah diukur dengan alat hematology Analyzer XN1500i dianalisis parameter berdasarkan hematologi yang telah ditentukan. HASIL DAN PEMBAHASAN sampel Karakteristik penelitian berdasarkan Umur, Jenis Kelamin, Jumlah",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 595,
    "paragraph": "leukosit, eritrosit, trombosit dan Tabel 1. Tabel karakteristik penelitian Leukemia Limfoblastik Akut pasien anak berdasarkan jenis kelamin, umur, dan immunofenotipe LLA (n=18) Jenis Kelamin Jumlah Persentase (%) Rerata Umur (th/sd) Immunofenotipe (%) LLA-B LLA-T Laki-laki Perempuan 12,00 6,00 66,67 33,33 7,2±4,3",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 596,
    "paragraph": "7,7±4,5 16 (88,89) 2 (11,11) Immunofenotipe LLA (tabel 1). Tabel 1 menunjukkan bahwa LLA-B lebih banyak dibanding LLA-T. Penelitian Hurtz et al., (2019) mengatakan sekitar 85% LLA sel B ditemukan pada anak-anak dengan jumlah kasus yang sama baik laki- laki maupun perempuan. Dan sekitar 15%",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 597,
    "paragraph": "LLA adalah jenis sel T. Rata-rata penderita LLA yang mengalami banyak keluhan yakni diumur 17 Tahun kebawah (Prashanti dan Rena, 2020). Pada pasien anak penderita LLA lebih banyak yang mengalami kelainan jumlah trombosit dan eritrosit, namun lebih juga yang mengalami kelainan",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 598,
    "paragraph": "banyak jumlah hb dan (Munthe dan Jeremia, 2021). leukosit limfoblastik Hasil pemeriksaan hematologi pasien terhadap leukemia parameter leukosit, eritrosit dan trombosit berdasarkan jenis kelamin dapat dilihat pada tabel 2. akut dan laki-laki Hasil darah pasien LLA anak pada tabel 2 memperlihatkan rerata jumlah leukosit",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 599,
    "paragraph": "72,10±155,91 pada laki-laki dan 4,50±3,01 pada perempuan, jumlah eritrosit 4,19±0,84 pada pada perempuan. Selanjutnya rerata trombosit 280±138,69 pada laki-laki dan 243±1,58 pada perempuan. Terjadi peningkatan leukosit pada laki-laki yaitu 72,10±155,91 sedangkan pada perempuan berada dalam rentang normal 4,50±3,01 (normal: 4,5-13,5) (tabel 2).",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 600,
    "paragraph": "3,66±0,81 Tabel 3 memperlihatkan nilai leukosit pasien LLA saat didiagnosis. Terdapat 13(72,22%) pasien LLA dengan leukosit normal, 2(11,11%) dan 3(16,67%) dengan leukopenia atau penurunan jumlah leukosit. Proliferasi teratur merupakan ciri khas LLA, dimana terdapat kondisi normal, leukositosis dan leukopenia leukosit secara",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 601,
    "paragraph": "tidak Tabel 2. Rarata Nilai Leukosit pasien Leukemia Limfoblastik Akut Anak berdasarkan jenis kelamin. Jenis Kelamin L (n=12) P (n=6) Rerata Nilai Trombosit*** (x103/mm3) 280±138,69 243±1,58 Rerata Nilai Eritrosit** (x106/ul) 4,19±0,84 3,66±0,81 Rerata Nilai Leukosit* (x103/mm3) 72,10±155,91 4,50±3,01 Ket : Nilai Normal *: 4,5-13,5; **: 4,0-5,40; ***: 150-450",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 602,
    "paragraph": "rentang nilai leukosit yang ditampilkan pada Tabel 3. Jumlah leukosit normal berada pada rentang 4,5-13,5; sedangkan jumlah leukosit >13,5 dikatakan peningkatan jumlah leukosit atau leukositosis dan jika jumlah leukosit berada dibawah 4,5 maka dikatakan penurunan leukosit atau leukopenia. Jumlah leukosit yang berada >50000 dikatakan",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 603,
    "paragraph": "hiperleukositosis. Dalam penelitian ini didapatkan 2 pasien dengan leukositosis bahkan jumlah leukosit yang sangat tinggi atau hiperleukositosis. Hiperleukositosis terjadi akibat gangguan dari sumsum tulang leukosit yang beredar dalam sehingga sirkulasi berlebihan. Hiperleukositosis terjadi pada 9- 13% kasus LLA anak. Hal ini",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 604,
    "paragraph": "dapat mengakibatkan viskositas darah meningkat, agregasi dan trombus sel blast pada mikrosirkulasi. Hiperleukositosis juga onkologi merupakan kegawatdaruratan pada pasien tersebut. Meskipun tidak semua kasus LLA didapatkan hiperleukositosis, namun kejadian ini perlu ditangani segera karena dapat menyebabkan efek yang buruk, pada penderita hingga menjadi",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 605,
    "paragraph": "pemicu kematian pada pasien LLA anak. (Chiaretti, S. et al. 2016). KESIMPULAN dan laki-laki 4,50±3,01 Rerata jumlah leukosit 72,10±155,91 pada pada perempuan, jumlah eritrosit 4,19±0,84 pada laki-laki dan 3,66±0,81 pada perempuan. Rerata trombosit 280±138,69 pada laki-laki dan 243±1,58 pada perempuan. Terjadi",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 606,
    "paragraph": "peningkatan laki-laki (72,10±155,91) sedangkan pada anak perempuan masih dalam rentang normal (4,50±3,01) (standar normal leukosit: 4,5- 13,5). leukosit pada UCAPAN TERIMA KASIH Ucapan terima kasih pada Laboratorium RSUP Dr. M Djamil Padang dan Parameter Leukosit Leukositosis >13,5 2(11,11%) Leukopenia <4,5 3(16,67%)",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 607,
    "paragraph": "Laboratorium Genetik Universitas Andalas yang telah membantu penelitian ini selesai. REFERENSI Alfani, H. 2021. Literature Review: Gambaran Hasil Pemeriksaan Eritrosit, Leukosit Dan Trombosit Pada Pasien Anak Dengan Leukemia Limfoblastik Akut (LLA) Setelah Terapi. Universitas ‘Aisyiyah Yogyakarta. American Cancer Society (ACS). 2019.",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 608,
    "paragraph": "Acute Lymphoblastic Leukemia (ALL). Cancer.org. 1.800.27.2345 12 February 2019. Boer, J. M. and den Boer, M. L. 2017. BCR- ABL1-like lymphoblastic acute leukaemia: From bench to bedside’, European Journal of Cancer. Elsevier Ltd, 82, pp. 203–218. Chiaretti, S. et al. 2016. Advances in the",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 609,
    "paragraph": "Genetics and Therapy of Acute Lymphoblastic Leukemia’, American Oncology Society Educational Book, 36, pp. e314–e322. Clinical of leukemia lymphoblastic Hunger, S. P. dan Mullighan, C. G. 2015. Acute in children’, New England Journal of Medicine. Massachussetts Medical Hurtz, C. et al. 2019. Rationale for targeting",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 610,
    "paragraph": "BCL6 acute in MLL-rearranged lymphoblastic leukemia’, Genes and Development. Cold Spring Harbor Laboratory Press, 33(17–18), pp. 1265– 1279. Iacobucci, I. and Mullighan, C. G. 2017. Genetic basis of acute lymphoblastic leukemia’, Journal of Clinical Oncology, 35(9), pp. 975–983. Isnaini, S. A. dan Tuntun, M. 2016. Kejadian",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 611,
    "paragraph": "Anemia Pada Penderita Leukemia Limfoblastik Akut di RSUD Dr. H. Abdul Moeloek Provinsi Lampung. Jurnal Analis Kesehatan : Volume 5 No. 1 Maret 2016. Munthe dan Jeremia, J. P. 2021. Gambaran Jumlah Trombosit Pada Penyakit Leukemia Limfoblastik Akut (LLA) Anak di RSUP Haji Adam Malik Medan Tahun",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 612,
    "paragraph": "Sanglah Denpasar Tahun 2014-2015. Jurnal Medika Udayana, Vol. 9 No. 4 April 2020. Rekam Medis RSUP Dr. M. Djamil Padang, Leukimia. Pemeriksaan 2019. Laboratorium Analis. Padang. Riskesdas. Laporan Provinsi Sumatera Barat. Badan Penelitian dan 2018. Pengembangan Kesehatan. Smith OP, Hann IM. 2006. Clinical",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 613,
    "paragraph": "features and therapy of lymphoblastic leukemia. In: Arceci RJ, editor. Pediatric Hematology (Third edition). Oxford: Blackwell Publishing Ltd Terwilliger, T. and Abdul-Hay, M. 2017. leukemia: a Acute review and 2017 comprehensive update’, Blood cancer journal, 7(6), p. e577. lymphoblastic WHO. 2019. Kematian Akibat Leukemia di",
    "jurnal": "admin2.RifkaRahmat.pdf"
  },
  {
    "id": 614,
    "paragraph": "British Journal of Cancer (1996) 73, 1141-1147 © 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 % Childhood leukaemias in New Zealand: time trends and ethnic differences JD Dockerty, B Cox and MG Cockburn Department of Preventive and Social Medicine, University of Otago Medical School, PO Box 913, Dunedin, New Zealand.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 615,
    "paragraph": "Summary Registrations from the New Zealand Cancer Registry were used to examine time trends in the incidence of leukaemias among children aged 0- 14. There was a statistically significant increase in the incidence of leukaemia among children aged 0-4 during 1953-57 to 1988 -90. In this age group, the recorded",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 616,
    "paragraph": "incidence rate increased from 4.89 per 100 000 person -years in 1953 -57 to 7.92 in 1988 -90. During 1973 -77 to 1988-90 (and probably in earlier years), the increase was due to an increase in acute lymphoblastic leukaemia (ALL). The trends were unlikely to be due to changes in diagnosis or case ascertainment. The",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 617,
    "paragraph": "childhood leukaemia trends might be related to trends in family size, maternal age, socioeconomic level or exposure to infections. However, there are uncertainties about the importance of these factors or about their trends. The incidence of acute non-lymphoblastic leukaemia (ANLL) decreased between 1968-72 and 1988-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 618,
    "paragraph": "90. The time trends highlight the likely importance of environmental factors in the aetiology of childhood leukaemias in New Zealand. The risk of ALL was lower in the Maori than in the non-Maori population (relative risk Maori/non-Maori 0.74). The risk of ANLL was higher among Maori (relative risk 1.84).",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 619,
    "paragraph": "Keywords: leukaemia; child; epidemiology; trend; aetiology; incidence al., Information on the incidence of childhood leukaemias has been collected by the New Zealand Cancer Registry since 1948. Until 1972, the Registry was mainly public hospital based, but since then it has included registrations from",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 620,
    "paragraph": "private hospitals, death certificates and autopsy reports (Cooke et al., 1988). The Registry was regarded as being truly population based from 1974 (Cooke et 1988). Childhood leukaemias are serious diseases, and affected children would usually have been admitted to hospital. Data",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 621,
    "paragraph": "on completeness suggest that registration of lymphatic and haematopoietic cancers was nearly complete from about 1953-55 (Medical Statistics Branch of the Department of Health, 1955). (Department Maori ethnicity 1992). Children of sole At the 1991 census, 14% of the childhood (ages 0-14)",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 622,
    "paragraph": "residents of New Zealand were reported as being of solely Maori ethnicity, and a further 7% were reported as being of mixed New Zealand of Statistics, Island ethnic groups made up 5% of the resident childhood population of Cancer registration data for Maori are thought to have been more",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 623,
    "paragraph": "closely related to sole Maori ethnicity than to mixed (plus sole) Maori ethnicity (New Zealand Health Information Service, 1995). 'Non-Maori' has been used in cancer registry publications to refer to the rest of the population, which is predominantly of British origin. Pacific Islanders form a",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 624,
    "paragraph": "small part of the non-Maori population. total Statistics, (Department 1993a). Pacific In a review of 49 countries, the highest age-standardised incidence rate for childhood acute lymphoblastic leukaemia (ALL) (ages 0- 14) was found in Costa Rica (4.5 per 100 000 person-years) (Parkin et al., 1988a). The rates of childhood",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 625,
    "paragraph": "ALL in New Zealand were 3.2 per 100000 person-years among non -Maori and 1.3 per 100 000 person -years among Maori (Parkin et al., 1988a). New Zealand Maori had the highest rate of childhood ANLL of any population studied (Parkin et al., 1988b), while non-Maori New Zealanders had",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 626,
    "paragraph": "the highest rate of any predominantly white population (Parkin et al., 1988a). Three studies of time trends in multiple countries have included data from the New Zealand Cancer Registry, and have given different results. Breslow and Langholz (1983) found no significant trends in the incidence of childhood",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 627,
    "paragraph": "leukaemia for Maori or non-Maori over 1962-66 to 1972- Correspondence: J Dockerty Received 20 June 1995; revised 14 November 1995; accepted 23 November 1995 76. Draper et al. (1994) calculated the cumulative incidence of combined childhood leukaemias among non-Maori as 66.0",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 628,
    "paragraph": "(per 100 000) in 1972-76, with this decreasing to 62.1 in 1978-82, then increasing to 79.0 in 1983-87. Statistical tests for trends were not presented. Coleman et al. (1993) found that boys in New Zealand (but not girls) had a statistically",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 629,
    "paragraph": "significant increase in the cumulative risk of childhood leukaemia during the period 1965-85. The present study examines the recorded incidence of childhood leukaemia in New Zealand between 1948 and 1990. Materials and methods Childhood (ages 0- 14 years) leukaemia registrations were",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 630,
    "paragraph": "obtained from the New Zealand Cancer Registry for each year during 1948 - 90. For the division into the different types [ALL, acute non-lymphoblastic leukaemia (ANLL), other and unspecified leukaemias] only the period 1968 -90 was used. The International Classification of Diseases (ICD) codes used",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 631,
    "paragraph": "for the leukaemia registrations in this study were decided after discussions with haematologists and Cancer Registry staff, and after referring to the literature. In classifying the leukaemias, the aim was to ensure comparability across the time periods studied. During 1948 - 67, the combined leukaemias were",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 632,
    "paragraph": "represented by the following ICD-7 codes: 204.0, 204.1, 204.2, 204.3 and 204.4. During 1968 -77, the different types of childhood leukaemia were assigned to the following ICD-8 codes: ALL 204.0, 207.0 and 204.9; ANLL 205.0, 206.0 and 207.2; 'other and unspecified' 204.1, 205.1, 206.1, 206.9, 207.1",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 633,
    "paragraph": "and 207.9. During 1978-87 (ICD-9) and 1988-90 (ICD-9 CM), the codes were: ALL 204.0, 204.8, 204.9 and 208.0; ANLL 205.0, 206.0, 207.0, 207.2, 205.3 and 206.8; 'other and unspecified' 204.1, 204.2, 205.1, 205.2, 205.8, 205.9, 206.1, 206.2, 206.9, 208.1, 208.2, 208.8 and 208.9. Childhood tumours",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 634,
    "paragraph": "such as acute unspecified leukaemias were classified under acute lymphoblastic leukaemia because of the high likelihood that most were in this category in earlier years. The study was restricted to children who had New Zealand residential addresses at registration. The correct birth date was available for 380 of the 444",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 635,
    "paragraph": "children diagnosed between 1976 and 1987 as their birth certificates were being used in another study. The ages of 27 children were changed on the basis of the more accurate birthdates. For eight children (all with ALL), the change was sufficient to alter which 5 year age group the child was in.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 636,
    "paragraph": "For one child, the corrected age was over 14 years, so the ft 1142 Childhood leukaemias in New Zealand JD Dockerty et a! child was excluded. For five of the eight, the corrections shifted the age group from that of 5 -9 to 0 -4. For one, the",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 637,
    "paragraph": "shift was from ages 10- 14 to ages 0 -4, and for the remaining child, the shift was from ages 10 -14 to 5 -9. The numbers of deaths from childhood leukaemia (1948- 90) were obtained from the New Zealand Health Information",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 638,
    "paragraph": "Service (for 1948 and 1949); and from annual publications of the Ministry of Health. Annual mean population estimates, based on national census data, were used for the calculation of age -specific and age- standardised rates. Registration rates were calculated for all the leukaemias combined (1948 -90); and for ALL,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 639,
    "paragraph": "ANLL, and other and unspecified leukaemias (1968 -90). Five year age groups were used, and the standard was the world standard population (Waterhouse et al., 1976). The rates were calculated using pooled quinquennial periods, except that the last period was truncated to 3 years (1988-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 640,
    "paragraph": "90). Rates were calculated for both sexes, Maori and non- Maori, and the total population. For combined leukaemias and ALL, the age group 0-4 was further subdivided, into the year' and '1 -4 years'. ages quinquennial age-specific and age-standardised rates, and",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 641,
    "paragraph": "heterogeneity among the age-specific rates, were examined 1987). The 95% (Mantel, confidence intervals for the age -standardised rates were based on the binomial approximation (Armitage and Berry, for 1987). Age -specific individual years of age using pooled data (1981-90 for ALL and 1968-90 for ANLL). Relative risks for sex and",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 642,
    "paragraph": "ethnic group were also calculated, using pooled data from 1968-90. These were age-adjusted relative risks with 95% confidence intervals, calculated using the formulae described by Breslow (1984). 1963; Armitage and Berry, rates were calculated Trends in incidence 'under 1 Results The number of children registered with leukaemia of any type",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 643,
    "paragraph": "during 1948-90 was 1409, among whom ALL (as defined in Materials and methods) was the commonest type. Of the 851 registrations for leukaemias during 1968-90, 633 (74%) were for ALL, 179 (21%) for ANLL and 39 (5%) for other and unspecified leukaemias. Ninety-five per cent of those classified",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 644,
    "paragraph": "as ALL had ICD codes corresponding to acute lymphatic or acute lymphoid leukaemias. Five per cent had ICD codes corresponding to other or unspecified lymphatic or acute leukaemias. In the first 5 years (1948 -52), the ratio of registrations to deaths was 0.86 (Table I). In every other",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 645,
    "paragraph": "registrations outnumbered deaths, and the ratio period, increased continually, from 1.03 in 1953 - 57 to 2.62 in 1988 -90. Trends in the incidence of combined leukaemias In view of the incomplete registrations during 1948 - 52 (Table I), the presented results and the tests for trend for combined",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 646,
    "paragraph": "leukaemias were restricted to the period 1953 -57 to 1988 -90. There was a continued increase in the recorded incidence of combined leukaemias during 1953 - 57 to 1968 - 72, then a drop to The from 1968 - 72 to 1973 - 77, followed by a further increase from",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 647,
    "paragraph": "1973 - 77 to 1983 - 87 (to a higher rate than before), with similar rates in 1983 -87 and 1988 -90 (Figure 1 and Table II). 1988 -90 1953 -57 (P=0.02). which explained In the total population, for all leukaemias combined, there",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 648,
    "paragraph": "was a significant increase in the age- standardised rates annual during percentage increase in the rate, relative to the average rate, was 0.81 % per year. There was significant heterogeneity among the rates in the different age groups (P= 0.02). Children aged under 5 years had a highly significant increase",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 649,
    "paragraph": "the age- (P = 0.0004), standardised rates (Table II), while no overall trends were found for children aged 5-9 and 10-14. The increase in incidence for children under 5 years of age was present among boys (P=0.01), girls (P=0.01), and non-Maori",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 650,
    "paragraph": "(P = 0.0003). For age groups 5-9 and 10- 14, there were no overall trends in boys or girls or among non-Maori. For Maori, there was no overall statistical trend in the rates among those aged under 5 years, and for ages 5 -9 and 10-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 651,
    "paragraph": "14 there were too few Maori children with leukaemia to allow interpretation of the trends. trend the in Trends in the incidence of ALL and ANLL Different trends in incidence were observed for ALL and 1 and Table III). The age -standardised",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 652,
    "paragraph": "ANLL (Figure incidence rate of ALL decreased from 1968-72 to 1973-77, then increased steadily in each quinquennium until 1988-90 (the rates were 3.22, 2.74, 3.22, 3.67 and 4.10 per 100 000 person-years). The incidence of ANLL decreased steadily between 1968-72 and 1978-82, then increased in 1983-87,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 653,
    "paragraph": "and decreased to a low point in 1988-90 (the rates were 1.13, 0.97, 0.78, 0.92 and 0.59 per 100 000 person-years). For ALL, the trend tests showed that the increase in the age-standardised rate was significant (1968-72 to 1988-90, P = 0.02) and there was no significant departure from",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 654,
    "paragraph": "5 4 3 2 1 0 U) cn a)c 0 L- U) a) CR @ '2R~~~969> 9~ 79~& 790 Time period Figure 1 Age- standardised registration for childhood leukaemias in New Zealand, ages 0- 14. *, All leukaemias combined; EI, acute lymphoblastic leukaemia; 0, acute non-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 655,
    "paragraph": "lymphoblastic leukaemia; 0, other and unspecified leukaemias. rates Table I Childhood leukaemia registrations and deathsa in New Zealand, 1948-90: all leukaemias combined, for ages 0-14 Time period 1948- 52 1953 -57 1958-62 1963 -67 1968 -72 1973- 77 1978-82 1983-87 1988 -90",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 656,
    "paragraph": "Number of registrations 90 126 151 191 207 175 169 190 110 Number of deaths 105 122 144 160 159 134 91 104 42 Ratio of registrations to deaths 0.86 1.03 1.05 1.19 1.30 1.31 1.86 1.83 2.62 aIn 1948, only non-Maori were included in the deaths. In all other years, Maori and non-Maori deaths were included.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 657,
    "paragraph": "Childhood leukaemias in New Zealand JD Dockerty et al $_ 1143 Table II Childhood leukaemia registrations (numbers, and rates per 100000 person-years) in New Zealand, 1953-90: combined leukaemias Time period 1953 -57 1958-62 1963-67 1968-72 1973-77 1978 -82 1983-87 1988-90 0-4",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 658,
    "paragraph": "Rate 4.89 4.93 6.63 6.91 5.58 6.62 7.92 7.92 No. 62 71 102 103 83 85 100 63 5-9 No. 39 53 53 57 48 46 43 29 Age group (years) Rate 3.39 4.13 3.62 3.69 3.13 3.12 3.33 3.87 No.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 659,
    "paragraph": "25 27 36 47 44 38 47 18 10-14 Rate 2.72 2.30 2.75 3.19 2.78 2.50 3.18 2.30 ASR, age-standardised rate; CI, confidence interval. 0-14 Crude rate ASR (with 95% CI) 3.78 3.88 4.43 4.59 3.80 3.95 4.71 4.73 3.70 (3.41-3.99)",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 660,
    "paragraph": "3.84 (3.57-4.11) 4.38 (4.11-4.66) 4.64 (4.36-4.93) 3.87 (3.61-4.12) 4.13 (3.85-4.41) 4.87 (4.56-5.18) 4.78 (4.38-5.18) No. 126 151 191 207 175 169 190 110 Table III Childhood leukaemia registrations (numbers and rates per 100000 person-years) by age, sex, and ethnic group, 1968-90:",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 661,
    "paragraph": "by type of leukaemia 0-4 Rate No. No. Age group (years) 5-9 10-14 Rate No. Rate 0-14 ASR No. Sex Boys ASR Girls ASR No. No. Maori ASR Non-Maori ASR No. Ethnic group Leukaemia type, time period ALL 1968-72 1973-77 1978-82",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 662,
    "paragraph": "1983 -87 1988-90 ANLL 1968-72 1973-77 1978-82 1983-87 1988-90 72 60 71 81 56 23 19 12 15 5 4.83 4.04 5.53 6.42 7.04 1.54 1.28 0.93 1.19 0.63 46 34 36 31 26 9 12 9 8 3 2.98 2.22",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 663,
    "paragraph": "2.44 2.40 3.47 0.58 0.78 0.61 0.62 0.40 25 30 23 30 12 19 13 12 14 6 1.69 1.89 1.51 2.03 1.53 1.29 0.82 0.79 0.95 0.77 3.22 2.74 3.22 3.67 4.10 1.13 0.97 0.78 0.92 0.59 79 79 78",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 664,
    "paragraph": "90 45 30 24 21 18 9 3.49 3.45 3.76 4.58 3.83 1.30 1.03 0.97 0.87 0.74 64 45 52 52 49 21 20 12 19 5 2.94 2.01 2.66 2.71 4.39 0.96 0.90 0.58 0.97 0.44 21 5 13 13",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 665,
    "paragraph": "10 7 8 11 10 2 Other/unspecified 1968-72 2 1973-77 1 1978-82 2 2 1983 -87 1988-90 1 ASR, age -standardised rate; ALL, acute lymphoblastic leukaemia; ANLL, acute non-lymphoblastic leukaemia. 0.40 0.14 0.19 0.14 0.08 0.54 0.27 0.16 0.32 0.25 0.13",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 666,
    "paragraph": "0.13 0.07 0.31 0.00 0.29 0.16 0.14 0.28 0.09 0.18 0.18 0.08 0.43 0.09 0.20 0.06 0.20 0.20 0.00 8 4 2 4 2 2 2 1 4 0 9 3 4 3 1 4 4 2 8 1 3 1",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 667,
    "paragraph": "3 3 0 3.80 0.88 2.41 2.63 3.45 1.28 1.40 1.94 1.91 0.70 0.36 0.18 0.40 0.37 0.35 122 119 117 129 84 44 36 22 27 12 11 6 4 9 1 3.14 3.02 3.34 3.83 4.20 1.11 0.90 0.60",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 668,
    "paragraph": "0.77 0.57 0.28 0.15 0.10 0.27 0.05 linearity, although the rate during 1973-77 was lower than the rates in adjacent time periods. The annual percentage increase in the rate of ALL (1968-90), relative to the average rate, was 2.2% per year. The increase in total leukaemias",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 669,
    "paragraph": "among children aged under 5 years (Table II), at least during 1968-90, was due to a significant (P = 0.002) increase in ALL for this age group (Table III). There were no overall trends in ALL incidence for ages 5 -9 or 10-14.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 670,
    "paragraph": "During 1968-72 to 1988-90, boys aged under 5 years had a significant increase in incidence (P = 0.04), and there was no significant departure from linearity. Girls aged under 5 years also had an increase in ALL incidence, but the trend was",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 671,
    "paragraph": "significantly rate was 4.7 per 100 000 person-years in 1968-72, 2.6 in 1973-77, 4.9 in 1978-82, 4.2 in 1983-87 and 8.0 in 1988-90). Non-Maori aged under 5 years had a highly significant increase in the incidence of ALL (P = 0.004).",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 672,
    "paragraph": "(the incidence non-linear In the total population, there were too few children aged under 1 year for the interpretation of time trends, though ALL incidence rates for ages under 1 year increased steadily in each quinquennium from 1968-72 to 1988-90. Children",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 673,
    "paragraph": "aged 1-4 experienced a significant increase in the incidence of ALL over the period (P=0.007). For ANLL, there was a significant linear decrease in the incidence rates (1968-72 to 1988-90; Figure 1 and Table III). There was no significant heterogeneity among the",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 674,
    "paragraph": "decrease, different relative to the average rate, was 3.8% per year. In boys, no overall trend in the age- standardised rates was found, and in girls the trend tests could not be interpreted owing to small numbers. Among non-Maori, there was a significant linear",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 675,
    "paragraph": "decrease in the incidence of ANLL (P=0.02). groups. The annual percentage age Age, sex and ethnic group For ALL, the age distribution by individual years of age showed a marked peak at ages 2-3 (the peak incidence rate was 9.3 per 100 000 person-years). Sequential data for",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 676,
    "paragraph": "combined leukaemias revealed that the size of the age peak increased during 1953-90. The early ALL age peak was marked for both Maori and non-Maori. The pooled (1968- 90) ALL registration rates for each 5 year age group (per 100 000 person-years) were: ages 0-4 Maori 6.0, non-Maori",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 677,
    "paragraph": "6.6; ages 5-9 Maori 1.6, non-Maori 2.9; and ages 10-14 Maori 1.0, non-Maori 1.8. For ANLL, although the total numbers were small, there were clearly high registration rates at ages 0-2, with lower rates at ages 3-14 years. Compared with girls, boys had a greater risk of both types",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 678,
    "paragraph": "of leukaemia (statistically significant for ALL but not for ANLL, Table IV). Maori had a lower risk of ALL and a higher risk of ANLL than non-Maori (Table IV). The crude relative risks (boys vs girls and Maori vs non-Maori) were",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 679,
    "paragraph": "virtually identical to the age-adjusted relative risks. Discussion The most interesting finding was the clear increase in leukaemia incidence rates for children aged 0-4 during 1953-57 to 1988-90 (Table II). During 1973-77 to 1988- 90 (and probably in earlier years), this was due to an increase",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 680,
    "paragraph": "in ALL (Table III). The incidence of ANLL decreased during 1968-72 to 1988-90 (Figure 1, Table III). What are the due to explanations trends? masking by other causes of death such as pneumonia in the Underdiagnosis these for 1144 Childhood leukaemias in New Zealand",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 681,
    "paragraph": "JD Dockerty et al Table IV Relative risks for sex and ethnicity, 1968-90: by type of leukaemia, for ages 0 -14 Age-adjusted relative risk boys/girls (95% CI) Age-standardised incidence rate per 100000 person -years Age-standardised incidence rate per 100 000 person -years",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 682,
    "paragraph": "Leukaemia type Acute lymphoblastic Acute non-lymphoblastic Boys 3.95 1.01 Girls 2.90 0.84 1.36 (1.16-1.59) 1.27 (0.94-1.70) Maori 2.65 1.55 Non-Maori 3.56 0.83 Age-adjusted relative risk Maori/non-Maori (95% CI) 0.73 (0.57-0.95) 1.84 (1.29-2.62) preantibiotic age (Stewart and Kneale, 1969) may have had",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 683,
    "paragraph": "an effect on the accuracy of diagnosis in the early years, but could not account for the continuation of the trends beyond the introduction of antibiotics. separates classification The childhood leukaemias in this study were classified into three types (ALL, ANLL and 'other and unspecified'), based",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 684,
    "paragraph": "on ICD site codes. Childhood cancers are better suited to classifications based on morphology rather than site. The the Birch and Marsden (1987) childhood leukaemias into five types (acute lymphocytic, other lymphoid, acute non-lymphocytic, chronic myeloid and based on ICD-O (oncology)",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 685,
    "paragraph": "'other and unspecified'), morphology codes. ICD-O codes have only been used by the New Zealand Cancer Registry since 1978. Site-based classifications were used in this study, and the aim was to enable the two main types of childhood leukaemia (ALL and",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 686,
    "paragraph": "ANLL) to be distinguished, from 1968 onwards. classification separate of leukaemia is considered to have been relatively accurate since the late 1960s in New Zealand (personal communica- tions from D Becroft, C Beresford and J Carter). There may have been some under-reporting of the myeloid leukaemias,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 687,
    "paragraph": "because specialists might have expected children to have lymphoid leukaemias and have classified them as such. Misclassification is likely to have had a moderating effect on the observed trends, rather than an effect that would lead to spurious trends. If anything, one would have expected a",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 688,
    "paragraph": "decrease in ALL and an increase in ANLL rather than the converse, which has been found. The trends are therefore unlikely to be related to changes in the diagnosis of the two main types of childhood leukaemia. Histological types the of",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 689,
    "paragraph": "is al., that there good Comparable analyses have shown that there were no rates of the significant time trends in the non-Hodgkin's lymphomas in New Zealand childhood during 1953-90 (work in progress). Thus, the leukaemia trends do not seem to be due to diagnostic shifts between",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 690,
    "paragraph": "ALL and the non-Hodgkin's lymphomas. registration assuming One indication of the quality of a cancer registry is the proportion of cases for which the diagnosis has a histological of basis, registration, and that the histology is accurate. During 1970-79, 100% of the children with ALL and ANLL on",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 691,
    "paragraph": "the New Zealand Cancer Register had a histological basis for 1988a). There is no published diagnosis (Parkin et earlier information on this for childhood leukaemias in periods. completeness The 5 year survival from childhood leukaemia in Britain was very low (2%) for children diagnosed during 1954-63",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 692,
    "paragraph": "(Birch et al., 1988), and is not likely to have been higher in New Zealand at the time. The recording of more registrations than deaths in 1953 -57 and in 1958-62 is evidence that case during ascertainment was nearly those ascertainment do not",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 693,
    "paragraph": "periods. explain the trends. The subsequent increases in the ratio of registrations to deaths (Table I) reflect improvements in treatment over time. Thus, improvements in complete, Researchers from other countries have reported increases in the incidence of ALL among children aged 0-4 or 1-4.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 694,
    "paragraph": "These include studies in Britain 1953-91 (Draper et al., 1994); north-west England 1954 - 77 (Birch et al., 1980; Birch et al., 1981); the Netherlands 1973-86 (temporary increase 1974-82) (Coebergh et al., 1989); and Connecticut 1935-79 (van Hoff et al., 1988). The data from north-west England",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 695,
    "paragraph": "were recently updated to include 1954-88, and although even there was an overall increase for ages 0- 14, there were no significant time trends for boys or girls aged 1-4 (Blair and Birch, 1994). A study of childhood ALL in Baltimore 1960-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 696,
    "paragraph": "74 (Gordis et al., 1981) did not show an increase for children aged 1 - 4. Two other studies (limited to all leukaemias combined) have shown increases among young children, including a study from Sweden 1958-74 (Ericsson et al., 1978), and one from Denmark 1943-84 (de Nully Brown et",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 697,
    "paragraph": "al., 1989). A study of combined leukaemias in upstate New York (1969-80) did not record a significant change in incidence among boys or girls aged under 5 years (Polednak, 1986). The New Zealand increase was one of the more latter obvious secular trends among young children in",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 698,
    "paragraph": "decades. For childhood ANLL, temporal decreases in incidence rates have been reported in two other studies: one in Britain 1962-91 (Draper et al., 1994), and another in Japan (Osaka) 1971 -88 (Ajiki et al., 1994). The decrease in Osaka may have",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 699,
    "paragraph": "been partly due to changes in the diagnosis or classification of ALL and ANLL, although the authors were of the opinion that most of the leukaemia changes they observed were real (Ajiki et al., 1994). Significant increases have been reported in Queensland 1973-88 (McWhirter and Pet-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 700,
    "paragraph": "roeschevsky, 1991); and among black children in Baltimore 1965-74 (Gordis et al., 1981). Incidence rates of childhood ANLL in the Netherlands 1973 -86 are reported to have been 1989). In north-west relatively constant (Coebergh et al., England 1954-88, there was no significant trend in the",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 701,
    "paragraph": "incidence of childhood ANLL (Blair and Birch, 1994). Relevance of time trends to aetiologicalfactors and hypotheses ALL Because ALL was by far the commonest type, the trends in combined leukaemias should mostly reflect trends in the incidence of ALL. Up until 1953 (at least), childhood",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 702,
    "paragraph": "leukaemia was 'rapidly and universally fatal', and mortality and incidence were equivalent (Draper et al., 1994). If the correct number of incident cases of childhood leukaemia for 1948-52 was 105 (deaths) and not 90 (registrations), the crude incidence rate for 1948-52 would be 3.77 per 100 000",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 703,
    "paragraph": "person-years, little different from 3.78 in 1953-57 (Table II). The increase for young children in 1958-62 was minor, but there were clear increases in 1963-67 and 1968-72 (Table II). Incidence dropped between 1968-72 and 1973- 77, then increased again in 1978-82 and 1983-87. Thus the",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 704,
    "paragraph": "combined leukaemia results suggest that the incidence of ALL in young children began to increase clearly in 1963-67. The risks of childhood leukaemia from ionising radiation exposure have been established (Doll, 1989). In New Zealand, we have no nuclear power stations or reprocessing plants. A",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 705,
    "paragraph": "study of childhood leukaemia incidence rates in Nordic countries in relation to fallout from nuclear weapons testing found no strong overall childhood leukaemia trends (Darby et al., 1992). However, the rates of childhood leukaemia were slightly higher in the late 1960s, when the effect would have",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 706,
    "paragraph": "been greatest (Darby et al., 1992). Fallout from nuclear weapons testing has been monitored in New Zealand by the of National strontium-90 and caesium-137 in cows' milk peaked in 1965 ..... and had decreased to the limits of detection by 1986',",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 707,
    "paragraph": "(Matthews, 1994). Initially (after the 1965 peak), the average radionuclide was less half-life 2 years effect on fallout had a (Matthews, If leukaemia in young children in New Zealand, it would be Laboratory, and 'concentrations of each 1994). than material Radiation",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 708,
    "paragraph": "to in 1946 expected to have led to a peak in incidence soon after 1965, followed by a decline. Thus, the continued increase in the incidence of childhood leukaemia in New Zealand does not appear to be related to fallout. Several case -control studies (and one cohort study) of",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 709,
    "paragraph": "childhood leukaemia and electromagnetic field exposures have been reported. While some have shown increased risks, others have not, and no firm conclusions can yet be drawn (Advisory Group on Non-ionising Radiation, 1992; 1994). Detailed data on domestic electricity Ross et al.,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 710,
    "paragraph": "consumption, supplied by Transpower New Zealand, showed a remarkably consistent and continued increase in average annual consumption from 2.5 megawatt hours (MWh) per Domestic household consumption then reached a plateau, remaining between 7.1 1993. The and 7.9 MWh per household from 1977 to",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 711,
    "paragraph": "incidence of childhood ALL has followed a different course, so it is unlikely that the leukaemia increases are related to household consumption of electricity (a crude measure of exposure to electromagnetic fields). 8.1 MWh in 1976. In a case-control study, Golding et al. (1990) reported",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 712,
    "paragraph": "that babies given drugs (mainly vitamin K) in the neonatal period had an increased risk of childhood cancer. Golding et al. (1992) tested the association in a second study, finding a doubling of the risk of childhood cancer in relation to",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 713,
    "paragraph": "intramuscular vitamin K administration, but no elevation in risk for oral administration. Three further studies of this issue risks of childhood leukaemia have not found elevated including a cohort following vitamin K administration, study from Sweden (Ekelund et al., 1993), a nested case-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 714,
    "paragraph": "control study from the USA (Klebanoff et al., 1993) and a descriptive study (of birth cohorts) from Denmark (Olsen et Health, of Department the al., for use in intramuscular vitamin K had been available neonates in New Zealand since the late 1960s. (K Ronaldson,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 715,
    "paragraph": "given But personal 5000 National Women's Hospital, routinely deliveries per year as early as 1962 (R Howie, personal communication). Thus, some of the New Zealand time trends are consistent with the vitamin K hypothesis. The British time trends for childhood leukaemia in relation to trends in",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 716,
    "paragraph": "intramuscular vitamin K administration, on the other hand, are probably not consistent with this hypothesis (Draper and Stiller, 1992). vitamin K was with communication). at According 1994). to Childhood ALL has been associated with advanced maternal age in some, but not all, studies (Ross et al.,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 717,
    "paragraph": "1994). The median age at which women had their first child in New Zealand increased by 5.7 years between 1962 and 1993, compared with a rise of only 2.1 years for all mothers (rather than new mothers) between these years (Statistics",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 718,
    "paragraph": "New Zealand, 1995). However, these figures conceal the fact that for all mothers there was a slight drop in the median maternal age at delivery between 1962 and 1972, at which point the increase began and continued until 1993 (Statistics New Zealand, 1995). Thus, the later childhood leukaemia",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 719,
    "paragraph": "trends (after the early 1970s), but not the earlier trends might be consistent with increasing maternal age. However, an effect of maternal age on childhood ALL risks has not been observed consistently in analytical studies, and the overall change in the age of New Zealand mothers has not been",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 720,
    "paragraph": "large. Changes in maternal age do not seem to offer a sufficient explanation for the increase in the incidence of childhood ALL observed in this study. Several studies (but not all) have reported a higher risk of childhood leukaemia for firstborn children (Ross et al., 1994).",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 721,
    "paragraph": "The proportion of firstborn children in the population is likely to have increased as family sizes have decreased. Family size in New Zealand increased in the post war years; there was a peak in the total fertility rate in 1961, then a",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 722,
    "paragraph": "decline until 1983, followed by a small increase (Department of Statistics, 1993b). Between 1976 and 1991, the average size of the New Zealand household declined from 3.2 to 2.8 members (Public Health Commission of New Zealand, 1993). Thus, if there is a real association between birth order and",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 723,
    "paragraph": "Childhood leukaemias in New Zealand JD Dockerty et al x 1145 childhood leukaemia, one might expect to have seen an increase in incidence rates beginning after the 1961 peak in the fertility rate. The results of this study have suggested that",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 724,
    "paragraph": "the incidence of childhood leukaemia probably began to increase in about 1963-67. Thus, the trends in family size may at least partly explain the increase in the incidence of childhood leukaemia. Studies of the class and childhood leukaemia have not been consistent, but some",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 725,
    "paragraph": "have found an increased risk among higher social classes (Draper and Elliott, 1991). Social class is a complex concept involving such factors as employment, housing, income and education. A detailed analysis of time trends in social class (and its component factors) is beyond the scope of the",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 726,
    "paragraph": "present work, but such work would be useful, as temporal changes in socioeconomic level could have a bearing on the leukaemia trends. relationship between social Kinlen (1988) hypothesised that childhood leukaemia occurs as a rare response to a common infection, and that",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 727,
    "paragraph": "population influxes into areas of low herd immunity favour the occurrence of epidemics of the infection, and increases in leukaemia incidence. If a virus that could cause childhood leukaemia was introduced into New Zealand, and if more and more people gradually became infected, one might expect",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 728,
    "paragraph": "to see an increase in incidence rates. But Kinlen's hypothesis local population has been tested mainly in movements, and the hypothesis cannot be confirmed or refuted by this study of national time trends. relation to in its pure form. precursor) ALL. The first",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 729,
    "paragraph": "Greaves and Chan (1986) hypothesised that spontaneous mutations in B-cell precursors could account for the majority of cases of ALL. The clear and continued increases in the incidence of ALL among children aged under 5 years, but not among older age groups, argue against this spontaneous",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 730,
    "paragraph": "Greaves (1988) mutation hypothesis elaborated the hypothesis by suggesting that two genetic events, both spontaneous mutations, were needed to produce common (B-cell event was in utero (following developmentally hypothesised to occur stress on B-cell precursors), and the driven proliferative second in infancy, (following proliferative stress resulting",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 731,
    "paragraph": "1988). from exposure to exogenous antigens) (Greaves, Greaves suggested that the incidence of ALL was associated with a certain pattern of exposure to infections and other antigens; such exposure would be affected by socioeconomic circumstances, and the responses to exposure would be",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 732,
    "paragraph": "modulated by genetic background, duration of breastfeeding and vaccinations (Greaves, 1988). The weak associations of common ALL with higher socioeconomic level and firstborn children could be due to delayed exposure to infections, 1988). A leading to more proliferative corollary of all this (if the hypothesis is correct) is that",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 733,
    "paragraph": "temporal changes in the factors related to the exposure of infants to antigens could lead to secular time trends. During there have been changes in the period of this breastfeeding, vaccinations, socialisation, education, family structure and income. The effect of this mixture of changes",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 734,
    "paragraph": "(in terms of Greaves' hypothesis) is complicated, and it is not practical to offer a simple interpretation of the ALL time trends in relation to it. Some factors relevant to Greaves' hypothesis (and infections in general) would also be relevant to certain specific infections.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 735,
    "paragraph": "stress (Greaves, study, In adults, there is strong Acute non-lymphoblastic leukaemia evidence that benzene exposure can cause ANLL (Austin et al., 1988). It is not known whether this is also the case for children. There are no long-term time trend data on the",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 736,
    "paragraph": "exposure of New Zealanders to benzene. Age and ethnic group This study confirms previous work by Gunz (1966), who identified a peak in the age distribution of childhood acute leukaemias at ages 2-3. The present work showed that the peak increased in size, in tandem with the increase in the",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 737,
    "paragraph": "9 1146 cmi,o.d Ii aenas in New Zdanad JD Dockerty et al ra incidence of ALL for young children. A similar peak developed in Britain in the 1920s and 1930s (Neglia and Robison, 1988) and increased in size between 1931 and 1953",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 738,
    "paragraph": "(Hewitt, 1955). After 1940, there was an increase in the age peak among US Whites (Court Brown and Doll, 1961). The early age peak has not been found in tropical Africa, even when an intensive search for cases of ALL has been made",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 739,
    "paragraph": "(Fleming, 1988). The early age peak is due to common ALL (Greaves et al., 1981; 1985). In New Zealand health statistics, ethnicity is not assigned in a uniform way, leading to possible bias because of differences in the ways numerator and denominator data",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 740,
    "paragraph": "are collected and classified (Brown, 1983; Smith and Pearce, 1984; Review Committee on Ethnic Statistics, 1988). In this study, population estimates were based on the national census. The census currently relies on self-identification of ethnic group. The registration data come mainly from",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 741,
    "paragraph": "hospitals. In hospital admission records, ethnicity could be assigned on the basis either of self/parent-identification or of observation by the admitting staff. is not possible to the properly trends and rates, comparisons that involve ethnic groups. The long time period of this study makes such assessments very difficult,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 742,
    "paragraph": "because of the the comparability of the numerator and denominator data for Maori and non-Maori. likelihood of temporal changes in It of the validity The lower rates of ALL (and higher rates of ANLL) among Maori than non-Maori may be due to genetic",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 743,
    "paragraph": "differences that affect susceptibility to ALL, or to causes of it. Alternatively (or additionally), lifestyle or environmental assess differences might result in differences in exposure to risk factors. Compared with the total New Zealand population, Maori have on average greater unemployment, lower income,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 744,
    "paragraph": "fewer educational qualifications, higher levels of overcrowd- ing in homes and lower levels of home ownership (Public Health Commission of New Zealand, 1994). It is of interest to compare the incidence rates for New Zealand Maori with those found in a previous study of",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 745,
    "paragraph": "another Polynesian population. Goodman et (1989) calculated the incidence of childhood ALL (ages 0-14) among Hawaiians in Hawaii, 1960-84. Their rates (per 100 000 person-years) were 2.5 for Hawaiian boys and 2.1 for Hawaiian girls, based on small numbers (19 girls and 14",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 746,
    "paragraph": "boys). New Zealand Maori had a similar incidence rate for ALL (2.5 per 100 000 person-years for both sexes combined, 1968-90). The temporal changes in the incidence rates of ALL and ANLL in New Zealand highlight the likely importance of environmental factors in the aetiology of these cancers in",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 747,
    "paragraph": "children. al. Ackowkledgemests For the duration of this study. John Dockerty's salary was provided by a grant from the Health Research Council of New Zealand. This project was funded from Cancer Research Bequest Funds of the University of Otago Medical School. Mark Elwood,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 748,
    "paragraph": "(1994). Incidence of childhood cancer in Osaka, Japan, 1971- 1988: Reclassification of registered cases by Birch's scheme using information on clinical diagnosis, histology and primary site. Jpn. J. Cancer Res., 85, 139 - 146. ARMITAGE P AND BERRY G. (1987). Statistical Methods in Medical",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 749,
    "paragraph": "Research, 2nd edn. Blackwell: Oxford. AUSTIN H, DELZELL E AND COLE P. (1988). Benzene and leukemia: a review of the literature and a risk assessment. Am. J. Epidemiol., 127, 419-439. BIRCH J AND MARSDEN HB. (1987). A classification scheme for childhood cancer. Int. J. Cancer, 40, 620- 624.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 750,
    "paragraph": "BIRCH JM, MARSDEN HB AND SWINDELL R. (1980). Incidence of malignant disease in childhood: A 24-year review of the Manchester Children's Tumour Registry data. Br. J. Cancer, 42, 215-223. BIRCH JM, SWINDELL R, MARSDEN HB AND MORRIS-JONES PH. (1981). Childhood leukaemia in north west England 1954-1977:",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 751,
    "paragraph": "epidemiology, incidence and survival. Br. J. Cancer, 43, 324- 329. BIRCH JM, MARSDEN HB, MORRIS-JONES PH, PEARSON D AND BLAIR V. (1988). Improvements in survival from childhood cancer: results of a population based survey over 30 years. Br. Med. J., 296, 1372-1376.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 752,
    "paragraph": "BLAIR V AND BIRCH JM. (1994). Patterns and temporal trends in the incidence of malignant disease in children: I. Leukaemia and lymphoma. Eur. J. Cancer, 30A, 1490-1498. BRESLOW NE. (1984). Elementary methods ofcohort analysis. Int. J. Epidemiol., 13, 112- 115. BRESLOW NE AND LANGHOLZ B. (1983). Childhood cancer",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 753,
    "paragraph": "incidence: Geographical and temporal variations. Int. J. Cancer, 32, 703-716. BROWN PG. (1983). An Investigation of Official Ethnic Statistics. Department of Statistics: Wellington. COEBERGH JWW. VAN DER DOES-VAN DEN BERG A. VAN WERING ER. VAN STEENSEL-MOLL HA, VALKENBURG HA. VAN'T VEER MB, SCHMITZ PIM AND VAN ZANEN GE. (1989).",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 754,
    "paragraph": "Childhood leukaemia in The Netherlands, 1973 - 1986: temporary variation of the incidence of acute lymphocytic leukaemia in young children. Br. J. Cancer, 59, 100 - 105. COLEMAN MP. ESTEVE J, DAMIECKI P. ARSLAN A AND RENARD H. (1993). Trends in Cancer Incidence and Mortality. Interna-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 755,
    "paragraph": "tional Agency for Research on Cancer: Lyon. COOKE KR. GRAY AJ, BURRY AF AND STEWART RJ. (1988). Cancer Registration in New Zealand: report of the Cancer Registration Working Group. Department of Statistics: Wellington. COURT BROWN WM AND DOLL R. (1961). Leukaemia in childhood",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 756,
    "paragraph": "and young adult life: Trends in mortality in relation to aetiology. Br. Med. J., 1. 981 -988. DARBY SC. OLSEN JH. DOLL R. THAKRAR B. DE NULLY BROWN P. STORM HH, BARLOW L, LANGMARK F, TEPPO L AND TULINIUS H. (1992). Trends in childhood leukaemia in the Nordic countries",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 757,
    "paragraph": "in relation to fallout from atmospheric nuclear weapons testing. Br. Med. J., 304, 1005 - 1009. DE NULLY BROWN P. HERTZ H. OLSEN JH. YSSING M, SCHEIBEL E AND JENSEN OM. (1989). Incidence of childhood cancer in Denmark 1963-1984. Int. J. Epidemiol., 18, 546-555.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 758,
    "paragraph": "DEPARTMENT OF STATISTICS. (1992). 1991 Census of Population and Dwellings. New Zealand Maori population and dwellings. Department of Statistics: Wellington. DEPARTMENT OF STATISTICS. (I 993a). 1991 New Zealand census of population and dwellings. New Zealand's multicultural society. Department of Statistics: Wellington.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 759,
    "paragraph": "DEPARTMENT OF STATISTICS. (1993b). New Zealand Official Yearbook 1993. 96th edn. Department of Statistics: Wellington. DOLL R. (1989). The epidemiology of childhood leukaemia. J. R. Stat. Soc. A., 152, 341-351. DRAPER GJ. KROLL ME AND STILLER CA. (1994). Childhood cancer. Cancer Surv., 19/20, 493 - 517.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 760,
    "paragraph": "DRAPER GJ AND ELLIOTT P. (1991). Variations in incidence rates and factors affecting them - summary. In: The Geographical Epidemiology of Childhood Leukaemia and non-Hodgkin Lympho- mas in Great Britain, 1966-83. Draper G (ed.) pp. 57-60. HMSO: London. DRAPER GJ AND STILLER CA. (1992). Intramuscular vitamin K and",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 761,
    "paragraph": "childhood cancer (letter). Br. Med. J., 305, 709. EKELUND H, FINNSTROM 0, GUNNARSKOG J. KALLEN B AND LARSSON Y. (1993). Administration of vitamin K to newborn infants and childhood cancer. Br. Med. J., 307, 89-91. ERICSSON IL. KARNSTROM L AND MATTSSON B. (1978). Child-",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 762,
    "paragraph": "hood cancer in Sweden, 1958-1974. Acta Paediatr. Scand., 67, 425-432. CMhood beeicauiias in Ne D Dockerty et a Zealand 9 1147 NEGLIA JP AND ROBISON LL. (1988). Epidemiology of the childhood acute leukemias. Pediatr. Clin. N. Am., 35, 675 -692. NEW ZEALAND HEALTH INFORMATION SERVICE. (1995). Cancer:",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 763,
    "paragraph": "New Registrations and Deaths 1992. Ministry of Health: Well- ington. OLSEN JH, HERTZ H, BLINKENBERG K AND VERDER H (1994). Vitamin K regimens and incidence of childhood cancer in Denmark. Br. Med. J., 308, 895 - 896. PARKIN DM, STILLER CA. DRAPER GJ. BIEBER CA. TERRACINI B",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 764,
    "paragraph": "AND YOUNG JL. (1988a). International Incidence of Childhood Cancer. International Agency For Research on Cancer: Lyon. PARKIN DM, STILLER CA, DRAPER GJ AND BIEBER CA. (1988b). The international incidence of childhood cancer. Int. J. Cancer. 42, 511-520. POLEDNAK AP. (1986). Recent trends in incidence and mortality",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 765,
    "paragraph": "rates for leukemias, and in survival rates for childhood acute lymphocytic leukemia, in Upstate New York. Cancer, 57, 1850- 1858. PUBLIC HEALTH COMMISSION OF NEW ZEALAND. (1993). Our Health, Our Future. The State of The Public Health in New Zealand 1993. Public Health Commission: Wellington.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 766,
    "paragraph": "PUBLIC HEALTH COMMISSION OF NEW ZEALAND. (1994). Our Health, Our Future. The State ofthe Public Health in New Zealand 1994. Public Health Commission: Wellington. REVIEW COMMITTEE ON ETHNIC STATISTICS. (1988). Report of the Review Committee on Ethnic Statistics. pp. I - 132. Department",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 767,
    "paragraph": "of Statistics: Wellington. ROSS JA, DAVIES SM, POTTER JD AND ROBISON LL. (1994). Epidemiology of childhood leukemia. with a focus on infants. Epidemiol. Rev., 16, 243-272. SMITH AH AND PEARCE NE. (1984). Determinants of differences in mortality between New Zealand Maonrs and non-Maonrs aged",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 768,
    "paragraph": "15-64. N. Z. Med. J., 97, 101 - 108. STATISTICS NEW ZEALAND. (1995). Demographic Trends 1994. Statistics New Zealand: Wellington. STEWART A AND KNEALE GW. (1969). Role of local infections in the recognition of haemopoietic neoplasms. Nature, 223, 741 - 742.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 769,
    "paragraph": "VAN HOFF J. SCHYMURA MJ AND MCCREA CURNEN MG. (1988). Trends in the incidence of childhood and adolescent cancer in Connecticut, 1935- 1979. Med. Pediatr. Oncol., 16, 78- 87. WATERHOUSE J, MUIR C, CORREA P. POWELL J AND DAVIS W. (1976). Cancer Incidence in Five Continents. Vol III. International",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 770,
    "paragraph": "Agency for Research on Cancer: Lyon. FLEMING AF. (1988). Possible aetiological factors in leukaemias in Africa. Leuk. Res., 12, 33-43. GOLDING J. PATERSON M AND KINLEN Li. (1990). Factors associated with childhood cancer in a national cohort study. Br. J. Cancer, 62, 304-308.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 771,
    "paragraph": "GOLDING J. GREENWOOD R. BIRMINGHAM K AND MOTT M. vitamin K, and (1992). Childhood cancer, pethidine given during labour. Br. Med. J., 305, 341- 346. intramuscular GOODMAN MT, YOSHIZAWA CN AND KOLONEL LN. (1989). Incidence trends and ethnic patterns for childhood leukaemia in",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 772,
    "paragraph": "Hawaii: 1960- 1984. Br. J. Cancer, 60, 93 - 97. in the GORDIS L, SZKLO M, THOMPSON B, KAPLAN E AND TONASCIA JA. of acute (1981). An apparent nonlymphocytic leukemia in black children. Cancer, 47, 2763- 2768. incidence increase GREAVES MF, JANOSSY G. PETO J AND KAY H.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 773,
    "paragraph": "(1981). Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br. J. Haematol., 48, 179-197. GREAVES MF, PEGRAM SM AND CHAN LC. (1985). Collaborative group study of the epidemiology of acute lymphoblastic leukaemia subtypes: Background and first report. Leuk. Res.. 9,",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 774,
    "paragraph": "715-733. GREAVES MF. (1988). Speculations on the cause of childhood acute lymphoblastic leukaemia. Leukemia, 2, 120 - 125. GREAVES MF AND CHAN LC. (1986). Annotation: Is spontaneous mutation the major cause' of childhood acute lymphoblastic leukaemia? Br. J. Haematol., 64, 1 - 13.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 775,
    "paragraph": "GUNZ FW. (1966). Studies on the incidence and aetiology of leukaemia in New Zealand. N. Z. Med. J., Haematologv Supplement. 65, 857-862. HEWITT D. (1955). Some features of leukaemia mortality. Br. J. Prev. Soc. Med., 9, 81-88. KINLEN L. (1988). Evidence for an infective cause of childhood",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 776,
    "paragraph": "leukaemia: Comparison of a Scottish new town with nuclear reprocessing sites in Britain. Lancet, 2, 1323 - 1327. KLEBANOFF MA, READ JS, MILLS JL AND SHIONO PH. (1993). The risk of childhood cancer after neonatal exposure to vitamin K. N. Engi. J. Med., 329, 905-908.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 777,
    "paragraph": "MANTEL N. (1963). Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc., 58, 690-700. MATrHEWS M. (1994). A review of fallout deposition and milk contamination. Radiat. Protection News Notes, 26, 15-17. MCWHIRTER WR AND PETROESCHEVSKY AL. (1991). Incidence",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 778,
    "paragraph": "trends in childhood cancer in Queensland, 1973- 1988. Med. J. Aust., 154, 453-455. MEDICAL STATISTICS BRANCH OF THE DEPARTMENT OF HEALTH. (1955). Report of the Medical Statistician on Cancer Morbidity and Mortality in New Zealand. Department of Health: Wellington.",
    "jurnal": "brjcancer00037-0121.pdf"
  },
  {
    "id": 779,
    "paragraph": "Br. J. Cancer (1980) 41, 966 IMMUNIZATION AGAINST PRIMARY, TRANSPLANTED AND SPONTANEOUS MURINE LEUKAEMIA USING A LIVE MOLONEY SARCOMA VIRUS VACCINE A. M. S. MAYER,* M. A. BASOMBRIOt AND C. D. PASQUALINIt From the Seccion Leucemia Experimental, Instituto de Investiqaciones Hematologicas,",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 780,
    "paragraph": "Academia Nacional de Medicina, Las Heras 3092, 1425, Buenos Aires, Argentina Received 9 October 1979 Accepted 16 January 1980 Summary.-The purpose of this study was to use an immunization protocol with Moloney sarcoma virus (MSV-M) as active immunogen against exogenous and endo-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 781,
    "paragraph": "genous leukaemia. The s.c. route was chosen since it offered advantages over the i.m. route: the primary sarcomas were smaller, the regression faster, there were fewer recurrences and there was good persistent immunity. Strong protection was obtained against primary leukaemias induced by Friend leukaemia virus (FLV), Moloney",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 782,
    "paragraph": "leukaemia virus (MLV), Rauscher leukaemia virus (RLV), Precerutti-Law leukaemia virus (PLLV/T2), and H179A leukaemia virus. It was not possible to protect against leukaemia induced by Gross leukaemia virus (GLV). With transplantable leukaemias the results varied: partial protection was observed against H110 leukaemia (induced",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 783,
    "paragraph": "with human material) and R14 leukaemia (induced by X-irradiation) whilst no pro- tection was obtained against P277 leukaemia (induced by Moloney leukaemia virus). As for spontaneous leukaemias, immunized BALB/c mice showed an increased incidence over the controls, while in Fl (Swiss x AKR) mice the incidence was similar",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 784,
    "paragraph": "but the latent period was shorter. Furthermore, in long-term observations the MSV- M-immunized mice showed an increased mortality, which could be related to (1) new phenotypic mixtures between MSV-M and leukaemia viruses; (2) reactivation of MSV-M sarcoma-genesis with age, and (3) genotype susceptibility to MSV-M.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 785,
    "paragraph": "To DATE, no standardized system has been used to compare the results of one and the same immunization protocol on the prevention of transplanted, primary and spontaneous leukaemia in the mouse. However, on different occasions, active immunization methods have been used,",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 786,
    "paragraph": "transplantable such as: syngeneic leukaemia in sub-threshold doses (Axelrad, 1963; Klein & Klein, 1964; Pasternak & Graffi, 1963); (2) allogeneic transplantable leukaemia (Klein & Klein, 1964; McCoy et al., 1967; Pasternak & Graffi, 1963); (3) culture cells chronically infected with virus (Barski & Youn, 1965; Mayyasi et",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 787,
    "paragraph": "(1) virus leukaemia al., 1968); (4) infectious leukaemia virus (Bianco et al., 1966; Glynn et al., 1964, 1968; Klein & Klein, 1964; Mayyasi & Moloney, 1967; McCoy et al., 1967; Sachs, 1962; Slettenmark & Klein, 1962); (5) attenuated (Fink & Rauscher, 1964; Friend, 1959; Huebner",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 788,
    "paragraph": "et al., 1976; Kelloff et al., 1976; Mayyasi & Moloney, 1967; McCoy et 1967; Tyndall, et al., 1967); (6) infectious murine sarcoma virus (Fefer et al., 1967; Huebner et al., 1976; Basombrio et al., 1977); and (7) purified viral components (Hunsmann",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 789,
    "paragraph": "et al., 1975; Ihle et al., 1976a,b). The varia- bility among experimental protocols makes al., Philosophy in Biological Sciences at the University of Buenos Aires, Buenos Aires, Argentina. * By wlhom tlhis work was submitted in partial fulfilment of the requirements for the degree of Doctor of",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 790,
    "paragraph": "t Member of Research Career, CONICET (Consejo Nacional de Inves tigaciones Cientificas y T&cnicas). Address for reprints: Christiane Dosne Pasqualini, Academia Nacional dIe Medicina, Las Heras 3092, 1425 Buenos Aires, Argentina. MURINE LEUKAEMIA IMMUNIZATION WITH MSV 967 it a direct comparison of the different results",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 791,
    "paragraph": "extremely difficult. replicates preferentially The Moloney sarcoma virus system (MSV-M) has been well characterized (Harvey & East, 1971). Its tissue tropism is different from that of leukaemic viruses, since in muscle and not in haemopoietic tissue (Perk & Maloney, 1966) and induces",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 792,
    "paragraph": "atypical granulomas (Simons & McCully, 1970). The tumours induced by MSV-M in normal adult mice regress after attain- ing considerable size, leaving the animals free of disease (Fefer, 1968). Immuno- logically, MSV-M has been studied ex- tensively; both the humoral and the",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 793,
    "paragraph": "cellular immune responses (Lamon et al., 1974) have been characterized. It has also been observed that MSV-M shares anti- gens with the Friend-Moloney-Rauscher complex (Fefer et al., 1967); its neutraliza- tion with rat anti-Gross serum (Fefer, 1967) opened up the possibility of using",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 794,
    "paragraph": "this virus for vaccination against Gross leukaemias. On the basis of the accumulated data, MSV-M seems to be the best characterized of all murine oncorna viral systems. There- fore, the purpose of this study was to use a with MSV-M as a live viral vaccine for the pre-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 795,
    "paragraph": "vention of primary, transplanted and spontaneous leukaemia in the mouse. standardized protocol unique MATERIALS AND METHODS Mice.-Inbred BALB/c and outbred Swiss mice, raised in our colony, 2 months old and of either sex, were used for immunization against primary and transplanted leukaemia.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 796,
    "paragraph": "(Swiss x AKR) Fl hybrids and BALB/c mice were used in studies involving spontaneous leukaemia. Leukaemia viruses. Six strains of murine leukaemia were Lyophilized Friend leukaemia virus (FLV, Lot 245 No. 5) frozen Rauscher leukaemia virus (RLV, Lot No. 1) and lyophilized Gross leukaemia",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 797,
    "paragraph": "virus (GLV, Lot 2D) were obtained from the American Type Culture Collection, Rockville, Md, U.S.A. Moloney leukaemia virus (MLV) was obtained from culture fluids of 3T3- murine leukaemia cells, provided by Dr Saal, used. virus 65 Centre Hayem, Hopital Saint Louis, Paris,",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 798,
    "paragraph": "France. Precerutti-Law leukaemia virus (PLLV/ T2) was introduced to our laboratory by Dr Precerutti 10 years ago as a BALB leukaemia of short latency, propagated by acellular extracts (Precerutti & Law, 1963). H179A leukaemia virus (H179A LV) was obtained from acellular extracts of leukaemia that",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 799,
    "paragraph": "appeared in a female BALB/c mouse, 2 months of age, 17 days after it had been inoculated with AKR leukaemic material (Pasqualini et al., 1968). Transplantable leukaemias.-Different leu- kaemias have been induced in our laboratory in the course of 20 years; many are main-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 800,
    "paragraph": "tained by serial cell passage (Pasqualini et al., 1968) of which the following were studied: HlIO Leukaemia, obtained from a 3 month old BALB female, 37 days after being inocu- lated with human material via the intra- splenic route; R14 leukaemia, obtained from",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 801,
    "paragraph": "a 10-month-old BALB/c female mouse that had received 3 weekly doses of 150 rad; P277 leukaemia, obtained from mice inocu- lated with Moloney leukaemia virus. a since strain, high-leukaemia Spontaneous leukaemias.-High- and low- leukaemia strains were needed for the experi- ments. (AKR x Swiss) Fl hybrids were used",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 802,
    "paragraph": "as they proved to have a 30% incidence of leukemia at an average age of 12 months. The BALB/c strain was selected as a low-leukaemia strain, having a 15% spontaneous incidence at an average age of 18 months, in our laboratory.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 803,
    "paragraph": "Preparation and titration of Moloney sar- coma virus vaccine.-MSV-M used in the ex- periments originated from lot SVR-P166 kindly forwarded by Dr. K. E. Hellstrom, University of Washington, Seattle, U.S.A. A large number of newborn BALB/c mice were sarcomas originating from this inoculum were disrupted",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 804,
    "paragraph": "in 10 volumes of cold phosphate-buffer saline plus streptomycin and penicillin (PBS) and then homogenized in a Virtis blender Model S23. The homogenate was centrifuged twice at 5000 and 10,000 revs/min for 15 and 20 min respectively. Supernatants were then transferred to glass ampoules, sealed and",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 805,
    "paragraph": "frozen at - 196°C for storage. Subcutaneous inoculated. The titre of MSV-M was calculated in vivo using the Reed-Muench method, estimating take doses at Day 35. 0-2 ml of 10-fold dilu- tions of MSV-M stock were inoculated i.m. into 2-month-old BALB/c and Swiss mice.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 806,
    "paragraph": "968 A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI Stock MSV-M, used in all experiments, con- tained 1P5 x 10J Take-dose 50/ml. Preparation and titration of murine leu- kaemia virus.-Leukaemic tissues (spleen and lymph nodes) were disrupted in 10 volumes of",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 807,
    "paragraph": "PBS with a glass homogenizer and processed in the same manner as for MSV-M sarcomas. Murine leukaemia viruses used to challenge MSV-M immunized mice were titrated in vivo in 2-3-month-old BALB/c mice. Tenfold dilutions of stored stock viruses were inocu- lated i.p., each mouse receiving 0-1 ml, and",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 808,
    "paragraph": "the proportion of mice dying with leukaemia within 3 months was recorded. The titre of the murine leukaemia viruses used was cal- culated by the Reed-Muench method esti- mating lethal doses at the day indicated between brackets in each case. Titres were:",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 809,
    "paragraph": "RLV: 3-7x102 LD50 (69)/ml; FLV: 5x102 LD50 (74)/ml; PLLV-T2LV: 51 x 103 LD50 (66)/ml and H179ALV: 5 x 104 LD50 (56)/ml. MLV and GLV were not titrated in this way, since they induced splenomegaly and death after prolonged periods. Massive doses of",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 810,
    "paragraph": "these viruses were inoculated in the challenge experiments. Preparation and titration of transplantable Transplantable leukaemias leukaemia cells. were maintained by in vivo cellular passage every 7-14 days. Stock material was prepared by mincing leukaemic tissues in 10 volumes of PBS, filtering through a cotton gauze and",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 811,
    "paragraph": "storing in glass ampoules, sealed and frozen at - 196TC for storage. For titration, the number of viable cells was determined in the material by Trypan-blue unfrozen exclusion. The concentration was adjusted so as to inoculate 101-105 cells per mouse in",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 812,
    "paragraph": "0-2 ml, i.p. Death by 25 days was recorded and LD50 calculated. The LD50 of the leu- stock kaemias used was respectively: H110: 80 cells in 19 days, R14: 100 cells in 25 days, and P277: 50 cells in 20 days.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 813,
    "paragraph": "The experimental protocol for immuno- prevention studies.-In order to test the live MSV-M immunogen, mice were subjected to a standardized protocol: inoculation of 0-2 ml MSV-M s.c. which induced localized sarcomas which quickly regressed, followed by a booster immunization 30-40 days later. The control",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 814,
    "paragraph": "group received 0-2 ml of a supernatant of normal BALB/c muscle extracts. Challenge of the MSV-M immunized mice with either leukaemia virus or cells was accomplished 30 days after the booster immunization, when 4 months old. The incidence of mice were",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 815,
    "paragraph": "primary and transplanted leukaemia in experi- mental and control mice was carefully recor- ded. All sick animals with evident spleno- megaly were sacrified and autopsied: presence of enlarged spleen, thymus or lymph nodes indicated leukaemia. The data were evaluated by the x2 and",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 816,
    "paragraph": "Mann-Whitney U tests. RESULTS Characterization of MS V-M stock using dilutions Tumour incidence, tumour growth, sur- vival rate and immunological status were of studied different MSV-M stock inoculated either i.m. or route, tumour incidence s.c. By s.c. (Table I) and growth (Fig. 1) were greatly",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 817,
    "paragraph": "reduced, tumour regression was complete in all animals and the survival rate was considerably greater (Table I). MSV-M of the immunized survivors challenge TABLE I. Comparison of tumour incidence and survival rate of BALB/c mice inoculated with MSV-M s.c. and i.an.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 818,
    "paragraph": "S.c. route I_ Incidence at Day 35 Sur-ival at Tumours/ No. mice* 11/12 10/12 9/12 2/10 0/1 2 ( 0 /o) 9 8 .3 7 75 2 0 D,_ ,y 35 0o/) DO 1( M() O( O() Of) 1( -- D)av 97",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 819,
    "paragraph": "(0%) 91 100 100 t100 100 I.m. route Inci(Ience at Day 35 -_- - Tumouirs/ No. mice* 12/12 12/12 12/12 8/12 0/12 (0) 100 100 loo 66 0 Survival at A D)ay '35 (0) 90 66 100 100 100 D)ay 97",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 820,
    "paragraph": "( 00) 30 16 70 100 100 Log of MSV-M (lillit ion - 1 -3 -4 -5 * Each mouise received 0-2 ml of MSV-INI, (liluitp(1 from a stock -with a titre of 15 x 105 TD50(35)/ml. MURINE LEUKAEMIA IMMIJNIZATION WITH MSV",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 821,
    "paragraph": "969 Subcutaneo I litramtisc l ar 12 .-..-.-.---------- 800 J 500 450 i 400 .350 x = 207 mg x = 329 mg 5 1 S1S 20 30 25 days S 10 1 '()20 5 30 .5 days @0 ~~~~~00 FiG. 1.- Tumour growth in BALB/c mice",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 822,
    "paragraph": "andl i.m. as average of dilution 10-1 - - --1 - - dilution 10-3; inoculated Tumour size 3 diam. (mm). dlilution ...... (lilution 10-4. with MSV-M s.c. calculated 10-2; - TABLE II. Comparison of tumour inci- dence (at 35 days) after MS V-M challenge",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 823,
    "paragraph": "of BALB/c mice previously MS V-M- immunized s.c. or i.m. S.c. route Ttumour takes/ total challenged* 0/11 0/12 0/12 1/12 5/12 8/12 Log (lilution of immunizing inocultum -I -2 -3 -4 -5 Controls challengedc % 0 0 0 10 50 I.m. route",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 824,
    "paragraph": "Tumour takes/ total 0/2 0/1 0/7 1/9 6/12 0 0 0 8 41 66 * Witlh 0-1 ml of a 10-1 diltution of stock MSV-M i.m. showed that the s.c. route immunized as well as the i.m. one, even though 3 months",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 825,
    "paragraph": "had since tumour regression (Table II). These data indicated clearly that with our MSV-M stock the s.c. route of immunization was the better of the two. elapsed Immunoprevention leukaemias of primary miurine Immunization against Moloney leuk- aemia.-Since the susceptibility to MLV",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 826,
    "paragraph": "decreased with age, adult BALB/c mice developed a moderate splenomegaly which progressed slowly, with many mice sur- viving beyond 1 year, so that immunity was evaluated by recording the inhibition of leukaemic splenomegaly (Basombrio et al., 1977). A group 15 MSV-M-immunized",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 827,
    "paragraph": "BALB/c mice received 0 5 ml of MLV i.p., of 150 u)iso 0 FIG. 2. immunized MSV-M Immunization Controls against primary Moloney leukaemia ........ Normal spleen. indicating leukaemia simultaneously with 1 5 controls. All mice were killed on Day 86 and the spleens",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 828,
    "paragraph": "weighed. There was a noticeable inhibition of splenomegaly protection against Moloney (P = 0 02, Mann-Whitney U test) in the MSV-M immunized mice (x = 207 mg; s.d. = 44 6 mg) with respect to the controls (x=329 mg; s.d. = 166 mg).",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 829,
    "paragraph": "Immunization against Rauscher leuk- aemia. Seventeen BALB/c mice immu- nized with MSV-M, together with 21 con- trols, received 0-2 ml of a 10-2 dilution of Survival % 100 90a 80- 70- , *\\ 60 50 40 30 - 20 10 50 100 150 200 250 300 350",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 830,
    "paragraph": "days FIG. 3. Immunization witlh MSV-M against im- primary Rauscher leukaemia. munized with MSV-M; ....... controls. 970 A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI TABLE III. Palpable splenomegaly (at 32 days) in BALB/c mice immunized with MS V-M and challenged with FL V",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 831,
    "paragraph": "Positive splenomegaly /Total mice Group o/ O MSV-M immunize(l Controls 5/20 16/23 25 69 <0-001 * Calculated by x2 test. the RLV stock. Both groups were ob- served for 358 days. A clear protection against the development of leukaemia was observed at Day 120 (Fig. 3). 14/17 (82%)",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 832,
    "paragraph": "of MSV-M immunized mice surviving controls against (P < 0'00 1). Further observation showed that mortality progressively increased in both groups, only 4/17 (23%) of the MSV-M immunized mice and 2/21 (90) of the controls surviving at 369 days. (19%) 4/21",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 833,
    "paragraph": "the of of group Immunization against Friend leukaemia. 21 MSV-M-immunized A group BALB/c mice, together with 23 controls, were challenged with FLV, each mouse receiving 0 2 ml of a 1/500 dilution of FLV stock. The survival rate was similar in both groups after 169 days of observa-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 834,
    "paragraph": "tion (7/21 immunized and 7/23 controls). As shown in Table III, there was a sig- inhibition of palpable spleno- nificant megaly 32 days after FLV challenge in the (P < 0-00 1) MSV-M immunized though this difference was not reflected in",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 835,
    "paragraph": "the survival data. Imnmunization Precerutti-Law against leukaemia.-A group of 19 MSV-M-im- munized BALB/c mice, together with 18 controls, were challenged i.p. with 0-2 ml of a 10-3 dilution of PLLV/T2. After 130 days clear protection was seen in the pre- treated group (Fig. 4) where 13/19 (68%)",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 836,
    "paragraph": "survived whereas all the controls had died (P < 0.001; x2 test). On further observa- tion, immunized mice showed a pro- gressive mortality, since after 365 days, only 6/19 (32%) survived. Immunization against HI 79A leukaemia. 14 MSV-M-immunized -A group BALB/c mice, together with 18 controls,",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 837,
    "paragraph": "of Survival % 100 90 80 \\ . K '.\\ 70 60 50 40 30 20 10 N* 50 100 150 200 250 300 350 days FIG. 4.-Immunization with MSV-M against primary PLLV/T2 leukaemia. Key as in Fig. 3. were challenged i.p. with 0-2 ml of a 10-3",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 838,
    "paragraph": "dilution of H179A LV. At Day 46, 11/14 survived, of immunized mice (78%) 5; (Fig. against none of the controls P < 0001, x2 test). The animals were observed for 137 days, at which time 7/14 (50%o) had survived. Survival %",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 839,
    "paragraph": "100 \\_--' 90 80 0 70 60 50 40 30 20 10 20 40 60 80 100 120 140 days FIG. 5.- Immunization witli MSV-M against primary H 179 A leukaemia. Key as in Fig. 3. MURINE LEUKAEMIA IMMUNIZATION WITH MSV",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 840,
    "paragraph": "971 Survival % 100 F- 90 80 70 60 50 40 30 20 10 40 80 120 160 200 240 2'89 days of FIG. 6. Immunization with MSV-M against primary Gross leukaemia. Key as in Fig. 3. Immunization against Gross leukaemia.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 841,
    "paragraph": "-A group 20 MSV-M-immunized Swiss mice, together with 22 controls, were challenged i.p. with 0-2 ml of a GLV supernatant. After 296 days, 9/20 (45%) immunized and 7/22 (31%) of control mice had survived (Fig. 6). There is no protection by MSV-M imnmunization",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 842,
    "paragraph": "against the development of Gross leuk- aemia. Imnmunoprotection of transplantable murine leukuaemias of Immunization against HI 1O leukaemnia. -A group 22 MSV-M-immunized BALB/c mice and 21 matched controls received 400 H1110 leukaemic cells in 0-2 ml i.p. Thirteen days after challenge,",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 843,
    "paragraph": "21/22 (950) of the immunized mice sur- vived, compared to only 9/21 (47%o) of the controls (P < 0001; Fig. 7). However, this significant inhibition of leukaemia was eventually lost, since at Day 165 6/22 (27%) of immunized and 4/21 (19%) of",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 844,
    "paragraph": "control mice survived. Protection against H1110 leukaemia was evident, but not long-lasting. Immunization against R14 leukaemia.- A group of 17 MSV-M-immunized BALB/c mice and 16 controls received 103 R14 Survival % 100 90 80 70 60 50 40 30 20 10",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 845,
    "paragraph": "10 20 30 40 50 100 165 days FIG. 7.- Immunization with MSV-M against transplantable HIIO leukaemia. Key as in Fig. 3. leukaemic cells in 0.2 ml i.p. Forty-four days later 12/17 (70%) of immunized and 6/16 (37%) of control mice survived",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 846,
    "paragraph": "(P<0 001; Fig. 8). However, at Day 102 only 1/17 (6%) of immunized and 3/16 (18%) of control mice survived. Thus, protection against R 14 leukaemia was evident but not long-lasting. Immunization against P277 leukaernia.- A group of 19 MSV-M-immunized mice",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 847,
    "paragraph": "Survival % 100 LO 90 - 80 - 70 60 \"'*I * 50 40- 30- 20 - 10o 15 30 45 60 75 90 105 days FIG. 8. Immunization with MSV-M against transplantable RI4 leukaemia. Key as in Fig. 3. 972",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 848,
    "paragraph": "A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI and 20 controls received only 14 cells of P277 leukaemia in 0-2 ml, i.p., since this leukaemia was highly lethal in very small cell doses. Neither the immunized nor the",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 849,
    "paragraph": "control mice survived more than 14 days, all mice dying of progressive leukaemia, against which it was not possible to detect any protection. MSV-M immunization against spontaneous leukaemias Effect in BALB/c mice.-A group of 47 BALB/c mice received consecutive MSV-M inoculations at 3, 4 and 9 months",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 850,
    "paragraph": "of age, while 51 matched controls re- After 504 days of mained untreated. observation (Fig. 9) mortality was greater 3 Survival 90 . 80 - 60 50 40 30 20 10 '0 0. 0 250 300 350 400 450 500 550",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 851,
    "paragraph": "days FIG. 9. Immunization against spontaneous leukaemia in BALB/c mice. Key as in Fig. 3. in the immunized than in the control mice; 29/36 (55%o) of the observed deaths in the MSV-M-immnunized group occurred between 300 and 370 days of age, which",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 852,
    "paragraph": "was 30 days after the final MSV-M booster inoculation. An analysis of leukaemia incidence (Table IV) showed that 4 con- firmed and 14 presumptive leukaemias appeared in the immunized group and in the controls. This protocol only 1 actually increased the incidence of spon-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 853,
    "paragraph": "taneous leukaemia in BALB/c mice. Effect in (Swiss x AKR) F1 mice. (Swiss x AKR) F1 mice presented a 350o incidence of spontaneous leukaemia in an average of 18 months. In this experiment only one inoculation of MSV-M was used to immunize the mice, in order to reduce",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 854,
    "paragraph": "TABLE IV. Incidence of spontaneous leuk- aemias in MSV-M-immunized BALB/c mice observed for 504 days Leukaemia Palpable spleens + lymph nodes* Normal Other causes of dleath* Other tumours Total MSV-MI immtunized Controls 4 14 11 18 47 1 27 22 1",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 855,
    "paragraph": "51 * Mice died suddenly so possible. that no necropsy was Sunrival °O 100 90 80 70 60 50 40 30 20 10 150 200 300 350 400 450 500 330 days FiG. 10. Immunization against spontaneous leukaemia in F1 (Swiss x AKR) mice. Key",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 856,
    "paragraph": "as in Fig. 3. the possibility of increased mortality as seen in MSV-M-immunized BALB/c mice. After 528 days of observation (Fig. 10) both the MSV-M-immunized and the con- trol mice showed a very similar pattern of mortality. However, pathological observa- tion demonstrated that although the inci-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 857,
    "paragraph": "I . tf I10 9 9 8 7 6 = ,, 0 5 4 r-: 3 m 2 i1 It- 0 If 7 8 9 10 l1l 12 13 14 15 16 17 18 Mornths (;age) FIG. 11. Immunization against spontaneous",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 858,
    "paragraph": "leukaemia in F1 (Swiss x AKR) mice. Key as in Fig. 3. MURINE LEUKAEMIA IMMUNIZATION WITH MSV 973 27°,) groups was similar, dence of leukaemia in both MSV-M- immunized (10/42, 23%) and control (11/47, the leukaemias appearing in the MSV-M- immunized mice up to 13 months of age",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 859,
    "paragraph": "had shorter latency than those seen in the controls (P < 0.02) (Fig. 11). Thus this protocol did not prevent spontaneous leukaemogenesis (Swiss x AKR) F1 hybrids, but rather accelerated the onset of leukaemia. in DISCUSSION Because of the different biological be-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 860,
    "paragraph": "haviour of MSV-M strains (Lavrin et al., 1973) our studies began with an immuno- logical and virological characterization of the MSV-M viral strain to be used. The s.c. route of inoculation was chosen be- cause it induced smaller tumours which regressed more rapidly, so that survival",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 861,
    "paragraph": "was greater, though the immunity in- duced was as strong as with the i.m. route. Moreover, the long-term pathogenicity responsible for recurrences of sarcoma in sites different from the first inoculation (diaphragm, spleen, liver) was also sig- nificantly reduced. The explanation may",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 862,
    "paragraph": "be that in the s.c. region there is less muscular tissue available for the replica- tion of the virus with special tropism for this tissue. The effectiveness of the experi- mental protocol using MSV-M as a live vaccine for immunoprevention studies",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 863,
    "paragraph": "was confirmed in the first group of experi- ments in which immunized mice were challenged with FLV, RLV7 and MLV, also used in other laboratories for immuno- prevention assays. Extension of the ex- periments to other leukaemia viruses originating our laboratory showed",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 864,
    "paragraph": "in effective protection against primary leuk- aemias induced by PLLV and HI 79A/LV. However, although serological data (Fefer, 1967) and in immunization with MSV-G (Basombrio et al., 1977) have indicated the presence of cross-reacting antigens in GLV' and MSV-M, no significant",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 865,
    "paragraph": "protection against GLV could be detected. Transplantable cellular leukaemias, to on the found in long-term negative to sensitive in vivo virus onco- genicity assays, were also tested. It was observed that the evolution of H 110 leukaemia, and to a lesser degree R 14",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 866,
    "paragraph": "leukaemia, could be retarded. However, P277, an extremely fast-growing and lethal leukaemia, could not be prevented, in spite of being originally induced by Moloney virus. The studies on the effect of MSV-M immunity leukaemo- spontaneous genesis in BALB/c and (Swiss x AKR) F1",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 867,
    "paragraph": "hybrids were complicated by difficulties related observations. In BALB/c mice, which had received 3 MSV-M injections, mortality was in- creased: MSV-M was shown to exist in leukaemic spleens of these mice, since acellular s.c. passage led to local growth of sarcoma. This increased mortality was",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 868,
    "paragraph": "(Swiss x AKR) F1 not hybrids, probably because only one MSV- M immunizing dose was used; leukaemia incidence was similar in both experimental and control groups, MSV-M-immunized mice showing significantly earlier spon- taneous leukaemia up to 13 months of age. observation",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 869,
    "paragraph": "of MSV-M- immunized mice challenged with leuk- aemia viruses, transplantable leukaemias or controlled for the incidence of spon- taneous leukaemias, revealed increased mortality. How can this be explained? In the first place, in vivo interaction between infectious FLV, MLV, RLV and MSV-M",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 870,
    "paragraph": "could increase the oncogenicity of MSV-M (Chirigos et al., 1968; Turner & Chirigos, 1969). New phenotypic mixtures might assemble between the inoculated leuk- aemia virus and the MSV-M used for immunization (Chieco-Bianchi et al., 1975). In certain mouse strains, notably C58 and",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 871,
    "paragraph": "AKR, the MSV-M forms phenotypic mix- tures with the endogenous GLV, pro- ducing new pseudotypes that could induce sarcomas of lethal and progressive growth (Chieco-Bianchi et al., 1974). Thus pheno- typic mixing could provide new genetic information which would modify the",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 872,
    "paragraph": "biology and pathogenicity of the original pseudotype used as immunogen. Secondly, Long-term 974 A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI it has been observed that after regression of MSV-M-induced sarcomas the virus remains in the lymphoid tissues of the",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 873,
    "paragraph": "mouse as a persistent infection controlled by the host (Chieco-Bianchi & Collavo, 1976; Giuliani et al., 1973). On the other hand, 6-month-old mice show again a great sensitivity to MSV-M oncogenesis (Pazmifio & Yuhas, 1973). Thus renewed MSV-M sarcomagenesis might cause un-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 874,
    "paragraph": "expected mortality in long-term experi- ments due to reactivation of the virus. Thirdly, the genotype of mice has a great bearing on the result of MSV-M onco- genesis: BALB/c mice are known to be very susceptible, whilst (Swiss x AKR) F1",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 875,
    "paragraph": "hybrids are very resistant (Colombatti et al., 1975) which could account for the observed difference in mortality. Could inactivation of the immunizing MSV-M virus override these difficulties? Probably not, since recent observations have shown that the protein fraction gp7l from FLV inoculated in C57 and AKR",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 876,
    "paragraph": "mice produces viral activation (Ihle et al., 1976a). This would suggest a mechanism mediated by viral components, an effect capable of complicating any study on the viral immunoprevention of murinie leuk- aemia. The blocking of viral replication would not be a sufficient guarantee to",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 877,
    "paragraph": "hinder the activation of endogenous virus which would lead to leukaemic transforma- tion in mice subjected to long observation. Recapitulating, our protocol, using a live MSV-M vaccine, proved successful in short-term experiments, protecting against the induction of primary leukaemias and leuk-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 878,
    "paragraph": "BARsKI, G. & YOUN, J. K. (1965) Immunization against Rauscher Mouse Leukemia with tissue culture material. Science, 149, 751. isotransplanted B SOMBRIO, M. A., MAYER, M. A. S. & PASQUALINI, Gross C. D. (1977) Murine sarcoma virus pseudotypes used as immunogens against viral and chemical",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 879,
    "paragraph": "oncogenesis. Cancer Res., 37, 1768. BIANCO, A. R., GLYNN, J. P. & GOLDIN, A. (1966) Induction of resistance against the transplanta- tion of leukemias induced by Rauscher virus. Cancer Res., 26, 1722. CHIECO-BIANCHI, L., COLLAVO, D., COLOMBATTI, A., SENDO, F., AOKI, T. & FIsCHINGER, P. J. (1974)",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 880,
    "paragraph": "Tumor induction by murine sarcoma virus in AKR and C58 mice. J. Exp. Med., 140, 1162. CHIECO-BIANCHI, L., COLLAVO, D., COLOMBATTI, A. & BIASI, G. (1975) In vivo interactions between murine leukemia and sarcoma viruses. In Com- parative Leukemia Research, 1973. p. 613.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 881,
    "paragraph": "CHIECO-BIANCHI, L. & COLLAVO, D. (1976) Some illustrative systems of viral carcinogenesis: The leukemia sarcoma virus complex in the mouse. In Scientiftc Foundations of Oncology. Ed. Sym- mington & Carter. CHIRIGos, M. A., PERK, K., TURNER, W., BURKA, B. & GOMEZ, M. (1968) Increased oncogenicity of the",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 882,
    "paragraph": "murine sarcoma virus (Moloney) by coinfection with murine leukemia viruses. Cancer Res., 28, 1055. COLOMBATTI, A., COLLAVO, D., BIASI, G. & CHIECO- BIANCHI, L. (1975) Genetic control of oncogenesis by murine sarcoma virus Moloney pseudotype. I. Genetics of resistance in AKR mice. Int. J.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 883,
    "paragraph": "Cancer, 16, 427. FEFER, A. FEFER, A., McCoy, J. L. & GLYNN, J. P. (1967) Antigenicity of a virus induced murine sarcoma (Moloney). Cancer Res., 27, 962. FEFER, A. (1967) Neutralization of the oncogenicity of Moloney Sarcoma virus and Moloney leukemia",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 884,
    "paragraph": "virus by anti-Gross serum. Int. J. Cancer, 3, 647. virologic and pathologic studies of regression of autochthonous Moloney Sarcoma virus induced tumors in mice. Cancer Res., 28, 1577. Immunologic, FINK, M. A. & RAUSCHER, F. J. (1964) Immune reactions to a murine leukemia virus. I. Induction",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 885,
    "paragraph": "of immunity to infection with virus in the natural host. J. Natl Cancer Inst., 32, 1075. (1968) FRIEND, C. (1959) Immunological relationships of a filterable agent causing leukemia in mice (adult). I. Neutralization of infectivity by specific anti- serum. J. Exp. Med., 109, 217.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 886,
    "paragraph": "GIULIANI, F., SORANZO, C., CASAZZA, A. M. & DI MARCO, A. (1973) Oncogenicita de celule linfoidi inmuni verso il sarcoma murino di Moloney. Tumori, 59, 269. GLYNN, J. P., BIANCO, A. R. & GOLDIN, A. (1964) Studies on induced resistance against isotrans-",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 887,
    "paragraph": "plants of virus-induced leukemia. Cancer Res., 24, 502. GLYNN, J. P., McCoy, J. L. & FEFER, A. (1968) Cross-resistance to the transplantation of syn- geneic Friend, Moloney and Rauscher virus- induced tumors. Cancer Res., 28, 434. HARVEY, J. J. & EAST, J. (1971) The murine sarcoma",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 888,
    "paragraph": "virus (MSV). Int. Rev. Exp. Pathol., 10, 265. HUEBNER, R. J., GILDEN, R. V., LANE, W. T., TONI, R., TRIMMER, R. W. & HILL, P. (1976) Suppression of murine type-C-RNA virogenes by type-specific oncornavirus vaccines: Prospects for prevention of cancer. Proc. Natl Acad. Sci.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 889,
    "paragraph": "U.S.A., 73, 620. HUNSMANN, G., MOENNIG, V. & SCHAFER, W. (1975) Properties of mouse leukemia viruses: IX. Active MURINE LEUKAEMIA IMMUNIZATION WITH MSV 975 passive immunization and against Friend Leukemia with isolated viral gp7l glyco- protein and its corresponding antiserum. Virology,",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 890,
    "paragraph": "66, 327. of mice (gp7l) (gp7l) IHLE, J. N., COLLINS, J. J., LEE, J. C. & 5 others (1976a) Characterization of the immune response of Friend to leukemia virus I. Response in BALB/c mice. Virology, 75, 74. the major glycoprotein IHLE, J. N., COLLINS, J. J., LEE, J. C. & 5 others",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 891,
    "paragraph": "(1976b) Characterization of the immune response to the major glycoprotein of Friend leukemia virus. II. Response in C57BL/6 mice. Virology, 75, 88. KELLOFF, G. J., PETERS, R. L., DONAHOE, R. M. & 4 others (1976) An approach to C-type virus immunoprevention of spontaneously occurring",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 892,
    "paragraph": "tumours in laboratory mice. Cancer Res., 36, 622. KLEIN, E. & KLEIN, G. (1964) Antigenic properties of lymphomas induced by the Moloney Agent. J. Natl Cancer Inst., 32, 547. LAMON, E. W., ANDERSSON, B., WIGZELL, H., FENYO, E. M. & KLEIN, E. (1974) The immune",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 893,
    "paragraph": "to primary Moloney sarcoma virus response tumors in BALB/c mice: Cellular and humoral activity of long-term regressors. Int. J. Cancer, 13, 91. LAVRIN, D. H., HERBERMAN, R. B., NUNN, M. & SOARES, N. (1973) In vitro cytotoxicity studies of Murine Sarcoma virus-induced immunity in mice.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 894,
    "paragraph": "J. Natl Cancer Inst., 51, 1497. MAYYASI, S. A. & MOLONEY, J. B. (1967) Induced resistance of mice to a lymphoid strain of leukemia virus (Moloney). Cancer, 20, 1124. MAYYASI, S. A., FOSTER, H. F., BULFONE, L. M., WRIGHT, B. S. & SHIBLEY, G. P. (1968) Induction",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 895,
    "paragraph": "of immunity in mice with tissue culture cells chronically infected with Rauscher leukemia virus. Proc. Soc. Exp. Biol. Med., 128, 1088. McCoy, J. L., FEFER, A. & GLYNN, J. P. (1967) Influence of infectious virus on the induction of transplantation resistance in the Friend tumor",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 896,
    "paragraph": "system. Cancer Re8., 27, 2266. PASQUALINI, C. D., SAAL, F., SEN, L. & RABASA, S. L. (1968) Leucemia murina. Medicina (B. Aires), 28, 116. PASTERNAK, G. & GRAFFI, A. (1963) Induction of resistance against isotransplantation of virus- induced myeloid leukaemias. Br. J. Cancer, 17,",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 897,
    "paragraph": "532. PAZMJNO, N. H. & YUHAS, J. M. (1973) Senescent loss of resistance to murine sarcoma virus (Molo- ney) in the mouse. Cancer Res., 33, 2668. PERK, K. & MOLONEY, J. B. (1966) Pathogenesis of a virus-induced rhabdomyosarcoma in mice. J.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 898,
    "paragraph": "Natl Cancer Inst., 37, 581. PRECERRUTTI, A. & LAW, L. W. (1963) Isolation of a murine leukaemogenic virus PLLV. Nature, 198, 801. SACHS, L. (1962) Transplantability of an X-ray- induced and a virus-induced leukemia in isologous mice inoculated with a leukemia virus. J. Natl",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 899,
    "paragraph": "Cancer Inst., 29, 759. SIMONS, P. J. & MCCULLY, D. J. (1970) Pathologic and virologic studies of tumors induced in mice by two strains of murine sarcoma virus. J. Natl Cancer Inst., 44, 1289. SLETTENMARK, B. & KLEIN, E. (1962) Cytotoxic",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 900,
    "paragraph": "and neutralization tests with serum and lymph node cells of isologous mice with induced resistance against Gross lymphoma. Cancer Res., 22, 947. TURNER, W. & CHIRIGOS, M. A. (1969) Enhancement of murine sarcoma virus (Moloney) infection and tumorigenesis in vivo by coinfection with Rauscher",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 901,
    "paragraph": "leukemia virus. Cancer Res., 29, 1956. TYNDALL, R. L., OTTEN, J. A., TEETER, E. & BOWLES, N. D. (1967) Inhibition of solid tumor formation by prior immunization with formalized neoplastic spleen extracts. Proc. Soc. Exp. Biol. Med., 125, 399.",
    "jurnal": "brjcancer00465-0111.pdf"
  },
  {
    "id": 902,
    "paragraph": "Article CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis Evgenia Sarrou 1, Laura Richmond 1, Ruaidhrí J. Carmody 2 Karen Keeshan 1,* , Brenda Gibson 3 and 1 Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 903,
    "paragraph": "Glasgow G12 0YN, UK; t.sarrou@gmail.com (E.S.); Laura.Richmond@glasgow.ac.uk (L.R.) 2 Centre for Immunobiology, Institute of Infection, Immunity & Inﬂammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK; ruaidhri.carmody@glasgow.ac.uk 3 Royal Hospital for Children, Glasgow G51 4TF, UK; Brenda.Gibson@ggc.scot.nhs.uk",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 904,
    "paragraph": "* Correspondence: Karen.keeshan@glasgow.ac.uk Received: 21 May 2020; Accepted: 10 June 2020; Published: 15 June 2020 Abstract: Chromosomal rearrangements of the mixed lineage leukaemia (MLL, also known as KMT2A) gene on chromosome 11q23 are amongst the most common genetic abnormalities observed in human",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 905,
    "paragraph": "acute leukaemias. MLL rearrangements (MLLr) are the most common cytogenetic abnormalities in infant and childhood acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) and do not normally acquire secondary mutations compared to other leukaemias. To model these leukaemias, we have used clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 906,
    "paragraph": "gene editing to induce MLL-AF9 (MA9) chromosomal rearrangements in murine hematopoietic stem and progenitor cell lines and primary cells. By utilizing a dual-single guide RNA (sgRNA) approach targeting the breakpoint cluster region of murine Mll and Af9 equivalent to that in human",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 907,
    "paragraph": "MA9 rearrangements, we show eﬃcient de novo generation of MA9 fusion product at the DNA and RNA levels in the bulk population. The leukaemic features of MA9-induced disease were observed including increased clonogenicity, enrichment of c-Kit-positive leukaemic stem cells and increased MA9 target gene expression. This approach provided a rapid and reliable means of de",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 908,
    "paragraph": "novo generation of Mll-Af9 genetic rearrangements in murine haematopoietic stem and progenitor cells (HSPCs), using CRISPR/Cas9 technology to produce a cellular model of MA9 leukaemias which faithfully reproduces many features of the human disease in vitro. Keywords: CRISPR/Cas9; chromosomal translocation; mixed lineage leukaemia; tumourigenesis;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 909,
    "paragraph": "stem cells 1. Introduction Rearrangements of the mixed lineage leukaemia gene (MLLr) are the most common cytogenetic abnormalities found in infant and childhood acute lymphocytic leukaemia (ALL) and acute myeloid leukaemia (AML) [1] and are found in 80% and 35–50% of all paediatric ALL and AML cases",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 910,
    "paragraph": "respectively [1]. These leukaemias do not typically acquire many secondary mutations [2] and are thought to result from inappropriate repair of DNA double strand breaks (DSBs) via nonhomologous end joining (NHEJ) in haematopoietic cells [3]. As the 8.3-kb breakpoint cluster region of mixed",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 911,
    "paragraph": "lineage leukaemia (MLL) is located between exons 8 and 13 for almost all MLLr cases [4], these fusion genes contain the ﬁrst 8–13 exons of MLL and a variable number of exons from the fusion partner genes (FPGs). Up to 135 MLL FPGs have been identiﬁed and are well described elsewhere [5–7].",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 912,
    "paragraph": "proteins. This category contains the most common FPGs such as ENL, ELL, AF4, AF9 and AF10, which account for approximately 80% of all MLL fusions [5]. Of these, MLL-AF9 (MA9) t(9;11)(p22;q23) translocations are found in 30% of MLLr AML cases [5] irrespective of age and are commonly found in",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 913,
    "paragraph": "a subset of adult patients with therapy-related AML [8]. Although the precise functional properties of AF9 are unknown, it has been demonstrated to form multimer complexes with members of the polycomb repressive complex 1 (PRC1) complex and disruptor of telomere silencing (DOT1L) via a conserved ANC1 homology domain (AHD),",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 914,
    "paragraph": "indicating a role in transcriptional regulation [9,10]. These properties appear to play a critical role in leukaemic transformation [11,12]. Oncogenic properties of MLL fusion proteins include interference with transcriptional elongation, resulting in dysregulation of target genes [13,14]. Aberrant expression of MLL target genes is strongly dependent on DOT1L-mediated H3K79 methylation [15], which is",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 915,
    "paragraph": "a critical requirement for MA9 leukaemogensis [16]. Members of the Homeobox (HOX) family are commonly overexpressed in MLLr leukaemias as a direct target of MLL fusion proteins [4,17]. The HOX family are critical factors in the self-renewing properties of haematopoietic stem cells (HSCs) and their",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 916,
    "paragraph": "overexpression results in a diﬀerentiation block and an increase in self-renewal of immature myeloid progenitor cells. The HOX cofactors MEIS1 [18,19] and PBX3 [20] are also direct targets of MLL fusion proteins [21] frequently found upregulated in coordination with HOX targets. Importantly, there is",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 917,
    "paragraph": "evidence to suggest that MA9-mediated leukaemia can progress even in the absence of HOX genes such as HOXA9 [22], indicating an important role of non-HOX family genes. This includes CDK6 [23], EVI-1 [24,25] and EYA1 [26,27], which are also found upregulated in MLLr leukaemias as a result of",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 918,
    "paragraph": "direct binding of MLL-FPG proteins to gene promoters [26,28,29], and play a vital role in leukaemic transformation including cellular immortalization [26], hyperproliferation [23,24], chemoresistance [24] and dysregulated self-renewal [25,27]. CDK6 speciﬁcally has been highlighted as a critical eﬀector of MLLr leukemogenesis as its depletion in mice with MA9-driven AML was shown to overcome the",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 919,
    "paragraph": "myeloid diﬀerentiation block and to prolong survival in vivo [29]. Numerous murine models of MLLr have been generated and have each oﬀered valuable insights. Limitations with murine models are in large part due to the technology used to mimic MLL chromosomal",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 920,
    "paragraph": "rearrangements. An early knock-in model [30] utilized homologous recombination (HR) to generate an Mll-Af9 fusion gene and displayed a myeloproliferative disorder (MPD), leading primarily to AML characterized by expansion of immature myeloid populations with a small percentage developing B-cell ALL (B-ALL) [31]; thus, this model resembles the phenotypic heterogeneity of MLLr leukaemias,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 921,
    "paragraph": "which can manifest as AML; ALL; or in a minority of cases, mixed phenotype acute leukaemia (MPAL). However, this system lacked tissue-speciﬁc control of MA9 expression throughout development and mice were prone to developmental defects as a result of heterozygosity for wild type (WT) Mll [32].",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 922,
    "paragraph": "To gain more insight into cell-type speciﬁc eﬀects, a subsequent approach involved enrichment of haematopoietic populations from these HR-generated MA9 knock-in mice, followed by secondary transplantation into WT recipients [33]. This also demonstrated eﬃcient generation of AML, especially when Lin−Sca-1+c-Kit+ (LSK) cells, which include HSCs and haematopoietic stem and progenitor",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 923,
    "paragraph": "(HSPCs), were transplanted. An advantage of these methods is the expression of the MA9 transgene from the endogenous Mll promoter, which results in physiological transgene expression levels. This model cannot however address the leukaemia stem cell origin with respect to de novo AML initiation.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 924,
    "paragraph": "Translocator models utilizing the Cre-loxP system have generated MA9 translocations via loxP sites inserted into those intronic regions of endogenous Mll and Af9 genes where breakpoints are most frequently found in human MLLr patients [34]. Using Lmo2-Cre to express Cre recombinase,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 925,
    "paragraph": "Mll-Af9 was generated in pluripotent stem cells and led exclusively to myeloid leukaemia whereas T-cell-restricted expression using lck-Cre did not lead to leukomogeneis [35]. The advantage of this Cre-loxP system is that MA9 expression can be driven by lineage-restricted promoters from",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 926,
    "paragraph": "the endogenous loci [35], reﬂecting physiological expression. Further models targeting Mll-Af9 Int. J. Mol. Sci. 2020, 21, 4266 3 of 15 expression to speciﬁc cells within the haematopoietic system have utilized retrovirus-driven expression followed by transduction and transplantation approaches. These methods beneﬁt from its speed",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 927,
    "paragraph": "and ease of use [36,37] and has led to the identiﬁcation of both the HSC and the granulocyte and macrophage progenitor (GMP) as potential leukaemic stem cells-of-origin with divergent clinical features [38]. Retrovirus-mediated expression models however drive transgene expressions that are not physiological. To gain greater control over the level of cell-restricted transgene expression,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 928,
    "paragraph": "Dox-inducible transgenic models have since been developed [39,40] enabling close-to-physiological levels and reversible transgene expression in a Dox dose-dependent manner. Using this model, it was demonstrated that long-term HSC (LT-HSC) populations result in an invasive and chemoresistant AML with a primitive progenitor phenotype and a distinct stemness-related gene expression pattern [39].",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 929,
    "paragraph": "Dox-inducible transgene expression is however not controlled by an endogenous promoter. “Leaky” Cre expression from tissue-speciﬁc promoters together with the expensive and time-consuming nature of tissue-restricted strain generation are major limitations with the Cre-loxP and Dox-inducible transgenic model systems. More recent attempts to circumvent some of the issues highlighted above have utilized",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 930,
    "paragraph": "transcription activator like eﬀector nucleases (TALEN) technology to generate endogenous MA9 [41,42]. These cells exhibited a signiﬁcantly higher clonogenic potential with colony morphologies consistent with an immature cell type and development of AML, ALL and MPAL upon xenotransplantation [41]. Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology facilitates",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 931,
    "paragraph": "creation of DSBs at almost any genomic sequence of interest technology and has revolutionised the way in which we are able to manipulate the genome, aﬀording a more ﬂexible and readily applicable method for generating novel disease models, including chromosomal translocations, with an ease and",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 932,
    "paragraph": "simplicity far outweighing prior technologies such as TALEN and Cre-LoxP. CRISPR technology has facilitated generation of chromosomal deletions [43] and rearrangements, including inversions [44] and translocations [45–48]. Here, we demonstrate eﬃcient CRISPR-mediated generation of an endogenous Mll-Af9 reciprocal translocation in a murine cell line and primary HSPCs. By utilizing a dual-single",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 933,
    "paragraph": "guide RNA (sgRNA) approach to target the most common breakpoints in human MA9 rearrangements, we show rapid, reliable generation of simultaneous breakpoints and a fusion product at the DNA and RNA levels. The resultant transformed cells reliably recapitulated features of human MLLr",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 934,
    "paragraph": "leukaemias. These include increased expression of MA9 target genes, reduced IL3 dependency, higher clonogenic potential and self-renewal in primary murine HSPCs. This multiplexed CRISPR technology oﬀers a robust and malleable approach for generating murine models of the multitude of human translocation-associated leukaemias.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 935,
    "paragraph": "2. Results 2.1. A CRISPR/Cas9 System for Mll-Af9 Genome Editing (302) We utilized a CRISPR/Cas9 system for the generation of murine t(4;9) MA9 chromosomal translocations in murine HSPCs, utilizing simultaneous targeting of the Mll and Af9 genes by CRISPR sgRNAs directed to chromosomes. Based on prior investigation of common MLL and AF9 breakpoint",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 936,
    "paragraph": "regions in AML patient samples [49] and murine models of MA9 [35], we designed guides targeting frequently translocated intronic regions between Mll exons 8 and 9 (Mll sg1 and 2) and exons 10 and 11 (Mll sg3 and 4) and between Af9 exons 8 and 9 (Af9 sg1, 2 and 3) (Figure 1A) to generate two potential",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 937,
    "paragraph": "MLL-AF9 fusion products (Figure 1B). Guide sequences were generated using the CRISPR.MIT web tool (http://crispr.mit.edu) [50,51], which scores each sequence based on a combination of on- and oﬀ-target potentials. We selected those guides with the highest scores, indicating an appropriate eﬃciency of on-target cleavage with minimal oﬀ-target potential. Single guide sequences were cloned",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 938,
    "paragraph": "into a lentiviral CRISPR-green ﬂuorescent protein (GFP) vector (Supplementary Figure S1), and the resultant high-titre lentivirus was used to transduce the murine HSPC myeloid progenitor 32D cell line, which is IL3-dependent. At day 5 post-transduction, cells were ﬂuorescent activated cell sorting (FACS)",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 939,
    "paragraph": "Int. J. Mol. Sci. 2020, 21, 4266 4 of 15 sorted for GFP expression and indel formation in GFP (Figure 1C). + populations were assessed by a surveyor assay Figure 1. Design and validation of clustered regularly interspaced short palindromic repeats",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 940,
    "paragraph": "(CRISPR)/Cas9 gene editing tools targeting murine mixed lineage leukaemia (Mll) and Af9 genes: (A) Schematic representation of partial Mll and Af9 genomic regions with sgRNA location. Four guides were designed targeting either introns 8 and 9 (Mll sg1 and -2) or introns 10 and 11 (Mll sg3 and",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 941,
    "paragraph": "-4) of the Mll gene, and three were designed to target introns 8 and 9 (AF9 sg1–3) of Af9. sgRNA locations/Cas9 cleavage sites are shown in orange. Red (Mll) and green (Af9) arrows represent PCR primers ﬂanking cleavage sites. Blue and purple arrows represent RT-PCR primers on MLL and AF9",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 942,
    "paragraph": "transcripts, respectively. (B) Representation of two predicted Mll-Af9 fusion gene products following editing with either set of Mll and Af9-targeting sgRNAs. (C) Surveyor assay of 32D cells transduced with a CRISPR vector expressing the indicated sgRNAs. PCR was performed on genomic DNA from",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 943,
    "paragraph": "transfected GFP cell populations using primers as indicated in Figure 1A. Products were assayed by the surveyor and analysed by 2% gel electrophoresis. Percentage indel formation was calculated by quantiﬁcation of each DNA band. Cells transduced with an empty CRISPR vector (Cas9 only) were",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 944,
    "paragraph": "used as the control sample for each. + Of those guides targeting Mll introns, Mll sg1-3 showed approximately equal indel eﬃciencies of 31–38%, with no cleavage seen using sg4 (Figure 1C and Figure S2). Similarly, Af9-targeting sgRNA1 and -3 showed approximately equal eﬃciencies of 28–37%, while sg2 gave a signiﬁcantly poorer indel",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 945,
    "paragraph": "frequency of 7% (Figure 1C). These data demonstrate eﬃcient cleavage of Mll and Af9 loci using a CRISPR system detectable in the bulk population. Based on these results, Mll sg2 was selected for targeting of Mll introns 8 and 9, sg3 was selected for introns 10 and 11, and Af9 sg1 and –3 were",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 946,
    "paragraph": "selected for Af9 introns 8 and 9. 2.2. Endogenous Generation of MA9 Translocation in Murine HSPCs (368) To generate MLL-AF9 translocations, simultaneous DNA DSBs in the Mll and Af9 genes of murine 32D HSPCs were created (Figure 2A). Cells were transduced with a CRISPR lentivirus",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 947,
    "paragraph": "targeting either the Mll or Af9 loci or both in combination and were FACS sorted for GFP at day 5 post-transduction. In 32D murine HSPCs, GFP expression > 20% was noted with each combination Int. J. Mol. Sci. 2020, 21, 4266 4 of 15 frequency of 7% (Figure 1C). These data demonstrate efficient cleavage of Mll and Af9 loci using a CRISPR system detectable in the bulk population. Based on these results, Mll sg2 was selected for targeting of Mll introns 8 and 9, sg3 was selected for introns 10 and 11, and Af9 sg1 and –3 were selected for Af9 introns 8 and 9. Figure 1. Design and validation of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing tools targeting murine mixed lineage leukaemia (Mll) and Af9 genes: (A) Schematic representation of partial Mll and Af9 genomic regions with sgRNA location. Four guides were designed targeting either introns 8 and 9 (Mll sg1 and -2) or introns 10 and 11 (Mll sg3 and -4) of the Mll gene, and three were designed to target introns 8 and 9 (AF9 sg1–3) of Af9. sgRNA locations/Cas9 cleavage sites are shown in orange. Red (Mll) and green (Af9) arrows represent PCR primers flanking cleavage sites. Blue and purple arrows represent RT-PCR primers on MLL and AF9 transcripts, respectively. (B) Representation of two predicted Mll-Af9 fusion gene products following editing with either set of Mll and Af9-targeting sgRNAs. (C) Surveyor assay of 32D cells transduced with a CRISPR vector expressing the indicated sgRNAs. PCR was performed on genomic DNA from transfected GFP+ cell populations using primers as indicated in Figure 1A. Products were assayed by the surveyor and analysed by 2% gel electrophoresis. Percentage indel formation was calculated by quantification of each DNA band. Cells transduced with an empty CRISPR vector (Cas9 only) were used as the control sample for each. 2.2. Endogenous Generation of MA9 Translocation in Murine HSPCs (368) To generate MLL-AF9 translocations, simultaneous DNA DSBs in the Mll and Af9 genes of murine 32D HSPCs were created (Figure 2A). Cells were transduced with a CRISPR lentivirus targeting either the Mll or Af9 loci or both in combination and were FACS sorted for GFP at day 5 post-transduction. In 32D murine HSPCs, GFP expression > 20% was noted with each combination of dual guides (Figure 2B) and GFP+ populations were sorted for verification of the MA9 translocation and downstream functional analysis. Verification of the MA9 translocation was carried out in GFP+ 32D cells at both the DNA and transcript levels by utilizing PCR primers flanking the breakpoint region (Figure 2A) followed by Sanger sequencing of PCR amplicons. Unique banding patterns were seen following electrophoretic analysis of PCR products from 3/4 Mll and Af9 guide combinations (Figures 2C and S3), with sg3/sg3 as the only guide combination which did not generate a product. Amplicons as indicated in Figure 2C were further analysed by Sanger sequencing and alignment to reference Mll and Af9 genomic Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 948,
    "paragraph": "5 of 15 of dual guides (Figure 2B) and GFP and downstream functional analysis. + populations were sorted for veriﬁcation of the MA9 translocation Figure 2. Endogenous generation of MLL-AF9 (MA9) translocation in murine haematopoietic cells: (A) Workﬂow schematic for generation of t(4;9) translocated 32D HSPCs. Cells were transduced with",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 949,
    "paragraph": "single or dual CRISPR/Cas9 lentivirus and sorted for GFP at day 5 for downstream analysis. (B) Flow + cells at day 5 post-transduction. (C) Validation of cytometry histograms showing percentage of GFP populations and PCR genomic MA9 translocation: Genomic DNA was extracted from sorted GFP",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 950,
    "paragraph": "ampliﬁed using primers ﬂanking the MA9 breakpoint. PCR products were then resolved by agarose gel electrophoresis. (D) Sanger sequencing of the PCR product from the sg2/sg3 sample (red “b” arrow, part C): Alignment of the sequence to reference genome veriﬁed the alignment with murine",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 951,
    "paragraph": "Mll and Af9. (E) RT-PCR analysis of the MA9 breakpoint region verifying MA9 translocation at RNA resolution: cDNA was reverse transcribed from RNA and PCR ampliﬁed using primers ﬂanking the MA9 breakpoint. (F) Sanger sequencing of the sg2/sg3 RT-PCR product: Alignment of the sequence to",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 952,
    "paragraph": "reference RNA showed alignment to murine Mll and Af9 transcripts. + + Veriﬁcation of the MA9 translocation was carried out in GFP 32D cells at both the DNA and transcript levels by utilizing PCR primers ﬂanking the breakpoint region (Figure 2A) followed by",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 953,
    "paragraph": "Sanger sequencing of PCR amplicons. Unique banding patterns were seen following electrophoretic analysis of PCR products from 3/4 Mll and Af9 guide combinations (Figure 2C and Figure S3), with sg3/sg3 as the only guide combination which did not generate a product. Amplicons as indicated",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 954,
    "paragraph": "in Figure 2C were further analysed by Sanger sequencing and alignment to reference Mll and Af9 genomic sequences, which identiﬁed the sg2/sg3-transduced sample (band b, Figure 2C) as having correct alignment to both murine Mll (NCBI gene ID: 214162) and Af9 (NCBI gene ID: 70122), validating",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 955,
    "paragraph": "generation of the MA9 translocation at the genomic level (Figure 2D). Sequence alignment of amplicons from samples transduced with alternative guide combinations (Figure 2C, red arrows excluding b) Int. J. Mol. Sci. 2020, 21, 4266 5 of 15 sequences, which identified the sg2/sg3-transduced sample (band b, Figure 2C) as having correct alignment to both murine Mll (NCBI gene ID: 214162) and Af9 (NCBI gene ID: 70122), validating generation of the MA9 translocation at the genomic level (Figure 2D). Sequence alignment of amplicons from samples transduced with alternative guide combinations (Figure 2C, red arrows excluding b) identified matches in exonic and intronic regions of the mouse genome, including a noncoding region of chromosome 14 and the Pigz gene on chromosome 16. This may be indicative of a potential off-target effect of these sgRNA combinations, in line with current knowledge regarding the off-target potential of Cas9 cleavage. RT-PCR and subsequent electrophoresis of RNA from the dual sg2/sg3-transduced sample further validated the translocation at the transcript level; utilizing primers flanking the mRNA breakpoint region (Figure 2B), we generated an amplicon unique to this sample (Figure 2E) which correctly aligned to murine Mll (NM_001357549.1) and Af9 (NM_027326.3) reference transcripts, thus supporting formation of the MA9 mRNA fusion (Figure 2F). Taken together, these data indicate that CRISPR/Cas9-mediated genome editing can be used to induce formation of a murine t(4;9) MA9 translocation in 32D HSPCs and that this fusion gene product is transcribed appropriately. Figure 2. Endogenous generation of MLL-AF9 (MA9) translocation in murine haematopoietic cells: (A) Workflow schematic for generation of t(4;9) translocated 32D HSPCs. Cells were transduced with single or dual CRISPR/Cas9 lentivirus and sorted for GFP at day 5 for downstream analysis. (B) Flow cytometry histograms showing percentage of GFP+ cells at day 5 post-transduction. (C) Validation of genomic MA9 translocation: Genomic DNA was extracted from sorted GFP+ populations and PCR amplified using primers flanking the MA9 breakpoint. PCR products were then resolved by agarose gel electrophoresis. (D) Sanger sequencing of the PCR product from the sg2/sg3 sample (red “b” arrow, part C): Alignment of the sequence to reference genome verified the alignment with murine Mll and Af9. (E) RT-PCR analysis of the MA9 breakpoint region verifying MA9 translocation at RNA resolution: cDNA was reverse transcribed from RNA and PCR amplified using primers flanking the Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 956,
    "paragraph": "6 of 15 identiﬁed matches in exonic and intronic regions of the mouse genome, including a noncoding region of chromosome 14 and the Pigz gene on chromosome 16. This may be indicative of a potential oﬀ-target eﬀect of these sgRNA combinations, in line with current knowledge regarding the oﬀ-target potential",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 957,
    "paragraph": "of Cas9 cleavage. RT-PCR and subsequent electrophoresis of RNA from the dual sg2/sg3-transduced sample further validated the translocation at the transcript level; utilizing primers ﬂanking the mRNA breakpoint region (Figure 2B), we generated an amplicon unique to this sample (Figure 2E) which",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 958,
    "paragraph": "correctly aligned to murine Mll (NM_001357549.1) and Af9 (NM_027326.3) reference transcripts, thus supporting formation of the MA9 mRNA fusion (Figure 2F). Taken together, these data indicate that CRISPR/Cas9-mediated genome editing can be used to induce formation of a murine t(4;9) MA9",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 959,
    "paragraph": "translocation in 32D HSPCs and that this fusion gene product is transcribed appropriately. 2.3. CRISPR-Mediated MA9 Translocations Recapitulate Features of MA9 Leukaemia In Vitro (622) Multifactorial functional analysis was carried out ﬁrstly on MA9-validated 32D murine HSPCs, in which we examined proliferative capability, IL3-dependency and expression of MA9-target genes.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 960,
    "paragraph": "Over 30 days in liquid culture, we saw no signiﬁcant diﬀerence in proliferation between 32D cells transduced with the sg2/sg3 guide combination compared to those transduced with either single guide (Figure 3A), indicating that the MA9 translocation does not confer a demonstrable proliferative",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 961,
    "paragraph": "advantage in this already immortalised cell line. MA9 leukemic cells have previously shown only moderate IL3 dependency in contrast to 32D cells which are strictly IL3 dependent [52]. Thus, we sought to examine the eﬀects of IL3 starvation on MA9 32D cells in culture. Over 24 h of IL3 starvation, we noted",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 962,
    "paragraph": "a slight but nonsigniﬁcant growth advantage and resistance to starvation-induced stress in the MA9 cells when compared with single guide controls (Figure 3B), suggesting a decrease in IL-3 dependency conferred by CRISPR-generated MA9 translocation in this cell type, consistent with previous data [52].",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 963,
    "paragraph": "Analysis of the expression of common MA9-associated genes in sg2/sg3 double-transduced cells revealed signiﬁcant upregulation of Dot1l, Cdk6 and Sirt1 mRNA (Figure 3C). Both DOT1l and CDK6 have critical and well-established roles in MLLr function and leukemogenesis [16,29], and Sirt1 has",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 964,
    "paragraph": "been shown to be upregulated in response to MA9 expression in murine models [53]. Taken together, these data strongly support that CRISPR-mediated generation of MA9 using the endogenous loci can recapitulate the functional properties of MA9 leukaemic features. + + Following veriﬁcation of the MA9 translocation in 32D murine HSPCs, we next sought to use our",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 965,
    "paragraph": "approach in primary murine HSPCs. C-Kit bone marrow (BM) cells were isolated from WT mice and transduced using the validated sg2/sg3 sgRNA singly or in combination. At day 5 post-transduction, and expanded in liquid culture for an additional 5 days prior to beginning",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 966,
    "paragraph": "cells were sorted for GFP functional analysis of the translocation in the primary bulk cell population. Equal numbers of cells from liquid cultures were assessed in colony forming cell (CFC) assays to determine self-renewal, proliferation and diﬀerentiation capabilities. Following 20 days in a CFC assay, cells transduced",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 967,
    "paragraph": "with the sg2/sg3 combination of guides displayed signiﬁcantly increased cell numbers and formed more colonies when compared to single transduced samples (Figure 3D,E). We next carried out immunophenotyping of day 20 CFC colonies in order to assess the myeloid diﬀerentiation status of",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 968,
    "paragraph": "the cells. We saw diﬀerences neither in the live/viable population (Figure 3G) nor in the CD11bGr1- or CD11b+F4/80+ myeloid fractions in any of the samples (Figure 3F,I,J), suggesting that the MA9 translocation in this model does not have a negative impact on cell viability or myeloid diﬀerentiation.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 969,
    "paragraph": "However, the sg2/sg3 MA9 cells showed a signiﬁcantly larger population of cells expressing the c-Kit progenitor marker (Figure 3F,H), which has been associated with the leukaemia stem cell (LSC) in AMLs including MA9 [36,37]. This highlights not only a proliferative advantage in the double-transduced",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 970,
    "paragraph": "MA9 population but also an enrichment of a self-renewing LSC-type population. These data indicate that the CRISPR-mediated generation of the MA9 translocation in murine HSPCs mediates leukaemic transformation, indicated by a proliferative advantage and an increase in self-renewal properties. Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 971,
    "paragraph": "7 of 15 Figure 3. Cont. Int. J. Mol. Sci. 2020, 21, 4266 7 of 15 Int. J. Mol. Sci. 2020, 21, 4266 8 of 15 Figure 3. CRISPR-mediated MA9 translocation recapitulates features of MA9 leukaemia: (A) Cumulative cell number and growth curve of 32D HSPCs transduced with either Mll sg2 or",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 972,
    "paragraph": "Af9 sg3 or combination. Cells did not show any signiﬁcant diﬀerence in proliferation following MA9 translocation. (B) Cell number and growth curve of 32D HSPCs transduced with Mll and/or Af9 guides as indicated with IL-3 starvation: MA9-translocated cells displayed reduced levels of IL-3 dependency",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 973,
    "paragraph": "compared to single-guide controls. (C) Expression of MA9 target genes: ∆∆CT values of the sg2/sg3 sample are normalised to Mll sg2 single guide control. The graph shows mean ± SD of representative experiments. All samples were analysed in technical duplicates. Statistical signiﬁcance was calculated",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 974,
    "paragraph": "by one-way ANOVA followed by Bonferroni posttest. p < 0.001 is represented as ***, and p < 0.05 is represented as *. (D) Representative colony pictures (400×) of CFC colonies after ten days in culture (left panel): Samples were plated in technical triplicates. (E) Mean ± SD of colony counts (left) and",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 975,
    "paragraph": "cell numbers (right). (F) Representative ﬂow cytometric plots from samples in Figure 3D with the percentage of relevant populations indicated numerically. (G–J) Percentage of each population in + samples shown as (G) live (DAPI-), (H) c-Kit , (I) CD11b . Each sample is",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 976,
    "paragraph": "shown as mean ± SD from three technical triplicates. Statistical signiﬁcance was calculated by one-way ANOVA followed by Bonferroni posttest. p < 0.001 is represented as ***, p < 0.01 is represented as ** and p < 0.05 is represented as *.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 977,
    "paragraph": "and (J) CD11b + F4/80 Gr-1 + + + 3. Discussion Herein, we have demonstrated generation of a de novo MA9 translocation in murine HSPCs using state-of-the-art CRISPR/Cas9 technology to create a novel murine leukaemia model which faithfully recapitulates multiple features of human MA9 leukaemia. By rational design of sgRNA ﬂanking",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 978,
    "paragraph": "breakpoint regions with common occurrence in MLLr AML patients and prior MA9 transgenic models, we identiﬁed optimal combinations of sgRNA sequences with which to induce simultaneous DSBs at the speciﬁc loci. Each guide was validated for individual cleavage eﬃciency, and subsequently,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 979,
    "paragraph": "optimal combinations were identiﬁed for multiplexed CRISPR genome editing to induce an MA9 chromosomal translocation in HSPCs. Following CRISPR editing, the presence of a successful MA9 translocation was veriﬁed at both the genomic and transcriptional levels by PCR analysis and sequencing. Analysis of proliferation, clonogenicity, diﬀerentiation and gene expression robustly",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 980,
    "paragraph": "demonstrated the functional ways in which this model recapitulates features of the disease in vitro. This novel approach circumvents common caveats of previous methods, with no requirement for transgenic or immunocompromised mice or primary human material. We have demonstrated the ease of use of this approach in cell line and primary murine HSPCs which can be applied to other",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 981,
    "paragraph": "chromosomal translocations. Increased clonogenicity and enrichment of progenitor cells with increased self-renewal capacity is a fundamental characteristic of leukaemias with MLL rearrangements. Although we saw no proliferative advantage in MA9 32D HSPCs, we did observe a modest reduction in growth factor dependence",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 982,
    "paragraph": "as previously demonstrated. Normal primary HSPC cells have limited growth potential in vitro, which showed increased colony growth and number when expressing MA9. Increased clonogenicity Int. J. Mol. Sci. 2020, 21, 4266 7 of 15 Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 983,
    "paragraph": "9 of 15 is associated with increased c-Kit expression, a cell surface marker found in myeloblasts in up to 80% of AML cases [54]. C-Kit expression has also been strongly associated with poor prognoses in other instances of chromosomal translocations such as t(8;21) [55]. We saw a signiﬁcant enrichment of",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 984,
    "paragraph": "c-Kit-expressing cells, indicating an enrichment of colony-forming LSC-like early progenitor cells in MA9-expressing cells consistent with leukaemic transformation. Assessment of myeloid diﬀerentiation did not reveal a block in expression of diﬀerentiation markers in MA9-mediated cells, indicating that, although cells have acquired self-renewal properties, they maintain the ability to diﬀerentiate toward the",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 985,
    "paragraph": "myeloid lineage. A block in terminal myeloid diﬀerentiation cannot be ruled out, and whether cells can complete myeloid diﬀerentiation remains to be investigated. Cells that are unable to diﬀerentiate to the GMP stage of diﬀerentiation in murine models of MLLr do not undergo leukaemic transformation [56],",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 986,
    "paragraph": "and so, it is understood that some level of diﬀerentiation down the myeloid pathway is required for MLLr AML transformation. Data produced by Stavropoulou et al. utilizing a Dox-inducible MA9 model show that surface marker analysis of colonies derived from iMLL-AF9 LT-HSC and GMP",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 987,
    "paragraph": "subpopulations showed cells expressing the Mac-1 and Gr-1 diﬀerentiation markers in addition to c-Kit in the presence of Dox [39]. MA9-initiated oncogenesis has been shown to depend on MA9 modiﬁcation of transcriptional elongation, resulting in dysregulated expression of target genes. We demonstrated an increase in",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 988,
    "paragraph": "expression of Dot1 and Cdk6, both of which are essential for the oncogenic function of MA9-rearranged cells [29,57]. Interestingly, we also noted a signiﬁcant increase in expression of Sirt1, which is found signiﬁcantly overexpressed at the protein level in LSC populations from AML patients [53], where it",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 989,
    "paragraph": "acts to maintain their survival, growth and drug resistance. The lack of increased HoxA9 expression observed in our cells may be due to low frequency of translocation within the bulk population analysed, as has been previously noted in TALEN-focused studies [41,42] and CRISPR-generated models [58].",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 990,
    "paragraph": "Recently, work by Jeong et al. [58] similarly demonstrated eﬃcient generation of MA9 translocations by CRISPR/Cas9 technology, utilizing methodologies in line with those described herein. The authors used the human system to generate MA9 translocation in human CD34+ cord blood (CB) cells in contrast",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 991,
    "paragraph": "to the murine system we have presented here. Consistent with our results, human MA9-expressing CB cells in that study demonstrated a growth advantage in liquid culture and clonal expansion in CFC analysis and induction of AML, ALL and MPAL following transplantation in immunocompromised",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 992,
    "paragraph": "mice. The translocation eﬃciency achieved by Jeong et al. [58] is considerably higher than in previous TALEN-generated models of MA9 at around 0.5–1%. However, it is important to note that this eﬃciency remains low overall and so should be taken into consideration when analysing the bulk population.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 993,
    "paragraph": "In contrast to the single-cell clonal analysis performed by Jeong et al. [58], we are able to demonstrate the leukaemic transformation eﬀects of CRISPR-generated MA9 in the bulk population that may be masking some eﬀects such as increased Hox gene expression. A considerable advantage of our",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 994,
    "paragraph": "methodology which allows eﬀects to be seen in the bulk population is the reduction in time in culture of primary HSPCs that is required with single-clone selection. Further single-cell analysis from bulk populations in both the 32D cell line and primary HSPCS would give further insight into individual",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 995,
    "paragraph": "aspects of MA9-mediated and context-speciﬁc gene regulation. A limitation with using primary human HSPCs is the requirement for immunocompromised mice for xenografts. Our work is the ﬁrst to show the use of this technology to generate the murine MA9 translocation from the endogenous loci",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 996,
    "paragraph": "faithfully recapitulating MA9-mediated transformation in murine HSPCs. A signiﬁcant advantage of the murine system is the potential for investigation into immune-, gene- and cell-speciﬁc contexts using the myriad of murine genetic models and xenotransplantation approaches. Our methodology has several advantages for use in genetic models. The tractability of this system",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 997,
    "paragraph": "is such that we can readily study MA9 translocations in combination with other genetic or epigenetic abnormalities. Generation of new sgRNAs targeting sequences of interest are quickly and easily cloned into the CRISPR vector validated in this work and can be multiplexed as required. Our sgRNA target",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 998,
    "paragraph": "sequences were also selected not only for their commonality within MLLr patients but also for their prior use in alterative murine models of MA9, and as such, our approach oﬀers not only a robust model Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 999,
    "paragraph": "10 of 15 of human disease but also a means of comparison to alterative methodologies [35,41,42]. The work presented here and by others [48,58] exempliﬁes the ongoing shift towards precise genome editing with CRISPR technologies to quickly and accurately recapitulate human disease in model systems.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1000,
    "paragraph": "We have demonstrated the tractability and potential of this methodology in modelling human MA9 leukaemias, which represents an important advancement in the study of MA9-driven leukaemia. 4. Materials and Methods 4.1. Cell Culture ◦ All cell cultures were grown at 37",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1001,
    "paragraph": "C, 5% CO2. Human embryonic kidney (HEK)-239T and murine embryonic ﬁbroblast NIH-3T3 cells were maintained in Dulbecco Modiﬁed Eagle Medium (DMEM; Gibco, Paisley, UK) supplemented with 10% heat-inactivated foetal bovine serum (FBS; Gibco, Paisley, UK), 2 mM L-glutamine (Gibco, Paisley, UK) and 1% Penicillin/ Streptomycin (Pen/Strep;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1002,
    "paragraph": "Gibco, Paisley, UK). 32D murine myeloid progenitor cell line HSPCs were maintained in Roswell Park Memorial Institute-1640 (RPMI-1640; Gibco, Paisley, UK) supplemented with 10% FBS, 10% WEHI-3B conditioned media, 2 mM L-glutamine and 1% Pen/Strep. Primary murine HSPCs were cultured in DMEM pre-stimulation media supplemented with 15 % FBS, 2 mM L-glutamine, 1% Pen/Strep,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1003,
    "paragraph": "10 ng/mL recombinant murine interleukin-3 (rmIL3; PeproTech, London, UK), 10 ng/mL recombinant murine interleukin-6 (rmIL6; PeproTech, London, UK) and 100 ng/mL recombinant murine stem cell factor (rmSCF; PeproTech, London, UK) immediately following isolation and were transferred to DMEM activation media supplemented with 15% FBS, 2 mM L-glutamine, 1% Pen/Strep, 10 ng/mL",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1004,
    "paragraph": "rmIL3, 10 ng/mL rmIL6, 100 ng/mL rmSCF and 4 µg/mL polybrene (Sigma-Aldrich, Dorset, UK) for transduction. 4.2. Murine Bone Marrow (BM) Harvest and c-Kit Enrichment C57BL/6 mice were purchased from Charles River UK and housed in the Beatson Biological Service and Research Units. All mouse experiments were approved by the local animal welfare ethical",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1005,
    "paragraph": "review body (AWERB) committee and United Kingdom (UK) home oﬃce and performed according to UK Home Oﬃce project license 60/4512 approved 25 April 2013(Animal Scientiﬁc Procedures Act 1986) guidelines. Femur, tibia and pelvic girdle of wild-type (WT) C57BL/6 mice were crushed in",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1006,
    "paragraph": "phosphate buﬀered saline (PBS)/2% FBS and passed through a 40-µM cell strainer (Fisher Scientiﬁc, Loughborough, UK) to harvest BM. C-kit enrichment was carried out by magnetic activated cell sorting (MACS) separation of BM samples following incubation with anti-CD117 microbeads (Miltenyi Biotech,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1007,
    "paragraph": "Bergisch Gladbach, Germany). 4.3. sgRNA Design, Synthesis and CRISPR Transduction Reference mRNA transcripts of genes of interest (http://www.ncbi.nlm.nih.gov/nucleotide/) were used for identiﬁcation of suitable protospacer sequences using the CRISPR MIT tool (previously available at http://crispr.mit.edu; accessed August 2015) [50,51]. Top and bottom strand protospacers",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1008,
    "paragraph": "were purchased as single stranded DNA (ssDNA) oligos (IDT, Surrey, UK) (Supplementary Table S1) and cloned into pL.CRISPR.EFS.GFP (Supplementary Methods and Figure S1). pL-CRISPR.EFS.GFP was a gift from Benjamin Ebert (Addgene plasmid # 57818) [59]. The all-in-one CRISPR lentivirus was used to constitutively express sgRNAs and Cas9 under the control of human U6 (hU6) and",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1009,
    "paragraph": "elongation factor 1α (EF-1α) promotors, respectively. HEK-293T and NIH-3T3 cells were used for lentiviral production and titration, respectively, and 32D or primary murine HSPCs were transduced with high-titre CRISPR lentivirus as previously described [60]. 4.4. Flow Cytometry and Cell Sorting Samples were stained and analysed in PBS or PBS/2% FBS or sorted for GFP in the same buﬀer.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1010,
    "paragraph": "Single cells were gated by forward scatter area (FSC-A) vs height (FSC-H), and then viable cells were Int. J. Mol. Sci. 2020, 21, 4266 11 of 15 gated by FSC-A vs side scatter area (SSC-A). For viability staining, analysis was performed only in",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1011,
    "paragraph": "(cid:48) single-cell gates and dead cells were excluded by 4 ,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, Dorset, UK) staining. Compensation was performed using unstained cells, single stained cells and single stained UltraComp eBeads (Thermo Scientiﬁc, Paisley, UK). A complete list of antibodies and dyes can be found in Supplementary Table S2.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1012,
    "paragraph": "4.5. Surveyor Assay Genomic DNA was extracted using QuickExtract™ DNA Extraction Solution (Epicentre Biotechnologies, Madison, WI, USA), and analysis with Surveyor Nuclease S was used to calculate indel frequency. Full methods and primer sequences can be found in the Supplementary Methods and",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1013,
    "paragraph": "Table S3. 4.6. Genomic Target Ampliﬁcation (GTA) Genomic DNA was extracted from GFP-sorted cells (day 5 post-sorting) using Epicentre QuickExtract™ DNA Extraction Solution. PCR ampliﬁcation of target loci was performed using Q5 High-Fidelity DNA Polymerase (New England Biolabs; NEB, Herts, UK), and the products were",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1014,
    "paragraph": "analysed on 2% agarose (Sigma-Aldrich, Dorset, UK) gel. Bands of interest were excised using the GeneJET Gel Extraction and DNA Cleanup Micro Kit (Thermo Scientiﬁc, Paisley, UK) before analysis by Sanger sequencing. Primer sequences can be found in Supplementary Table S3.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1015,
    "paragraph": "4.7. Reverse Transcription PCR Total RNA was isolated from GFP-sorted cells (day 5 post-sorting) by either Arcturus PicoPure RNA Isolation Kit (Thermo Scientiﬁc, Paisley, UK) or RNeasy Mini Kit (QIAGEN, Manchester, UK)), and target-speciﬁc cDNA synthesis was carried out by Superscript III (Thermo Scientiﬁc, Paisley,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1016,
    "paragraph": "UK) using primers speciﬁc for locus of interest. cDNA was ampliﬁed using Taq DNA polymerase (NEB, Herts, UK) and target-speciﬁc primers. Puriﬁed products were analysed on 2% agarose gel, and bands of interest were excised and analysed by Sanger sequencing. Primer sequences can be found",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1017,
    "paragraph": "in Supplementary Table S4. 4.8. Gene Expression Analysis (qRT-PCR) Total RNA was isolated from GFP-sorted cells, and gene expression analysis was carried out as previously described [60]. Results were calculated by the ∆∆Ct method with normalization to the Gusb housekeeping gene. Primer sequences can be found in Supplementary Table S5.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1018,
    "paragraph": "4.9. Colony-Forming Cell (CFC) Assay Methocult GF M3434 (Stem Cell Technologies, Vancouver, BC, Canada) methylcellulose media containing recombinant murine stem cell factor (rmSCF), recombinant murine interleukin-3 (rmIL-3), recombinant human interleukin-6 (rhIL-6) and recombinant human erythropoietin (rhEPO) was used. Equal numbers of BM c-kit-enriched, GFP-sorted cells were prepared in triplicate and resuspended",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1019,
    "paragraph": "in culture media. Cell suspension was added to methylcellulose and transferred to 3 × 35 mm dishes (Greiner-Bio-One, Gloucestershire, UK) for 10–20 days. Colonies were scored, and cells were analysed by ﬂow cytometry. If required, cells were replated to a second round of CFC following the",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1020,
    "paragraph": "same protocol. 4.10. Statistics GraphPad Prism (version 5.00.288; LA Jolla, CA, USA) was used for statistical analysis and graphing. Statistical signiﬁcance was determined by one-way ANOVA with Bonferroni posttest. Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/12/ 4266/s1. Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1021,
    "paragraph": "12 of 15 Author Contributions: E.S. designed and performed the experiments, analysed and interpreted the data, and made all ﬁgures. L.R. and R.J.C. provided data analysis and cowrote the manuscript. B.G. supervised the study. K.K. cowrote the manuscript, designed the research and supervised the study. All authors have read and agreed to the",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1022,
    "paragraph": "published version of the manuscript. Funding: This research was funded by Kay Kendall Leukaemia Fund: NA, The Howat Foundation: NA, Cancer Research UK Glasgow Centre: C596/A18076, Cancer Research UK Beatson Institute: C596/A17196, Yorkhill Children’s Leukaemia Research Fund: NA, and Children with Cancer UK: NA.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1023,
    "paragraph": "Acknowledgments: We acknowledge the technical assistance of Jennifer Cassells and Karen Dunn for ﬂow cytometry and animal experiments respectively. We thank all staﬀ at the Paul O’Gorman Leukaemia Research Centre for their support and advice. Conﬂicts of Interest: The authors declare no conﬂict of interest.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1024,
    "paragraph": "Nat. Genet. 2015, 47, 330–337. [CrossRef] [PubMed] Richardson, C.; Jasin, M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000, 405, 697–700. [CrossRef] [PubMed] Slany, R.K. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol. 2005, 23, 1–9. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1025,
    "paragraph": "4. 5. Meyer, C.; Burmeister, T.; Gröger, D.; Tsaur, G.; Fechina, L.; Renneville, A.; Sutton, R.; Venn, N.C.; Emerenciano, M.; Pombo-De-Oliveira, M.S.; et al. The MLL recombinome of acute leukemias in 2017. Leukemia 2018, 32, 273–284. [CrossRef] 3. 6. Meyer, C.; Kowarz, E.; Hofmann, J.; Renneville, A.; Zuna, J.; Trka, J.; Ben Abdelali, R.; Macintyre, E.; De",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1026,
    "paragraph": "Braekeleer, E.; De Braekeleer, M.; et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23, 1490–1499. [CrossRef] 8. 7. Huret, J.L.; Ahmad, M.; Arsaban, M.; Bernheim, A.; Cigna, J.; Desangles, F.; Guignard, J.C.; Jacquemot-Perbal, M.C.; Labarussias, M.; Leberre, V.; et al. Atlas of genetics and cytogenetics in oncology",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1027,
    "paragraph": "and haematology in 2013. Nucleic Acids Res. 2013, 41, D920–D924. [CrossRef] Super, H.J.G.; McCabe, N.R.; Thirman, M.J.; Larson, R.A.; Le Beau, M.M.; Pedersen- Bjergaard, J.; Philip, P.; Diaz, M.O.; Rowley, J.D. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1028,
    "paragraph": "in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993, 82, 3705–3711. [CrossRef] 9. Malik, B.; Hemenway, C.S. CBX8, a component of the Polycomb PRC1 complex, modulates DOT1L-mediated gene expression through AF9/MLLT3. FEBS Lett. 2013, 587, 3038–3044. [CrossRef] 10. Zhang, W.; Xia, X.; Reisenauer, M.R.; Hemenway, C.S.; Kone, B.C. Dot1a-AF9 complex mediates histone H3",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1029,
    "paragraph": "Lys-79 hypermethylation and repression of ENaCα in an aldosterone-sensitive manner. J. Biol. Chem. 2006, 281, 18059–18068. [CrossRef] 11. Erfurth, F.; Hemenway, C.S.; de Erkenez, A.C.; Domer, P.H. MLL fusion partners AF4 and AF9 interact at subnuclear foci. Leukemia 2004, 18, 92–102. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1030,
    "paragraph": "12. Leach, B.I.; Kuntimaddi, A.; Schmidt, C.R.; Cierpicki, T.; Johnson, S.A.; Bushweller, J.H. Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure 2013, 21, 176–183. [CrossRef] [PubMed] 13. Mueller, D.; Bach, C.; Zeisig, D.; Garcia-Cuellar, M.P.; Monroe, S.; Sreekumar, A.; Zhou, R.; Nesvizhskii, A.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1031,
    "paragraph": "Chinnaiyan, A.; Hess, J.L.; et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modiﬁcation. Blood 2007, 110, 4445–4454. [CrossRef] [PubMed] 14. Mueller, D.; García-Cuéllar, M.P.; Bach, C.; Buhl, S.; Maethner, E.; Slany, R.K. Misguided transcriptional",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1032,
    "paragraph": "elongation causes mixed lineage leukemia. PLoS Biol. 2009, 7, e1000249. [CrossRef] 15. Kuntimaddi, A.; Achille, N.J.; Thorpe, J.; Lokken, A.A.; Singh, R.; Hemenway, C.S.; Adli, M.; Zeleznik-Le, N.J.; Bushweller, J.H. Degree of Recruitment of DOT1L to MLL-AF9 Deﬁnes Level of H3K79 Di- and Tri-methylation",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1033,
    "paragraph": "on Target Genes and Transformation Potential. Cell Rep. 2015, 11, 808–820. [CrossRef] Int. J. Mol. Sci. 2020, 21, 4266 13 of 15 16. Nguyen, A.T.; Taranova, O.; He, J.; Zhang, Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9—Mediated leukemogenesis. Blood 2011, 117, 6912–6922. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1034,
    "paragraph": "17. Yokoyama, A.; Somervaille, T.C.P.; Smith, K.S.; Rozenblatt-Rosen, O.; Meyerson, M.; Cleary, M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123, 207–218. [CrossRef] 18. Armstrong, S.A.; Staunton, J.E.; Silverman, L.B.; Pieters, R.; Den Boer, M.L.; Minden, M.D.; Sallan, S.E.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1035,
    "paragraph": "Lander, E.S.; Golub, T.R.; Korsmeyer, S.J. MLL translocations specify a distinct gene expression proﬁle that distinguishes a unique leukemia. Nat. Genet. 2002, 30, 41–47. [CrossRef] 19. Zeisig, B.B.; Milne, T.; Garcia-Cuellar, M.-P.; Schreiner, S.; Martin, M.-E.; Fuchs, U.; Borkhardt, A.; Chanda, S.K.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1036,
    "paragraph": "Walker, J.; Soden, R.; et al. Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization. Mol. Cell. Biol. 2004, 24, 617–628. [CrossRef] 20. Guo, H.; Chu, Y.; Wang, L.; Chen, X.; Chen, Y.; Cheng, H.; Zhang, L.; Zhou, Y.; Yang, F.C.; Cheng, T.; et al.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1037,
    "paragraph": "PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia. Int. J. Cancer 2017, 141, 324–335. [CrossRef] 21. Prange, K.H.M.; Mandoli, A.; Kuznetsova, T.; Wang, S.Y.; Sotoca, A.M.; Marneth, A.E.; Van Der Reijden, B.A.; Stunnenberg, H.G.; Martens, J.H.A. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1038,
    "paragraph": "repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene 2017, 36, 3346–3356. [CrossRef] [PubMed] 22. Kumar, A.R.; Hudson, W.A.; Chen, W.; Nishiuchi, R.; Yao, Q.; Kersey, J.H. Hoxa9 inﬂuences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood 2004, 103, 1823–1828. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1039,
    "paragraph": "23. Van Der Linden, M.H.; Willekes, M.; Roon, E.; Seslija, L.; Schneider, P.; Pieters, R.; Stam, R.W. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle 2014, 13, 834–844. [CrossRef] 24. Bindels, E.M.J.; Havermans, M.; Lugthart, S.; Erpelinck, C.; Wocjtowicz, E.; Krivtsov, A.V.; Rombouts, E.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1040,
    "paragraph": "Armstrong, S.A.; Taskesen, E.; Haanstra, J.R.; et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 2012, 119, 5838–5849. [CrossRef] [PubMed] 25. Laricchia-Robbio, L.; Nucifora, G. Signiﬁcant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol. Dis. 2008, 40, 141–147. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1041,
    "paragraph": "26. Wang, Q.F.; Wu, G.; Mi, S.; He, F.; Wu, J.; Dong, J.; Luo, R.T.; Mattison, R.; Kaberlein, J.J.; Prabhakar, S.; et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011, 117, 6895–6905. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1042,
    "paragraph": "27. Takacova, S.; Luzna, P.; Stranecky, V.; Divoky, V. The Potential Role of the Six1/Eya1 Pathway in the Establishment of Leukemia Stem Cells in MLL-ENL—Induced Leukemia. Blood 2011, 118, 1362. [CrossRef] 28. Arai, S.; Yoshimi, A.; Shimabe, M.; Ichikawa, M.; Nakagawa, M.; Imai, Y.; Goyama, S.; Kurokawa, M. Evi-1 is",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1043,
    "paragraph": "a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 2011, 117, 6304–6314. [CrossRef] 29. Placke, T.; Faber, K.; Nonami, A.; Putwain, S.L.; Salih, H.R.; Heidel, F.H.; Krämer, A.; Root, D.E.; Barbie, D.A.; Krivtsov, A.V.; et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 2014, 124,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1044,
    "paragraph": "13–23. [CrossRef] 30. Corral, J.; Lavenir, I.; Impey, H.; Warren, A.J.; Forster, A.; Larson, T.A.; Bell, S.; McKenzie, A.N.J.; King, G.; Rabbitts, T.H. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996, 85, 853–861. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1045,
    "paragraph": "31. Dobson, C.L.; Warren, A.J.; Pannell, R.; Forster, A.; Lavenir, I.; Corral, J.; Smith, A.J.H.; Rabbitts, T.H. The Mll-AF9 gene fusion in mice controls myeloproliferation and speciﬁes acute myeloid leukaemogenesis. EMBO J. 1999, 18, 3564–3574. [CrossRef] [PubMed] 32. Chen, W.; Li, Q.; Hudson, W.A.; Kumar, A.; Kirchhof, N.; Kersey, J.H. Amurine Mll-AF4 knock-in model",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1046,
    "paragraph": "results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 2006, 108, 669–677. [CrossRef] [PubMed] 33. Chen, W.; Kumar, A.R.; Hudson, W.A.; Li, Q.; Wu, B.; Staggs, R.A.; Lund, E.A.; Sam, T.N.; Kersey, J.H. Malignant Transformation Initiated by Mll-AF9: Gene Dosage and Critical Target Cells. Cancer Cell 2008, 13,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1047,
    "paragraph": "432–440. [CrossRef] [PubMed] 34. Collins, E.C.; Pannell, R.; Simpson, E.M.; Forster, A.; Rabbitts, T.H. Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-lox in mouse development. EMBO Rep. 2000, 1, 127–132. [CrossRef] Int. J. Mol. Sci. 2020, 21, 4266 14 of 15",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1048,
    "paragraph": "35. Drynan, L.F.; Pannell, R.; Forster, A.; Chan, N.M.M.; Cano, F.; Daser, A.; Rabbitts, T.H. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J. 2005, 24, 3136–3146. [CrossRef] 36. Krivtsov, A.V.; Twomey, D.; Feng, Z.; Stubbs, M.C.; Wang, Y.; Faber, J.; Levine, J.E.; Wang, J.; Hahn, W.C.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1049,
    "paragraph": "Gilliland, D.G.; et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442, 818–822. [CrossRef] [PubMed] Somervaille, T.C.P.; Cleary, M.L. Identiﬁcation and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10, 257–268. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1050,
    "paragraph": "37. 38. Krivtsov, A.V.; Figueroa, M.E.; Sinha, A.U.; Stubbs, M.C.; Feng, Z.; Valk, P.J.M.; Delwel, R.; Döhner, K.; Bullinger, L.; Kung, A.L.; et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013, 27, 852–860. [CrossRef] Stavropoulou, V.; Kaspar, S.; Brault, L.; Sanders, M.A.; Juge, S.; Morettini, S.; Tzankov, A.; Iacovino, M.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1051,
    "paragraph": "Lau, I.J.; Milne, T.A.; et al. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. Cancer Cell 2016, 30, 43–58. [CrossRef] 39. 40. Chen, X.; Burkhardt, D.B.; Hartman, A.A.; Hu, X.; Eastman, A.E.; Sun, C.; Wang, X.; Zhong, M.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1052,
    "paragraph": "Krishnaswamy, S.; Guo, S. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors. Nat. Commun. 2019, 10, 5767. [CrossRef] [PubMed] 41. Buechele, C.; Breese, E.H.; Schneidawind, D.; Lin, C.H.; Jeong, J.; Duque-Afonso, J.; Wong, S.H.K.; Smith, K.S.; Negrin, R.S.; Porteus, M.; et al. MLL leukemia induction by genome editing of human CD34+ hematopoietic",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1053,
    "paragraph": "cells. Blood 2015, 126, 1683–1694. [CrossRef] [PubMed] 42. Breese, E.H.; Buechele, C.; Dawson, C.; Cleary, M.L.; Porteus, M.H. Use of genome engineering to create patient speciﬁc MLL translocations in primary human hematopoietic stem and progenitor cells. PLoS ONE 2015, 10, e0136644. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1054,
    "paragraph": "43. Adikusuma, F.; Williams, N.; Grutzner, F.; Hughes, J.; Thomas, P. Targeted Deletion of an Entire Chromosome Using CRISPR/Cas9. Mol. Ther. 2017, 25, 1736–1738. [CrossRef] [PubMed] 44. Maddalo, D.; Manchado, E.; Concepcion, C.P.; Bonetti, C.; Vidigal, J.A.; Han, Y.C.; Ogrodowski, P.; Crippa, A.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1055,
    "paragraph": "Rekhtman, N.; De Stanchina, E.; et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 2014, 516, 423–427. [CrossRef] 45. Torres, R.; Martin, M.C.; Garcia, A.; Cigudosa, J.C.; Ramirez, J.C.; Rodriguez-Perales, S. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat. Commun.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1056,
    "paragraph": "2014, 5, 3964. [CrossRef] Jiang, J.; Zhang, L.; Zhou, X.; Chen, X.; Huang, G.; Li, F.; Wang, R.; Wu, N.; Yan, Y.; Tong, C.; et al. Induction of site-speciﬁc chromosomal translocations in embryonic stem cells by CRISPR/Cas9. Sci. Rep. 2016, 6, 21918.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1057,
    "paragraph": "[CrossRef] 46. 48. 47. Reimer, J.; Knöß, S.; Labuhn, M.; Charpentier, E.M.; Göhring, G.; Schlegelberger, B.; Klusmann, J.H.; Heckl, D. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica 2017, 102, 1558–1566. [CrossRef] Schneidawind, C.; Jeong, J.; Schneidawind, D.; Kim, I.S.; Duque-Afonso, J.; Wong, S.H.K.; Iwasaki, M.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1058,
    "paragraph": "Breese, E.H.; Zehnder, J.L.; Porteus, M.; et al. MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing. Blood Adv. 2018, 2, 832–845. [CrossRef] Jansen, M.W.J.C.; van der Velden, V.H.J.; van Dongen, J.J.M. Eﬃcient and easy detection of MLL-AF4,",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1059,
    "paragraph": "MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler [11,12]. Leukemia 2005, 19, 2016–2018. [CrossRef] [PubMed] 49. 50. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraﬃni, L.A.; et al.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1060,
    "paragraph": "Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [CrossRef] 51. Hsu, P.D.; Scott, D.A.; Weinstein, J.A.; Ran, F.A.; Konermann, S.; Agarwala, V.; Li, Y.; Fine, E.J.; Wu, X.; Shalem, O.; et al. DNA targeting speciﬁcity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013, 31, 827–832.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1061,
    "paragraph": "[CrossRef] [PubMed] 52. Metcalf, D.; Glaser, S.P.; Xu, Z.; Di Rago, L.; Mifsud, S. Reversible growth factor dependency and autonomy during murine myelomonocytic leukemia induced by oncogenes. Proc. Natl. Acad. Sci. USA 2013, 110, 17029–17034. [CrossRef] [PubMed] Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1062,
    "paragraph": "15 of 15 53. 54. Sasca, D.; Hähnel, P.S.; Szybinski, J.; Khawaja, K.; Kriege, O.; Pante, S.V.; Bullinger, L.; Strand, S.; Strand, D.; Theobald, M.; et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 2014, 124, 121–133. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1063,
    "paragraph": "Ikeda, H.; Kanakura, Y.; Tamaki, T.; Kuriu, A.; Kitayama, H.; Ishikawa, J.; Kanayama, Y.; Yonezawa, T.; Tarui, S.; Griﬃn, J.D. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991, 78, 2962–2968. [CrossRef] 55. Paschka, P.; Marcucci, G.; Ruppert, A.S.; Mrózek, K.; Chen, H.; Kittles, R.A.; Vukosavljevic, T.; Perrotti, D.;",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1064,
    "paragraph": "Vardiman, J.W.; Carroll, A.J.; et al. Adverse prognostic signiﬁcance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study. J. Clin. Oncol. 2006, 24, 3904–3911. [CrossRef] 56. Ohlsson, E.; Hasemann, M.S.; Willer, A.; Lauridsen, F.K.B.; Rapin, N.; Jendholm, J.; Porse, B.T. Initiation of",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1065,
    "paragraph": "MLL-rearranged AML is dependent on C/EBPα. J. Exp. Med. 2014, 211, 5–13. [CrossRef] 57. Chang, M.J.; Wu, H.; Achille, N.J.; Reisenauer, M.R.; Chou, C.W.; Zeleznik-Le, N.J.; Hemenway, C.S.; Zhang, W. Histone H3 Lysine 79 Methyltransferase Dot1 Is Required for Immortalization by MLL Oncogenes.",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1066,
    "paragraph": "Cancer Res. 2010, 70, 10234–10242. [CrossRef] Jeong, J.; Jager, A.; Domizi, P.; Pavel-Dinu, M.; Gojenola, L.; Iwasaki, M.; Wei, M.C.; Pan, F.; Zehnder, J.L.; Porteus, M.H.; et al. High-eﬃciency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells. Blood Adv. 2019, 3, 2825–2835. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1067,
    "paragraph": "58. 59. Heckl, D.; Kowalczyk, M.S.; Yudovich, D.; Belizaire, R.; Puram, R.V.; McConkey, M.E.; Thielke, A.; Aster, J.C.; Regev, A.; Ebert, B.L. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 2014, 32, 941–946. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1068,
    "paragraph": "60. O’Connor, C.; Yalla, K.; Salomé, M.; Ananyambica Moka, H.; Gómez Castañeda, E.; Eyers, P.A.; Keeshan, K. Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. Oncotarget 2018, 9, 14977–14992. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1069,
    "paragraph": "article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).",
    "jurnal": "ijms-21-04266.pdf"
  },
  {
    "id": 1070,
    "paragraph": "Immunology, 1971, 20, 1087. Specificity of Rabbit Antisera against Mouse Leukaemias in vitro A. E. REIF AND CHUNG-AI H. KIM Department of Surgery, Tufts University School of Medicine, and the First (Tufts) Surgical Service, Boston City Hospital, Boston, Massachusetts (Received 26th August 1970)",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1071,
    "paragraph": "Summary. Rabbit antisera were prepared against mouse leukaemias from several inbred strains, and against a mixture of these leukaemias. The potencies of these antisera were tested against each of the different leukaemias, and against certain normal cells and tissues. As determined by immune cytolysis, the potencies of antisera were strongest",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1072,
    "paragraph": "against the homologous leukaemias. The potencies against unrelated leukaemias were generally within 50 per cent of those against the homologous leukaemias, with some exceptions. Antisera prepared by injection of a mixture of the leukaemia cells showed remarkably high potencies against all leukaemias tested.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1073,
    "paragraph": "As measured by C fixation, the same antisera showed less specificity for the homologous leukaemias. The potencies of antisera for C fixation on a variety of normal tissues was quite strong, and decreased approximately in the following order: testis, kidney, liver, lung, brain, muscle, erythrocytes. For antiserum pre-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1074,
    "paragraph": "pared against DBA/2 leukaemia L1210, the C fixation reaction against normal lymph node lymphocytes was about 20 per cent as strong as the reaction against the homologous leukaemia L1210. A hypothesis concerning the mechanism of immune cytolysis is presented to explain these results. Exhaustive absorption of",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1075,
    "paragraph": "anti-L1210 sera with normal DBA/2 tissues produced only a slight increase in anti- leukaemia specificity. INTRODUCTION A number of studies on the effect of heterologous antisera on experimental leukaemias have shown mild but significant therapeutic benefits (Mohos and Kidd, 1957; Levi,",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1076,
    "paragraph": "Golden, Zerubavel and Fisher, 1966; Schabel, Skipper, Laster and Thompson, 1966; Miller, Molovanu, Kaplan and Tocci, 1968; Hill and Littlejohn, 1970; Mempel and Thierfelder, 1970; Siegel and Morton, 1970), despite the immunosuppressive nature of such sera (Witz, Yagi and Pressman, 1968). We recently found that passive therapy with",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1077,
    "paragraph": "antileukaemia sera can give positive results only when the highest possible number of cytolytic potency units is administered (Reif and Kim, 1969). To prepare highly potent antisera, both immunization schedules and the dependence of the specificity of antisera on the types of leukaemias injected (Mohos and Kidd, 1957) require investigation. In a",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1078,
    "paragraph": "separate investigation (Kim and Reif, 1971), we have studied immunization schedules. In the present paper, the requirements for specificity of antisera, in terms of the strain of 1087 1088 A. E. Reif and Chung-Ai H. Kim origin of the injected leukaemia cells, are examined. This provides further insight into the",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1079,
    "paragraph": "preparation of such antisera. We previously determined the specificity of rabbit antisera to thymic, splenic and leukaemic lymphocytes (Asakuma and Reif, 1968). Cross-reactions between antisera prepared against leukaemia cells and normal lymphoid cells, rather than cross-reactions between antisera prepared against leukaemia cells from different inbred strains, were",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1080,
    "paragraph": "studied. We found that unabsorbed antisera to leukaemias showed little or no specificity against leukaemia cells relative to non-thymic lymphocytes, but specificity appeared after absorption with a mixture of liver, kidney, and spleen. Antisera prepared against normal tissues were also tested (Asakuma and Reif, 1968).",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1081,
    "paragraph": "In this study, antisera have been prepared against four different leukaemias, against a mixture of these leukaemias, and against an ovarian teratoma. These antisera were tested against each of the various leukaemias and against certain normal tissues. Two assays of antibody activity were used: immune cytolysis, and complement fixation.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1082,
    "paragraph": "MATERIALS AND METHODS Mice and leukaemias All mice were obtained from the Jackson Laboratory. Tumours and leukaemias were transplanted with sterile precautions in congenic strains. The route of transplantation was intraperitoneal (IP), unless stated otherwise. Leukaemia C is an abbreviation for myeloid leukaemia C1498 II of C57BL/6 mice,",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1083,
    "paragraph": "obtained from Miss Brown of the Children's Cancer Research Foundation, Boston, and converted into the ascites form in our laboratory. Leukaemia M is an abbreviation for plasma cell neoplasm MOPC-21A of BALB/c mice, obtained in generation 89 from Dr Michael Potter of the National Cancer Institute, and transplanted subcutaneously. The",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1084,
    "paragraph": "C3HeB/Fe lymphosarcoma Gardner originated in a C3H mouse injected with estradiol benzoate (Gardner, Dougherty and Williams, 1944), and was transplanted in the low mammary tumour substrain C3HeB/Fe. E6A is an abbreviation for the ovarian teratoma E6496 of C3HeB/Fe mice, obtained in ascites form from Dr A. B. Griffen of the Jackson",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1085,
    "paragraph": "Laboratory. Lymphocytic leukaemia L1210 of DBA/2 mice was derived by Law, Dunn, Boyle and Miller (1949). Both Gardner and L1210 leukaemias were provided by Mr I. Wodinsky of Arthur D. Little, Inc. Leukaemia RA9 originated spontaneously in an AKR mouse; cells from the enlarged spleen and thymus were initially transplanted in our",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1086,
    "paragraph": "laboratory in May 1968. The H-2 genotype of the strains of origin of the various tumours and leukaemias are as follows: C57BL/6, H-2b; BALB/c and DBA/2, H-2d; AKR, C3H and C3HeB/Fe, H-2k (Snell and Stimpfling, 1966). Antisera Rabbits were immunized with mouse tissues by two courses of injection. Each course",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1087,
    "paragraph": "consisted of one subcutaneous injection of 1-2 ml of tumour cells incorporated in Freund- McDermott complete adjuvant (Reif and Norris, 1960), followed by five to seven intra- venous injections (spaced over 3 weeks) of5 ml of 1 per cent suspensions ofviable leukaemia",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1088,
    "paragraph": "cells in isotonic saline. Antisera were inactivated by heating at 560 for 30 minutes and absorbed with 1/13 volume of AKR plasma, followed by three absorptions, each with 1/10 volume of packed mouse erythrocytes for 30 minutes at room temperature, as previously",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1089,
    "paragraph": "Specificity of Antisera against Leukaemias 1089 described (Reif and Allen, 1964). Normal rabbit serum (NRS) was inactivated but not absorbed. Antisera were stored in small portions at -200 without preservative. Rabbit antisera were tested either whole (-w in Tables 1 and 2), or else yG fractions",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1090,
    "paragraph": "(-yG) were prepared by precipitation with 40 per cent ammonium sulphate, followed by batch-fractionation with DEAE-cellulose (Reif, 1969). Antisera to leukaemia M and ovarian tumour E6A were treated similarly, except that ammonium sulphate precipita- tion was omitted. Antiserum X was prepared by injection of a mixture of leukaemias",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1091,
    "paragraph": "RA9, Gardner, L1210, C and M. Cytolysis assay system A small-scale assay system (Reif and Allen, 1964) was used. In outline, each assay tube contained 100,000 viable lymphocytes, suitably absorbed 10 per cent complement (Reif, 1962), and various dilutions of antiserum. Tubes were incubated for 1 hour at 370 and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1092,
    "paragraph": "placed in ice water. For each tube in turn, the supernatant was sucked off the cells that had settled, 0f02 ml of vital dye was added, and 200 cells were classified under the microscope as stained or unstained. Results, in percentage of stained cells, were plotted against final",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1093,
    "paragraph": "antiserum concentration (per cent), and the cytolytic titre was read at 50 per cent stained cells, with a correction for stained cells in the control tube (Reif, 1962). The potency* of an antiserum was expressed as 100 divided by the cytolytic titre obtained in this assay",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1094,
    "paragraph": "system (Reif and Allen, 1964). Complement fixation A small-scale modification (Asakuma and Reif, 1968) of the complement (C) fixation method of Mayer (1961) was used. In outline, serial doubling dilutions of antiserum were assayed for complement fixation with known numbers of tissue cells, or else with a known wet weight of a tissue homo-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1095,
    "paragraph": "genate. Disappearance ofcomplement was determined by the failure ofantibody-sensitized sheep erythrocytes, which were added later, to haemolyse. Reaction conditions and controls were as previously described (Asakuma and Reif, 1968). The final concentration of antiserum in the experimental tubes was plotted against per",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1096,
    "paragraph": "cent haemolysis on semilogarithmic paper. From this plot, the C fixation titre of the anti- serum was read as the final percentage concentration of antiserum at 50 per cent haemo- lysis, after correction for C fixation in control tubes. The C fixation potency* was calcu-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1097,
    "paragraph": "lated as 100 divided by the C fixation titre (Asakuma and Reif, 1968). RESULTS IMMUNE CYTOLYSIS Rabbit antisera were prepared by hyperimmunization of groups of rabbits with different leukaemias or tumours. Both whole antisera and their yG fractions (named respectively -w",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1098,
    "paragraph": "and -yG in Table 1) were tested against various leukaemias, an ovarian tumour, and normal lymph node cells (Table 1). * The reason for a conversion from 'titre' to 'potency' is that titres are difficult to visualize, since the stronger an",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1099,
    "paragraph": "antiserum the lower its titre. Use of the reciprocal of titre which we have called potency (Reif and Allen, 1964), is more meaningful, because the potency increases in direct proportion to the strength of the antiserum. A factor of 100 is used to make the 'potency' numerically equal to the final dilution of the antiserum.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1100,
    "paragraph": "Q 1090 A. E. Reif and Chung-Ai H. Kim C.) M m c() C,~w Ce4 cq4 eq ( V Vz-MoOOODo C14 00 At l- C14 v v_ I ce - 14 E~ rc Ce o CD tCa L CN ~. LO t",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1101,
    "paragraph": "0sX0 X + (D COO . ere 0 0 w 0 LO LO, ~c CO co u IL ao .Y8 Lr w C. 0e) s0; vv W L0_O _o e~w e - LO t- z. C; v C/\\,OO t- MO---X C4",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1102,
    "paragraph": "4 o CO 14_ v vwoobt- V V + *nc. O - N Ccr4CO Cl?~~~~~~~ U.0 0 U- U: LO- U 0 .a r. w 0 c V C) 0 - 1-CO tD - r- CC °L ° _ C'4 X X",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1103,
    "paragraph": "1-4 IM v E Y C13 . _i _o ,,: tDV v IL)- - v 3 4 z z to, -gOco m O U; U U 0 0) a.. a.) C._ U -e U) U C._ *. 6 U bO *3",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1104,
    "paragraph": "0 C-U ~0. 0 4-a 0 0 .n C4.) o 0 U 0 r. C.) C- U 0 O Ca10 0 Xo el*B.a 02 C1) 6z*: E 0 ui z z z C a) Ca) z C' 0e Specificity of Antisera against Leukaemias",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1105,
    "paragraph": "1091 _ < Q V V° VC-qc v itv e oa LO 4 0-- CE~, C~ ~~ ~'- VV~~~LL'4 V) I0CN uz zzb ; 6 u _ Q r~-cN~- ce~o - - t- - to Loeq t Q ~~~~rAchv - co v co",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1106,
    "paragraph": "£ 0 o - o E~~~~~~~~~ Cfi cgv v J C1 C1 LO30 10 r-(.0>+ Lo J o 4 t Cl o o z4 o CV 0 o 4 V W4 m0L 0~~~~~~~ C\"~~~~~~~~~~C C ~v vvvv ,- ^ 0C~4CO_ w",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1107,
    "paragraph": "_ w~~~ UX:_ F-~~~~~~~~~- o~ ~ ~~,o z IO.~ V 0~~~~~~~~~~~ F- 0 ~ 0~ \"~~~C9-~oV-0M o~o0 ~ ~ gigs0 1 092 A. E. Reif and Chung-Ai H. Kim Normal rabbit serum or its yG fraction (top two lines, Table 1) was either inactive, or else",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1108,
    "paragraph": "active at a very low potency, when tested similarly (Table 1). Antiserum C-yG (third line) was the weakest antiserum tested. While it reacted most strongly with the homologous leukaemia C, the reaction was almost as strong against leukaemias Gardner and RA9, which are of different H-2 genotype (both k rather than",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1109,
    "paragraph": "b). The reaction against leukaemia L12 10 of DBA/2 mice was weak. Similarly low poten- cies against leukaemia L 1210 were also obtained with other antisera (see below); possible reasons for this are given in the Discussion. The reaction of antiserum C-yG with normal",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1110,
    "paragraph": "lymph node lymphocytes (columns 6, 7 and 8) was strongest with the homologous (C57- BL/6) cells. Antiserum TM-yG (fourth line) reacted more strongly against the H-2k leukaemias Gardner and RA9 than to leukaemia L12 10, which originated in the same strain (H-2d) as",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1111,
    "paragraph": "the leukaemia against which the antiserum was prepared. Antiserum G-yG (fifth line) reacted almost as strongly against another H-2k leukaemia, RA9, as against the homologous leukaemia cells. The reaction against normal lympho- cytes was strongest against those of homologous genotype (column 7). There was little",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1112,
    "paragraph": "cross-reaction with an ovarian teratoma which originated in the same strain. Again, the reaction against leukaemia L1210 (which differs in H-2 genotype) was remarkably low. Antiserum E6A yG (sixth line) reacted similarly, except that the reaction against the homologous ovarian tumour cells was far stronger. The higher potency seen versus",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1113,
    "paragraph": "leukaemia L1210 may well reflect similarly higher potencies seen in the reactions with normal lymphocytes (columns 6, 7 and 8). Antiserum L-yG (seventh line), on the basis of a stronger reaction against homologous (DBA/2) normal lymph node cells (than against those of other strains: columns 6, 7 and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1114,
    "paragraph": "8), was expected to react most strongly against the homologous (L1210) leukaemia cells. This was not the case (columns 1, 2, 3 and 5). This result is in line with the lower reactivi- ties against L12 10 cells also found for antisera prepared against other leukaemias (see above).",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1115,
    "paragraph": "Antiserum X (last two lines, Table 1), from rabbits immunized with several leukaemias, showed as strong or stronger cytolytic potencies against the various leukaemias, than did any other antiserum tested. C FIXATION We previously used C fixation to evaluate the specificity of antilymphocyte sera",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1116,
    "paragraph": "(Asakuma and Reif, 1968). While immune cytolysis proved superior for this purpose, C fixation gives additional information and permits estimation of antibody binding with non- viable tissue residues, which is not possible with immune cytolysis. The same antisera were therefore tested by C fixation against leukaemias of three different H-2 genotypes, and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1117,
    "paragraph": "against various normal DBA/2 tissues (Table 2). Normal rabbit serum (first two lines, Table 2) showed weak reactivity against leukaemia Antiserum C-yG (third line) showed stronger C fixation with leukaemia L1210 than with other leukaemias. Similar results were obtained with other antisera (see below). Such",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1118,
    "paragraph": "results are in direct contrast to those obtained by immune cytolysis (Table 1); an explana- tion is suggested in the Discussion. Antiserum TM- yG (fourth line) reacted strongly against leukaemia L1210. Reactions against normal tissue residues were of comparable potencies to the reaction against",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1119,
    "paragraph": "leukaemias. L1210. Specificity of Antisera against Leukaemias 1093 Antiserum G-yG (fifth line) reacted more strongly against the homologous leukaemia than against leukaemia C. However, the reactions of this serum, and of Antiserum E6A-yG (sixth line), were strongest against leukaemia L1210. Antiserum L (seventh line) reacted very strongly with the homologous leukaemia L1 210.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1120,
    "paragraph": "Also, Antiserum X (last two lines, Table 2) prepared against mixed leukaemias, reacted very strongly with all leukaemias, but especially strongly with leukaemia L12 10. The reactions of all antisera with normal tissue residues was relatively strong, and decreased in approxi-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1121,
    "paragraph": "mately the following order: testis, kidney, liver, lung, brain, muscle, with very little reac- tion against erythrocytes. EXHAUSTIVE ABSORPTION OF ANTI-L1210 SERUM A potent rabbit antiserum prepared against L1 210 leukaemia cells was absorbed with 1/4 volume of packed mouse erythrocytes. Portions of this absorbed antiserum (AA) were",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1122,
    "paragraph": "further absorbed with lymphocytes (lymph node, splenic and thymic) and once again with washed residues of liver and kidney. The ratio of the number of DBA/2 mice from which 1: 10, these tissues were derived to the volume of antiserum (ml) varied as follows: (a)",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1123,
    "paragraph": "(b) 1:3, (c) 1:1, (d) 3:1. All absorptions were done for 30 minutes at 370. Each portion of separately absorbed antiserum was tested by immune cytolysis against L1 210 cells, lymph node lymphocytes, and splenic lymphocytes. Relative to antiserum AA, the mean cytolytic potencies ofportions absorbed according",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1124,
    "paragraph": "to schedules (a), (b), (c) and (d) above were 47, 25, 12 and 5-6 per cent, respectively, when determined against L1 210 cells. For any portion of antiserum, the cytolytic potency against L1 210 cells, divided by the cytolytic potency against lymph node lymphocytes,",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1125,
    "paragraph": "was a measure of the specificity of a particular portion of antiserum against leukaemia cells relative to normal lymphocytes (Reif, Allen and McVety, 1965). The values of this 'specificity ratio' for antiserum portions (a), (b), (c) and (d) were 0 54, 0-72, 0 74 and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1126,
    "paragraph": "1 26, compared to 0-65 for antiserum AA. The equivalent specificity ratios for the reaction against L1210 cells relative to splenic lymphocytes were 1 29, 1 38, 1-57 and 2 34, com- pared to 0 90 for antiserum AA. When compared to the reaction with either lymph node or",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1127,
    "paragraph": "splenic lymphocytes, a substantial increase in specificity against L1 210 leukaemia cells was thus obtained only with schedule (d), which represents very thorough absorption and concomitantly high loss of cytolytic potency. DISCUSSION Heterologous antisera have long been used for the treatment of human leukaemia",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1128,
    "paragraph": "(Lindstrom, 1927; Brittingham and Chaplin, 1960). While interest has quickened recently (Sekla, Holeckova,Janele, Libnaisky and Hnevkovsky, 1967; Tsirimbas, Pfisterer, Hornung, Thierfelder, Michlmayr and Stich, 1969; Fernbach, Rossen and Butler, 1970; Mempel and Thierfelder, 1970), there is no convincing evidence that such sera produce",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1129,
    "paragraph": "or prolong remissions in human leukaemia. The present model study in mice is not con- cerned with the in vivo effectiveness of such sera, but helps to answer questions that arise in their preparation. For instance, must antisera to human leukaemias be prepared by",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1130,
    "paragraph": "immunizations of animals with leukaemias of the same HL-A type as the patient to be treated? Can immunization with a mixture of leukaemias produce antisera potent against leukaemias of different HL-A types ? Resolution of these questions must await experi- mentation in man. However, there is a sufficiently close parallel between the H-2 system",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1131,
    "paragraph": "A. E. Reif and Chung-Ai H. Kim 1094 of mice and the HL-A system of man, that work with mice is apt to provide useful sug- gestions as to the likely outcome of equivalent work in man. CELLULAR ANTIGENS What murine antigens are able to stimulate formation of antibodies in rabbits? Four",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1132,
    "paragraph": "classes of cell surface antigens come into consideration: allogenic, organ-specific, tumour- specific and species-specific. With few exceptions (Snell and Stimpfling, 1966), allogenic specificities such as H-1 to H-l 1, TL and 0 are expressed on the cell surface of the corresponding leukaemias. To",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1133,
    "paragraph": "predict the cross-reactions of antisera prepared against different leukaemias, it must be remembered that mouse strains (and therefore also leukaemias) of different H-2 genotype often share some H-2 antigens. For instance, leukaemia C (H-2b) shares H-2 specificity No. 5 with leukaemias Gardner and RA9 (both H-2k) and specificities Nos. 6, 14, 27, 28",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1134,
    "paragraph": "and 29 with leukaemia L1210 (H-2d), while L1210 shares specificities Nos. 3 and 8 with leukaemias Gardner and RA9 (Snell and Stimpfling, 1966). In the present study, antisera prepared by immunization with a leukaemia of a certaina genotype were most potent for immune cytolysis of leukaemias of the same H-2 genotype",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1135,
    "paragraph": "in the case of antisera G and E6A (Table 1). Similarly, antiserum TM reacted more strongly against L1210 cells (also ofgenotype H-2d) than all sera other than those prepared by injection of L1210 cells (sera L and X). The results for antisera C and L are not readily",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1136,
    "paragraph": "evaluated, since these were the only leukaemias tested that were of H-2b and H-2d geno- types, respectively. With regard to the two allogenic specificities 6-AKR find O-C3H, we were only able to differentiate these with heterologous antisera after exhaustive absorptions (Asakama and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1137,
    "paragraph": "Reif, 1968). It seems questionable whether other alloantigens, such as the PC alloantigens of plasma cells (Takahashi, Old and Boyse, 1970), can be detected with heterologous anti- sera without similarly extensive absorptions. While such alloantigens possess characteristic organ distributions, the term 'organ-specific' should probably be reserved for antigens",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1138,
    "paragraph": "present only in a single organ, or else in cells of closely related type. Tumour-specific transplantation antigens (Gorer, 1938; Boyse, Old, Stockert and Shigeno, 1968; Klein, 1969; Watson, Ralph, Sarkar and Cohn, 1970) are relatively weakly immunogenic on allogenic immunization. Nevertheless, the more difficult feat of demon-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1139,
    "paragraph": "strating such antigens with heterologous antisera has been accomplished for chronic lymphocytic leukaemia (Bentwitch, Cohen, Sulitzeanu, Izak and Weiss, 1970). No evidence of specificity to such antigens, nor to the species-specific antigens T, C and F (Boyle and Davies, 1966) and MSLA (Shigeno, Hammerling, Arpels, Boyse and Old,",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1140,
    "paragraph": "1968) was obtained here. In the present study, an antiserum with high cytolytic potency against leukaemias of three different H-2 genotypes was prepared by immunization with a mixture of leukaemia cells. Previously, a close correlation between the results of in vitro immune cytolysis and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1141,
    "paragraph": "in vivo antileukaemia therapy has been found (Mohos and Kidd, 1957; Reif and Kim, 1969). Therefore, such an antiserum would be expected to be effective in vivo. Finally, the present data suggest that heteroimmunization with a mixture of leukaemia cells from",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1142,
    "paragraph": "different patients might well result in antisera with high in vitro potencies against human leukaemias of different HL-A types. Specificity of Antisera against Leukaemias 1095 RELATIONSHIP BETWEEN C FIXATION AND IMMUNE CYTOLYSIS An interesting facet of the data is the apparent contradiction between the consistently",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1143,
    "paragraph": "low potencies of various antisera for immune cytolysis of L1210 cells (Table 1) and the consistently high potencies for C fixation by the same cells (Table 2). The discrepancies in this connection were smaller for the other leukaemias. How can these data be explained?",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1144,
    "paragraph": "Recent work on immune lysis of erythrocytes or leukaemia cells suggests that after attachment to antigen sites on the cell surface, two molecules of the usual type of yG (Borsos and Rapp, 1965a), a single molecule of yM (Borsos and Rapp, 1965b), or a single",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1145,
    "paragraph": "molecule of an unusual type of yG (Frank and Gaither, 1970) are able to fix the first component of complement, C1. To explain why the efficiency of C1 for haemolysis of yM-sensitized sheep erythrocytes decreases dramatically as the density of antigen sites",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1146,
    "paragraph": "decreases (Linscott, 1970), it is suggested that two sites of antibody attachment to the cell ~~~~ ~~C complex ,YG Antibody a FIG. 1. A molecular model of immune cytolysis. It is suggested that penetration of the cell surface can occur only if the complement (C) complex is bound by one (yM) or two (yG) antibody molecules",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1147,
    "paragraph": "attached to closely-spaced antigen sites, and if the C complex is oriented to make optimal contact with the cell surface. Antibody binding is illustrated (a) without binding of C, (b) with lytically ineffective binding of C, and (c) with lytically effective binding of C.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1148,
    "paragraph": "surface are necessary before C1 can be fixed by any type of antibody. In the case of yM, a single molecule would attach to two adjacent antigen sites (Fig. 1), while the unusual property of 'unusual' yG (Frank and Gaither, 1970) might be a flexible structure that",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1149,
    "paragraph": "permits two-point contact with the cell surface. The above work suggests that lytically effective binding of the C complex can occur only when two antigen sites are relatively closely spaced. However, fixation of C1 to cell- bound molecules of antibodies does not guarantee either binding of the remaining C com-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1150,
    "paragraph": "ponents or sufficient damage of the membrane to lyse the cell (Linscott, 1970). The effi- A. E. Reif and Chung-Ai H. Kim 1096 ciency of this latter step is 30-50 per cent with yG-sensitized sheep erythrocytes (Rapp and Borsos, 1966), but only about 0*03 per cent with yM-sensitized mouse leukaemia cells",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1151,
    "paragraph": "(Borsos, Colten, Spalter, Rogentine, and Rapp, 1968), a 1000-fold difference. To explain these data as well as our own, it is suggested that immune lysis can occur only when the antibody-bound complement complex is correctly oriented for optimal (and presumably close) contact with the cell surface. The illustration of this (Fig. 1) has been arranged to fit",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1152,
    "paragraph": "current concepts on the structure of antibody molecules (Svehag, Chesebro and Bloth, 1967; Green, 1969) and the attachment of C1 to the Fc portion of yG or yM antibodies (Weiser, Myrvik and Pearsall, 1969). According to the above explanation, the present anomalous data with L1210 would be",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1153,
    "paragraph": "explicable on the basis of a lower surface antigen concentration on L 1210 cells relative to other mouse leukaemias: sufficient L1210 antigen sites would be available to fix 50 per cent of the small quantity of C added in the C fixation test (especially since 10 times more",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1154,
    "paragraph": "cells were used than in the cytolysis assay), but would be insufficient to provide as ready immune cytolysis, with its more stringent requirement for closely-spaced antigen sites. Since different cell types possess widely different sensitivites to non-immune lysis, implying differences in the strength of different cell surfaces (Reif and Allen, 1966), the sensitivities",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1155,
    "paragraph": "leukemic lymphocytes.' Cancer Res., 28, 707. BENTWITCH, Z., COHEN, I., SULrrZEANU, D., IZAK, G. and WEwss, D. W. (1970). 'Antigenicity of lympho- cytes from chronic lymphocytic patients and from normal newborns.' Proc. Amer. Ass. Cancer Res., 11, 7. BORSOS, T., COLTEN, H. R., SPALTER, J. S., ROGEN-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1156,
    "paragraph": "TINE, N. and RAPP, H. J. (1968). 'The C'la fixation and transfer test: examples of its applicability to the detection and enumeration of antigens and anti- bodies at cell surfaces.'_7. Immunol., 101, 392. BoRsos, T. and RAPP, H. J. (1965a). 'Complement",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1157,
    "paragraph": "fixation on cell surfaces by 19S and 7S antibodies.' Science, 150, 505. BoRsos, T. and RAPP, H. J. (1965b). 'Hemolysin titration based on fixation of the activated first com- ponent of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte.'J.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1158,
    "paragraph": "Immunol., 95, 559. BOYLE, W. and DAVIES, D. A. L. (1966). 'Antigens of the surface of mouse ascites tumour cells. I. Studies with rabbit anti-mouse cell sera.' Immunology, 11, 353. BOYSE, E. A., OLD, L. J., STOCKERT, E. and SHIGENO, 'Genetic origin of tumor antigens.'",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1159,
    "paragraph": "N. (1968). Cancer Res., 28, 1280. BRrrINGM4, T. E. and CHAPLIN, H., JR (1960). 'Production of a human \"antileukemic leukocyte\" serum and its therapeutic trial.' Cancer, 13, 412. FERNBACH, D. J., ROSSEN, R. D. and BUTLER, W. T. (1970). 'Studies of antilymphocyte globulin (ALG)",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1160,
    "paragraph": "treatment of children with acute leukemia (AL).' Proc. Amer. Ass. Cancer Res., 11, 25. FRNK, M. M. and GAITHER, T. A. (1970). 'Comple- ment fixation by a single molecule of yG hemolysin.' J. Immunol., 104, 1458. GARDNER, W. U., DOUGHERTY, T. F. and WILLIAMS,",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1161,
    "paragraph": "W. L. (1944). 'Lymphoid tumors in mice receiving steroid hormones.' Cancer Res., 4, 73. GORER, P. A. (1938). 'The antigenic basis of tumor transplantation.' J. Path. Bact., 47, 231. GREEN, N. M. (1969). Advances in Immunology (Ed. by F. J. Dixon, Jr and H. G. Kunkel), p. 1. Academic",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1162,
    "paragraph": "Press, New York. HILL, G. J., II and LITTLEJOHN, K. (1970). 'Compari- son ofheterologous antiserum and cyclophosphamide in therapy of mouse leukemia.' Proc. Amer. Ass. Cancer Res., 11, 37. Kim, C.-A. H. and REIF, A. E. (1971). 'Immunization schedules for potent rabbit antisera to leukemia",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1163,
    "paragraph": "L12 10.' Cancer Res., 31, 7. KLEIN, G. (1969). 'Experimental studies in tumor im- munology.' Fed. Proc., 28, 1739. LAW, L. W., DUNN, T. B., BOYLE, P. J. and MILLER, J. H. (1949). 'Observations on the effect of a folic acid antagonist on transplantable lymphoid leu-",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1164,
    "paragraph": "kemias in mice.' N. nat. Cancer Inst., 10, 179. LEVI, E., GOLDEN, R., ZERUBAVEL, R. and FISCHER, J. (1966). 'The activity of tolerant antileukemia sera. I. in vitro effects.' Cancer Res., 26, 659. LINDSTROM, G. A. (1927). 'An experimental study of",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1165,
    "paragraph": "myelotoxic sera. Therapeutic attempts in myeloid leukemia.' Acta med. scand. (suppl.), 22, 1. Specificity of Antisera against Leukaemias LINSCOTT, W. D. (1970). 'An antigen density effect on the hemolytic efficiency of complement.' J. Im- munol., 104, 1307. MAYER, M. M. (1961). 'Complement and complement",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1166,
    "paragraph": "fixation.' Experimental Immunochemistry (Ed. by E. A. Kabat), 2nd edn, p. 133. Thomas, Springfield. MEMPEL, W. and THIERFELDER, S. (1970). 'Die Wirk- ung von Antilymphozytenserum allein oder in Ver- bindung mit einem Zytostatikum auf eine Mauseleu- kaemie.' Blut, 20, 37. MILLER, D. G., MOLOVANU, G., KAPLAN, A. and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1167,
    "paragraph": "ToCCI, S. (1968). 'Antilymphocytic leukemic serum and chemotherapy in the treatment of murine leukemia.' Cancer, 22, 1192. MOHOS, S. C. and KIDD, J. G. (1957). 'Effects of various immune rabbit serums on the cells of several transplanted mouse lymphomas in vitro and in",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1168,
    "paragraph": "vivo.'_7. exp. Med., 105, 233. RAPP, H. J. and BORSOS, T. (1966). 'Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by pre- cipitin analysis, by C'la fixation and by hemolytic activity.'7. Immunol., 96, 913. ascites tumors.'_7. Immunol., 89, 849.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1169,
    "paragraph": "REIF, A. E. (1969). 'Batch preparation of rabbit yG globulin with DEAE-Cellulose.' Immunochemistiy, 6, 723. REIF, A. E. (1962). 'Immune cytolysis of three mouse REIF, A. E. and ALLEN, J. M. (1964). 'The AKR thymic antigen and its distribution in leukemias and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1170,
    "paragraph": "nervous tissues.'7. exp. Med., 120, 413. REIF, A. E. and ALLEN, J. M. (1966). 'The fragility of normal and leukemic lymphocytes of AKR mice: a study of cell injury by physical agents.' Cancer Res., 26, 131. REIF, A. E., ALLEN, J. M. V. and MCVETY, L. M.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1171,
    "paragraph": "(1965). 'A general method for the calculation of serological specificity.' Immunology, 8, 384. REIF, A. F. and KIM, C.-A. H. (1969). 'Therapy of transplantable mouse leukaemias with antileukae- mia sera.' Nature (Lond.), 223, 1377. REIF, A. E. and NORRIS, H. J. (1960), 'A system for",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1172,
    "paragraph": "quantitative determination of cytotoxic activity of antisera to ascites tumor cells.' Cancer Res., 20, 1235. 1097 SCHABEL, F. M., JR, SKIPPER, H. E., LASTER, W. R., JR and THOMPSON, S. A. (1966). 'Experimental evaluation of potential anticancer agents. XX. Development of immunity to leukemia L1210 in",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1173,
    "paragraph": "BDF1 mice and effects of therapy.' Cancer Chem. Rep., 50, 55. SEKLA, B., HOLECKOVA, E., JANELE, J., LIBANSKI1, J. and HNEVKOVSKI+, 0. (1967). 'The effects of hetero- logous immune globulins upon human cancer in vivo.' Neoplasma, 14, 64 1. SHIGENO, N., HAMMERLING, U., ARPELS, C., BoYSE,",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1174,
    "paragraph": "E. A. and OLD, L. J. (1968). 'Preparation of lym- antibody from anti-lymphocyte phocyte-specific serum.' Lancet, ii, 320. SIEGEL, B. V. and MORTON, J. I. (1970). 'Rauscher viral leukemogenesis in BALB/c mice treated with rabbit antimouse thymocyte serum.' 7. nat. Cancer",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1175,
    "paragraph": "Inst., 44, 573. SNELL, G. D. and STIMPFLING, J. H. (1966). 'Genetics of tissue transplantation.' Biology of the Laboratory Mouse (Ed. by E. L. Green), 2nd edn, p. 457. McGraw-Hill, New York. SVEHAG, S.-E., CHESEBRO, B. and BLOTH, B. (1967). 'Ultrastructure of gamma M immunoglobulin and",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1176,
    "paragraph": "alpha macroglobulin: electron-microscopic study.' Science, 158, 933. TAKAHASHI, T., OLD, L. J. and BOYSE, E. A. (1970). 'Surface allo-antigens of plasma cells.'J. exp. Med., 131, 1325. TSIRIMBAS, A. D., PFISTERER, H., HORNUNG, B., THIERFELDER, S., MICHLMAYR, G. and STICH, W. (1969). 'Studies with heterologous antilymphocytic",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1177,
    "paragraph": "serum as a therapy for chronic lymphocytic leu- kemia.' Blut, 19, 420. WATSON, J., RALPH, P., SARKAR, S. and COHN, M. (1970). 'Leukemia viruses associated with mouse myeloma cells.' Proc. nat. Acad. Sci. (Wash.), 66, 344. WEISER, R. S., MYRVIK, Q. N. and PEARSALL, N. N.",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1178,
    "paragraph": "(1969). Fundamentals of Immunology, p. 25. Lea & Febiger, Philadelphia, Pa. WITZ, I., YAGI, Y. and PRESSMAN, D. (1968). 'Immuno- directed suppressive against mouse lymphocytic leukemia L1210.' Proc. Soc. exp. Biol. (N.r.), 127, 562. activity of rabbit antisera",
    "jurnal": "immunology00365-0229.pdf"
  },
  {
    "id": 1179,
    "paragraph": "LEUKEMIA/ KANKER DARAH Alyano Rantumbanua, Tania I.M Lampa Triana Virenza Madil, Vanessa Umboh DASAR BIOMEDIK III DR.dr. WULAN PINGKAN JULIA KAUNANG GRAD.DIP, M.KES FAKULTAS KESEHATAN MASYARAKAT UNIVERSITAS SAM RATULANGI MANADO 1 KATA PENGANTAR Puji dan Syukur kami panjatkan karena atas tuntunan dari Tuhan Yang Maha Esa,",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1180,
    "paragraph": "Sehingga Kami dapat diberi kesempatan untuk menyelesaikan tugas yang berjudul “LEUKIMIA”, Tidak lupa juga diucapkan terimakasih Kepada dosen mata kuliah DASAR BIOMEDIK III yaitu Dr.dr. Wulan Pingkan Julia Kaunang Grad.Dip, M.Kes, yang telah memberikan tugas dan juga membimbing untuk menyelesaikan Tugas ini.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1181,
    "paragraph": "Tugas ini ditulis untuk memperluas pengetahuan mengenai Penyakit menular khususnya LEUKIMIA, Semoga is dari Tugas ini dapat bermanfaat dan memberikan wawasan yang lebih luas bagi para pembaca terlebih bagi diri penulis sendiri. Akhirnya, dengan segala kerendahan hati kami penyusun menyadari masih terdapat",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1182,
    "paragraph": "banyak kekurangan dalam penulisan dan pembuatan tugas ini, sehingga kami tim penysun mengharapkan adanya saran dan kritik yang membangun. Manado, 4 November 2024 Penulis, Kelompok 10 i DAFTAR ISI KATA PENGANTAR .............................................................................................. i DAFTAR ISI .............................................................................................................. ii",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1183,
    "paragraph": "Pengertian Leukemia (Kanker darah) Leukemia adalah salah satu tipe kanker yang menyerang sel-sel darah putih. Dalam kasus leukemia, sel-sel darah putih yang seharusnya bertugas melawan infeksi tumbuh secara tidak normal dan tidak terkontrol. Keadaan ini dapat merusak kemampuan sumsum tulang untuk memproduksi sel",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1184,
    "paragraph": "darah. Salah satu penyakit paling berbahaya adalah kanker darah, yang juga dikenal sebagai leukemia. penyakit ini disebabkan oleh produksi berlebihan sel darah putih dan kurangnya sel darah merah dalam proses produksi darah di tubuh. Kanker ini menyerang sel darah putih yang diproduksi di sumsum tulang. Sumsum tulang",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1185,
    "paragraph": "Penyebab Meskipun penyebab pasti dari leukemia belum sepenuhnya dipahami, ada beberapa faktor yang dapat menyebabkan penyakit ini, seperti: a. Faktor genetik dari beberapa virus yang memodifikasi gen (virus limfoma sel t/HTLV) b. Paparan radiasi yang tinggi c. Penggunaan obat imunosupresif seperti dietilstilbestrol d. Faktor herediter, seperti kembar identik e.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1186,
    "paragraph": "Kelainan kromosom, seperti sindrom Down. Penyebab leukemia belum jelas. Beberapa faktor yang diduga berkontribusi pada kejadian leukemia meliputi: A. Radiasi: Berdasarkan penelitian yang ada, 1) Pekerja di bidang radiologi memiliki risiko lebih tinggi terkena leukemia, 2) Pasien yang mendapatkan radioterapi berisiko mengalami leukemia, dan",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1187,
    "paragraph": "3) Penyakit leukemia terdeteksi pada korban yang selamat dari pemboman atom di Hiroshima dan Nagasaki di Jepang. B. Faktor Leukemogenik: Beberapa bahan kimia bisa menyebabkan leukemia: 1). Racun dari lingkungan seperti benzena: paparan tinggi terhadap benzena di tempat kerja dapat berisiko menyebabkan leukemia.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1188,
    "paragraph": "2) Bahan kimia dari industri, seperti insektisida dan formaldehid. 3) Pasien kanker yang menjalani kemoterapi dengan obat tertentu kadang-kadang mengembangkan leukemia di kemudian hari. Sebagai contoh, ada hubungan antara pemakaian obat yang dikenal sebagai agen alkilasi dan munculnya leukemia di tahun-",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1189,
    "paragraph": "tahun berikutnya. A. Sindrom Down, yang disebabkan oleh kelainan kromosom, dapat meningkatkan risiko leukemia dengan insiden leukemia akut 20 kali lebih tinggi dibandingkan orang normal. B. Virus tertentu dapat menyebabkan leukemia, seperti retrovirus, virus leukemia kucing, dan virus HTLV-1 pada orang dewasa.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1190,
    "paragraph": "2 komplikasi kanker darah (leukemia) Jika tidak ditangani dengan benar, leukemia bisa menimbulkan beberapa komplikasi yang serius, berikut beberapa komplikasi yang dapat terjadi: • Tubuh akan mudah terkena infeksi karena minimnya sel darah putih dalam tubuh. • dapat terjadi Pendarahan pada bagian tubuh yang berbahaya atau pada bagian tubuh",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1191,
    "paragraph": "yang sensitif, seperti otak, paru-paru, lambung, dan usus • Terjadi Gangguan pada tulang yang menyebabkan patah tulang, pengapuran dan nyeri . • Terjadi gangguan pada fungsi ginjal, bahkan bisa terkena penyakit gagal ginjal. • Beresiko timbulnya jenis penyakit kanker darah lain. Penanganan leukemia yang",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1192,
    "paragraph": "dilakukan juga mungkin menyebabkan komplikasi, seperti penyakit anemia hemolitik, penyakit sindrom lisis tumor, bahkan bisa terkena penyakit ketidaksuburan (infertilitas), dan juga sel kanker yang timbul kembali setelah melakukan pengobatan, dan juga bisa menyebabkan gangguan sistem pada bagian saraf pusat pada anak-anak,",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1193,
    "paragraph": "seperti katarak.. 1) Tombositopenia: Pada leukemia akut, penurunan jumlah trombosit biasanya disebabkan oleh kemoterapi bisa juga disebut dengan infiltrasi sumsun tulang , tetapi bisa juga disebabkan oleh yang lainnya contohnya koagulasi intravaskuler diseminata, dan proses imunologis, dan juga 3 hipersplenisme sekunder pada",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1194,
    "paragraph": "proses pembesaran limpa. Trombositopenia yang selalu terjadi selalu juga bervariasi atau tidak sama dan kebanyakan selalu ditemukan saat leukemia didiagnosis. 3 2) Koagulasi Intravaskuler diseminata : penyakit ini juga ditandai terhadap aktivasi koagulasi intravaskuler sistemik, yang juga terdiri antara lain dari pembentukan",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1195,
    "paragraph": "dan penyebaran deposit fibrin dalam proses sirkulasi. Penyakit ini juga dapat menimbulkan trombus mikrovaskuler pada beberapa organ, yang juga dapat mengakibatkan kegagalan multiorgan. Aktivasi koagulasi yang selalu tidak berhenti atau terus menerus dapat menyebabkan terjadinya pengonsumsian faktor pembekuan dan trombosit yang terlalu berlebihan, yang menyebabkan kegagalan.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1196,
    "paragraph": "KID bukanlah penyakit sendiri, sebaliknya, itu adalah hasil dari penyakit lain yang mendasari. 3) Fibrinolisis Primer: peneliti telah menemukan bahwa sesungguhnya leukosit pada leukemia akut adalah melakukan aktivitas fibrinolitik, yang bisa mengakibatkan fibrinolisis primer. Terutama terjadinya kepada leukemia promielositik akut. Fibrinolisis primer, perdarahan dapat terjadi juga dikarenakan salah satu faktor",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1197,
    "paragraph": "Faktor Risiko Leukemia Beberapa faktor dapat meningkatkan risiko terkena leukemia, meskipun Penyebab yang akurat dari penyakit ini masih belum sepenuhnya dipahami. Usia leukimia Lebih sering terjadi pada orang dewasa serta anak-anak. Riwayat keluarga: Memiliki seorang anggota keluarga yang pernah didiagnosis dengan",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1198,
    "paragraph": "leukemia dapat meningkatkan risiko penyakit tersebut. - Paparan terhadap bahan kimia: seperti benzena yang terkandung dalam bahan bakar dan produk-produk industri, dapat meningkatkan risiko. - Radiasi: Paparan radiasi dalam dosis tinggi, seperti dari pengobatan kanker lainnya, dapat menjadi faktor risiko. - Kelainan genetik: Risiko terkena leukemia dapat meningkat karena sindrom Down",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1199,
    "paragraph": "dan beberapa kelainan genetik lainnya. - Merokok: Risiko terkena beberapa jenis leukemia lebih tinggi jika Anda merokok. Gejala Leukemia Gejala leukemia bervariasi tergantung pada jenis leukemia dan stadiumnya. • Kelelahan: Rasa lelah yang terus-menerus yang tidak hilang meskipun sedang beristirahat • Demam dan infeksi: Orang yang menderita leukemia memiliki sistem kekebalan",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1200,
    "paragraph": "tubuh yang lemah, yang membuat mereka lebih rentan terhadap infeksi. • Pucat: Kulit dapat terlihat pucat karena anemia akibat kekurangan sel darah merah. • Mudah berdarah dan memar: Darah sulit membeku karena jumlah trombosit yang rendah. • Nyeri tulang: Sel-sel leukemia yang menumpuk di tulang dapat menyebabkan nyeri.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1201,
    "paragraph": "• Pembesaran kelenjar getah bening: Akibat pembesaran sel leukemia, kelenjar getah bening dapat membesar. 5 • Turunnya berat badan tanpa sebab: penurunan berat badan yang signifikan dapat merupakan gejala leukemia. • Keringat malam: Keringat berlebih sering terjadi pada malam hari. • Bengkak pada perut: Rasa sakit perut dapat disebabkan oleh pembesaran limpa atau",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1202,
    "paragraph": "Pencegahan kanker darah (leukemia) Pencegahan kanker darah (leukemia) Semua penyakit keganasan pada anak, penyakit ini adalah yang paling umum. Dibandingkan dengan anak kulit hitam di negara berkembang, anak kulit putih bertanggung jawab atas 83% ALL dan 17% AML 93% terdiri dari leukemia akut,",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1203,
    "paragraph": "yang dibagi menjadi 82% LLA, 18% LMA, dan 3% LMK. Dari segi epidemiologi, leukemia akut menyumbang 30-40% dari seluruh kasus keganasan pada anak, dengan puncak kejadian pada usia 2–5 tahun. Rata-rata, ada sekitar 4–4,5 kasus per 100.000 anak per tahun. Dari tahun 2006 hingga 2010, ada angka kematian anak akibat",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1204,
    "paragraph": "leukemia di Rumah Sakit Cipto Mangunkusumo (RSCM) dan Rumah Sakit Kanker “Dharmais” (RSKD). Jumlah penderita laki-laki lebih tinggi 1,15 kali dibandingkan dengan perempuan untuk LLA, sementara jumlah penderita perempuan hampir sama untuk LMA. Sebagian besar, penyebab utama leukemia adalah terjadinya mutasi (perubahan) pada",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1205,
    "paragraph": "DNA sel darah, yang mengakibatkan sel darah tersebut tidak berfungsi dengan baik. Meskipun demikian, penyebab yang memicu kesembuhan leukemia masih belum dapat dipastikan. Jika sumsum tulang menghasilkan jumlah sel darah putih yang terlalu banyak dan tidak normal, kondisi ini dikenal dengan nama leukemia atau",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1206,
    "paragraph": "kanker darah. Karena penyebab kanker ini seringkali sulit dipastikan, pencegahan leukemia tidak sepenuhnya diketahui. Namun, melalui perubahan gaya hidup sehat dan menghindari paparan zat tertentu, beberapa faktor risiko dapat dikurangi. 6 Penyebab penyakit ini masih belum sepenuhnya dipahami. Namun, terdapat beberapa",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1207,
    "paragraph": "langkah yang dapat diambil untuk mengurangi risiko Anda mengalami leukemia, antara lain: • Melakukan olahraga secara teratur; baca juga manfaat olahraga di pagi hari untuk kesehatan yang lebih baik. • Menghentikan atau menjauhi kebiasaan merokok. • Menghindari paparan bahan kimia, seperti benzene",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1208,
    "paragraph": "• Mengurangi paparan radiasi sinar-X yang tidak diperlukan. • Segera konsultasikan dengan dokter jika merasakan perubahan atau gejala tertentu pada tubuh. Berikut adalah beberapa langkah pencegahan yang dapat dilakukan: Leukemia, yang juga dikenal sebagai kanker darah, merupakan suatu kondisi di mana",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1209,
    "paragraph": "sumsum tulang memproduksi sel darah putih yang tidak normal dalam jumlah yang berlebihan. Pencegahan leukemia bukan sepenuhnya diketahui karena penyebab pasti dari kanker ini sering kali sulit dipastikan. Namun, beberapa faktor risiko dapat dikurangi melalui perubahan gaya hidup sehat dan menghindari paparan zat tertentu.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1210,
    "paragraph": "Berikut adalah beberapa langkah pencegahan yang dapat dilakukan: 1. Menghindari Paparan Radiasi Paparan radiasi tinggi, seperti y terjadi pada pasien dengan riwayat pengobatan radiasi, dapat meningkatkan risiko leukemia. Hindari atau minimalkan paparan radiasi yang tidak diperlukan. 2. Mengurangi Paparan Bahan Kimia Berbahaya, seperti benzena yang terdapat",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1211,
    "paragraph": "dalam produk industri tertentu dan asap rokok terkait dengan peningkatan risiko leukemia. Hindari pekerjaan atau lingkungan yang sering terpapar bahan kimia berbahaya, atau gunakan perlindungan yang sesuai. 3. Tidak Merokok: Merokok dapat meningkatkan risiko terjadinya berbagai jenis kanker, termasuk leukemia. Oleh karena itu, hindarilah atau berhentilah merokok",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1212,
    "paragraph": "adalah langkah penting dalam pencegahan kanker. 7 4. Menjaga Pola Makan Sehat dan Gaya Hidup Aktif: Pola makan yang kaya akan buah-buahan, sayuran, dan biji-bijian serta rendah lemak jenuh. Dapat meningkatkan daya tahan tubuh terhadap penyakit. Gaya hidup aktif dan olahraga",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1213,
    "paragraph": "teratur juga berkontribusi pada kesehatan secara keseluruhan. 5. Menghindari Paparan Infeksi Tertentu Beberapa infeksi virus, seperti virus Epstein-Barr, terkait dengan risiko kanker darah tertentu. Menjaga kebersihan diri, terutama dalam kontak fisik yang intensif, dapat membantu mengurangi risiko terinfeksi virus ini. 6. Konsultasi Medis Rutin Menjalani pemeriksaan kesehatan rutin dan melaporkan",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1214,
    "paragraph": "gejala yang tidak biasa kepada dokter dapat membantu mendeteksi. Masalah kesehatan sejak dini. Ini termasuk tes darah atau pemeriksaan tambahan untuk individu yang mungkin berisiko lebih tinggi. Menjalani gaya hidup sehat dan meminimalkan paparan terhadap faktor risiko dapat membantu menurunkan kemungkinan terjadinya kanker ini.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1215,
    "paragraph": "Pengobatan Leukemia 1. Kemoterapi Kemoterapi merupakan terapi yang bersifat sitotoksik yang bertujuan untuk mencegah perluasan keganasan dan penyebaran [Tomlinson, 2019). Terdapat zangkaian protokol (fase) kemoterapi pada LLA diantaranya adalah: a) Fase induksi b) Fase Konsolidast c) Fase Reintensifikasi d) Terapi CNS-Directed",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1216,
    "paragraph": "e) Fase Maintenance f) Fase Maintenance 2. Transplantasi sel induk hematopoetik/ Hematopoietic Stem Cell 8 Transplantasi sel induk hematopoietik (HSCT) dilakukan untuk menggantikan HSC yang sakit, rusak, atau tidak ada. Dengan ISC yang umumnya sehat, transplantasi alogenik digunakan ketika sel induk hematopoietik sakit (seperti leukemia), rusak",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1217,
    "paragraph": "(seperti penyakit sel sabit), atau tidak ada (seperti penyakit defisiensi imun berat). Sel punca dapat diselamatkan melalui transplantasi autologus setelah dosis kemoterapi atau radiasi yang lebih tinggi; ini digunakan dalam pengobatan tumor padat (Tomlinson, 2019). Anak leukemia yang menunjukkan respons baik terhadap",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1218,
    "paragraph": "perawatan atau yang kambuh lebih awal setelah masuk ke dalam remisi dapat diobati dengan transplantasi sel punca sumsum tulang. Tidak jelas apakah SCT harus digunakan pada anak-anak dengan LLA yang muncul lebih dari enam bulan setelah kemoterați pertama. Anak- anak ini biasanya dirawat dengan Daik.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1219,
    "paragraph": "3. Radioterapi Menurut Tomlinson (2019), radioterapi adalah jenis pengobatan ganas yang menggunakan radiasi pengion. Pada pengobatan kanker masa kanak-kanak, radioterapi kurang penting karena rejimen kemoterapi yang sangat efektif dan efek lambat radioterapi, yang dapat berdampak pada anak yang masih dalam tahap perkembangan.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1220,
    "paragraph": "Kira-kira 20% anak dan remaja yang menderita kanker masih membutuhkan radioterapi. Radioterapi adalah salah satu metode utama pengobatan tumor otak dan sangat penting dalam gejala paliatif . Radioterapi memainkan peran penting dalam pengobatan anak-anak dengan kanker karena tujuannya adalah untuk mencapai kontrol",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1221,
    "paragraph": "HEMATOLOGI, p.69. Kementerian Kesehatan RI 2023, Pedoman nasional pelayanan kedokteran tata laksana leukemia, Kemenkes RI, Jakarta. Panca, R., 2024. PENGARUH EDUKASI PENGOBATAN PALIATIF DENGAN METODE KONSELING KEPADA ORANG TUA TERHADAP KEPATUHAN PEMBERIAN OBAT PADA ANAK LEUKEMIA LIMFOBLASTIK AKUT DI IRNA ANAK RSUD Dr. SOETOMO (Doctoral",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1222,
    "paragraph": "dissertation, STIKES HANG TUAH SURABAYA). Putri, A., Sihotang, M.M., Pane, M.G.O.V., Agustina, M., Rangkuti, N.S. and Lubis, F., 2024. Penggalangan Dana Bersama Yayasan Kanker Indonesia Melalui Penjualan Minuman Inovatif Berbahan Dasar Bunga Telang Dan Melon. Innovative: Journal Of Social Science Research, 4(5), pp.5658-5668.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1223,
    "paragraph": "Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia 2022, Panduan praktik klinis: diagnosis dan tatalaksana leukemia, PAPDI, Jakarta. Safitri, A., Rasyid, H., Bukhari, A. and Madjid, M., 2018. Pengaruh Gizi Terhadap Respon Terapi Pasien Chronic Myelocystic Leukimia (Cml). Ijcnp (Jurnal Dokter Gizi Klinik Indonesia) , 1 (1), pp.57-66.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1224,
    "paragraph": "Sismonika Putri, R., 2022. ASUHAN KEPERAWATAN PADA NN. F DENGAN ACUTE LYMPHOCYTIC LEUKIMIA (ALL) DI RUANG DAHLIA 1 RSUP Dr. SARDJITO YOGYAKARTA (Doctoral dissertation, Poltekkes Kemenkes Yogyakarta). 10 Ramatillah, D.L., Lucyanawati, S., Pangestu, A.A. and Kurniatu, A., 2019. Edukasi dan Deteksi Dini Penyakit Leukimia Kepada Masyarakat di RPTRA Tunas",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1225,
    "paragraph": "Harapan Sunter Jakarta. BERDIKARI, 2(2). World Health Organization, 2023, ‘Leukemia Fact Sheet’, WHO International Agency for Research on Cancer. Yulianti, E. and Adnan, N., 2020. Faktor-Faktor Prognostik Kesintasan 5 Tahun Leukemia Limfoblastik Akut Pada Anak Usia 1-18 Tahun. Promotif: Jurnal Kesehatan Masyarakat, 10(2), pp.86-96.",
    "jurnal": "LEUKEMIAMATERI.pdf"
  },
  {
    "id": 1226,
    "paragraph": "A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1227,
    "paragraph": "u s c r i p t A u t h o r M a n u s c r i p t HHS Public Access Author manuscript Br J Haematol. Author manuscript; available in PMC 2019 March 01. Published in final edited form as:",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1228,
    "paragraph": "Harvard Medical School, Boston, Massachusetts, USA 2Molecular Pharmacology Program, Sloan Kettering Institute, and Department of Pediatrics, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, New York, USA Summary Advances in the classification of acute leukaemias have led to improved outcomes for a substantial",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1229,
    "paragraph": "fraction of patients. However, chemotherapy resistance remains a major problem for specific subsets of acute leukaemias. Here, we propose that a molecularly distinct subtype of acute leukaemia with shared myeloid and T cell lymphoblastic features, which we term acute myeloid/T- lymphoblastic leukaemia (AMTL), is divided across 3 diagnostic categories owing to variable",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1230,
    "paragraph": "expression of markers deemed to be defining of myeloid and T-lymphoid lineages, such as myeloperoxidase and CD3. This proposed diagnostic group is supported by i) retained myeloid differentiation potential during early T cell lymphoid development, ii) recognition that some cases of acute myeloid leukaemia (AML) harbour hallmarks of T cell development, such as T-cell",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1231,
    "paragraph": "receptor gene rearrangements and iii) common gene mutations in subsets of AML and T cell acute lymphoblastic leukaemia (T-ALL), including WT1, PHF6, RUNX1 and BCL11B. This proposed diagnostic entity overlaps with early T cell precursor (ETP) T-ALL and T cell/myeloid mixed",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1232,
    "paragraph": "phenotype acute leukaemias (MPALs), and also includes a subset of leukaemias currently classified as AML with features of T-lymphoblastic development. The proposed classification of AMTL as a distinct entity would enable more precise prospective diagnosis and permit the development of improved therapies for patients whose treatment is inadequate with current",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1233,
    "paragraph": "approaches. Keywords acute leukaemia; classifications; AML; ALL *Correspondence to: Professor Alex Kentsis, Memorial Sloan-Kettering Cancer Center, Sloan Kettering Institute, 1275 York Ave, Box 223, New York, NY 10065-6007, USA, Tel: 1-646-888-2593, kentsisresearchgroup@gmail.com And Dr. Alejandro Gutierrez, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1234,
    "paragraph": "alejandro.gutierrez@childrens.harvard.edu. DR. ALEJANDRO GUTIERREZ (Orcid ID : 0000-0002-0249-9007) PROF. ALEX KENTSIS (Orcid ID : 0000-0002-8063-9191) A u t h o r M a n u s c r i p t A u t h o r M a n u",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1235,
    "paragraph": "s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1236,
    "paragraph": "Introduction Page 2 Acute leukaemias are aggressive neoplasms characterized by the pathological accumulation of immature haematopoietic progenitors. Improvements in clinical outcomes for patients with acute leukaemias treated with modern chemotherapy regimens have been variable. The introduction of molecularly targeted therapies has had a major impact on a small subset of",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1237,
    "paragraph": "genetically-defined acute leukaemias. For example, arsenic trioxide and retinoic acid, which target the PML-RARA fusion oncoprotein via distinct mechanisms (de The, 2015), can now cure the majority of patients with acute promyelocytic leukaemia without exposure to cytotoxic chemotherapies (Lo-Coco et al, 2013). However, clinical outcomes for a",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1238,
    "paragraph": "substantial fraction of acute leukaemias have seen little improvement despite the application of treatment regimens that are among the most intensive and toxic used for any disease. Consequently, improving clinical outcomes for these patients will require linking an improved molecular understanding to the application of effective targeted therapies.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1239,
    "paragraph": "Classification of acute leukaemias Acute leukaemias have traditionally been classified based on the normal cell types most closely resembling the leukaemic cell population. Lymphoblastic leukaemias are those with evidence of differentiation arrest at immature stages of B- or T-cell lymphoid development,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1240,
    "paragraph": "whereas acute myeloid leukaemias encompass malignancies with immunophenotypic features that lie along a broad spectrum of haematopoietic progenitors, ranging from minimally differentiated leukaemias to those with evidence of granulocytic, monocytic, erythroid or megakaryocytic differentiation. Although this classification scheme is intuitive, lineage assignment is complicated by the high frequency of aberrant differentiation states in",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1241,
    "paragraph": "acute leukaemias. Indeed, the simultaneous expression of markers that are not known to be co-expressed in any normal haematopoietic progenitor is common. To address the requirement for consistent diagnostic criteria for the successful performance and interpretation of clinical trials, the World Health Organization (WHO) has devised a",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1242,
    "paragraph": "classification scheme that allows most acute leukaemias to be unambiguously classified as specific diagnostic entities, which has been regularly revised (Swerdlow et al 2008; Arber et al, 2016). The genetics of leukaemia are beginning to be incorporated into the WHO classification,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1243,
    "paragraph": "with increasing weight being given to specific chromosomal translocations and, in some cases, somatic gene mutations, as disease-defining genetic lesions (Arber et al, 2016). Thus, the presence of a characteristic genetic feature can define a disease, independent of the phenotypic lineage which can be difficult to assign in practice. For example, leukaemias",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1244,
    "paragraph": "with FGFR1 translocations that can present with T cell lymphoblastic or myeloid markers are defined as a single diagnostic entity, regardless of the immunophenotype of the presenting leukaemic cells (Arber et al, 2016; Macdonald et al, 2002). Similarly, acute myeloid leukaemia (AML) cases with t(8;21) translocations exhibit aberrant expression of",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1245,
    "paragraph": "CD19, a marker typically associated with B cell lymphoid malignancies, due to lineage- inappropriate PAX5 expression induced by the RUNX1-RUNX1T1 (previously termed AML1-ETO) oncogene (Walter et al, 2010). While we anticipate that genomic classification will have an increasingly important role in defining leukaemia subsets in the future, the",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1246,
    "paragraph": "Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1247,
    "paragraph": "p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 3 current diagnostic classification for most acute leukaemias does not rely on genetic",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1248,
    "paragraph": "mutations. Thus, phenotypic lineage assignment remains a central component of diagnostic classification and treatment assignment for most patients with acute leukaemia. The current WHO classification considers strong expression of a small number of immunophenotypic markers to be lineage-assigning: myeloperoxidase (MPO) or at least two",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1249,
    "paragraph": "monocytic markers (CD11c, CD14, CD64 or lysozyme) for myeloid lineage; surface or cytoplasmic CD3 expression for T cell lineage; and CD19 with at least one additional B cell marker (CD79a, cytoplasmic CD22, or CD10) for B cell lineage (Arber et al, 2016). While",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1250,
    "paragraph": "the specificity of these markers is widely agreed upon, some prominent clinical trials groups use subtly different criteria for lineage assignment (Dworzak et al, 2017). Nevertheless, it is recognized that these classification schemes are imperfect, and the strict application of the",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1251,
    "paragraph": "WHO criteria for lineage assignment is not required to make a diagnosis of AML, T cell acute lymphoblastic leukaemia (T-ALL) or B cell acute lymphoblastic leukaemia (B-ALL) unless a diagnosis of mixed phenotype acute leukaemia (MPAL) is also being considered (Arber et al, 2016). Thus, while MPALs that meet formal criteria for assignment to two",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1252,
    "paragraph": "distinct lineages are very rare, leukaemias classified as AML, T-ALL or B-ALL based on their predominant morphology and immunophenotype commonly co-express markers that indicate aberrant differentiation towards another lineage. Acute myeloid/T-lymphoblastic leukaemia (AMTL): Acute leukaemias with shared T cell lymphoid and myeloid features",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1253,
    "paragraph": "The classical model of haematopoiesis postulates an early binary split between common myeloid and lymphoid progenitors that subsequently give rise to both B- and T-cell lymphocytes. However, more recent work using clonal tracking assays has shown the existence of progenitors that retain T cell/myeloid or B cell/myeloid bi-lineage potential. By",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1254,
    "paragraph": "contrast, individual progenitors whose potential is restricted to T cell and B cell (but not myeloid) lineages have been difficult to identify (Kawamoto et al, 2010). These findings fit the clinical observation that MPALs most commonly present with B cell/myeloid or T cell/",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1255,
    "paragraph": "myeloid marker co-expression, whereas B/T cell MPALs are very rare (Matutes et al, 2011). Here, we propose AMTL as a molecularly distinct subtype of acute leukaemias associated with shared T cell lymphoid and myeloid features. Expression of markers deemed to be",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1256,
    "paragraph": "defining of the myeloid and T cell lymphoid lineages, including myeloperoxidase and CD3, is variable in this disease, resulting in its separation across three diagnostic categories in the current WHO classification scheme: early T cell precursor (ETP) T-ALL, T/myeloid MPAL, and a specific subset of AML harbouring hallmarks of T-lymphoblastic differentiation.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1257,
    "paragraph": "This proposed diagnostic entity overlaps with subsets of ETP T-ALL, which is characterized by differentiation arrest at early stages of T cell development. While a number of biomarkers have been described to identify these cases (Coustan-Smith et al, 2009; Gutierrez et al, 2010;",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1258,
    "paragraph": "Homminga et al, 2011; Zuurbier et al, 2014), these are most commonly defined clinically using an immunophenotypic classifier that includes absent expression of CD1a and CD8, CD5 expression that is substantially lower than that of normal peripheral blood T cells, and",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1259,
    "paragraph": "the presence of one or more markers of myeloid or haematopoietic progenitors (CD117, Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1260,
    "paragraph": "u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1261,
    "paragraph": "s c r i p t Gutierrez and Kentsis Page 4 CD34, HLA-DR, CD13, CD33, CD11b or CD65) (Conter et al, 2016; Coustan-Smith et al, 2009; Patrick et al, 2014). Currently, ETP is classified as a subtype of T-ALL due to the",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1262,
    "paragraph": "expression of CD3, but has a genetic mutational profile that is similar to those observed in myeloid malignancies, such as AML, whereas mutations characteristic of other subtypes of T-ALL, such as CDKN2A deletions, are less common (Gutierrez et al, 2010; Van",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1263,
    "paragraph": "Vlierberghe et al, 2011a; Zhang et al, 2012). While similarities between ETP T-ALL and AML have been previously recognized (Van Vlierberghe et al, 2011a; Zhang et al, 2012; Zuurbier et al, 2014), we propose that the biological overlap of AMTL is not with AML per se, but with a specific subset of AML",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1264,
    "paragraph": "cases that also exhibit T cell lymphoid features. Namely, a subset of AMLs has long been recognized to harbour clonal T-cell receptor (TCR) or immunoglobulin (Ig) gene rearrangements, indicating activity of the RAG recombinase that is responsible for generating somatic V(D)J recombination at these loci at specific stages of lymphoid",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1265,
    "paragraph": "development (Norton et al, 1987; Parreira et al, 1992; Schmidt et al, 1992). These AML cases can also express the lymphoid marker terminal deoxynucleotidyltransferase (TdT, also known as DNTT), which generates diversity at the TCR and Ig genes by mutating the",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1266,
    "paragraph": "junctions of rearrangements during V(D)J recombination (Drexler et al, 1993; Patel et al, 2013). Non-megakaryoblastic AMLs with TCR rearrangements typically co-express phenotypic markers of T-lymphoblastic differentiation, such as CD7, CD2 and CD4 (Schmidt et al, 1992). We postulate that this is the subset of AMLs that also harbour",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1267,
    "paragraph": "mutations that are commonly observed in a distinct subset of T-ALL, including WT1, PHF6, RUNX1 and BCL11B (The Cancer Genome Atlas Research Network, 2013; Della Gatta et al, 2012; Ding et al, 2012; Klco et al, 2015; Tosello et al, 2009; Van Vlierberghe et al, 2010;",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1268,
    "paragraph": "Van Vlierberghe et al, 2011b; Zhang et al, 2012). Thus, a similar group of acute leukaemias exhibit shared features of myeloid and T cell lymphoid differentiation, and shared genetic mutations, which will need to be formally assessed in future studies. Potential mechanisms for combined T-lymphoblastic and myeloid",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1269,
    "paragraph": "differentiation in acute leukaemia At least two non-mutually exclusive mechanisms can explain the development of acute leukaemias with differentiation potential shared with myeloid and T-lymphoid lineages: 1. Transformation of normal haematopoietic progenitors with T-lymphoblastic and myeloid bi-lineage potential. While studies of endogenous haematopoiesis have",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1270,
    "paragraph": "revealed limited evidence of a putative normal progenitor whose fate is restricted to T-lymphoid and myeloid lineages, the identification of such a progenitor may have been hindered by differences in the lifespan of mature myeloid versus T- lymphoid cells. Nevertheless, even if a normal progenitor whose differentiation",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1271,
    "paragraph": "fate is restricted to T-lymphocytes and myeloid cells is lacking, such leukaemias can arise from cells that retain multi-lineage potential, even though their fate is normally restricted to a single lineage by microenvironmental signals. Immature intrathymic T cell progenitors at early double-negative stages of differentiation",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1272,
    "paragraph": "represent one potential cell of origin for such leukaemias. Indeed, the most immature intrathymic T cell progenitors retain myeloid (but not B-lymphoid) Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1273,
    "paragraph": "n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1274,
    "paragraph": "u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 5 2. potential until they progress through a BCL11B-dependent commitment to the T cell lineage (Balciunaite et al, 2005; Ikawa et al, 2010; Li et al, 2010) (Figure 1).",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1275,
    "paragraph": "Further, lineage tracing studies have demonstrated that immature T cell progenitors give rise to some macrophages and neutrophils harbouring TCR gene rearrangements in vivo (Bell & Bhandoola, 2008; Wada et al, 2008). Ectopic expression of Myc and Bcl2 in mouse early double-negative T cell progenitors",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1276,
    "paragraph": "can drive development of acute leukaemias with variable expression of markers of myeloid and T-lymphoid lineages (Riemke et al, 2016), demonstrating that early T cell progenitors can function as the potential cell of origin of AMTL. Induction of aberrant trans-differentiation by leukemogenic mutations. It is now",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1277,
    "paragraph": "established that specific gene mutations can induce T cell lymphoid or myeloid differentiation. For example, activation of NOTCH1 signalling in mouse bone marrow cells causes aberrant T cell differentiation independent of thymic microenvironmental signals (Pui et al, 1999). Likewise, mutations inactivating",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1278,
    "paragraph": "Runx1 in haematopoietic progenitors cause, aberrant myeloid differentiation (Goyama et al, 2013). Thus, aberrant trans-differentiation of AMTL cells can in principle, occur as a result of combinations of mutations that cooperatively result in combined myeloid and T-lymphoid lineage commitment with differentiation",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1279,
    "paragraph": "arrest (Figure 1). These mutations include genes encoding regulators of chromatin and DNA remodelling, and transcription factors with key functions in controlling lymphoid and myeloid cell fate specification. Future studies using emerging approaches for combinatorial gene editing and conditional gene manipulation in vivo may reveal how the specific combinations of mutations in",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1280,
    "paragraph": "specific cell progenitor populations cooperate to induce AMTL and other non- canonical leukaemia subtypes. Identification of Acute Myeloid/T-Lymphoblastic Leukaemia To a first approximation, AMTL can be defined as acute leukaemias that fit the diagnostic criteria of ETP T-ALL or of T/myeloid MPALs, together with AMLs with clonal TCR gene",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1281,
    "paragraph": "rearrangements and evidence of T-lymphoid differentiation (CD3, CD7, CD2 or CD4 expression). However, we note that aberrant expression of CD4 and CD7 is relatively common in acute megakaryoblastic leukaemia (AMKL), a subtype of AML that is molecularly distinct from AMTL (de Rooij et al, 2017). Therefore, AMKL should be",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1282,
    "paragraph": "excluded from the definition of AMTL, based on absence of megakaryblastic morphology and expression of the platelet markers CD41 or CD61. Thus, our initial proposal for AMTL as a diagnostic entity includes all cases currently classified as ETP T-ALL and T/myeloid",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1283,
    "paragraph": "MPALs, together with the subset of AMLs with TCR rearrangements and expression of T- lymphoblastic markers. Given the variability in cell surface marker expression in acute leukaemias, we propose that clinical genomic profiling will enhance the classification of AMTL as a specific diagnostic",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1284,
    "paragraph": "entity. Indeed, ETP T-ALLs harbour mutations of several genes that are commonly mutated in myeloid neoplasms, such as RAS family members, ETV6, MEF2C and EZH2, but whose mutations are rare in other T-ALL subtypes, (Homminga et al, 2011; Van Vlierberghe et al,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1285,
    "paragraph": "Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1286,
    "paragraph": "p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 6 2011a; Zhang et al, 2012; Zuurbier et al, 2014). We also suggest that the subset of AML",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1287,
    "paragraph": "cases harbouring clonal TCR gene rearrangements should demonstrate substantial overlap with those AML cases harbouring mutations that are common in T-ALL, such as WT1, RUNX1, PHF6 and BCL11B (The Cancer Genome Atlas Research Network, 2013; Ding et al, 2012; Klco et al, 2015; Zhang et al, 2012). We anticipate that future investigation will",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1288,
    "paragraph": "lead to an improved classifier of AMTL based on both immunophenotypic and genetic diagnostic markers. Conclusions We propose acute myeloid/T-lymphoblastic leukaemia (AMTL) as a new diagnostic entity for acute leukaemias with shared myeloid and T cell lymphoblastic features. Defining the detailed molecular mechanisms of aberrant cell differentiation may lead to the development",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1289,
    "paragraph": "of improved therapies by targeting specific molecular dependencies in these cells. For example, mutant transcription factors function in the context of corepressor and coactivator complexes, which have specific enzymatic functions, such as histone deacetylase (HDAC) inhibitors (Haberland et al, 2009). Isoform-specific HDAC inhibitors are beginning to be",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1290,
    "paragraph": "developed (West & Johnstone, 2014), and specific inhibitors may warrant therapeutic investigation in AMTL with dysregulation of MEF2 family members, for example. Likewise, specific mutations may engender synthetic lethal dependencies, such as, for example, inhibition of the EZH2 methyltransferase in cases of cancers with mutations of",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1291,
    "paragraph": "genes encoding components of the SWItch/Sucrose Non-Fermentable/BRG1-associated factors (SWI/SNF/BAF) chromatin remodelling complex (Kim et al, 2015). Recently, acetyltranferase inhibitors have been found to have therapeutic efficacy in CBP-deficient lymphomas (Ogiwara et al, 2016). Finally, many leukaemias exhibit aberrant resistance to mitochondrial apoptosis, conferring resistance to intensive combination chemotherapies,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1292,
    "paragraph": "such as those used for treatment of refractory AML and T-ALL. Recent data suggest that AMTLs are particularly susceptible to inhibitors of BCL2 (Chonghaile et al, 2014; Pan et al, 2014), and emerging inhibitors of other regulators of intrinsic apoptosis are expected to offer",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1293,
    "paragraph": "useful therapeutic strategies for AMTL patients as well. Acknowledgments We thank Misha Roshal, Mark Fleming, and Peter Steinherz for helpful discussions. This work was supported by NIH R01 CA204396 and CA193651, and P30 CA008748. A.G. and A.K. are Damon Runyon Clinical Investigators.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1294,
    "paragraph": "T, significant macrophage, and natural killer cell but no B-lymphocyte potential. Blood. 2005; 105:1930–1936. [PubMed: 15522952] Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature. 2008; 452:764–767. [PubMed: 18401411] The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1295,
    "paragraph": "acute myeloid leukemia. N Engl J Med. 2013; 368:2059–2074. [PubMed: 23634996] Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u t",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1296,
    "paragraph": "h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1297,
    "paragraph": "r i p t Gutierrez and Kentsis Page 7 Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A. Maturation stage of",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1298,
    "paragraph": "T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014; 4:1074–1087. [PubMed: 24994123] Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, Santoro N, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Pierani P,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1299,
    "paragraph": "Cesaro S, Cellini M, Silvestri D, Cazzaniga G, Biondi A, Basso G. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016; 3:e80–86. [PubMed: 26853647] Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1300,
    "paragraph": "JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10:147–156. [PubMed: 19147408] de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, Obulkasim A, Dang J, Easton J, Verboon",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1301,
    "paragraph": "LJ, Mulder HL, Zimmermann M, Koss C, Gupta P, Edmonson M, Rusch M, Lim JY, Reinhardt K, Pigazzi M, Song G, Yeoh AE, Shih LY, Liang DC, Halene S, Krause DS, Zhang J, Downing JR, Locatelli F, Reinhardt D, van den Heuvel-Eibrink MM, Zwaan CM, Fornerod M, Gruber TA.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1302,
    "paragraph": "Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017; 49:451–456. [PubMed: 28112737] de The H. Lessons taught by acute promyelocytic leukemia cure. Lancet. 2015; 386:247–248. [PubMed: 26194524] Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1303,
    "paragraph": "Keersmaecker K, Sole X, Xu L, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Meijerink JP, Califano A, Ferrando AA. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med. 2012; 18:436–440. [PubMed: 22366949] Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1304,
    "paragraph": "McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1305,
    "paragraph": "Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481:506– 510. [PubMed: 22237025] Drexler HG, Sperling C, Ludwig WD. Terminal deoxynucleotidyl transferase (TdT) expression in",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1306,
    "paragraph": "acute myeloid leukemia. Leukemia. 1993; 7:1142–1150. [PubMed: 7688837] Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin JP, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig WD, Biondi A, Schrappe",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1307,
    "paragraph": "Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest. 2013; 123:3876–3888. [PubMed: 23979164] Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1308,
    "paragraph": "LB, Chin L, Hunger SP, Sallan SE, Look AT. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010; 28:3816–3823. [PubMed: 20644084] Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1309,
    "paragraph": "physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10:32–42. [PubMed: 19065135] Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, Vuerhard M, Buijs- Gladdines J, Kooi C, Klous P, van Vlierberghe P, Ferrando AA, Cayuela JM, Verhaaf B, Beverloo",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1310,
    "paragraph": "HB, Horstmann M, de Haas V, Wiekmeijer AS, Pike-Overzet K, Staal FJ, de Laat W, Soulier J, Sigaux F, Meijerink JP. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as Br J Haematol. Author manuscript; available in PMC 2019 March 01.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1311,
    "paragraph": "A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1312,
    "paragraph": "u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 8 potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011; 19:484–497. [PubMed: 21481790]",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1313,
    "paragraph": "Kawamoto H. An essential developmental checkpoint for production of the T cell lineage. Science. 2010; 329:93–96. [PubMed: 20595615] Kawamoto H, Ikawa T, Masuda K, Wada H, Katsura Y. A map for lineage restriction of progenitors during hematopoiesis: the essence of the myeloid-based model. Immunol Rev. 2010; 238:23–36.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1314,
    "paragraph": "[PubMed: 20969582] Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, Wang W, Haswell JR, Walensky LD, Hahn WC, Orkin SH, Roberts CW. SWI/SNF-mutant cancers depend on catalytic and non- catalytic activity of EZH2. Nat Med. 2015; 21:1491–1496. [PubMed: 26552009]",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1315,
    "paragraph": "Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, Wartman LD, Christopher M, Lamprecht TL, Helton NM, Duncavage EJ, Payton JE, Baty J, Heath SE, Griffith OL, Shen D, Hundal J, Chang GS, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Larson DE,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1316,
    "paragraph": "Kulkarni S, Ozenberger BA, Welch JS, Walter MJ, Graubert TA, Westervelt P, Radich JP, Link DC, Mardis ER, DiPersio JF, Wilson RK, Ley TJ. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA. 2015; 314:811–822. [PubMed: 26305651]",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1317,
    "paragraph": "Li L, Leid M, Rothenberg EV. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science. 2010; 329:89–93. [PubMed: 20595614] Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1318,
    "paragraph": "Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1319,
    "paragraph": "Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano Malattie Ematologiche dA, German-Austrian Acute Myeloid Leukemia Study G, Study Alliance",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1320,
    "paragraph": "L. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369:111–121. [PubMed: 23841729] Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002; 107:101–107. [PubMed:",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1321,
    "paragraph": "11919391] Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, Porwit A, Orfao A, Lemez P, Schabath R, Ludwig WD. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1322,
    "paragraph": "the WHO 2008 classification. Blood. 2011; 117:3163–3171. [PubMed: 21228332] Norton JD, Campana D, Hoffbrand AV, Janossy G, Coustan-Smith E, Jani H, Yaxley JC, Prentice HG. Rearrangement of immunoglobulin and T cell antigen receptor genes in acute myeloid leukemia with lymphoid-associated markers. Leukemia. 1987; 1:757–761. [PubMed: 3500372]",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1323,
    "paragraph": "Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y, Kohno T. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. Cancer Discov. 2016; 6:430–445. [PubMed: 26603525] Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1324,
    "paragraph": "H, Dohner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Muschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1325,
    "paragraph": "BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014; 4:362–375. [PubMed: 24346116] Parreira L, Carvalho C, Moura H, Melo A, Santos P, Guimaraes JE, Parreira A. Configuration of immunoglobulin and T cell receptor beta and gamma genes in acute myeloid leukaemia: pitfalls in",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1326,
    "paragraph": "the analysis of 40 cases. J Clin Pathol. 1992; 45:193–200. [PubMed: 1372916] Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1327,
    "paragraph": "t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1328,
    "paragraph": "c r i p t Gutierrez and Kentsis Page 9 Patel KP, Khokhar FA, Muzzafar T, James You M, Bueso-Ramos CE, Ravandi F, Pierce S, Medeiros LJ. TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1329,
    "paragraph": "transplantation. Mod Pathol. 2013; 26:195–203. [PubMed: 22936064] Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, Jenkinson S, Hough R, Vora A. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014; 166:421–424.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1330,
    "paragraph": "[PubMed: 24708207] Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, Lee JY, Kadesch T, Hardy RR, Aster JC, Pear WS. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999; 11:299–308. [PubMed: 10514008] Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1331,
    "paragraph": "ML, Mah N, Weilemann A, Grau M, Groning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Muller-Tidow C, Rosenbauer F. Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. EMBO J. 2016; 35:2399–2416. [PubMed: 27572462]",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1332,
    "paragraph": "Schmidt CA, Oettle H, Neubauer A, Seeger K, Thiel E, Huhn D, Siegert W, Ludwig WD. Rearrangements of T-cell receptor delta, gamma and beta genes in acute myeloid leukemia coexpressing T-lymphoid features. Leukemia. 1992; 6:1263–1267. [PubMed: 1333555] Swerdlow, SH., Campo, E., Harris, NL., Jaffe, ES., Pileri, SA., Stein, H., Thiele, J., Vardiman, JW.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1333,
    "paragraph": "WHO classification of tumours of haematopoietic and lymphoid tissues. 4. International Agency for Research on Cancer Press; Lyon, France: 2008. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368:2059–2074. [PubMed: 23634996]",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1334,
    "paragraph": "Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA. WT1 mutations in T-ALL. Blood.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1335,
    "paragraph": "2009; 114:1038–1045. [PubMed: 19494353] Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippe J, Gonzalez-Garcia S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1336,
    "paragraph": "Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010; 42:338–342. [PubMed: 20228800] Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, Tosello V,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1337,
    "paragraph": "Della Gatta G, Paietta E, Racevskis J, Wiernik PH, Luger SM, Rowe JM, Rue M, Ferrando AA. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011a; 208:2571–2579. [PubMed: 22162831] Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1338,
    "paragraph": "Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, Cools J, Levine R, Ferrando A. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011b; 25:130–134. [PubMed: 21030981] Wada H, Masuda K, Satoh R, Kakugawa K, Ikawa T, Katsura Y, Kawamoto H. Adult T-cell",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1339,
    "paragraph": "progenitors retain myeloid potential. Nature. 2008; 452:768–772. [PubMed: 18401412] Walter K, Cockerill PN, Barlow R, Clarke D, Hoogenkamp M, Follows GA, Richards SJ, Cullen MJ, Bonifer C, Tagoh H. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5. Oncogene. 2010; 29:2927–2937. [PubMed: 20208555]",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1340,
    "paragraph": "West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124:30–39. [PubMed: 24382387] Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1341,
    "paragraph": "Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1342,
    "paragraph": "Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1343,
    "paragraph": "r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1344,
    "paragraph": "r M a n u s c r i p t Gutierrez and Kentsis Page 10 Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK,",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1345,
    "paragraph": "Downing JR, Mullighan CG. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481:157–163. [PubMed: 22237106] Zuurbier L, Gutierrez A, Mullighan CG, Cante-Barrett K, Gevaert AO, de Rooi J, Li Y, Smits WK, Buijs-Gladdines JG, Sonneveld E, Look AT, Horstmann M, Pieters R, Meijerink JP. Immature",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1346,
    "paragraph": "MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica. 2014; 99:94–102. [PubMed: 23975177] Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1347,
    "paragraph": "r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1348,
    "paragraph": "p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 11 Figure 1. Potential mechanisms leading to acute leukaemia with shared myeloid and T- lymphoblastic features The fate of multipotent haematopoietic progenitors first entering the thymus is directed to",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1349,
    "paragraph": "the T cell lineage via thymic microenvironmental signals, but these cells retain myeloid potential until BCL11B-dependent commitment to the T cell lineage at the DN2a to DN2b transition (Hosokawa & Rothenberg, 2017). Such T cell progenitors with myeloid potential can function as a cell of origin of AMTL (Riemke et al, 2016) (A). Alternatively, AMTL can",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1350,
    "paragraph": "in principle arise from mutations that induce aberrant T cell differentiation in myeloid or multipotent haematopoietic progenitors (B), or from mutations in T cell restricted progenitors leading to their myeloid differentiation (C). Note that the developmental stages shown (top) are based on mouse T cell development, because human early T cell",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1351,
    "paragraph": "development is less well-defined. AMTL: acute myeloid/T-lymphoblastic leukaemia; DN: CD4/CD8 double-negative T cell progenitor; DP: CD4/CD8 double-positive T cell progenitor; ETP: early T cell precursor; HSC: haematopoietic stem cell; MPP: multipotent progenitor. Br J Haematol. Author manuscript; available in PMC 2019 March 01.",
    "jurnal": "nihms934397.pdf"
  },
  {
    "id": 1352,
    "paragraph": "Original Article Densitometry of STR-PAGE for donor chimerism in acute leukemia’s: A simple method for routine use Ayesha Nayyar1, Suhaib Ahmed2 ABSTRACT Objective: To evaluate a PCR based method of polyacrylamide gel electrophoresis of short tandem repeats and its quantification for detecting donor chimerism after haematopoietic stem cell transplantation in acute leukaemias.",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1353,
    "paragraph": "Methods: The descriptive study was conducted at Genetic Resource Centre (GRC) Lab Rawalpindi from Feb 2018 - Nov 2020. A total of twenty patients with acute leukaemias having undergone HSCT were selected and assessed for the analysis of chimerism status. DNA extraction from the whole blood was done by chelex method and short tandem",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1354,
    "paragraph": "repeats were amplified by using conventional STR- PCR assay. Electrophoresis was carried out and 6% polyacrylamide gels were used for the resultant amplified DNA products and then followed by their densitometry. These patients had undergone HSCT from Pakistan Institute of Medical Science and Armed Forces Bone Marrow Transplant Centre.",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1355,
    "paragraph": "Results: The peaks in the PAGE densitometry represented the donor chimerism in all post transplant samples of the patients. Conclusion: Our study showed that densitometry of STR PCR PAGE is a useful and cheaper method for demonstration of donor chimerism in acute leukaemia patients having undergone HSCT. Hence this method can be a valuable option",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1356,
    "paragraph": "in the monitoring of chimerism status in these patients and therefore helps in preventing graft failure by fast and early treatment strategies for these patients. KEYWORDS: DC, STR, PCR, PAGE, Densitometry, Informative allele. How to cite this: Nayyar A, Ahmed S. Densitometry of STR-PAGE for donor chimerism in acute leukemia’s: A simple method for routine use. Pak J",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1357,
    "paragraph": "INTRODUCTION repeats tandem Short (STRs), also known as Microsatellites are small sequences of DNA (two to six base pairs) which are tandemly repeated and these repeat units are different among individuals, making them highly distinguishable1 and are highly useful and widely",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1358,
    "paragraph": "used in human identity testing applications.2,3 Ayesha Nayyar, M. Phil, PhD 1. 2. Suhaib Ahmed, FCPS, PhD 1-2: Department of Pathology, Islamic International Medical College, Riphah International University, Islamabad, Pakistan. Correspondence: Prof. Ayesha Nayyar, MBBS, M.Phil, PhD Pathology Department, Islamic International Medical College,",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1359,
    "paragraph": "Riphah International University, Islamabad, Pakistan. Email: ayesha.nayyar@riphah.edu.pk * Received for Publication: * Edited & Corrected: * Accepted for Publication: December 3, 2023 January 18, 2024 February 5, 2024 Analysis of short tandem repeats (STR-PCR) is thought to be the standard PCR based assay for detection of chi-",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1360,
    "paragraph": "merism4 Chimerism refers to the presence of mixture of DNA of both the donor and recipient after a hematopoi- etic stem cell transplant as HSCT has been widely used for the cure of patients suffering from malignant and nonmalignant hematological disorders and considered.5",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1361,
    "paragraph": "Nevertheless testing of hematopoietic chimerism influ- ences clinical decision and therapeutic intervention in patients after haematopoietic stem cell transplantation but HSCT may get failed due to relapse, and graft-versus- host disease (GVHD).6 Estimation of chimerism pattern has a central part in monitoring of patients having un-",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1362,
    "paragraph": "dergone stem cell transplant 7 and short tandem repeats (STR-PCR) are considered the standard PCR based meth- od for detecting chimerism.8 The method of STR-PCR us- ing a genetic analyzer is sensitive but costly. The analysis of polyacrylamide gel electrophoresis with subsequent densitometric quantification of the",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1363,
    "paragraph": "DNA fragments is another alternative which is cheaper than the use of genetic analyzer.9 PCR of short tandem repeats using PAGE by genetic analyzer is having lesser sensitivity with high coefficient of variation.10 The troubles most likely faced using genetic analyzer are",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1364,
    "paragraph": "Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 875 Ayesha Nayyar et al. the artifacts of polymerase slippages i.e stutter peaks, ultimately interfering with the analysis of chimerism pattern.11 Hence by analyzing the samples of peripheral blood",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1365,
    "paragraph": "or bone marrow of the recipient over time may help in detecting the patterns of Chimerism by conventional STR-PCR PAGE after a stem cell transplant in several malignant and non-malignant hematological diseases. Therefore a continuous monitoring of chimerism is of primary importance in the effective tailoring of the",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1366,
    "paragraph": "treatment strategies wherever required.12 This paper provides a simple, reliable and successful use of STR- PCR by densitometric evaluation of donor chimerism pattern in acute leukaemias. METHODS This descriptive study was conducted at Genetic Resource Centre Rawalpindi. The Twenty post- transplant samples of the patients with acute leukaemias",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1367,
    "paragraph": "who had their stem cell transplanr were studied. About 3-ml of peripheral blood was taken in EDTA container. DNA was extracted using ChelexTM method.11 To flank the repeat units in the gene regions, specific STR primers were designed and PCR conditions for STR were same",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1368,
    "paragraph": "as described by Ahmed.11 Each sibling pair (donor and recipient) were first run at ten different autosomal STR loci (Table-I). The informative locus was identified i.e. donor and recipient had at least one exclusive allele. The donor and the recipient post-transplant",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1369,
    "paragraph": "samples were run for the informative STR locus. The STR amplified products were analysed on 10 X 20 cm polyacrylamide gels (PAGE) after silver staining. The results of PAGE results were photographed and were analysed by a software image analysis (http://thal-it.",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1370,
    "paragraph": "com). The donor Chimerism was then calculated and demonstrated as percent of complete donor Chimerism. Ethical Approval: The study was approved by the institutional ethical review board, Faculty of Medical Sciences, Riphah International University Islamabad- Pakistan (Ref. # Riphah/IIMC/IRC/23/3036). Table-I: Relative informative-ness of eight",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1371,
    "paragraph": "STR loci in the 20 sibling (donor/recipient) pairs. STR Loci Informative in sibling pairs % Common D5S818 D3S1358 D7S820 D8S1179 Uncommon FGA TH01 TPOX D13S317 Rare D18S51-R D21S1411-F 8/20 8/20 5/20 5/20 4/20 3/20 2/20 2/20 1/20 1/20 40.0 (0.40) 40.0 (0.40)",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1372,
    "paragraph": "25.0 (0.25) 25.0 (0.25) 20.0 (0.20) 15.0 (0.15) 10.0 (0.10) 10.0 (0.10) 5 (0.05) 5 (0.05) Fig.1: Silver stained polyacrylamide gel electrophoresis of STR PCR at D5S818 locus. Lane 1 shows two distinct alleles in the recipient pre-transplant sample. Lane 2 shows two alleles of the",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1373,
    "paragraph": "same size (homozygous) appearing as a single thick band in the donor sample. Lane 3 shows the recipient post-transplant sample with two alleles but the intensity of the shorter allele (lower band) is significantly less than the larger allele (upper band). The reap-",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1374,
    "paragraph": "pearance of the recipient specific allele (lower band) indicates a reappearance of the recipient’s tissue (decreasing chimerism). RESULTS Informative STR loci in the Donor/Recipient pairs (sibling pairs): All the twenty sibling pairs when analyzed by STR-PCR showed that at least one",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1375,
    "paragraph": "informative STR locus was found in every pair (Table-I). The informative STR loci were divided into “Common”, “Uncommon” loci and “rare”. In each donor/recipient pair the number of informative loci varied from 1 to 8. The usefulness of each STR locus,",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1376,
    "paragraph": "Fig.1.1: Densitometric evaluation of the polyacrylamide gel electrophoresis of the recipient’s post-transplant sample shown in the figure 1. Peak 2 (39.4%) is the recipient specific allele and its reappearance indicates a reappearance of the recipient’s tissue (decreasing chimerism). The donor chimerism in this",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1377,
    "paragraph": "case was reported as 60.6% (60.6% donor component and 39.4% recipient component). Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 876 Ayesha Nayyar et al. Fig.2: Silver stained polyacrylamide gel electrophoresis of STR PCR at D3S1358 locus. Lane 1 shows two closely",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1378,
    "paragraph": "packed alleles in the recipient pre-transplant sample. Lane 2 shows two distinct alleles in the donor sample. Lanes 3 & 4 show the recipient post-transplant samples with three alleles. The middle allele (indicated by arrow) is the recipient’s exclusive allele. Its reappearance in the",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1379,
    "paragraph": "post-transplant sample indicates a reappearance of the recipient’s tissue (decreasing chimerism). defined by the number of informative loci, varied from 5% to 40% as shown in Table-I. Donor Chimerism by STR PCR: The results achieved from STR-PCR in all the sibling pairs were obtained",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1380,
    "paragraph": "and read from the silver stained polyacrylamide gels. Densitometric evaluation of the polyacrylamide gel of STR-PCR was done later on. (Fig.1 to Fig.2.2). The densitometric evaluation of PAGE clearly showed donor chimerism in post transplant samples of the patients in regards to their percentages estimated. The",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1381,
    "paragraph": "overall results of the 20 sibling pairs and the level of chimerism in these pairs ranged from 13.2% to 98.9%. Donor Chimerism by STR-PCR: Results of donor chi- merism by STR PCR in the 20 sibling pairs were read from the silver-stained polyacrylamide gels and their",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1382,
    "paragraph": "densitometry. DISCUSSION for managing different Currently Haematopoietic stem cell transplant is considered to be an effective and efficient therapeutic strategy hematologic malignancies, but alongwith is compounded by various complications, such as disease recurrence, toxicity related to treatment related toxicity, Graft rejection and",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1383,
    "paragraph": "GVHD.13 The main cause of failure of haematopoietic stem cell transplant is relapse inspite of continuous improvement in this therapeutic modality especially in patients with acute leukemia. As recommended by EuroChimerism consortium PCR analysis of STR is the standard method for estimation of quantitative",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1384,
    "paragraph": "chimerism in the prediction of relapses.14 Fig.2.2: Densitometric evaluation of polyacrylamide gel electrophoresis of the recipient’s post-transplant sample shown in the figure 2. Peak 2 (20.6%) is the recipient specific allele and its reappearance in a post-transplant sample indicates a reappearance of the recipient’s tissue",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1385,
    "paragraph": "(decreasing chimerism). The donor chimerism in this case was reported as 79.4% (79.4% donor component and 20.6% recipient component). Regarding routine chimerism monitoring there are promising investigations on the new methods; however, for monitoring of chimerism status currently STR-PCR is the established method which not only determines",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1386,
    "paragraph": "the type of chimeras, but also determines the percentage of both donor and recipient cells.8 Hence after HSCT reappearance or persistence of recipient cells can indicate the recurrence of the recipient’s hematopoietic cells or presence of malignant cells or both.15 Many",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1387,
    "paragraph": "researchers have proved that the PCR analysis of short tandem repeat profiles of DNA sequences and single nucleotide polymorphisms analysis with real-time quantitative PCR based methods are major techniques used for detection of chimerism.12,16 The STRs have an advantage over other molecular markers for estimating",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1388,
    "paragraph": "the chimerism because of increase number of allels and low amount of DNA required in a PCR reaction.17 The detection limit of STR-PCR for recipient chimerism is ranging from 1 to 10% in few studies. Although technical variability among laboratories may be noticeable.18,19",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1389,
    "paragraph": "Few researchers found out that by using STR markers in 56 children with ALL after HSCT early detection of chimerism can be found out easily.20 Hence for analysis of chimerism, the preferred technique should be easy to perform, rapid, cheap, easily interpretable and",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1390,
    "paragraph": "applicable to every patient. In addition, results should have less variation between the samples and should be highly reproducible. However these consideration should be taken into account for analyzing the exact quantification of donor/recipient DNA for assessing engraftment of the donor DNA and diagnosing the",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1391,
    "paragraph": "failure of graft in an early manner.4 In a study by Andrikovics et al a total of 12 STR markers are needed to obtain 95% informativity for the analysis of chimerism.21 A group of researchers in Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 877",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1392,
    "paragraph": "Ayesha Nayyar et al. their study of 230 patients of malignant hematological disorders found out that five STR informative markers were able to find chimerism in all patients except ten patients who deceased and also suggested that STR is more informative in detecting mixed chimerism",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1393,
    "paragraph": "as compared to other method.22 A Japanese study suggested that using 20 STR markers and the KMR kit markers the informativity in donor/recipient pairs for estimation of chimerism may be detected in a large variety of donor/recipient pairs.23 Few researchers have suggested that at least 40",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1394,
    "paragraph": "markers are required to discriminate a large number of the donor recipient pairs. 24 A group of researchers in their study have observed the status of chimerism by using STR markers in 39 donor/recipient pairs and found chimerism in all the pairs.25",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1395,
    "paragraph": "CONCLUSION Our study demonstrates that STR -PCR using densitometric evaluation is a simple and favourable technique without use of any special instrumentation and expensive reagents making it suitable for a use in routine laboratory practices. Hopefully this will help in analysis of the outcomes after hematopoietic stem",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1396,
    "paragraph": "haematopoietic stem cell transplantation for malignant and non ma- lignat diseases. Transplantation and Cellular Therapy. 2021; 27:872 doi.org/10.1016/j.jtct.2021.07.014 4. 5. 6. Waterhouse M., Pfeifer D., Duque-Afonso J., Follo M., Duyster J., Depner M., et al. Development and Performance of a next Generation",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1397,
    "paragraph": "detection after allogeneic haematopoietic stem cell transplantation by chimerism assays: Digital PCR versus quantitative real-time PCR of insertion/deletion polymorphisms. PLoS ONE 2019; 14(2): e0212708. https://doi.org/10.1371/journal.pone.0212708 15. Peter B, Carreras E, Dufour C , Mohty M , Kröger N. Documentation of Engraftment and Chimerism After HSCT 7th edition. The EBMT",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1398,
    "paragraph": "17. Deniskova TE, Sermyagin AA, Bagirov VA, Okhlopkov IM, Gladyr EA, Ivanov RV et al. 18. Comparative analysis of the effectiveness of STR and SNP markers for intraspecific and interspecific differentiation of the genus Ovis. Russ J Genet. 2016; 52: 79–84.",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1399,
    "paragraph": "19. Pedini P, Cherouat N , Basire A , Simon S, Budon L , Pourtein M et al. Evaluation of next-generation sequencing and crystal digital PCR for chimerism monitoring of post-allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021; 27, 89.e1-89.e10",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1400,
    "paragraph": "20. Llaurador G , Nicoletti E , Prockop SE , Hsu S, Fuller K, Mauguen A et al. Donor-host lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: In- fluence of pretransplantation variables and correlation with post-trans-",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1401,
    "paragraph": "merism test that uses selection of short tandem repeat or quantitative PCR depending on patient’s chimerism status. J. Mol. Diagn. 2019; 21: 483–490 24. Minakawa K, Ono S, Watanabe M, Sato Y, Suzuki S, Odawara S, et al. Evaluation of a quantitative PCR-based method for chimerism",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1402,
    "paragraph": "analysis of Japanese donor/recipient pairs. Sci Rep 2022; 12: 21328 https://doi.org/10.1038/s41598-022-25878-9 25. Vynck, M, Nollet, F, Sibbens, L., Devos, H. Chimerism monitoring us- ing biallelic single nucleotide or insertion/deletion polymorphisms: How many markers to screen? Clin. Chim. Acta 2022; 532: 123–129",
    "jurnal": "PJMS-40-875.pdf"
  },
  {
    "id": 1403,
    "paragraph": "AN: literature search, study design and concept, data collection, data analysis, data interpretation, drafting. SA: Study design and concept, data analysis, data interpretation, Critical Review, Final approval. Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 878",
    "jurnal": "PJMS-40-875.pdf"
  }
]